**BI 3822971 — Not disclosed**

| Feld                      | Änderung | Beschreibung                                                                                                                                               | Evidenz                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| ------------------------- | -------- | ---------------------------------------------------------------------------------------------------------------------------------------------------------- | ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- |
| product\_code             | NONE     | —                                                                                                                                                          | —                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| product\_name             | NONE     | —                                                                                                                                                          | —                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| modality\_name            | MAJOR    | In **„Bispecific antibody (T‑cell engager)“** ändern; CD3‑gerichtete TcEs sind bispezifische Antikörper/IgG‑ähnliche Formate, nicht „monoclonal antibody“. | BI‑Plattformübersicht zu T‑cell engagers (TcE) bestätigt Modalitätsklassifizierung als bispezifische Antikörper; Grundlagen zu BiTE/TcE‑Formaten. [T‑cell engagers – BI](https://www.boehringer-ingelheim.com/science-innovation/human-health-innovation/science-stories/t-cell-engagers-reawakening-t-cells-fight-cancer) [\[boehringer...elheim.com\]](https://www.boehringer-ingelheim.com/science-innovation/human-health-innovation/science-stories/t-cell-engagers-reawakening-t-cells-fight-cancer); [Bi‑specific T‑cell engager](https://en.wikipedia.org/wiki/Bi-specific_T-cell_engager) [\[en.wikipedia.org\]](https://en.wikipedia.org/wiki/Bi-specific_T-cell_engager) |
| product\_type             | NONE     | —                                                                                                                                                          | —                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| therapeutic\_area         | NONE     | —                                                                                                                                                          | —                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| mechanism\_of\_action     | NONE     | —                                                                                                                                                          | —                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| short\_description        | NONE     | —                                                                                                                                                          | —                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| dosage\_form              | NONE     | —                                                                                                                                                          | —                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| route\_of\_administration | NONE     | —                                                                                                                                                          | —                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| base\_technology          | MINOR    | **„T‑cell engager (CD3×pMHC)“** ergänzen; präzisere Technologiebezeichnung.                                                                                | Grundlagen zu TcE/IgG‑ähnlichen bispezifischen Formaten. [T‑cell engagers – BI](https://www.boehringer-ingelheim.com/science-innovation/human-health-innovation/science-stories/t-cell-engagers-reawakening-t-cells-fight-cancer) [\[boehringer...elheim.com\]](https://www.boehringer-ingelheim.com/science-innovation/human-health-innovation/science-stories/t-cell-engagers-reawakening-t-cells-fight-cancer); [Bi‑specific T‑cell engager](https://en.wikipedia.org/wiki/Bi-specific_T-cell_engager) [\[en.wikipedia.org\]](https://en.wikipedia.org/wiki/Bi-specific_T-cell_engager)                                                                                          |
| current\_phase            | NONE     | —                                                                                                                                                          | —                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |

**BI 3968621 — Not disclosed**

| Feld                      | Änderung | Beschreibung                                                                               | Evidenz                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| ------------------------- | -------- | ------------------------------------------------------------------------------------------ | --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- |
| product\_code             | NONE     | —                                                                                          | —                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| product\_name             | NONE     | —                                                                                          | —                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| modality\_name            | MINOR    | **„Small molecule (PROTAC degrader)“** präzisieren.                                        | BI erläutert Protein‑Degrader als strategische Modalität; PROTACs sind niedermolekulare Heterobifunktionale Wirkstoffe. [Protein Degraders – BI](https://www.boehringer-ingelheim.com/us/science-innovation/human-health-innovation/science-stories/protein-degraders-changing-game-cancer-drug-discovery) [\[boehringer...elheim.com\]](https://www.boehringer-ingelheim.com/us/science-innovation/human-health-innovation/science-stories/protein-degraders-changing-game-cancer-drug-discovery); Überblick PROTAC‑Pipeline (HPK1 als I‑O‑Programm in der Branche). [Arvinas PROTAC Pipeline](https://www.arvinas.com/research-and-development/pipeline/) [\[arvinas.com\]](https://www.arvinas.com/research-and-development/pipeline/) |
| product\_type             | NONE     | —                                                                                          | —                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| therapeutic\_area         | NONE     | —                                                                                          | —                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| mechanism\_of\_action     | NONE     | —                                                                                          | —                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| short\_description        | NONE     | —                                                                                          | —                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| dosage\_form              | NONE     | —                                                                                          | —                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| route\_of\_administration | NONE     | —                                                                                          | —                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| base\_technology          | MINOR    | **„Targeted protein degrader (CRBN‑recruiting PROTAC)“** ergänzen; deckungsgleich mit MoA. | Beispiele/Referenzen zu CRBN‑basierten HPK1‑Degradern stützen Begriffsverwendung (konzeptionell, nicht BI‑spezifisch). [Probechem HPK1 PROTAC (CRBN)](https://probechem.com/products_HPK1PROTACSS44.aspx) [\[probechem.com\]](https://probechem.com/products_HPK1PROTACSS44.aspx); [MCE HPK1 PROTAC Degrader](https://www.medchemexpress.com/protac-hpk1-degrader-4.html) [\[medchemexpress.com\]](https://www.medchemexpress.com/protac-hpk1-degrader-4.html)                                                                                                                                                                                                                                                                         |
| current\_phase            | NONE     | —                                                                                          | —                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |

**Spesolimab**

| Feld                      | Änderung | Beschreibung                                                                                                                                                                                                  | Evidenz                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| ------------------------- | -------- | ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- | ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- |
| product\_code             | NONE     | —                                                                                                                                                                                                             | —                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| product\_name             | NONE     | —                                                                                                                                                                                                             | —                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| modality\_name            | NONE     | —                                                                                                                                                                                                             | —                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| product\_type             | NONE     | —                                                                                                                                                                                                             | —                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| therapeutic\_area         | NONE     | —                                                                                                                                                                                                             | —                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| mechanism\_of\_action     | NONE     | —                                                                                                                                                                                                             | —                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| short\_description        | MINOR    | **Klarstellen, dass Spesolimab für GPP‑Flares zugelassen ist; PG bleibt investigational.**                                                                                                                    | Interne Materialien belegen IL‑36R‑MoA und GPP‑Zulassung; PG wird als investigational geführt. [BI-MED-09-EFF-OVER-SAFETY-VILT\_EffSafety Understanding Safety of Spesolimab in GPP from the Effisayil CTProgram.pptx](https://boehringer.sharepoint.com/sites/z365medicineacademyarchive/_layouts/15/Doc.aspx?sourcedoc=%7B918B49B7-8851-43CF-81FC-EDC207CC004C%7D\&file=BI-MED-09-EFF-OVER-SAFETY-VILT_EffSafety%20Understanding%20Safety%20of%20Spesolimab%20in%20GPP%20from%20the%20Effisayil%20CTProgram.pptx\&action=edit\&mobileredirect=true\&DefaultItemOpen=1\&EntityRepresentationId=fb3a8f0f-d65e-4f1a-9bbd-d66829109b93) [\[BI-MED-09-...CTProgram | PowerPoint\]](https://boehringer.sharepoint.com/sites/z365medicineacademyarchive/_layouts/15/Doc.aspx?sourcedoc=%7B918B49B7-8851-43CF-81FC-EDC207CC004C%7D&file=BI-MED-09-EFF-OVER-SAFETY-VILT_EffSafety%20Understanding%20Safety%20of%20Spesolimab%20in%20GPP%20from%20the%20Effisayil%20CTProgram.pptx&action=edit&mobileredirect=true&DefaultItemOpen=1); [g-SPESO-048(EN)\_CombinedSafety\_Feb25.docx](https://boehringer.sharepoint.com/sites/z365medicalaffairsropusa/_layouts/15/Doc.aspx?sourcedoc=%7BEF37040C-A3E6-4FDE-A099-BB52E44D145E%7D\&file=g-SPESO-048%28EN%29_CombinedSafety_Feb25.docx\&action=default\&mobileredirect=true\&DefaultItemOpen=1\&EntityRepresentationId=ebe99b5e-1300-46f7-b532-00a7c0014044) (PG‑Studie NCT06624670 erwähnt) [\[g-SPESO-04...fety_Feb25 | Word\]](https://boehringer.sharepoint.com/sites/z365medicalaffairsropusa/_layouts/15/Doc.aspx?sourcedoc=%7BEF37040C-A3E6-4FDE-A099-BB52E44D145E%7D&file=g-SPESO-048(EN)_CombinedSafety_Feb25.docx&action=default&mobileredirect=true&DefaultItemOpen=1)                                                                                                                                     |
| dosage\_form              | NONE     | —                                                                                                                                                                                                             | —                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| route\_of\_administration | NONE     | —                                                                                                                                                                                                             | —                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| base\_technology          | NONE     | —                                                                                                                                                                                                             | —                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| current\_phase            | MAJOR    | **Auf „Marketed (GPP flares)“ ändern; etwaige Line‑Extension(en) (z. B. PG) laufen investigational, Phase für PG in gesichteten Quellen nicht eindeutig → Phase/Indikation aus Ihren Daten für PG belassen.** | Mehrere interne Quellen bestätigen kommerzielle Verfügbarkeit für GPP‑Flares und SC‑Prävention; PG als laufend/geplant. [g-SPESO-030(EN)\_Eff2\_Apr2025.pdf](https://boehringer.sharepoint.com/sites/z365medicalaffairsropusa/Shared%20Documents/Medical%20Information/Working%20on%20.-/Documentos%20Globales/Spesolimab/g-SPESO-030%28EN%29_Eff2_Apr2025.pdf?web=1\&EntityRepresentationId=e678b57e-db73-4f5a-bb65-9343984d6004) [\[g-SPESO-03...f2_Apr2025 | PDF\]](https://boehringer.sharepoint.com/sites/z365medicalaffairsropusa/Shared%20Documents/Medical%20Information/Working%20on%20.-/Documentos%20Globales/Spesolimab/g-SPESO-030(EN)_Eff2_Apr2025.pdf?web=1); [Spevigo IBP 2024 FINAL.pptx](https://boehringer.sharepoint.com/sites/z365biclimmunology/_layouts/15/Doc.aspx?sourcedoc=%7B80A62507-4026-4B57-8DD6-682969241A73%7D\&file=Spevigo%20IBP%202024%20FINAL.pptx\&action=edit\&mobileredirect=true\&DefaultItemOpen=1\&EntityRepresentationId=96088c5c-e89c-401a-a4be-d79305ad5353) [\[Spevigo IB...2024 FINAL | PowerPoint\]](https://boehringer.sharepoint.com/sites/z365biclimmunology/_layouts/15/Doc.aspx?sourcedoc=%7B80A62507-4026-4B57-8DD6-682969241A73%7D&file=Spevigo%20IBP%202024%20FINAL.pptx&action=edit&mobileredirect=true&DefaultItemOpen=1); [SPEVIGO® 2026-2030 IAP.pdf](https://boehringer.sharepoint.com/sites/z365biclimmunology/Shared%20Documents/IAP%20ICP%20LRR/2026%20IAP%20ICP/Spevigo%20IAP%20Update%20-%20HPC%20%28June%2023%29/SPEVIGO%c2%ae%202026-2030%20IAP.pdf?web=1\&EntityRepresentationId=b1fc52fe-159b-4755-b617-509b126729f2) [\[SPEVIGO® 2...6-2030 IAP | PDF\]](https://boehringer.sharepoint.com/sites/z365biclimmunology/Shared%20Documents/IAP%20ICP%20LRR/2026%20IAP%20ICP/Spevigo%20IAP%20Update%20-%20HPC%20(June%2023)/SPEVIGO%c2%ae%202026-2030%20IAP.pdf?web=1) |

**BI 3814916 — Not yet assigned**

| Feld                      | Änderung | Beschreibung                                                                                           | Evidenz                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| ------------------------- | -------- | ------------------------------------------------------------------------------------------------------ | --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- |
| product\_code             | NONE     | —                                                                                                      | —                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| product\_name             | NONE     | —                                                                                                      | —                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| modality\_name            | NONE     | **Kein belastbarer interner/öffentlicher Nachweis zur BI‑Entität gefunden; keine Änderung empfohlen.** | Weitrecherche (intern/extern) ergab keine treffsicheren BI‑Quellen zu „BI 3814916 / anti‑TLR4 in MASH“. (Keine passenden interne <File> Treffer; generische TLR4‑Antikörperquellen ohne BI‑Bezug) [\[boehringer...elheim.com\]](https://www.boehringer-ingelheim.com/partnering/boehringer-ingelheim-bioxcellence/newsroom/monoclonal-antibodies-bioxcellence), [\[thermofisher.com\]](https://www.thermofisher.com/antibody/gene/TLR4), [\[cellsignal.com\]](https://www.cellsignal.com/products/primary-antibodies/toll-like-receptor-4-d8l5w-rabbit-mab/14358) |
| product\_type             | NONE     | —                                                                                                      | —                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| therapeutic\_area         | NONE     | —                                                                                                      | —                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| mechanism\_of\_action     | NONE     | —                                                                                                      | —                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| short\_description        | NONE     | —                                                                                                      | —                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| dosage\_form              | NONE     | —                                                                                                      | —                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| route\_of\_administration | NONE     | —                                                                                                      | —                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| base\_technology          | NONE     | **Mangels Evidenz keine Ergänzung.**                                                                   | (s. o.) [\[boehringer...elheim.com\]](https://www.boehringer-ingelheim.com/partnering/boehringer-ingelheim-bioxcellence/newsroom/monoclonal-antibodies-bioxcellence), [\[thermofisher.com\]](https://www.thermofisher.com/antibody/gene/TLR4)                                                                                                                                                                                                                                                                                                                     |
| current\_phase            | NONE     | **Mangels Evidenz keine Anpassung.**                                                                   | (s. o.) [\[boehringer...elheim.com\]](https://www.boehringer-ingelheim.com/partnering/boehringer-ingelheim-bioxcellence/newsroom/monoclonal-antibodies-bioxcellence), [\[thermofisher.com\]](https://www.thermofisher.com/antibody/gene/TLR4)                                                                                                                                                                                                                                                                                                                     |

**BI 3819026 — Anti‑LAYN antibody**

| Feld                      | Änderung | Beschreibung                                                                                                                | Evidenz                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| ------------------------- | -------- | --------------------------------------------------------------------------------------------------------------------------- | ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- |
| product\_code             | NONE     | —                                                                                                                           | —                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| product\_name             | NONE     | —                                                                                                                           | —                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| modality\_name            | NONE     | —                                                                                                                           | —                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| product\_type             | NONE     | —                                                                                                                           | —                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| therapeutic\_area         | NONE     | —                                                                                                                           | —                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| mechanism\_of\_action     | NONE     | —                                                                                                                           | Literatur unterstützt Target‑Rationale (LAYN auf Tregs; immunmodulatorische Rolle). [J. Immunology (Layilin anchors Tregs)](https://academic.oup.com/jimmunol/article/207/7/1763/7944338) [\[academic.oup.com\]](https://academic.oup.com/jimmunol/article/207/7/1763/7944338); [Journal of Experimental Medicine (Layilin augments…)](https://rupress.org/jem/article/217/9/e20192080/151858/Layilin-augments-integrin-activation-to-promote) [\[rupress.org\]](https://rupress.org/jem/article/217/9/e20192080/151858/Layilin-augments-integrin-activation-to-promote) |
| short\_description        | NONE     | —                                                                                                                           | —                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| dosage\_form              | NONE     | —                                                                                                                           | —                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| route\_of\_administration | NONE     | —                                                                                                                           | —                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| base\_technology          | MINOR    | **„Afucosylated IgG1 (enhanced ADCC)“** als Technologie ergänzen (entspricht Ihrer Beschreibung; präzisierende Einordnung). | Hintergrund zur Afucosylierung/ADCC‑Steigerung. [Afucosylated monoclonal antibodies](https://en.wikipedia.org/wiki/Afucosylated_monoclonal_antibodies) [\[en.wikipedia.org\]](https://en.wikipedia.org/wiki/Afucosylated_monoclonal_antibodies)                                                                                                                                                                                                                                                                                                                                                        |
| current\_phase            | NONE     | —                                                                                                                           | —                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |

**BI 3821001 — DcR3‑Fc**

| Feld                      | Änderung | Beschreibung                                                                           | Evidenz                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| ------------------------- | -------- | -------------------------------------------------------------------------------------- | ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ |
| product\_code             | NONE     | —                                                                                      | —                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| product\_name             | NONE     | —                                                                                      | —                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| modality\_name            | MAJOR    | **Von „Recombinant Proteins“ auf „Fc‑Fusionsprotein (Decoy receptor)“ ändern.**        | Interne Poster/Abstracts bezeichnen BI 3821001 explizit als DcR3‑Fc (dimeres Fc‑Fusionsprotein; duale TL1A/LIGHT‑Neutralisation). [2024 Biotherapeutics Symposium\_PosterAbstractBooklet FINAL.pdf](https://boehringer.sharepoint.com/sites/z365biotherapeuticssymposium/Shared%20Documents/Apps/Yammer/2024%20Biotherapeutics%20Symposium_PosterAbstractBooklet%20FINAL.pdf?web=1\&EntityRepresentationId=2ec83246-6010-4755-8eaa-20f1b5b16bd4) [\[2024 Bioth...klet FINAL | PDF\]](https://boehringer.sharepoint.com/sites/z365biotherapeuticssymposium/Shared%20Documents/Apps/Yammer/2024%20Biotherapeutics%20Symposium_PosterAbstractBooklet%20FINAL.pdf?web=1); [HallK.pdf](https://boehringer.sharepoint.com/sites/z365posterday2024/Shared%20Documents/General/Digital%20Posters%20in%20PDF%20Digital%20Posters%20by%20last%20name%20of%20presenter%202025/Hall/HallK.pdf?web=1\&EntityRepresentationId=c890c13a-b5ca-42d6-96ba-efd5df7e2b77) [\[HallK | PDF\]](https://boehringer.sharepoint.com/sites/z365posterday2024/Shared%20Documents/General/Digital%20Posters%20in%20PDF%20Digital%20Posters%20by%20last%20name%20of%20presenter%202025/Hall/HallK.pdf?web=1)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| product\_type             | NONE     | —                                                                                      | —                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| therapeutic\_area         | NONE     | —                                                                                      | —                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| mechanism\_of\_action     | NONE     | —                                                                                      | Duale TL1A/LIGHT‑Neutralisation durch DcR3‑Fc beschrieben. [Inflammation\_Insider\_Edition\_15\_20240319\_3.0.pdf](https://boehringer.sharepoint.com/sites/mybi_tainflammation/SiteAssets/SitePages/Inflammation-Insider%281%29/Inflammation_Insider_Edition_15_20240319_3.0.pdf?web=1\&EntityRepresentationId=48139a3c-be18-4a5d-84be-d4551d134030) [\[Inflammati...240319_3.0 | PDF\]](https://boehringer.sharepoint.com/sites/mybi_tainflammation/SiteAssets/SitePages/Inflammation-Insider(1)/Inflammation_Insider_Edition_15_20240319_3.0.pdf?web=1)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| short\_description        | NONE     | —                                                                                      | —                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| dosage\_form              | NONE     | —                                                                                      | —                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| route\_of\_administration | NONE     | —                                                                                      | —                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| base\_technology          | MINOR    | **„Engineered DcR3‑Fc (reduzierte FasL‑Affinität); dualer TL1A/LIGHT‑Trap“** ergänzen. | Interne Kommunikation beschreibt Engineering (FASL‑Affinität reduziert) und Dual‑Targeting. [Inflammation\_Insider\_Edition\_15.pdf](https://boehringer.sharepoint.com/sites/mybi_tainflammation/Shared%20Documents/Inflammation%20Insiders/Inflammation_Insider_Edition_15.pdf?web=1\&EntityRepresentationId=a952fc0d-9a25-49e6-b24a-188d3500a874) [\[Inflammati...Edition_15 | PDF\]](https://boehringer.sharepoint.com/sites/mybi_tainflammation/Shared%20Documents/Inflammation%20Insiders/Inflammation_Insider_Edition_15.pdf?web=1)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| current\_phase            | MAJOR    | **Auf „Preclinical/SoD (Ende 2024); kein Nachweis für Phase IIb“ ändern.**             | Interne Poster/Abstracts nennen SoD 12/2024 bzw. präklinische Rationale; kein Hinweis auf IIb. [2024-PosterAbstractBooklet.pdf](https://boehringer.sharepoint.com/sites/z365biotherapeuticssymposium/SiteAssets/SitePages/Biotherapeutics-Symposium/2024-PosterAbstractBooklet.pdf?web=1\&EntityRepresentationId=5bd84019-5df4-44e3-b90c-be19010b5f81) [\[2024-Poste...actBooklet | PDF\]](https://boehringer.sharepoint.com/sites/z365biotherapeuticssymposium/SiteAssets/SitePages/2024%20Programm/2024-PosterAbstractBooklet.pdf?web=1); [BioSym24\_Poster34\_JeremyMorgan\_Jeremy Morgan.pdf](https://boehringer.sharepoint.com/sites/z365biotherapeuticssymposium/Shared%20Documents/Apps/Microsoft%20Forms/2024%20Biotherapeutics%20Symposium%20Poster%20Submission%20%28/Please%20upload%20your%20poster%20in%20PDF%20format/BioSym24_Poster34_JeremyMorgan_Jeremy%20Morgan.pdf?web=1\&EntityRepresentationId=088bf37a-1019-4932-8ac7-98f92dad7747) [\[BioSym24_P...emy Morgan | PDF\]](https://boehringer.sharepoint.com/sites/z365biotherapeuticssymposium/Shared%20Documents/Apps/Microsoft%20Forms/2024%20Biotherapeutics%20Symposium%20Poster%20Submission%20(/Please%20upload%20your%20poster%20in%20PDF%20format/BioSym24_Poster34_JeremyMorgan_Jeremy%20Morgan.pdf?web=1); [HallK.pdf](https://boehringer.sharepoint.com/sites/z365posterday2024/Shared%20Documents/General/Digital%20Posters%20in%20PDF%20Digital%20Posters%20by%20last%20name%20of%20presenter%202025/Hall/HallK.pdf?web=1\&EntityRepresentationId=c890c13a-b5ca-42d6-96ba-efd5df7e2b77) [\[HallK | PDF\]](https://boehringer.sharepoint.com/sites/z365posterday2024/Shared%20Documents/General/Digital%20Posters%20in%20PDF%20Digital%20Posters%20by%20last%20name%20of%20presenter%202025/Hall/HallK.pdf?web=1) |

**BI 3814916 — Not yet assigned**

| Feld                      | Änderung | Beschreibung                                                                                                                 | Evidenz                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| ------------------------- | -------- | ---------------------------------------------------------------------------------------------------------------------------- | -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- |
| product\_code             | NONE     | —                                                                                                                            | —                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| product\_name             | NONE     | —                                                                                                                            | —                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| modality\_name            | NONE     | —                                                                                                                            | —                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| product\_type             | NONE     | —                                                                                                                            | —                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| therapeutic\_area         | MAJOR    | Auf **Hepatologie (ACLF)** ändern; interne NBE‑Übersicht führt **BI 3814916** explizit mit Indikation **ACLF** (nicht MASH). | [NBE Portfolio\_Q-uriosity\_Sep25\_Higel.pptx](https://boehringer.sharepoint.com/sites/z365qualityexcellenceprogram/_layouts/15/Doc.aspx?sourcedoc=%7B2D068FB4-0E13-425F-9084-68229917E85A%7D\&file=NBE%20Portfolio_Q-uriosity_Sep25_Higel.pptx\&action=edit\&mobileredirect=true\&DefaultItemOpen=1\&EntityRepresentationId=0e5e1250-06f6-4ad6-9614-47d2aa218869) [\[NBE Portfo...ep25_Higel | PowerPoint\]](https://boehringer.sharepoint.com/sites/z365qualityexcellenceprogram/_layouts/15/Doc.aspx?sourcedoc=%7B2D068FB4-0E13-425F-9084-68229917E85A%7D&file=NBE%20Portfolio_Q-uriosity_Sep25_Higel.pptx&action=edit&mobileredirect=true&DefaultItemOpen=1)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| mechanism\_of\_action     | MINOR    | Präzisieren zu „**anti‑TLR4** monoklonaler Antikörper“ (Formulierung konsistent mit interner Portfolio‑Nennung).             | [NBE Portfolio\_Q-uriosity\_Sep25\_Higel.pptx](https://boehringer.sharepoint.com/sites/z365qualityexcellenceprogram/_layouts/15/Doc.aspx?sourcedoc=%7B2D068FB4-0E13-425F-9084-68229917E85A%7D\&file=NBE%20Portfolio_Q-uriosity_Sep25_Higel.pptx\&action=edit\&mobileredirect=true\&DefaultItemOpen=1\&EntityRepresentationId=0e5e1250-06f6-4ad6-9614-47d2aa218869) [\[NBE Portfo...ep25_Higel | PowerPoint\]](https://boehringer.sharepoint.com/sites/z365qualityexcellenceprogram/_layouts/15/Doc.aspx?sourcedoc=%7B2D068FB4-0E13-425F-9084-68229917E85A%7D&file=NBE%20Portfolio_Q-uriosity_Sep25_Higel.pptx&action=edit&mobileredirect=true&DefaultItemOpen=1)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| short\_description        | MINOR    | Indikationsbezug auf **ACLF** anpassen (nicht MASH).                                                                         | [NBE Portfolio\_Q-uriosity\_Sep25\_Higel.pptx](https://boehringer.sharepoint.com/sites/z365qualityexcellenceprogram/_layouts/15/Doc.aspx?sourcedoc=%7B2D068FB4-0E13-425F-9084-68229917E85A%7D\&file=NBE%20Portfolio_Q-uriosity_Sep25_Higel.pptx\&action=edit\&mobileredirect=true\&DefaultItemOpen=1\&EntityRepresentationId=0e5e1250-06f6-4ad6-9614-47d2aa218869) [\[NBE Portfo...ep25_Higel | PowerPoint\]](https://boehringer.sharepoint.com/sites/z365qualityexcellenceprogram/_layouts/15/Doc.aspx?sourcedoc=%7B2D068FB4-0E13-425F-9084-68229917E85A%7D&file=NBE%20Portfolio_Q-uriosity_Sep25_Higel.pptx&action=edit&mobileredirect=true&DefaultItemOpen=1)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| dosage\_form              | MAJOR    | Auf **Lösung zur Injektion/Infusion, 150 mg/mL (Vial)** ändern.                                                              | [BI-VQD-2500916-JM-3814916-A-final.docx](https://boehringer.sharepoint.com/sites/z365plattformdokumentenreviewadb/_layouts/15/Doc.aspx?sourcedoc=%7B901F3E1A-CD6E-425A-9257-A9F17E322986%7D\&file=BI-VQD-2500916-JM-3814916-A-final.docx\&action=default\&mobileredirect=true\&DefaultItemOpen=1\&EntityRepresentationId=bbc7fc98-a9e3-4f76-ba17-43b94171f611); [BI-VQD-2500922-SPEC final.docx](https://boehringer.sharepoint.com/sites/z365plattformdokumentenreviewadb/Shared%20Documents/General/SPEC%20Kommentierung/BI%203814916/Drug%20Product/BI-VQD-2500922-SPEC%20final.docx?web=1\&EntityRepresentationId=0a1f6c40-97ea-4b75-b416-234c6eb44490) [\[BI-VQD-250...16-A-final | Word\]](https://boehringer.sharepoint.com/sites/z365plattformdokumentenreviewadb/_layouts/15/Doc.aspx?sourcedoc=%7B901F3E1A-CD6E-425A-9257-A9F17E322986%7D&file=BI-VQD-2500916-JM-3814916-A-final.docx&action=default&mobileredirect=true&DefaultItemOpen=1), [\[BI-VQD-250...SPEC final | Word\]](https://boehringer.sharepoint.com/sites/z365plattformdokumentenreviewadb/Shared%20Documents/General/SPEC%20Kommentierung/BI%203814916/Drug%20Product/BI-VQD-2500922-SPEC%20final.docx?web=1) |
| route\_of\_administration | MAJOR    | Auf **parenteral (i.v. oder s.c.)** setzen.                                                                                  | [BI-VQD-2500916-JM-3814916-A-final.docx](https://boehringer.sharepoint.com/sites/z365plattformdokumentenreviewadb/_layouts/15/Doc.aspx?sourcedoc=%7B901F3E1A-CD6E-425A-9257-A9F17E322986%7D\&file=BI-VQD-2500916-JM-3814916-A-final.docx\&action=default\&mobileredirect=true\&DefaultItemOpen=1\&EntityRepresentationId=bbc7fc98-a9e3-4f76-ba17-43b94171f611) [\[BI-VQD-250...16-A-final | Word\]](https://boehringer.sharepoint.com/sites/z365plattformdokumentenreviewadb/_layouts/15/Doc.aspx?sourcedoc=%7B901F3E1A-CD6E-425A-9257-A9F17E322986%7D&file=BI-VQD-2500916-JM-3814916-A-final.docx&action=default&mobileredirect=true&DefaultItemOpen=1)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| base\_technology          | NONE     | —                                                                                                                            | —                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| current\_phase            | MAJOR    | Auf **Phase I** aktualisieren (CMC‑JoS nennt „Clinical phase: phase I“).                                                     | [BI-VQD-2500916-JM-3814916-A-final.docx](https://boehringer.sharepoint.com/sites/z365plattformdokumentenreviewadb/_layouts/15/Doc.aspx?sourcedoc=%7B901F3E1A-CD6E-425A-9257-A9F17E322986%7D\&file=BI-VQD-2500916-JM-3814916-A-final.docx\&action=default\&mobileredirect=true\&DefaultItemOpen=1\&EntityRepresentationId=bbc7fc98-a9e3-4f76-ba17-43b94171f611) [\[BI-VQD-250...16-A-final | Word\]](https://boehringer.sharepoint.com/sites/z365plattformdokumentenreviewadb/_layouts/15/Doc.aspx?sourcedoc=%7B901F3E1A-CD6E-425A-9257-A9F17E322986%7D&file=BI-VQD-2500916-JM-3814916-A-final.docx&action=default&mobileredirect=true&DefaultItemOpen=1)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |

**BI 3819026 — Anti-LAYN antibody**

| Feld                      | Änderung | Beschreibung                                                                                                                    | Evidenz                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| ------------------------- | -------- | ------------------------------------------------------------------------------------------------------------------------------- | ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- |
| product\_code             | NONE     | —                                                                                                                               | —                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| product\_name             | NONE     | —                                                                                                                               | —                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| modality\_name            | NONE     | —                                                                                                                               | —                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| product\_type             | NONE     | —                                                                                                                               | —                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| therapeutic\_area         | NONE     | —                                                                                                                               | —                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| mechanism\_of\_action     | MINOR    | „**IgG1 anti‑LAYN** (CD16a‑Bindung belegt); **Afukosylierung nicht eindeutig dokumentiert** → entspr. Hinweis statt Behauptung. | [BI-VQD-2298039-SPEC.docx](https://boehringer.sharepoint.com/sites/z365plattformdokumentenreviewadb/_layouts/15/Doc.aspx?sourcedoc=%7BE22074BF-1F12-4CD8-88FA-2AD2F1C370DA%7D\&file=BI-VQD-2298039-SPEC.docx\&action=default\&mobileredirect=true\&DefaultItemOpen=1\&EntityRepresentationId=4730c534-4a59-463f-a30d-4fdc7322f70e) (LAYN‑ & **CD16a**‑Bindung in SPR‑Assays) [\[BI-VQD-2298039-SPEC | Word\]](https://boehringer.sharepoint.com/sites/z365plattformdokumentenreviewadb/_layouts/15/Doc.aspx?sourcedoc=%7BE22074BF-1F12-4CD8-88FA-2AD2F1C370DA%7D&file=BI-VQD-2298039-SPEC.docx&action=default&mobileredirect=true&DefaultItemOpen=1)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| short\_description        | MINOR    | Auf „IgG1‑Antikörper gegen LAYN mit gezeigter **CD16a‑Bindung**; Ziel: Treg‑Depletion in soliden Tumoren“ präzisieren.          | [BI-VQD-2298039-SPEC.docx](https://boehringer.sharepoint.com/sites/z365plattformdokumentenreviewadb/_layouts/15/Doc.aspx?sourcedoc=%7BE22074BF-1F12-4CD8-88FA-2AD2F1C370DA%7D\&file=BI-VQD-2298039-SPEC.docx\&action=default\&mobileredirect=true\&DefaultItemOpen=1\&EntityRepresentationId=4730c534-4a59-463f-a30d-4fdc7322f70e) [\[BI-VQD-2298039-SPEC | Word\]](https://boehringer.sharepoint.com/sites/z365plattformdokumentenreviewadb/_layouts/15/Doc.aspx?sourcedoc=%7BE22074BF-1F12-4CD8-88FA-2AD2F1C370DA%7D&file=BI-VQD-2298039-SPEC.docx&action=default&mobileredirect=true&DefaultItemOpen=1)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| dosage\_form              | MAJOR    | Auf **Konzentrat zur Herstellung einer Infusionslösung, 150 mg/mL (2 mL‑Vial)** ändern.                                         | BI 3819026, concentrate for solution for infusion, 150 mg/vial (150 mg/mL); [1](https://boehringer.sharepoint.com/sites/z365submissionrequestsystemv2/Lists/Sub%20Taskand%20Publishing%20List/DispForm.aspx?ID=1217\&web=1\&EntityRepresentationId=376fe3f1-e50b-4e28-a58c-e890d6247fa0) [\[BI 3819026...150 mg/mL) | Extern\]](https://bi-docs-vault-quality.veevavault.com/ui/#doc_info/2511329?itemid=ZJAvxe7vRjdCBYOK2uz9C6GbzQdhxWyYSPYDYIzA9gU), [\[STORM, BI...2012-0001 | Extern\]](https://bi-docs-vault-quality.veevavault.com/ui/#doc_info/2506395?itemid=RgA76KZ5d9j8V88XbnLf03i1rVAZUbphnL8qhYfxo)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| route\_of\_administration | MAJOR    | Auf **intravenöse Infusion** setzen (SC nicht belegt).                                                                          | [1](https://boehringer.sharepoint.com/sites/z365submissionrequestsystemv2/Lists/Sub%20Taskand%20Publishing%20List/DispForm.aspx?ID=1217\&web=1\&EntityRepresentationId=376fe3f1-e50b-4e28-a58c-e890d6247fa0) [\[STORM, BI...2012-0001 | Extern\]](https://bi-docs-vault-quality.veevavault.com/ui/#doc_info/2506395?itemid=RgA76KZ5d9j8V88XbnLf03i1rVAZUbphnL8qhYfxo)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| base\_technology          | NONE     | —                                                                                                                               | —                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| current\_phase            | MAJOR    | Auf **Phase I (FIH)** ändern (ICF „first‑in‑human“; klinische Lieferkette & IND vorhanden).                                     | [bi3819026-2012-p1-icf-safety-23Sep2025.docx](https://boehringer.sharepoint.com/sites/z365icfsafetylaylanguage/_layouts/15/Doc.aspx?sourcedoc=%7B8BDD7BB9-D482-4595-9D4C-7998BE47F02F%7D\&file=bi3819026-2012-p1-icf-safety-23Sep2025.docx\&action=default\&mobileredirect=true\&DefaultItemOpen=1\&EntityRepresentationId=9e0c73e1-176a-4858-834d-ea4748fec3b9); [BI 3819026 IND 177942.pdf](https://boehringer.sharepoint.com/sites/z365ridgefieldenvironmentalhealthandsafetymybi/EHS%20Documents/Environmental/Environmental%20Risk%20Assessments/Product%20Environmental%20Risk%20Assessment/INDs/BI%203819026/BI%203819026%20IND%20177942.pdf?web=1\&EntityRepresentationId=28862e22-124e-4a69-907c-c14d16ab4a6e); BI 3819026 … SPI Version 2.0 [\[bi3819026-...-23Sep2025 | Word\]](https://boehringer.sharepoint.com/sites/z365icfsafetylaylanguage/_layouts/15/Doc.aspx?sourcedoc=%7B8BDD7BB9-D482-4595-9D4C-7998BE47F02F%7D&file=bi3819026-2012-p1-icf-safety-23Sep2025.docx&action=default&mobileredirect=true&DefaultItemOpen=1), [\[BI 3819026...IND 177942 | PDF\]](https://boehringer.sharepoint.com/sites/z365ridgefieldenvironmentalhealthandsafetymybi/EHS%20Documents/Environmental/Environmental%20Risk%20Assessments/Product%20Environmental%20Risk%20Assessment/INDs/BI%203819026/BI%203819026%20IND%20177942.pdf?web=1), [\[BI 3819026...150 mg/mL) | Extern\]](https://bi-docs-vault-quality.veevavault.com/ui/#doc_info/2511329?itemid=ZJAvxe7vRjdCBYOK2uz9C6GbzQdhxWyYSPYDYIzA9gU) |

**BI 3812465**

| Feld                      | Änderung | Beschreibung                                                                                                            | Evidenz                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| ------------------------- | -------- | ----------------------------------------------------------------------------------------------------------------------- | ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- |
| product\_code             | NONE     | —                                                                                                                       | —                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| product\_name             | NONE     | —                                                                                                                       | —                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| modality\_name            | NONE     | —                                                                                                                       | —                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| product\_type             | NONE     | —                                                                                                                       | —                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| therapeutic\_area         | NONE     | —                                                                                                                       | —                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| mechanism\_of\_action     | MINOR    | Begriff auf **FZD4/LRP5‑Modulator (Wnt‑/Norrin‑Mimetikum)** vereinheitlichen.                                           | [NBE Portfolio\_Q-uriosity\_Sep25\_Higel.pptx](https://boehringer.sharepoint.com/sites/z365qualityexcellenceprogram/_layouts/15/Doc.aspx?sourcedoc=%7B2D068FB4-0E13-425F-9084-68229917E85A%7D\&file=NBE%20Portfolio_Q-uriosity_Sep25_Higel.pptx\&action=edit\&mobileredirect=true\&DefaultItemOpen=1\&EntityRepresentationId=0e5e1250-06f6-4ad6-9614-47d2aa218869) [\[BI 3812465...nd solvent | Extern\]](https://bi-docs-vault-quality.veevavault.com/ui/#doc_info/207862?itemid=0scXk2W3TdikEjTj6j3kK5FefkkLJMKFIMAJ8MyI) |
| short\_description        | MINOR    | Kurzbeschreibung auf o.g. Modulator/Mimetikum angleichen.                                                               | [NBE Portfolio\_Q-uriosity\_Sep25\_Higel.pptx](https://boehringer.sharepoint.com/sites/z365qualityexcellenceprogram/_layouts/15/Doc.aspx?sourcedoc=%7B2D068FB4-0E13-425F-9084-68229917E85A%7D\&file=NBE%20Portfolio_Q-uriosity_Sep25_Higel.pptx\&action=edit\&mobileredirect=true\&DefaultItemOpen=1\&EntityRepresentationId=0e5e1250-06f6-4ad6-9614-47d2aa218869) [\[BI 3812465...nd solvent | Extern\]](https://bi-docs-vault-quality.veevavault.com/ui/#doc_info/207862?itemid=0scXk2W3TdikEjTj6j3kK5FefkkLJMKFIMAJ8MyI) |
| dosage\_form              | MAJOR    | Auf **Lösung zur intravitrealen Injektion, 100 mg/mL (Single‑dose Vial) + Solvent‑Vial** ändern.                        | BI‑VQD‑195771‑SPI‑3812465‑A (3.0); [1](https://boehringer.sharepoint.com/sites/z365submissionrequestsystemv2/Lists/Sub%20Taskand%20Publishing%20List/DispForm.aspx?ID=1217\&web=1\&EntityRepresentationId=376fe3f1-e50b-4e28-a58c-e890d6247fa0) [\[STORM, BI...1523-0001 | Extern\]](https://bi-docs-vault-quality.veevavault.com/ui/#doc_info/2316161), [\[PD: Proces...ess (CMC1) | Extern\]](https://bi-docs-vault-quality.veevavault.com/ui/#doc_info/2390820)                                                                                                                                                           |
| route\_of\_administration | NONE     | **Intravitreal** bestätigt.                                                                                             | [1](https://boehringer.sharepoint.com/sites/z365submissionrequestsystemv2/Lists/Sub%20Taskand%20Publishing%20List/DispForm.aspx?ID=1217\&web=1\&EntityRepresentationId=376fe3f1-e50b-4e28-a58c-e890d6247fa0) [\[PD: Proces...ess (CMC1) | Extern\]](https://bi-docs-vault-quality.veevavault.com/ui/#doc_info/2390820)                                                                                                                                                                                                                                                                                                                                      |
| base\_technology          | MAJOR    | **SWAP™** intern nicht belegt → auf „**CHO‑exprimiertes rekombinantes bispezifisches Protein (Wnt‑Mimetikum)**“ ändern. | [1](https://boehringer.sharepoint.com/sites/z365submissionrequestsystemv2/Lists/Sub%20Taskand%20Publishing%20List/DispForm.aspx?ID=1217\&web=1\&EntityRepresentationId=376fe3f1-e50b-4e28-a58c-e890d6247fa0); CSB Upstream Handover & Campaign Report [\[BI 3812465...Year 2024 | Extern\]](https://bi-docs-vault-quality.veevavault.com/ui/#doc_info/256733?itemid=a8VHYHohsGDdoc8t84i8EIVLhASVz2YH0FjwOJA6Xk), [\[BI 3812465...Preharvest | Extern\]](https://bi-docs-vault-quality.veevavault.com/ui/#doc_info/2327297?itemid=7m4QhFHxQABgKmshgNxA7B64zwKgjHWHHr40lBq8)                                                                                                                                                   |
| current\_phase            | MAJOR    | Auf **Phase I** ändern (klinische Kits/SPI & Pre‑Harvest/CoA vorhanden).                                                | BI‑VQD‑195771‑SPI‑3812465‑A (3.0); BI 3812465, Preharvest [\[STORM, BI...1523-0001 | Extern\]](https://bi-docs-vault-quality.veevavault.com/ui/#doc_info/2316161), [\[VISION pro...ion to OPS | PowerPoint\]](https://boehringer-my.sharepoint.com/personal/stefan_krahulec_boehringer-ingelheim_com/Documents/Desktop/Ablage/pr%c3%a4sentationen/VISION%20projection%20to%20OPS.pptx?web=1)                                                                                                                                                                                                                                                                                                 |

**BI 3798489 — BI 3798489**

| Feld                      | Änderung | Beschreibung                                                                                  | Evidenz                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| ------------------------- | -------- | --------------------------------------------------------------------------------------------- | ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ |
| product\_code             | NONE     | —                                                                                             | —                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| product\_name             | NONE     | —                                                                                             | —                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| modality\_name            | NONE     | —                                                                                             | —                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| product\_type             | NONE     | —                                                                                             | —                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| therapeutic\_area         | NONE     | —                                                                                             | —                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| mechanism\_of\_action     | MINOR    | „außerhalb der BBB“ entfernen (nicht belegt); auf **NMUR2‑Agonist für Adipositas** verkürzen. | [VISION projection to OPS.pptx](https://boehringer-my.sharepoint.com/personal/oliver_gluth_boehringer-ingelheim_com/_layouts/15/Doc.aspx?sourcedoc=%7BEF7C7213-ACF0-47A5-85CA-6707578BD0EB%7D\&file=VISION%20projection%20to%20OPS.pptx\&action=edit\&mobileredirect=true\&DefaultItemOpen=1\&EntityRepresentationId=ad0ff778-6308-4f6e-9a12-6d4a1502277d) (Listet **NMUR2 agonist BU (BI 3798489)**) [\[CoA_BI 379...ot-P200954 | Extern\]](https://bi-docs-vault-quality.veevavault.com/ui/#doc_info/2472037) |
| short\_description        | MINOR    | Entsprechend auf **NMUR2‑Agonist‑Peptid für Adipositas** vereinfachen.                        | [VISION projection to OPS.pptx](https://boehringer-my.sharepoint.com/personal/oliver_gluth_boehringer-ingelheim_com/_layouts/15/Doc.aspx?sourcedoc=%7BEF7C7213-ACF0-47A5-85CA-6707578BD0EB%7D\&file=VISION%20projection%20to%20OPS.pptx\&action=edit\&mobileredirect=true\&DefaultItemOpen=1\&EntityRepresentationId=ad0ff778-6308-4f6e-9a12-6d4a1502277d) [\[CoA_BI 379...ot-P200954 | Extern\]](https://bi-docs-vault-quality.veevavault.com/ui/#doc_info/2472037)                                            |
| dosage\_form              | NONE     | —                                                                                             | —                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| route\_of\_administration | NONE     | —                                                                                             | —                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| base\_technology          | NONE     | —                                                                                             | —                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| current\_phase            | NONE     | **Präklinisch** bleibt (nur nicht‑klinische/GLP‑Materialien identifiziert).                   | CoA\_BI 3798489 NA … [\[Justificat...BI 3797479 | Extern\]](https://bi-docs-vault-quality.veevavault.com/ui/#doc_info/2529304?itemid=Z7ZBHev6jjHd52ExZZpLtzNj1ihfvF7zwhx5siH48)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |

**BI 3797479**

| Feld                      | Änderung | Beschreibung                                                                                                            | Evidenz                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| ------------------------- | -------- | ----------------------------------------------------------------------------------------------------------------------- | --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- |
| product\_code             | NONE     | —                                                                                                                       | —                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| product\_name             | NONE     | —                                                                                                                       | —                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| modality\_name            | NONE     | —                                                                                                                       | —                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| product\_type             | NONE     | —                                                                                                                       | —                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| therapeutic\_area         | NONE     | —                                                                                                                       | —                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| mechanism\_of\_action     | NONE     | —                                                                                                                       | —                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| short\_description        | NONE     | —                                                                                                                       | —                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| dosage\_form              | NONE     | **Tablette/solide Darreichungsform** bleibt plausibel (Reinigungsvalidierung für „manufacturing area solid“ vorhanden). | BI‑VQD‑2498886‑JM‑R (Justification of Specifications – cleaning, solids) [\[2025_03 BR...line Folie | PowerPoint\]](https://boehringer-my.sharepoint.com/personal/oliver_gluth_boehringer-ingelheim_com/Documents/BI%20-%20Work/01_PROJECTS/2025_iManagement-private/02%20Pipeline/2025_03%20BRM%20Pipeline%20Folie.pptx?web=1)                                                                                                                                                                                                                                                                                                                                                                                |
| route\_of\_administration | NONE     | —                                                                                                                       | —                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| base\_technology          | NONE     | —                                                                                                                       | —                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| current\_phase            | NONE     | **Präklinisch/Frühe Entwicklung** bleibt (keine klinischen Dokumente identifiziert).                                    | [2025\_03 BRM Pipeline Folie.pptx](https://boehringer-my.sharepoint.com/personal/oliver_gluth_boehringer-ingelheim_com/_layouts/15/Doc.aspx?sourcedoc=%7B762B7FA9-FBB1-4D91-A1D2-A467EC915984%7D\&file=2025_03%20BRM%20Pipeline%20Folie.pptx\&action=edit\&mobileredirect=true\&DefaultItemOpen=1\&EntityRepresentationId=3cd628ee-3efd-440f-ad43-815ee4188d47) |

**BI 3820768**

| Feld                      | Änderung | Beschreibung                                                                                                                | Evidenz                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| ------------------------- | -------- | --------------------------------------------------------------------------------------------------------------------------- | ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- |
| product\_code             | NONE     | Unverändert.                                                                                                                | [BI-VQD-2475587-RAT\_25JUN2025.docx](https://boehringer.sharepoint.com/sites/z365plattformdokumentenreviewadb/_layouts/15/Doc.aspx?sourcedoc=%7B268A86B8-51C5-4567-9E70-BF9B80C67EE7%7D\&file=BI-VQD-2475587-RAT_25JUN2025.docx\&action=default\&mobileredirect=true\&DefaultItemOpen=1\&EntityRepresentationId=d3cdd31f-016c-46bc-a023-0b7c790621f2) (bezeichnet „BI 3820768“ im MoA‑Kontext). [\[BI-VQD-247..._25JUN2025 | Word\]](https://boehringer.sharepoint.com/sites/z365plattformdokumentenreviewadb/_layouts/15/Doc.aspx?sourcedoc=%7B268A86B8-51C5-4567-9E70-BF9B80C67EE7%7D&file=BI-VQD-2475587-RAT_25JUN2025.docx&action=default&mobileredirect=true&DefaultItemOpen=1)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| product\_name             | NONE     | Kein belastbarer öffentlicher Produktname gefunden; belassen.                                                               | Keine abweichende Nennung in [2025\_02\_Development CMC Biologicals Townhall Meeting.pptx](https://boehringer.sharepoint.com/sites/devbiologicals/_layouts/15/Doc.aspx?sourcedoc=%7B3172840F-62B9-43EE-8448-B2883C076529%7D\&file=2025_02_Development%20CMC%20Biologicals%20Townhall%20Meeting.pptx\&action=edit\&mobileredirect=true\&DefaultItemOpen=1\&EntityRepresentationId=188c5342-b0f9-46eb-a5ff-339da222dd37). [\[2025_02_De...ll Meeting | PowerPoint\]](https://boehringer.sharepoint.com/sites/devbiologicals/_layouts/15/Doc.aspx?sourcedoc=%7B3172840F-62B9-43EE-8448-B2883C076529%7D&file=2025_02_Development%20CMC%20Biologicals%20Townhall%20Meeting.pptx&action=edit&mobileredirect=true&DefaultItemOpen=1)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| modality\_name            | NONE     | „T‑cell Engager“ korrekt (2+1‑Format, ALPG/CD3).                                                                            | [BI-VQD-2475587-RAT\_25JUN2025.docx](https://boehringer.sharepoint.com/sites/z365plattformdokumentenreviewadb/_layouts/15/Doc.aspx?sourcedoc=%7B268A86B8-51C5-4567-9E70-BF9B80C67EE7%7D\&file=BI-VQD-2475587-RAT_25JUN2025.docx\&action=default\&mobileredirect=true\&DefaultItemOpen=1\&EntityRepresentationId=d3cdd31f-016c-46bc-a023-0b7c790621f2). [\[BI-VQD-247..._25JUN2025 | Word\]](https://boehringer.sharepoint.com/sites/z365plattformdokumentenreviewadb/_layouts/15/Doc.aspx?sourcedoc=%7B268A86B8-51C5-4567-9E70-BF9B80C67EE7%7D&file=BI-VQD-2475587-RAT_25JUN2025.docx&action=default&mobileredirect=true&DefaultItemOpen=1)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| product\_type             | NONE     | „NBE“ passend.                                                                                                              | Design-/CMC‑Beschreibung ohne Hinweise auf zugelassenes Analogon. [BI-VQD-2475587-RAT\_25JUN2025.docx](https://boehringer.sharepoint.com/sites/z365plattformdokumentenreviewadb/_layouts/15/Doc.aspx?sourcedoc=%7B268A86B8-51C5-4567-9E70-BF9B80C67EE7%7D\&file=BI-VQD-2475587-RAT_25JUN2025.docx\&action=default\&mobileredirect=true\&DefaultItemOpen=1\&EntityRepresentationId=d3cdd31f-016c-46bc-a023-0b7c790621f2). [\[BI-VQD-247..._25JUN2025 | Word\]](https://boehringer.sharepoint.com/sites/z365plattformdokumentenreviewadb/_layouts/15/Doc.aspx?sourcedoc=%7B268A86B8-51C5-4567-9E70-BF9B80C67EE7%7D&file=BI-VQD-2475587-RAT_25JUN2025.docx&action=default&mobileredirect=true&DefaultItemOpen=1)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| therapeutic\_area         | NONE     | „Oncology (Solid Tumors)“ bestätigt (u. a. endometrial/pankreatisch diskutiert).                                            | [2025\_02\_Development CMC Biologicals Townhall Meeting.pptx](https://boehringer.sharepoint.com/sites/devbiologicals/_layouts/15/Doc.aspx?sourcedoc=%7B3172840F-62B9-43EE-8448-B2883C076529%7D\&file=2025_02_Development%20CMC%20Biologicals%20Townhall%20Meeting.pptx\&action=edit\&mobileredirect=true\&DefaultItemOpen=1\&EntityRepresentationId=188c5342-b0f9-46eb-a5ff-339da222dd37). [\[2025_02_De...ll Meeting | PowerPoint\]](https://boehringer.sharepoint.com/sites/devbiologicals/_layouts/15/Doc.aspx?sourcedoc=%7B3172840F-62B9-43EE-8448-B2883C076529%7D&file=2025_02_Development%20CMC%20Biologicals%20Townhall%20Meeting.pptx&action=edit&mobileredirect=true&DefaultItemOpen=1)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| mechanism\_of\_action     | NONE     | Bispezifischer Antikörper (2 × ALPG, 1 × CD3) – korrekt.                                                                    | [BI-VQD-2475587-RAT\_25JUN2025.docx](https://boehringer.sharepoint.com/sites/z365plattformdokumentenreviewadb/_layouts/15/Doc.aspx?sourcedoc=%7B268A86B8-51C5-4567-9E70-BF9B80C67EE7%7D\&file=BI-VQD-2475587-RAT_25JUN2025.docx\&action=default\&mobileredirect=true\&DefaultItemOpen=1\&EntityRepresentationId=d3cdd31f-016c-46bc-a023-0b7c790621f2). [\[BI-VQD-247..._25JUN2025 | Word\]](https://boehringer.sharepoint.com/sites/z365plattformdokumentenreviewadb/_layouts/15/Doc.aspx?sourcedoc=%7B268A86B8-51C5-4567-9E70-BF9B80C67EE7%7D&file=BI-VQD-2475587-RAT_25JUN2025.docx&action=default&mobileredirect=true&DefaultItemOpen=1)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| short\_description        | NONE     | Kurzbeschreibung konsistent mit internem MoA.                                                                               | [BI-VQD-2475587-RAT\_25JUN2025.docx](https://boehringer.sharepoint.com/sites/z365plattformdokumentenreviewadb/_layouts/15/Doc.aspx?sourcedoc=%7B268A86B8-51C5-4567-9E70-BF9B80C67EE7%7D\&file=BI-VQD-2475587-RAT_25JUN2025.docx\&action=default\&mobileredirect=true\&DefaultItemOpen=1\&EntityRepresentationId=d3cdd31f-016c-46bc-a023-0b7c790621f2). [\[BI-VQD-247..._25JUN2025 | Word\]](https://boehringer.sharepoint.com/sites/z365plattformdokumentenreviewadb/_layouts/15/Doc.aspx?sourcedoc=%7B268A86B8-51C5-4567-9E70-BF9B80C67EE7%7D&file=BI-VQD-2475587-RAT_25JUN2025.docx&action=default&mobileredirect=true&DefaultItemOpen=1)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| dosage\_form              | MAJOR    | Zielwert: **„Injectable (IV infusion); Formulierung nicht offengelegt“** – keine Evidenz für „lyophilized powder“ gefunden. | CMC‑/Format‑Dokumente nennen keine Darreichungsform. [BI-VQD-2475587-RAT\_25JUN2025.docx](https://boehringer.sharepoint.com/sites/z365plattformdokumentenreviewadb/_layouts/15/Doc.aspx?sourcedoc=%7B268A86B8-51C5-4567-9E70-BF9B80C67EE7%7D\&file=BI-VQD-2475587-RAT_25JUN2025.docx\&action=default\&mobileredirect=true\&DefaultItemOpen=1\&EntityRepresentationId=d3cdd31f-016c-46bc-a023-0b7c790621f2); [2025\_02\_Development CMC Biologicals Townhall Meeting.pptx](https://boehringer.sharepoint.com/sites/devbiologicals/_layouts/15/Doc.aspx?sourcedoc=%7B3172840F-62B9-43EE-8448-B2883C076529%7D\&file=2025_02_Development%20CMC%20Biologicals%20Townhall%20Meeting.pptx\&action=edit\&mobileredirect=true\&DefaultItemOpen=1\&EntityRepresentationId=188c5342-b0f9-46eb-a5ff-339da222dd37). [\[BI-VQD-247..._25JUN2025 | Word\]](https://boehringer.sharepoint.com/sites/z365plattformdokumentenreviewadb/_layouts/15/Doc.aspx?sourcedoc=%7B268A86B8-51C5-4567-9E70-BF9B80C67EE7%7D&file=BI-VQD-2475587-RAT_25JUN2025.docx&action=default&mobileredirect=true&DefaultItemOpen=1), [\[2025_02_De...ll Meeting | PowerPoint\]](https://boehringer.sharepoint.com/sites/devbiologicals/_layouts/15/Doc.aspx?sourcedoc=%7B3172840F-62B9-43EE-8448-B2883C076529%7D&file=2025_02_Development%20CMC%20Biologicals%20Townhall%20Meeting.pptx&action=edit&mobileredirect=true&DefaultItemOpen=1) |
| route\_of\_administration | MINOR    | Zielwert: **„Intravenous (to be confirmed)“** – RoA wahrscheinlich IV, jedoch intern nicht explizit belegt.                 | Keine explizite RoA‑Angabe in zugänglichen Unterlagen. [BI-VQD-2475587-RAT\_25JUN2025.docx](https://boehringer.sharepoint.com/sites/z365plattformdokumentenreviewadb/_layouts/15/Doc.aspx?sourcedoc=%7B268A86B8-51C5-4567-9E70-BF9B80C67EE7%7D\&file=BI-VQD-2475587-RAT_25JUN2025.docx\&action=default\&mobileredirect=true\&DefaultItemOpen=1\&EntityRepresentationId=d3cdd31f-016c-46bc-a023-0b7c790621f2). [\[BI-VQD-247..._25JUN2025 | Word\]](https://boehringer.sharepoint.com/sites/z365plattformdokumentenreviewadb/_layouts/15/Doc.aspx?sourcedoc=%7B268A86B8-51C5-4567-9E70-BF9B80C67EE7%7D&file=BI-VQD-2475587-RAT_25JUN2025.docx&action=default&mobileredirect=true&DefaultItemOpen=1)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| base\_technology          | MINOR    | Zielwert: **„Bispecific IgG‑like antibody (2+1, Fc knob‑into‑hole)“** – Ergänzung.                                          | Formatbeschreibung inkl. Knob‑Hole‑Fc. [BI-VQD-2475587-RAT\_25JUN2025.docx](https://boehringer.sharepoint.com/sites/z365plattformdokumentenreviewadb/_layouts/15/Doc.aspx?sourcedoc=%7B268A86B8-51C5-4567-9E70-BF9B80C67EE7%7D\&file=BI-VQD-2475587-RAT_25JUN2025.docx\&action=default\&mobileredirect=true\&DefaultItemOpen=1\&EntityRepresentationId=d3cdd31f-016c-46bc-a023-0b7c790621f2). [\[BI-VQD-247..._25JUN2025 | Word\]](https://boehringer.sharepoint.com/sites/z365plattformdokumentenreviewadb/_layouts/15/Doc.aspx?sourcedoc=%7B268A86B8-51C5-4567-9E70-BF9B80C67EE7%7D&file=BI-VQD-2475587-RAT_25JUN2025.docx&action=default&mobileredirect=true&DefaultItemOpen=1)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| current\_phase            | NONE     | „Preclinical“ plausibel; keine klinischen Aktivitäten gefunden.                                                             | Interne Präsentation beschreibt Entwicklungsformat ohne klinische Daten. [2025\_02\_Development CMC Biologicals Townhall Meeting.pptx](https://boehringer.sharepoint.com/sites/devbiologicals/_layouts/15/Doc.aspx?sourcedoc=%7B3172840F-62B9-43EE-8448-B2883C076529%7D\&file=2025_02_Development%20CMC%20Biologicals%20Townhall%20Meeting.pptx\&action=edit\&mobileredirect=true\&DefaultItemOpen=1\&EntityRepresentationId=188c5342-b0f9-46eb-a5ff-339da222dd37). [\[2025_02_De...ll Meeting | PowerPoint\]](https://boehringer.sharepoint.com/sites/devbiologicals/_layouts/15/Doc.aspx?sourcedoc=%7B3172840F-62B9-43EE-8448-B2883C076529%7D&file=2025_02_Development%20CMC%20Biologicals%20Townhall%20Meeting.pptx&action=edit&mobileredirect=true&DefaultItemOpen=1)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |

**BI 4018711 — CT‑156 (working title)**

| Feld                      | Änderung | Beschreibung                                                                              | Evidenz                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| ------------------------- | -------- | ----------------------------------------------------------------------------------------- | ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- |
| product\_code             | NONE     | Unverändert.                                                                              | [Potential Launches 2025\_05\_05.pptx](https://boehringer-my.sharepoint.com/personal/oliver_gluth_boehringer-ingelheim_com/_layouts/15/Doc.aspx?sourcedoc=%7BD49B5E99-63D9-46D1-8855-BCE1CBDD3CCC%7D\&file=Potential%20Launches%202025_05_05.pptx\&action=edit\&mobileredirect=true\&DefaultItemOpen=1\&EntityRepresentationId=b4b80e61-55cc-4950-a10b-65c5ea384813) (Zuordnung BI 4018711 ↔ CT‑156). [\[Potential...2025_05_05 | PowerPoint\]](https://boehringer-my.sharepoint.com/personal/oliver_gluth_boehringer-ingelheim_com/_layouts/15/Doc.aspx?sourcedoc=%7BD49B5E99-63D9-46D1-8855-BCE1CBDD3CCC%7D&file=Potential%20Launches%202025_05_05.pptx&action=edit&mobileredirect=true&DefaultItemOpen=1)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| product\_name             | NONE     | „CT‑156 (working title)“ korrekt.                                                         | [Potential Launches 2025\_05\_05.pptx](https://boehringer-my.sharepoint.com/personal/oliver_gluth_boehringer-ingelheim_com/_layouts/15/Doc.aspx?sourcedoc=%7BD49B5E99-63D9-46D1-8855-BCE1CBDD3CCC%7D\&file=Potential%20Launches%202025_05_05.pptx\&action=edit\&mobileredirect=true\&DefaultItemOpen=1\&EntityRepresentationId=b4b80e61-55cc-4950-a10b-65c5ea384813). [\[Potential...2025_05_05 | PowerPoint\]](https://boehringer-my.sharepoint.com/personal/oliver_gluth_boehringer-ingelheim_com/_layouts/15/Doc.aspx?sourcedoc=%7BD49B5E99-63D9-46D1-8855-BCE1CBDD3CCC%7D&file=Potential%20Launches%202025_05_05.pptx&action=edit&mobileredirect=true&DefaultItemOpen=1)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| modality\_name            | NONE     | „Prescription Digital Therapeutic (SaMD/PDT)“ korrekt.                                    | [Pipeline-slide-Jan-2025.pptx](https://boehringer.sharepoint.com/sites/mybi_tacns/_layouts/15/Doc.aspx?sourcedoc=%7BAD388315-2399-457E-B565-E12A95CE7F0E%7D\&file=Pipeline-slide-Jan-2025.pptx\&action=edit\&mobileredirect=true\&DefaultItemOpen=1\&EntityRepresentationId=140449c4-dfd3-4082-83a4-185741bc2078). [\[Pipeline-s...e-Jan-2025 | PowerPoint\]](https://boehringer.sharepoint.com/sites/mybi_tacns/_layouts/15/Doc.aspx?sourcedoc=%7BAD388315-2399-457E-B565-E12A95CE7F0E%7D&file=Pipeline-slide-Jan-2025.pptx&action=edit&mobileredirect=true&DefaultItemOpen=1)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| product\_type             | NONE     | „DTx (SaMD)“ korrekt.                                                                     | [Pipeline-slide-Jan-2025.pptx](https://boehringer.sharepoint.com/sites/mybi_tacns/_layouts/15/Doc.aspx?sourcedoc=%7BAD388315-2399-457E-B565-E12A95CE7F0E%7D\&file=Pipeline-slide-Jan-2025.pptx\&action=edit\&mobileredirect=true\&DefaultItemOpen=1\&EntityRepresentationId=140449c4-dfd3-4082-83a4-185741bc2078). [\[Pipeline-s...e-Jan-2025 | PowerPoint\]](https://boehringer.sharepoint.com/sites/mybi_tacns/_layouts/15/Doc.aspx?sourcedoc=%7BAD388315-2399-457E-B565-E12A95CE7F0E%7D&file=Pipeline-slide-Jan-2025.pptx&action=edit&mobileredirect=true&DefaultItemOpen=1)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| therapeutic\_area         | NONE     | Schizophrenie (TA CREA) korrekt.                                                          | [Pipeline-slide-Jan-2025.pptx](https://boehringer.sharepoint.com/sites/mybi_tacns/_layouts/15/Doc.aspx?sourcedoc=%7BAD388315-2399-457E-B565-E12A95CE7F0E%7D\&file=Pipeline-slide-Jan-2025.pptx\&action=edit\&mobileredirect=true\&DefaultItemOpen=1\&EntityRepresentationId=140449c4-dfd3-4082-83a4-185741bc2078). [\[Pipeline-s...e-Jan-2025 | PowerPoint\]](https://boehringer.sharepoint.com/sites/mybi_tacns/_layouts/15/Doc.aspx?sourcedoc=%7BAD388315-2399-457E-B565-E12A95CE7F0E%7D&file=Pipeline-slide-Jan-2025.pptx&action=edit&mobileredirect=true&DefaultItemOpen=1)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| mechanism\_of\_action     | NONE     | Software‑basierte verhaltensorientierte Interventionen – konsistent.                      | [SFS\_Ingelheim.pptx](https://boehringer.sharepoint.com/sites/z365bihivecoreteam/_layouts/15/Doc.aspx?sourcedoc=%7B9424B3AA-FDB8-470D-8E6A-7696FF7FB564%7D\&file=SFS_Ingelheim.pptx\&action=edit\&mobileredirect=true\&DefaultItemOpen=1\&EntityRepresentationId=a4135366-aa1b-4b0b-85f3-f5000723fb4d) (PDT‑Typ), [Schizophrenia indication strategy draft v4.0.pptx](https://boehringer.sharepoint.com/sites/z365virtualcampussharepoint/_layouts/15/Doc.aspx?sourcedoc=%7BF9D23452-0BA1-41EA-9573-9386CC038E44%7D\&file=Schizophrenia%20indication%20strategy%20draft%20v4.0.pptx\&action=edit\&mobileredirect=true\&DefaultItemOpen=1\&EntityRepresentationId=1540b8cb-f675-4cfc-96b1-486785485211). [\[SFS_Ingelheim | PowerPoint\]](https://boehringer.sharepoint.com/sites/z365bihivecoreteam/_layouts/15/Doc.aspx?sourcedoc=%7B9424B3AA-FDB8-470D-8E6A-7696FF7FB564%7D&file=SFS_Ingelheim.pptx&action=edit&mobileredirect=true&DefaultItemOpen=1), [\[Schizophre...draft v4.0 | PowerPoint\]](https://boehringer.sharepoint.com/sites/z365virtualcampussharepoint/_layouts/15/Doc.aspx?sourcedoc=%7BF9D23452-0BA1-41EA-9573-9386CC038E44%7D&file=Schizophrenia%20indication%20strategy%20draft%20v4.0.pptx&action=edit&mobileredirect=true&DefaultItemOpen=1) |
| short\_description        | NONE     | Konsistent mit oben.                                                                      | [SFS\_Ingelheim.pptx](https://boehringer.sharepoint.com/sites/z365bihivecoreteam/_layouts/15/Doc.aspx?sourcedoc=%7B9424B3AA-FDB8-470D-8E6A-7696FF7FB564%7D\&file=SFS_Ingelheim.pptx\&action=edit\&mobileredirect=true\&DefaultItemOpen=1\&EntityRepresentationId=a4135366-aa1b-4b0b-85f3-f5000723fb4d). [\[SFS_Ingelheim | PowerPoint\]](https://boehringer.sharepoint.com/sites/z365bihivecoreteam/_layouts/15/Doc.aspx?sourcedoc=%7B9424B3AA-FDB8-470D-8E6A-7696FF7FB564%7D&file=SFS_Ingelheim.pptx&action=edit&mobileredirect=true&DefaultItemOpen=1)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| dosage\_form              | NONE     | „Software application (mobile/connected)“ korrekt.                                        | [SFS\_Ingelheim.pptx](https://boehringer.sharepoint.com/sites/z365bihivecoreteam/_layouts/15/Doc.aspx?sourcedoc=%7B9424B3AA-FDB8-470D-8E6A-7696FF7FB564%7D\&file=SFS_Ingelheim.pptx\&action=edit\&mobileredirect=true\&DefaultItemOpen=1\&EntityRepresentationId=a4135366-aa1b-4b0b-85f3-f5000723fb4d). [\[SFS_Ingelheim | PowerPoint\]](https://boehringer.sharepoint.com/sites/z365bihivecoreteam/_layouts/15/Doc.aspx?sourcedoc=%7B9424B3AA-FDB8-470D-8E6A-7696FF7FB564%7D&file=SFS_Ingelheim.pptx&action=edit&mobileredirect=true&DefaultItemOpen=1)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| route\_of\_administration | NONE     | „Digital (software‑delivered)“ korrekt.                                                   | [SFS\_Ingelheim.pptx](https://boehringer.sharepoint.com/sites/z365bihivecoreteam/_layouts/15/Doc.aspx?sourcedoc=%7B9424B3AA-FDB8-470D-8E6A-7696FF7FB564%7D\&file=SFS_Ingelheim.pptx\&action=edit\&mobileredirect=true\&DefaultItemOpen=1\&EntityRepresentationId=a4135366-aa1b-4b0b-85f3-f5000723fb4d). [\[SFS_Ingelheim | PowerPoint\]](https://boehringer.sharepoint.com/sites/z365bihivecoreteam/_layouts/15/Doc.aspx?sourcedoc=%7B9424B3AA-FDB8-470D-8E6A-7696FF7FB564%7D&file=SFS_Ingelheim.pptx&action=edit&mobileredirect=true&DefaultItemOpen=1)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| base\_technology          | MINOR    | Zielwert: **„SaMD (mobile smartphone application)“** – präzisiert.                        | [Pipeline-slide-Jan-2025.pptx](https://boehringer.sharepoint.com/sites/mybi_tacns/_layouts/15/Doc.aspx?sourcedoc=%7BAD388315-2399-457E-B565-E12A95CE7F0E%7D\&file=Pipeline-slide-Jan-2025.pptx\&action=edit\&mobileredirect=true\&DefaultItemOpen=1\&EntityRepresentationId=140449c4-dfd3-4082-83a4-185741bc2078); [SFS\_Ingelheim.pptx](https://boehringer.sharepoint.com/sites/z365bihivecoreteam/_layouts/15/Doc.aspx?sourcedoc=%7B9424B3AA-FDB8-470D-8E6A-7696FF7FB564%7D\&file=SFS_Ingelheim.pptx\&action=edit\&mobileredirect=true\&DefaultItemOpen=1\&EntityRepresentationId=a4135366-aa1b-4b0b-85f3-f5000723fb4d). [\[Pipeline-s...e-Jan-2025 | PowerPoint\]](https://boehringer.sharepoint.com/sites/mybi_tacns/_layouts/15/Doc.aspx?sourcedoc=%7BAD388315-2399-457E-B565-E12A95CE7F0E%7D&file=Pipeline-slide-Jan-2025.pptx&action=edit&mobileredirect=true&DefaultItemOpen=1), [\[SFS_Ingelheim | PowerPoint\]](https://boehringer.sharepoint.com/sites/z365bihivecoreteam/_layouts/15/Doc.aspx?sourcedoc=%7B9424B3AA-FDB8-470D-8E6A-7696FF7FB564%7D&file=SFS_Ingelheim.pptx&action=edit&mobileredirect=true&DefaultItemOpen=1)                                                                                                                            |
| current\_phase            | MAJOR    | Zielwert: **„Phase II“** – interne Pipeline weist CT‑156 in Phase II aus (nicht Phase I). | [Pipeline-slide-Jan-2025.pptx](https://boehringer.sharepoint.com/sites/mybi_tacns/_layouts/15/Doc.aspx?sourcedoc=%7BAD388315-2399-457E-B565-E12A95CE7F0E%7D\&file=Pipeline-slide-Jan-2025.pptx\&action=edit\&mobileredirect=true\&DefaultItemOpen=1\&EntityRepresentationId=140449c4-dfd3-4082-83a4-185741bc2078). [\[Pipeline-s...e-Jan-2025 | PowerPoint\]](https://boehringer.sharepoint.com/sites/mybi_tacns/_layouts/15/Doc.aspx?sourcedoc=%7BAD388315-2399-457E-B565-E12A95CE7F0E%7D&file=Pipeline-slide-Jan-2025.pptx&action=edit&mobileredirect=true&DefaultItemOpen=1)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |

**BI 3972080 — CT‑155**

| Feld                      | Änderung | Beschreibung                                                                                                                     | Evidenz                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| ------------------------- | -------- | -------------------------------------------------------------------------------------------------------------------------------- | ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- |
| product\_code             | NONE     | Unverändert.                                                                                                                     | [Press-Release--.aspx](https://boehringer.sharepoint.com/sites/mybi_news_usa/SitePages/Press-Release--.aspx?web=1\&EntityRepresentationId=4b1dd9f5-2b23-444d-a96a-5b0e61335f34) (CT‑155 (BI 3972080) benannt). [\[Press Rele...enia study | SharePoint\]](https://boehringer.sharepoint.com/sites/mybi_news_usa/SitePages/Press-Release--.aspx?web=1)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| product\_name             | NONE     | „CT‑155“ korrekt.                                                                                                                | [Press-Release---Boehringer-and-Click-Therapeutics-present-pivotal-data-for-investigational-prescription.aspx](https://boehringer.sharepoint.com/sites/mybi_news_usa/SitePages/Press-Release---Boehringer-and-Click-Therapeutics-present-pivotal-data-for-investigational-prescription.aspx?web=1\&EntityRepresentationId=544c72c0-785c-4dfb-bc7b-fa7eb568f645). [\[Boehringer...escription | SharePoint\]](https://boehringer.sharepoint.com/sites/mybi_news_usa/SitePages/Press-Release---Boehringer-and-Click-Therapeutics-present-pivotal-data-for-investigational-prescription.aspx?web=1)                                                                                                                                                                                                                                                                                                   |
| modality\_name            | NONE     | „Prescription Digital Therapeutic (SaMD/PDT)“ korrekt.                                                                           | [12. CT-155 overview.pptx](https://boehringer.sharepoint.com/sites/mybi_tacns/_layouts/15/Doc.aspx?sourcedoc=%7B721D56DC-5E0D-4954-924A-B1C80A7E0073%7D\&file=12.%20CT-155%20overview.pptx\&action=edit\&mobileredirect=true\&DefaultItemOpen=1\&EntityRepresentationId=c5437584-577f-4e9a-8524-3005ca39917d). [\[12. CT-155 overview | PowerPoint\]](https://boehringer.sharepoint.com/sites/mybi_tacns/_layouts/15/Doc.aspx?sourcedoc=%7B721D56DC-5E0D-4954-924A-B1C80A7E0073%7D&file=12.%20CT-155%20overview.pptx&action=edit&mobileredirect=true&DefaultItemOpen=1)                                                                                                                                                                                                                                                                                                                       |
| product\_type             | NONE     | „DTx“ korrekt.                                                                                                                   | [12. CT-155 overview.pptx](https://boehringer.sharepoint.com/sites/mybi_tacns/_layouts/15/Doc.aspx?sourcedoc=%7B721D56DC-5E0D-4954-924A-B1C80A7E0073%7D\&file=12.%20CT-155%20overview.pptx\&action=edit\&mobileredirect=true\&DefaultItemOpen=1\&EntityRepresentationId=c5437584-577f-4e9a-8524-3005ca39917d). [\[12. CT-155 overview | PowerPoint\]](https://boehringer.sharepoint.com/sites/mybi_tacns/_layouts/15/Doc.aspx?sourcedoc=%7B721D56DC-5E0D-4954-924A-B1C80A7E0073%7D&file=12.%20CT-155%20overview.pptx&action=edit&mobileredirect=true&DefaultItemOpen=1)                                                                                                                                                                                                                                                                                                                       |
| therapeutic\_area         | NONE     | „Mental Health / CNS (CREA)“ korrekt.                                                                                            | [Pipeline-slide-Jan-2025.pptx](https://boehringer.sharepoint.com/sites/mybi_tacns/_layouts/15/Doc.aspx?sourcedoc=%7BAD388315-2399-457E-B565-E12A95CE7F0E%7D\&file=Pipeline-slide-Jan-2025.pptx\&action=edit\&mobileredirect=true\&DefaultItemOpen=1\&EntityRepresentationId=140449c4-dfd3-4082-83a4-185741bc2078). [\[Pipeline-s...e-Jan-2025 | PowerPoint\]](https://boehringer.sharepoint.com/sites/mybi_tacns/_layouts/15/Doc.aspx?sourcedoc=%7BAD388315-2399-457E-B565-E12A95CE7F0E%7D&file=Pipeline-slide-Jan-2025.pptx&action=edit&mobileredirect=true&DefaultItemOpen=1)                                                                                                                                                                                                                                                                                                                   |
| mechanism\_of\_action     | NONE     | Psychosoziale, app‑basierte Interventionen – konsistent.                                                                         | [12. CT-155 overview.pptx](https://boehringer.sharepoint.com/sites/mybi_tacns/_layouts/15/Doc.aspx?sourcedoc=%7B721D56DC-5E0D-4954-924A-B1C80A7E0073%7D\&file=12.%20CT-155%20overview.pptx\&action=edit\&mobileredirect=true\&DefaultItemOpen=1\&EntityRepresentationId=c5437584-577f-4e9a-8524-3005ca39917d). [\[12. CT-155 overview | PowerPoint\]](https://boehringer.sharepoint.com/sites/mybi_tacns/_layouts/15/Doc.aspx?sourcedoc=%7B721D56DC-5E0D-4954-924A-B1C80A7E0073%7D&file=12.%20CT-155%20overview.pptx&action=edit&mobileredirect=true&DefaultItemOpen=1)                                                                                                                                                                                                                                                                                                                       |
| short\_description        | NONE     | „…negative symptoms in schizophrenia“ korrekt.                                                                                   | [Press-Release--.aspx](https://boehringer.sharepoint.com/sites/mybi_news_usa/SitePages/Press-Release--.aspx?web=1\&EntityRepresentationId=4b1dd9f5-2b23-444d-a96a-5b0e61335f34). [\[Press Rele...enia study | SharePoint\]](https://boehringer.sharepoint.com/sites/mybi_news_usa/SitePages/Press-Release--.aspx?web=1)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| dosage\_form              | NONE     | „Software / Mobile App (SaMD)“ korrekt.                                                                                          | [12. CT-155 overview.pptx](https://boehringer.sharepoint.com/sites/mybi_tacns/_layouts/15/Doc.aspx?sourcedoc=%7B721D56DC-5E0D-4954-924A-B1C80A7E0073%7D\&file=12.%20CT-155%20overview.pptx\&action=edit\&mobileredirect=true\&DefaultItemOpen=1\&EntityRepresentationId=c5437584-577f-4e9a-8524-3005ca39917d). [\[12. CT-155 overview | PowerPoint\]](https://boehringer.sharepoint.com/sites/mybi_tacns/_layouts/15/Doc.aspx?sourcedoc=%7B721D56DC-5E0D-4954-924A-B1C80A7E0073%7D&file=12.%20CT-155%20overview.pptx&action=edit&mobileredirect=true&DefaultItemOpen=1)                                                                                                                                                                                                                                                                                                                       |
| route\_of\_administration | NONE     | „Digital (smartphone‑delivered)“ korrekt.                                                                                        | [12. CT-155 overview.pptx](https://boehringer.sharepoint.com/sites/mybi_tacns/_layouts/15/Doc.aspx?sourcedoc=%7B721D56DC-5E0D-4954-924A-B1C80A7E0073%7D\&file=12.%20CT-155%20overview.pptx\&action=edit\&mobileredirect=true\&DefaultItemOpen=1\&EntityRepresentationId=c5437584-577f-4e9a-8524-3005ca39917d). [\[12. CT-155 overview | PowerPoint\]](https://boehringer.sharepoint.com/sites/mybi_tacns/_layouts/15/Doc.aspx?sourcedoc=%7B721D56DC-5E0D-4954-924A-B1C80A7E0073%7D&file=12.%20CT-155%20overview.pptx&action=edit&mobileredirect=true&DefaultItemOpen=1)                                                                                                                                                                                                                                                                                                                       |
| base\_technology          | MINOR    | Zielwert: **„SaMD (mobile smartphone application)“** – Ergänzung.                                                                | [12. CT-155 overview.pptx](https://boehringer.sharepoint.com/sites/mybi_tacns/_layouts/15/Doc.aspx?sourcedoc=%7B721D56DC-5E0D-4954-924A-B1C80A7E0073%7D\&file=12.%20CT-155%20overview.pptx\&action=edit\&mobileredirect=true\&DefaultItemOpen=1\&EntityRepresentationId=c5437584-577f-4e9a-8524-3005ca39917d). [\[12. CT-155 overview | PowerPoint\]](https://boehringer.sharepoint.com/sites/mybi_tacns/_layouts/15/Doc.aspx?sourcedoc=%7B721D56DC-5E0D-4954-924A-B1C80A7E0073%7D&file=12.%20CT-155%20overview.pptx&action=edit&mobileredirect=true&DefaultItemOpen=1)                                                                                                                                                                                                                                                                                                                       |
| current\_phase            | MINOR    | Zielwert: **„Phase III – pivotal CONVOKE abgeschlossen; primärer Endpunkt erreicht“** (Präzisierung ggü. „Phase III Completed“). | [Press-Release--.aspx](https://boehringer.sharepoint.com/sites/mybi_news_usa/SitePages/Press-Release--.aspx?web=1\&EntityRepresentationId=4b1dd9f5-2b23-444d-a96a-5b0e61335f34); [Press-Release---Boehringer-and-Click-Therapeutics-present-pivotal-data-for-investigational-prescription.aspx](https://boehringer.sharepoint.com/sites/mybi_news_usa/SitePages/Press-Release---Boehringer-and-Click-Therapeutics-present-pivotal-data-for-investigational-prescription.aspx?web=1\&EntityRepresentationId=544c72c0-785c-4dfb-bc7b-fa7eb568f645). [\[Press Rele...enia study | SharePoint\]](https://boehringer.sharepoint.com/sites/mybi_news_usa/SitePages/Press-Release--.aspx?web=1), [\[Boehringer...escription | SharePoint\]](https://boehringer.sharepoint.com/sites/mybi_news_usa/SitePages/Press-Release---Boehringer-and-Click-Therapeutics-present-pivotal-data-for-investigational-prescription.aspx?web=1) |

**BI 765128**

| Feld                      | Änderung | Beschreibung                                                                                                    | Evidenz                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| ------------------------- | -------- | --------------------------------------------------------------------------------------------------------------- | --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- |
| product\_code             | NONE     | Unverändert.                                                                                                    | [MECR - February 2022.pdf](https://boehringer.sharepoint.com/sites/mybi_hp_fra/Shared%20Documents/Sant%c3%a9%20Humaine/Portail%20m%c3%a9dicale/Recherche%20Clinique/Archives/MECR%20-%20February%202022.pdf?web=1\&EntityRepresentationId=c9997060-6e02-437e-b066-d7ab5597d9b0). [\[MECR - February 2022 | PDF\]](https://boehringer.sharepoint.com/sites/mybi_hp_fra/Shared%20Documents/Sant%c3%a9%20Humaine/Portail%20m%c3%a9dicale/Recherche%20Clinique/Archives/MECR%20-%20February%202022.pdf?web=1)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| product\_name             | NONE     | Kein öffentlicher Name; belassen.                                                                               | Portfolio‑/Trial‑Unterlagen nutzen BI‑Code. [1336-0007\_RH Trial portfolio and BI 836880\_wetAMD.pptx](https://boehringer.sharepoint.com/sites/z365eco/UNDER%20CONSTRUCTION/ECT%20Fileshare%20%28General%29/02_Meetings/05_ECT%20Presentations%20to%20Other%20Functions/TA%20Retinal%20Health/Research%20Retinopathy%2016-Dec-2021/1336-0007_RH%20Trial%20portfolio%20and%20BI%20836880_wetAMD.pptx?web=1\&EntityRepresentationId=45343e27-b5ec-42cc-8e61-134b63437ad1). [\[1336-0007_...880_wetAMD | PowerPoint\]](https://boehringer.sharepoint.com/sites/z365eco/UNDER%20CONSTRUCTION/ECT%20Fileshare%20(General)%20-Structure/02_Meetings/05_ECT%20Presentations%20to%20Other%20Functions/TA%20Retinal%20Health/Research%20Retinopathy%2016-Dec-2021/1336-0007_RH%20Trial%20portfolio%20and%20BI%20836880_wetAMD.pptx?web=1)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| modality\_name            | NONE     | „Monoclonal Antibody“ korrekt.                                                                                  | [1336-0007\_RH Trial portfolio and BI 836880\_wetAMD.pptx](https://boehringer.sharepoint.com/sites/z365eco/UNDER%20CONSTRUCTION/ECT%20Fileshare%20%28General%29/02_Meetings/05_ECT%20Presentations%20to%20Other%20Functions/TA%20Retinal%20Health/Research%20Retinopathy%2016-Dec-2021/1336-0007_RH%20Trial%20portfolio%20and%20BI%20836880_wetAMD.pptx?web=1\&EntityRepresentationId=45343e27-b5ec-42cc-8e61-134b63437ad1). [\[1336-0007_...880_wetAMD | PowerPoint\]](https://boehringer.sharepoint.com/sites/z365eco/UNDER%20CONSTRUCTION/ECT%20Fileshare%20(General)/02_Meetings/05_ECT%20Presentations%20to%20Other%20Functions/TA%20Retinal%20Health/Research%20Retinopathy%2016-Dec-2021/1336-0007_RH%20Trial%20portfolio%20and%20BI%20836880_wetAMD.pptx?web=1)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| product\_type             | NONE     | „NBE“ passend.                                                                                                  | FIH/klinische Planung ausgewiesen. [MECR - February 2022.pdf](https://boehringer.sharepoint.com/sites/mybi_hp_fra/Shared%20Documents/Sant%c3%a9%20Humaine/Portail%20m%c3%a9dicale/Recherche%20Clinique/Archives/MECR%20-%20February%202022.pdf?web=1\&EntityRepresentationId=c9997060-6e02-437e-b066-d7ab5597d9b0). [\[MECR - February 2022 | PDF\]](https://boehringer.sharepoint.com/sites/mybi_hp_fra/Shared%20Documents/Sant%c3%a9%20Humaine/Portail%20m%c3%a9dicale/Recherche%20Clinique/Archives/MECR%20-%20February%202022.pdf?web=1)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| therapeutic\_area         | NONE     | „Eye Health“ (DMI/DR‑Kontext) korrekt.                                                                          | [1336-0007\_RH Trial portfolio and BI 836880\_wetAMD.pptx](https://boehringer.sharepoint.com/sites/z365eco/UNDER%20CONSTRUCTION/ECT%20Fileshare%20%28General%29/02_Meetings/05_ECT%20Presentations%20to%20Other%20Functions/TA%20Retinal%20Health/Research%20Retinopathy%2016-Dec-2021/1336-0007_RH%20Trial%20portfolio%20and%20BI%20836880_wetAMD.pptx?web=1\&EntityRepresentationId=45343e27-b5ec-42cc-8e61-134b63437ad1). [\[1336-0007_...880_wetAMD | PowerPoint\]](https://boehringer.sharepoint.com/sites/z365eco/UNDER%20CONSTRUCTION/ECT%20Fileshare%20(General)/02_Meetings/05_ECT%20Presentations%20to%20Other%20Functions/TA%20Retinal%20Health/Research%20Retinopathy%2016-Dec-2021/1336-0007_RH%20Trial%20portfolio%20and%20BI%20836880_wetAMD.pptx?web=1)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| mechanism\_of\_action     | NONE     | „Anti‑NRP1 antibody“ korrekt.                                                                                   | [BI11.pdf](https://boehringer.sharepoint.com/sites/z365clinicaltrialspatientandsiteengagement/Shared%20Documents/Trial%20Diversity%20and%20Inclusion/Protocols%20-%20Ph2%20or%203%20&%20Interventional%20&%20Jan%202021%20-%20July%202025%20start%20BOEHRINGER/BI11.pdf?web=1\&EntityRepresentationId=c7b0bed1-01e3-456a-946a-ec5338efccfb). [\[BI11 | PDF\]](https://boehringer.sharepoint.com/sites/z365clinicaltrialspatientandsiteengagement/Shared%20Documents/Trial%20Diversity%20and%20Inclusion/Protocols%20-%20Ph2%20or%203%20&%20Interventional%20&%20Jan%202021%20-%20July%202025%20start%20BOEHRINGER/BI11.pdf?web=1)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| short\_description        | MAJOR    | Zielwert: **„Anti‑NRP1 mAb für diabetische Makulaischämie (DMI)“** – Hinweis „(discontinued)“ ist nicht belegt. | FIH‑/MECR‑Unterlagen zeigen aktive/planmäßige Studien (PARTRIDGE 1451‑0001). [MECR - February 2022.pdf](https://boehringer.sharepoint.com/sites/mybi_hp_fra/Shared%20Documents/Sant%c3%a9%20Humaine/Portail%20m%c3%a9dicale/Recherche%20Clinique/Archives/MECR%20-%20February%202022.pdf?web=1\&EntityRepresentationId=c9997060-6e02-437e-b066-d7ab5597d9b0); [BI11.pdf](https://boehringer.sharepoint.com/sites/z365clinicaltrialspatientandsiteengagement/Shared%20Documents/Trial%20Diversity%20and%20Inclusion/Protocols%20-%20Ph2%20or%203%20&%20Interventional%20&%20Jan%202021%20-%20July%202025%20start%20BOEHRINGER/BI11.pdf?web=1\&EntityRepresentationId=c7b0bed1-01e3-456a-946a-ec5338efccfb); [1336-0007\_RH Trial portfolio and BI 836880\_wetAMD.pptx](https://boehringer.sharepoint.com/sites/z365eco/UNDER%20CONSTRUCTION/ECT%20Fileshare%20%28General%29/02_Meetings/05_ECT%20Presentations%20to%20Other%20Functions/TA%20Retinal%20Health/Research%20Retinopathy%2016-Dec-2021/1336-0007_RH%20Trial%20portfolio%20and%20BI%20836880_wetAMD.pptx?web=1\&EntityRepresentationId=45343e27-b5ec-42cc-8e61-134b63437ad1). [\[MECR - February 2022 | PDF\]](https://boehringer.sharepoint.com/sites/mybi_hp_fra/Shared%20Documents/Sant%c3%a9%20Humaine/Portail%20m%c3%a9dicale/Recherche%20Clinique/Archives/MECR%20-%20February%202022.pdf?web=1), [\[BI11 | PDF\]](https://boehringer.sharepoint.com/sites/z365clinicaltrialspatientandsiteengagement/Shared%20Documents/Trial%20Diversity%20and%20Inclusion/Protocols%20-%20Ph2%20or%203%20&%20Interventional%20&%20Jan%202021%20-%20July%202025%20start%20BOEHRINGER/BI11.pdf?web=1), [\[1336-0007_...880_wetAMD | PowerPoint\]](https://boehringer.sharepoint.com/sites/z365eco/UNDER%20CONSTRUCTION/ECT%20Fileshare%20(General)/02_Meetings/05_ECT%20Presentations%20to%20Other%20Functions/TA%20Retinal%20Health/Research%20Retinopathy%2016-Dec-2021/1336-0007_RH%20Trial%20portfolio%20and%20BI%20836880_wetAMD.pptx?web=1) |
| dosage\_form              | NONE     | „Injectable“ korrekt (IVT‑Injektion).                                                                           | [BI11.pdf](https://boehringer.sharepoint.com/sites/z365clinicaltrialspatientandsiteengagement/Shared%20Documents/Trial%20Diversity%20and%20Inclusion/Protocols%20-%20Ph2%20or%203%20&%20Interventional%20&%20Jan%202021%20-%20July%202025%20start%20BOEHRINGER/BI11.pdf?web=1\&EntityRepresentationId=c7b0bed1-01e3-456a-946a-ec5338efccfb). [\[BI11 | PDF\]](https://boehringer.sharepoint.com/sites/z365clinicaltrialspatientandsiteengagement/Shared%20Documents/Trial%20Diversity%20and%20Inclusion/Protocols%20-%20Ph2%20or%203%20&%20Interventional%20&%20Jan%202021%20-%20July%202025%20start%20BOEHRINGER/BI11.pdf?web=1)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| route\_of\_administration | NONE     | „Intravitreal“ korrekt.                                                                                         | [BI11.pdf](https://boehringer.sharepoint.com/sites/z365clinicaltrialspatientandsiteengagement/Shared%20Documents/Trial%20Diversity%20and%20Inclusion/Protocols%20-%20Ph2%20or%203%20&%20Interventional%20&%20Jan%202021%20-%20July%202025%20start%20BOEHRINGER/BI11.pdf?web=1\&EntityRepresentationId=c7b0bed1-01e3-456a-946a-ec5338efccfb). [\[BI11 | PDF\]](https://boehringer.sharepoint.com/sites/z365clinicaltrialspatientandsiteengagement/Shared%20Documents/Trial%20Diversity%20and%20Inclusion/Protocols%20-%20Ph2%20or%203%20&%20Interventional%20&%20Jan%202021%20-%20July%202025%20start%20BOEHRINGER/BI11.pdf?web=1)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| base\_technology          | NONE     | „Mammalian“ als Produktionsplattform akzeptabel.                                                                | Keine gegenteilige Evidenz in Klinik/CMC‑Docs. [MECR - February 2022.pdf](https://boehringer.sharepoint.com/sites/mybi_hp_fra/Shared%20Documents/Sant%c3%a9%20Humaine/Portail%20m%c3%a9dicale/Recherche%20Clinique/Archives/MECR%20-%20February%202022.pdf?web=1\&EntityRepresentationId=c9997060-6e02-437e-b066-d7ab5597d9b0). [\[MECR - February 2022 | PDF\]](https://boehringer.sharepoint.com/sites/mybi_hp_fra/Shared%20Documents/Sant%c3%a9%20Humaine/Portail%20m%c3%a9dicale/Recherche%20Clinique/Archives/MECR%20-%20February%202022.pdf?web=1)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| current\_phase            | MAJOR    | Zielwert: **„Phase I/II (PARTRIDGE 1451‑0001)“** statt „Pre‑Clinical“.                                          | MECR/Trial‑Design beschreiben First‑in‑Human/Randomized Teile. [MECR - February 2022.pdf](https://boehringer.sharepoint.com/sites/mybi_hp_fra/Shared%20Documents/Sant%c3%a9%20Humaine/Portail%20m%c3%a9dicale/Recherche%20Clinique/Archives/MECR%20-%20February%202022.pdf?web=1\&EntityRepresentationId=c9997060-6e02-437e-b066-d7ab5597d9b0); [MECR---February-2022.pdf](https://boehringer.sharepoint.com/sites/mybi_hp_fra/SiteAssets/SitePages/OpC3A9rations-Cliniques-France/MECR---February-2022.pdf?web=1\&EntityRepresentationId=2f59c412-e475-4966-b67a-781f9a14400d). [\[MECR - February 2022 | PDF\]](https://boehringer.sharepoint.com/sites/mybi_hp_fra/Shared%20Documents/Sant%c3%a9%20Humaine/Portail%20m%c3%a9dicale/Recherche%20Clinique/Archives/MECR%20-%20February%202022.pdf?web=1), [\[MECR---February-2022 | PDF\]](https://boehringer.sharepoint.com/sites/mybi_hp_fra/SiteAssets/SitePages/OpC3A9rations-Cliniques-France/MECR---February-2022.pdf?web=1)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |

**BI 3720931**

| Feld                      | Änderung | Beschreibung                                                                                                                         | Evidenz                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| ------------------------- | -------- | ------------------------------------------------------------------------------------------------------------------------------------ | ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- |
| product\_code             | NONE     | Unverändert.                                                                                                                         | [genetherapycysticfibrosis.aspx](https://boehringer.sharepoint.com/sites/mybi_news_onehp/SitePages/genetherapycysticfibrosis.aspx?web=1\&EntityRepresentationId=9506df9b-a6b7-463b-bdcd-f98a14007d0b). [\[Gene thera...c fibrosis | SharePoint\]](https://boehringer.sharepoint.com/sites/mybi_news_onehp/SitePages/genetherapycysticfibrosis.aspx?web=1)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| product\_name             | NONE     | Kein öffentlicher Name; belassen.                                                                                                    | Konsistente Nennung über BI‑Code. First enrolment into Lenticlair 01…. [\[First enro...3720931)  | Viva Engage\]](https://engage.cloud.microsoft/main/threads/eyJfdHlwZSI6IlRocmVhZCIsImlkIjoiMzA1OTYzMzE0MjgwODU3NyJ9)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| modality\_name            | MINOR    | Zielwert: **„Inhaled Lentiviral Gene Therapy (LVGT)“** – präzisiert.                                                                 | BI 3720931: Nebulizer… Investigator’s Brochure 1504; [genetherapycysticfibrosis.aspx](https://boehringer.sharepoint.com/sites/mybi_news_onehp/SitePages/genetherapycysticfibrosis.aspx?web=1\&EntityRepresentationId=9506df9b-a6b7-463b-bdcd-f98a14007d0b). [\[BI 3720931...chure 1504 | Extern\]](https://bi-docs-vault-quality.veevavault.com/ui/#doc_info/1265109), [\[Gene thera...c fibrosis | SharePoint\]](https://boehringer.sharepoint.com/sites/mybi_news_onehp/SitePages/genetherapycysticfibrosis.aspx?web=1)                                                                                                                                                                                                                                                                                                                                                                                    |
| product\_type             | NONE     | „NBE“ passend.                                                                                                                       | IB/Corporate‑Seite beschreibt neuartige GT. BI 3720931: Nebulizer…. [\[BI 3720931...chure 1504 | Extern\]](https://bi-docs-vault-quality.veevavault.com/ui/#doc_info/1265109)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| therapeutic\_area         | MINOR    | Zielwert: **„Cystic Fibrosis (Respiratory)“** – Spezifizierung der Indikation.                                                       | [genetherapycysticfibrosis.aspx](https://boehringer.sharepoint.com/sites/mybi_news_onehp/SitePages/genetherapycysticfibrosis.aspx?web=1\&EntityRepresentationId=9506df9b-a6b7-463b-bdcd-f98a14007d0b). [\[Gene thera...c fibrosis | SharePoint\]](https://boehringer.sharepoint.com/sites/mybi_news_onehp/SitePages/genetherapycysticfibrosis.aspx?web=1)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| mechanism\_of\_action     | MINOR    | Zielwert: **„Drittgenerations, selbst‑inaktivierende lentivirale Vektortherapie zur CFTR‑Genübertragung (inhalativ)“** – präzisiert. | BI 3720931: Nebulizer…; [BI 3720931\_Core CAF\_V\_1.0\_NL\_26Jan2024.docx](https://boehringer.sharepoint.com/sites/z365ridgefieldenvironmentalhealthandsafetymybi/_layouts/15/Doc.aspx?sourcedoc=%7BFAAA866B-5792-4D7C-8AFA-0753579A2F55%7D\&file=BI%203720931_Core%20CAF_V_1.0_NL_26Jan2024.docx\&action=default\&mobileredirect=true\&DefaultItemOpen=1\&EntityRepresentationId=b21e6e7e-ee2f-458e-9174-9c02873bfff1). [\[BI 3720931...chure 1504 | Extern\]](https://bi-docs-vault-quality.veevavault.com/ui/#doc_info/1265109), [\[BI 3720931..._26Jan2024 | Word\]](https://boehringer.sharepoint.com/sites/z365ridgefieldenvironmentalhealthandsafetymybi/_layouts/15/Doc.aspx?sourcedoc=%7BFAAA866B-5792-4D7C-8AFA-0753579A2F55%7D&file=BI%203720931_Core%20CAF_V_1.0_NL_26Jan2024.docx&action=default&mobileredirect=true&DefaultItemOpen=1)                                                   |
| short\_description        | MINOR    | Ergänzung „inhaled“: **„Inhaled lentiviral gene therapy for cystic fibrosis“**.                                                      | [genetherapycysticfibrosis.aspx](https://boehringer.sharepoint.com/sites/mybi_news_onehp/SitePages/genetherapycysticfibrosis.aspx?web=1\&EntityRepresentationId=9506df9b-a6b7-463b-bdcd-f98a14007d0b). [\[Gene thera...c fibrosis | SharePoint\]](https://boehringer.sharepoint.com/sites/mybi_news_onehp/SitePages/genetherapycysticfibrosis.aspx?web=1)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| dosage\_form              | MAJOR    | Zielwert: **„Nebulizer solution for inhalation“** statt „Inhalable (SFInh)“.                                                         | Core CAF/IB beschreiben sterile Nebulizer‑Lösung. [BI 3720931\_Core CAF\_V\_1.0\_NL\_26Jan2024.docx](https://boehringer.sharepoint.com/sites/z365ridgefieldenvironmentalhealthandsafetymybi/_layouts/15/Doc.aspx?sourcedoc=%7BFAAA866B-5792-4D7C-8AFA-0753579A2F55%7D\&file=BI%203720931_Core%20CAF_V_1.0_NL_26Jan2024.docx\&action=default\&mobileredirect=true\&DefaultItemOpen=1\&EntityRepresentationId=b21e6e7e-ee2f-458e-9174-9c02873bfff1); BI 3720931: Nebulizer…. [\[BI 3720931..._26Jan2024 | Word\]](https://boehringer.sharepoint.com/sites/z365ridgefieldenvironmentalhealthandsafetymybi/_layouts/15/Doc.aspx?sourcedoc=%7BFAAA866B-5792-4D7C-8AFA-0753579A2F55%7D&file=BI%203720931_Core%20CAF_V_1.0_NL_26Jan2024.docx&action=default&mobileredirect=true&DefaultItemOpen=1), [\[BI 3720931...chure 1504 | Extern\]](https://bi-docs-vault-quality.veevavault.com/ui/#doc_info/1265109) |
| route\_of\_administration | MAJOR    | Zielwert: **„Inhalation (nebulized)“** – war leer.                                                                                   | Corporate‑Seite/IB nennen inhalative Gabe. [genetherapycysticfibrosis.aspx](https://boehringer.sharepoint.com/sites/mybi_news_onehp/SitePages/genetherapycysticfibrosis.aspx?web=1\&EntityRepresentationId=9506df9b-a6b7-463b-bdcd-f98a14007d0b); BI 3720931: Nebulizer…. [\[Gene thera...c fibrosis | SharePoint\]](https://boehringer.sharepoint.com/sites/mybi_news_onehp/SitePages/genetherapycysticfibrosis.aspx?web=1), [\[BI 3720931...chure 1504 | Extern\]](https://bi-docs-vault-quality.veevavault.com/ui/#doc_info/1265109)                                                                                                                                                                                                                                                                                                                                                                      |
| base\_technology          | MINOR    | Zielwert: **„Third‑generation self‑inactivating lentiviral vector“** – Ergänzung.                                                    | BI 3720931: Nebulizer…. [\[BI 3720931...chure 1504 | Extern\]](https://bi-docs-vault-quality.veevavault.com/ui/#doc_info/1265109)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| current\_phase            | MAJOR    | Zielwert: **„Phase I/II (Lenticlair‑01 FIH gestartet Nov 2024)“** statt „Pre‑Clinical“.                                              | First enrolment into Lenticlair 01…; UK achieves First enrolment into Lenticlair 01…. [\[First enro...3720931)  | Viva Engage\]](https://engage.cloud.microsoft/main/threads/eyJfdHlwZSI6IlRocmVhZCIsImlkIjoiMzA1OTYzMzE0MjgwODU3NyJ9), [\[UK achieve...therapy ( | Viva Engage\]](https://engage.cloud.microsoft/main/threads/eyJfdHlwZSI6IlRocmVhZCIsImlkIjoiMzA2NTAxNTkwMjEwOTY5NyJ9)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |

**BI 3810477**

| Feld                      | Änderung | Beschreibung                                                                                                                                       | Evidenz                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| ------------------------- | -------- | -------------------------------------------------------------------------------------------------------------------------------------------------- | ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- |
| product\_code             | NONE     | Korrekt (BI 3810477).                                                                                                                              | [1530-0001\_CTP\_Version3.7\_20241029\_clean for QC\_Archive.docx](https://boehringer.sharepoint.com/sites/z365eco/_layouts/15/Doc.aspx?sourcedoc=%7B38BC2770-09A4-4575-8A94-1B1CB381C223%7D\&file=1530-0001_CTP_Version3.7_20241029_clean%20for%20QC_Archive.docx\&action=default\&mobileredirect=true\&DefaultItemOpen=1\&EntityRepresentationId=29626e0b-a913-4d39-8e5f-d62328a665bd) bestätigt Code in klinischem Kontext. [\[1530-0001_...QC_Archive | Word\]](https://boehringer.sharepoint.com/sites/z365eco/_layouts/15/Doc.aspx?sourcedoc=%7B38BC2770-09A4-4575-8A94-1B1CB381C223%7D&file=1530-0001_CTP_Version3.7_20241029_clean%20for%20QC_Archive.docx&action=default&mobileredirect=true&DefaultItemOpen=1)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| product\_name             | NONE     | Keine offizielle INN/Bezeichnung gefunden; Feld kann leer bleiben.                                                                                 | Investigator’s Brochure & CTP führen nur den Code. [ib-bi3810477-1530-p1-version-1\_20240618.pdf](https://boehringer.sharepoint.com/sites/z365eco/UNDER%20CONSTRUCTION/ECT%20Fileshare%20%28General%29/04_Clinical%20Information/Deborah%20Roberts/ib-bi3810477-1530-p1-version-1_20240618.pdf?web=1\&EntityRepresentationId=71fd91e9-9b00-4934-ad1c-518ceae0fc78), [1530-0001\_CTP\_Version3.7\_20241029\_clean for QC\_Archive.docx](https://boehringer.sharepoint.com/sites/z365eco/_layouts/15/Doc.aspx?sourcedoc=%7B38BC2770-09A4-4575-8A94-1B1CB381C223%7D\&file=1530-0001_CTP_Version3.7_20241029_clean%20for%20QC_Archive.docx\&action=default\&mobileredirect=true\&DefaultItemOpen=1\&EntityRepresentationId=29626e0b-a913-4d39-8e5f-d62328a665bd). [\[ib-bi38104...1_20240618 | PDF\]](https://boehringer.sharepoint.com/sites/z365eco/UNDER%20CONSTRUCTION/ECT%20Fileshare%20(General)/04_Clinical%20Information/Deborah%20Roberts/ib-bi3810477-1530-p1-version-1_20240618.pdf?web=1), [\[1530-0001_...QC_Archive | Word\]](https://boehringer.sharepoint.com/sites/z365eco/_layouts/15/Doc.aspx?sourcedoc=%7B38BC2770-09A4-4575-8A94-1B1CB381C223%7D&file=1530-0001_CTP_Version3.7_20241029_clean%20for%20QC_Archive.docx&action=default&mobileredirect=true&DefaultItemOpen=1)                                                                                                                                      |
| modality\_name            | NONE     | „Monoclonal Antibody“ ist korrekt.                                                                                                                 | IB beschreibt BI 3810477 als humanisierten IgG1‑mAb. [ib-bi3810477-1530-p1-version-1.pdf](https://boehringer.sharepoint.com/sites/z365ridgefieldenvironmentalhealthandsafetymybi/EHS%20Documents/Environmental/Environmental%20Risk%20Assessments/Product%20Environmental%20Risk%20Assessment/INDs/BI%203810477/ib-bi3810477-1530-p1-version-1.pdf?web=1\&EntityRepresentationId=81e64d3b-ac97-48a8-9ce6-218bf82eacd8). [\[ib-bi38104...-version-1 | PDF\]](https://boehringer.sharepoint.com/sites/z365ridgefieldenvironmentalhealthandsafetymybi/EHS%20Documents/Environmental/Environmental%20Risk%20Assessments/Product%20Environmental%20Risk%20Assessment/INDs/BI%203810477/ib-bi3810477-1530-p1-version-1.pdf?web=1)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| product\_type             | NONE     | „NBE“ ist korrekt (Biologikum).                                                                                                                    | IB/CTP bestätigen mAb. [ib-bi3810477-1530-p1-version-1\_20240618.docx](https://boehringer.sharepoint.com/sites/z365eco/_layouts/15/Doc.aspx?sourcedoc=%7BFBF52F62-E8D1-4BE8-A7A0-4D44C819D10A%7D\&file=ib-bi3810477-1530-p1-version-1_20240618.docx\&action=default\&mobileredirect=true\&DefaultItemOpen=1\&EntityRepresentationId=1f434833-3470-4417-bd08-b1ed676fb85a). [\[ib-bi38104...1_20240618 | Word\]](https://boehringer.sharepoint.com/sites/z365eco/_layouts/15/Doc.aspx?sourcedoc=%7BFBF52F62-E8D1-4BE8-A7A0-4D44C819D10A%7D&file=ib-bi3810477-1530-p1-version-1_20240618.docx&action=default&mobileredirect=true&DefaultItemOpen=1)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| therapeutic\_area         | MINOR    | Auf „Inflammation & Respiratory“ präzisieren (intern so geführt).                                                                                  | TA‑Publikationen listen BI 3810477 unter I\&R. [Inflammation Insider Edition 21.pdf](https://boehringer.sharepoint.com/sites/mybi_tainflammation/Shared%20Documents/Inflammation%20Insiders/Inflammation%20Insider%20Edition%2021.pdf?web=1\&EntityRepresentationId=55cfeb47-be52-4b2c-bbc5-a740297fe33a). [\[Inflammati...Edition 21 | PDF\]](https://boehringer.sharepoint.com/sites/mybi_tainflammation/Shared%20Documents/Inflammation%20Insiders/Inflammation%20Insider%20Edition%2021.pdf?web=1)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| mechanism\_of\_action     | MINOR    | Von „Anti‑CTGF antibody“ auf „bindet einzigartiges CTGF‑Epitop, verhindert Zelloberflächenbindung und MMP7‑vermittelte CTGF‑Spaltung“ präzisieren. | IB & Präsentationen zeigen Differenzierung ggü. Pamrevlumab (KD < 2 pM; andere Epitope; Hemmung Zellbind./Spaltung). [ib-bi3810477-1530-p1-version-1\_20240618.docx](https://boehringer.sharepoint.com/sites/z365eco/_layouts/15/Doc.aspx?sourcedoc=%7BFBF52F62-E8D1-4BE8-A7A0-4D44C819D10A%7D\&file=ib-bi3810477-1530-p1-version-1_20240618.docx\&action=default\&mobileredirect=true\&DefaultItemOpen=1\&EntityRepresentationId=1f434833-3470-4417-bd08-b1ed676fb85a), [Lize\_BI3810477\_CIVM use in IND.pptx](https://boehringer.sharepoint.com/sites/z365cop1/_layouts/15/Doc.aspx?sourcedoc=%7B74E60A43-90AA-48F7-A346-1DFC23CB19CF%7D\&file=Lize_BI3810477_CIVM%20use%20in%20IND.pptx\&action=edit\&mobileredirect=true\&DefaultItemOpen=1\&EntityRepresentationId=d4338140-7a73-4b8b-a63d-9c6c31c773ec). [\[ib-bi38104...1_20240618 | Word\]](https://boehringer.sharepoint.com/sites/z365eco/_layouts/15/Doc.aspx?sourcedoc=%7BFBF52F62-E8D1-4BE8-A7A0-4D44C819D10A%7D&file=ib-bi3810477-1530-p1-version-1_20240618.docx&action=default&mobileredirect=true&DefaultItemOpen=1), [\[Lize_BI381...use in IND | PowerPoint\]](https://boehringer.sharepoint.com/sites/z365cop1/_layouts/15/Doc.aspx?sourcedoc=%7B74E60A43-90AA-48F7-A346-1DFC23CB19CF%7D&file=Lize_BI3810477_CIVM%20use%20in%20IND.pptx&action=edit&mobileredirect=true&DefaultItemOpen=1)                                                                              |
| short\_description        | MINOR    | Präzisieren: „Humanisierter IgG1‑mAb gegen CTGF mit geplanter Entwicklung für IPF/PPF“.                                                            | IB/CTP zeigen IPF/PPF‑Programm. [ib-bi3810477-1530-p1-version-1\_20240618.pdf](https://boehringer.sharepoint.com/sites/z365eco/UNDER%20CONSTRUCTION/ECT%20Fileshare%20%28General%29/04_Clinical%20Information/Deborah%20Roberts/ib-bi3810477-1530-p1-version-1_20240618.pdf?web=1\&EntityRepresentationId=71fd91e9-9b00-4934-ad1c-518ceae0fc78), [1530-0002\_CTP\_version 0.6\_20241118\_commRD2.docx](https://boehringer.sharepoint.com/sites/z365eco/_layouts/15/Doc.aspx?sourcedoc=%7B18429E40-F6B0-4228-8DFC-3A3C29AD685A%7D\&file=1530-0002_CTP_version%200.6_20241118_commRD2.docx\&action=default\&mobileredirect=true\&DefaultItemOpen=1\&EntityRepresentationId=bebd85c0-215b-4249-b407-f85da276b4d4). [\[ib-bi38104...1_20240618 | PDF\]](https://boehringer.sharepoint.com/sites/z365eco/UNDER%20CONSTRUCTION/ECT%20Fileshare%20(General)/04_Clinical%20Information/Deborah%20Roberts/ib-bi3810477-1530-p1-version-1_20240618.pdf?web=1), [\[1530-0002_...18_commRD2 | Word\]](https://boehringer.sharepoint.com/sites/z365eco/_layouts/15/Doc.aspx?sourcedoc=%7B18429E40-F6B0-4228-8DFC-3A3C29AD685A%7D&file=1530-0002_CTP_version%200.6_20241118_commRD2.docx&action=default&mobileredirect=true&DefaultItemOpen=1)                                                                                                                                                                                                  |
| dosage\_form              | MINOR    | Auf „Injektionslösung“ aktualisieren.                                                                                                              | Ph‑I‑Design mit i.v. und s.c. Dosierung. [1530-0001\_CTP\_Version3.7\_20241029\_clean for QC\_Archive.docx](https://boehringer.sharepoint.com/sites/z365eco/_layouts/15/Doc.aspx?sourcedoc=%7B38BC2770-09A4-4575-8A94-1B1CB381C223%7D\&file=1530-0001_CTP_Version3.7_20241029_clean%20for%20QC_Archive.docx\&action=default\&mobileredirect=true\&DefaultItemOpen=1\&EntityRepresentationId=29626e0b-a913-4d39-8e5f-d62328a665bd). [\[1530-0001_...QC_Archive | Word\]](https://boehringer.sharepoint.com/sites/z365eco/_layouts/15/Doc.aspx?sourcedoc=%7B38BC2770-09A4-4575-8A94-1B1CB381C223%7D&file=1530-0001_CTP_Version3.7_20241029_clean%20for%20QC_Archive.docx&action=default&mobileredirect=true&DefaultItemOpen=1)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| route\_of\_administration | MINOR    | Auf „i.v. und s.c.“ aktualisieren.                                                                                                                 | CTP/Planung zeigen i.v. (SRD/MRD) und s.c. (geplant q1w). [1530-0001\_CTP\_Version3.7\_20241029\_clean for QC\_Archive.docx](https://boehringer.sharepoint.com/sites/z365eco/_layouts/15/Doc.aspx?sourcedoc=%7B38BC2770-09A4-4575-8A94-1B1CB381C223%7D\&file=1530-0001_CTP_Version3.7_20241029_clean%20for%20QC_Archive.docx\&action=default\&mobileredirect=true\&DefaultItemOpen=1\&EntityRepresentationId=29626e0b-a913-4d39-8e5f-d62328a665bd), [1530-0002\_CTP\_version 0.6\_20241118\_commRD2.docx](https://boehringer.sharepoint.com/sites/z365eco/_layouts/15/Doc.aspx?sourcedoc=%7B18429E40-F6B0-4228-8DFC-3A3C29AD685A%7D\&file=1530-0002_CTP_version%200.6_20241118_commRD2.docx\&action=default\&mobileredirect=true\&DefaultItemOpen=1\&EntityRepresentationId=bebd85c0-215b-4249-b407-f85da276b4d4). [\[1530-0001_...QC_Archive | Word\]](https://boehringer.sharepoint.com/sites/z365eco/_layouts/15/Doc.aspx?sourcedoc=%7B38BC2770-09A4-4575-8A94-1B1CB381C223%7D&file=1530-0001_CTP_Version3.7_20241029_clean%20for%20QC_Archive.docx&action=default&mobileredirect=true&DefaultItemOpen=1), [\[1530-0002_...18_commRD2 | Word\]](https://boehringer.sharepoint.com/sites/z365eco/_layouts/15/Doc.aspx?sourcedoc=%7B18429E40-F6B0-4228-8DFC-3A3C29AD685A%7D&file=1530-0002_CTP_version%200.6_20241118_commRD2.docx&action=default&mobileredirect=true&DefaultItemOpen=1)                                              |
| base\_technology          | MINOR    | Ergänzen: „Humanisierter IgG1 mit LALA‑Fc‑Mutation“.                                                                                               | Internes Deck nennt LALA‑Modifikation. [Presentation.pptx](https://boehringer.sharepoint.com/sites/z365biotherapeuticssymposium/_layouts/15/Doc.aspx?sourcedoc=%7B70843CAC-CA1D-4C3E-91D4-E53DD327FBD4%7D\&file=Presentation.pptx\&action=edit\&mobileredirect=true\&DefaultItemOpen=1\&EntityRepresentationId=19fc9244-8576-44a3-a2f8-4662b557e2eb). [\[Presentation | PowerPoint\]](https://boehringer.sharepoint.com/sites/z365biotherapeuticssymposium/_layouts/15/Doc.aspx?sourcedoc=%7B70843CAC-CA1D-4C3E-91D4-E53DD327FBD4%7D&file=Presentation.pptx&action=edit&mobileredirect=true&DefaultItemOpen=1)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| current\_phase            | MAJOR    | Von „Pre‑Clinical“ auf „Phase I“ aktualisieren (FIM gestartet).                                                                                    | IB/CTP & Patient‑Centric‑Sampling‑Plan nennen Ph I; FPI Nov 2024. [1530-0001\_CTP\_Version3.7\_20241029\_clean for QC\_Archive.docx](https://boehringer.sharepoint.com/sites/z365eco/_layouts/15/Doc.aspx?sourcedoc=%7B38BC2770-09A4-4575-8A94-1B1CB381C223%7D\&file=1530-0001_CTP_Version3.7_20241029_clean%20for%20QC_Archive.docx\&action=default\&mobileredirect=true\&DefaultItemOpen=1\&EntityRepresentationId=29626e0b-a913-4d39-8e5f-d62328a665bd), [PCSWG\_Achievement2024\_draft (1).pptx](https://boehringer.sharepoint.com/sites/z365clinicaltrialspatientandsiteengagement/_layouts/15/Doc.aspx?sourcedoc=%7BAFED75F5-FC4F-46C3-A40E-87964C5FFD91%7D\&file=PCSWG_Achievement2024_draft%20%281%29.pptx\&action=edit\&mobileredirect=true\&DefaultItemOpen=1\&EntityRepresentationId=5b83e0ce-7f31-4053-a84b-7b8524245d71). [\[1530-0001_...QC_Archive | Word\]](https://boehringer.sharepoint.com/sites/z365eco/_layouts/15/Doc.aspx?sourcedoc=%7B38BC2770-09A4-4575-8A94-1B1CB381C223%7D&file=1530-0001_CTP_Version3.7_20241029_clean%20for%20QC_Archive.docx&action=default&mobileredirect=true&DefaultItemOpen=1), [\[PCSWG_Achi..._draft (1) | PowerPoint\]](https://boehringer.sharepoint.com/sites/z365clinicaltrialspatientandsiteengagement/_layouts/15/Doc.aspx?sourcedoc=%7BAFED75F5-FC4F-46C3-A40E-87964C5FFD91%7D&file=PCSWG_Achievement2024_draft%20(1).pptx&action=edit&mobileredirect=true&DefaultItemOpen=1) |

**BI 765243**

| Feld                      | Änderung | Beschreibung                                                                                                            | Evidenz                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| ------------------------- | -------- | ----------------------------------------------------------------------------------------------------------------------- | ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- |
| product\_code             | MAJOR    | Asset/Code in internen Pipeline‑Übersichten und Eye‑Health‑Materialien nicht auffindbar → Verifizierung empfohlen.      | Kein Treffer in [Approved Uniform Pipeline Slide.pptx](https://boehringer.sharepoint.com/sites/mybi_news_onehp/_layouts/15/Doc.aspx?sourcedoc=%7B63F14EE4-3C76-49DB-B840-D27AE08037F2%7D\&file=Approved%20Uniform%20Pipeline%20Slide.pptx\&action=edit\&mobileredirect=true\&DefaultItemOpen=1\&EntityRepresentationId=892f150e-b2ab-4118-84ec-f51cca3a9751), Eye‑Health‑Summit‑Ankündigung und HPLS‑Decks; andere Eye‑Health‑Assets (z. B. BI 3812465, BI 764524) sind gelistet, BI 765243 nicht. [\[Approved U...line Slide | PowerPoint\]](https://boehringer.sharepoint.com/sites/mybi_news_onehp/_layouts/15/Doc.aspx?sourcedoc=%7B63F14EE4-3C76-49DB-B840-D27AE08037F2%7D&file=Approved%20Uniform%20Pipeline%20Slide.pptx&action=edit&mobileredirect=true&DefaultItemOpen=1), [\[👁 1st Eye...the invite | Viva Engage\]](https://engage.cloud.microsoft/main/threads/eyJfdHlwZSI6IlRocmVhZCIsImlkIjoiMzQ2ODMxNjAyMDQzMjg5NyJ9), [\[HPLS 2024...W_16x9_v02 | PowerPoint\]](https://boehringer.sharepoint.com/sites/z365hplsmeetingwebsite/_layouts/15/Doc.aspx?sourcedoc=%7B707D421A-0A84-46A9-986C-066DFC515499%7D&file=HPLS%202024%20-%20D2_SHOW_16x9_v02.pptx&action=edit&mobileredirect=true&DefaultItemOpen=1), [\[HPLS 2024...W_16x9_v02 | PowerPoint\]](https://boehringer.sharepoint.com/sites/z365hplsmeetingwebsite/_layouts/15/Doc.aspx?sourcedoc=%7B75F97424-5C60-455A-B7A7-4E958AAD43AE%7D&file=HPLS%202024%20-%20D2_SHOW_16x9_v02.pptx&action=edit&mobileredirect=true&DefaultItemOpen=1) |
| product\_name             | MAJOR    | Keine verlässliche Quelle für Produktnamen; Feld vorerst leer lassen, bis Code/Projekt bestätigt.                       | s. o. (keine Nennung in offiziellen BI‑Pipelines/Decks). [\[Approved U...line Slide | PowerPoint\]](https://boehringer.sharepoint.com/sites/mybi_news_onehp/_layouts/15/Doc.aspx?sourcedoc=%7B63F14EE4-3C76-49DB-B840-D27AE08037F2%7D&file=Approved%20Uniform%20Pipeline%20Slide.pptx&action=edit&mobileredirect=true&DefaultItemOpen=1), [\[👁 1st Eye...the invite | Viva Engage\]](https://engage.cloud.microsoft/main/threads/eyJfdHlwZSI6IlRocmVhZCIsImlkIjoiMzQ2ODMxNjAyMDQzMjg5NyJ9)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| modality\_name            | MAJOR    | Modalität („Recombinant Proteins/Bispezifisch“) nicht verifizierbar. Bitte nach Bestätigung des Projekts erneut prüfen. | s. o. [\[Approved U...line Slide | PowerPoint\]](https://boehringer.sharepoint.com/sites/mybi_news_onehp/_layouts/15/Doc.aspx?sourcedoc=%7B63F14EE4-3C76-49DB-B840-D27AE08037F2%7D&file=Approved%20Uniform%20Pipeline%20Slide.pptx&action=edit&mobileredirect=true&DefaultItemOpen=1)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| product\_type             | MAJOR    | „NBE“ nicht belegbar ohne Projektbestätigung.                                                                           | s. o. [\[Approved U...line Slide | PowerPoint\]](https://boehringer.sharepoint.com/sites/mybi_news_onehp/_layouts/15/Doc.aspx?sourcedoc=%7B63F14EE4-3C76-49DB-B840-D27AE08037F2%7D&file=Approved%20Uniform%20Pipeline%20Slide.pptx&action=edit&mobileredirect=true&DefaultItemOpen=1)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| therapeutic\_area         | MAJOR    | „Eye Health“ für BI 765243 nicht belegbar; keine Projektspur.                                                           | s. o. [\[👁 1st Eye...the invite | Viva Engage\]](https://engage.cloud.microsoft/main/threads/eyJfdHlwZSI6IlRocmVhZCIsImlkIjoiMzQ2ODMxNjAyMDQzMjg5NyJ9)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| mechanism\_of\_action     | MAJOR    | „TrkB/anti‑VEGF (bispezifisch)“ nicht verifizierbar.                                                                    | s. o. [\[HPLS 2024...W_16x9_v02 | PowerPoint\]](https://boehringer.sharepoint.com/sites/z365hplsmeetingwebsite/_layouts/15/Doc.aspx?sourcedoc=%7B707D421A-0A84-46A9-986C-066DFC515499%7D&file=HPLS%202024%20-%20D2_SHOW_16x9_v02.pptx&action=edit&mobileredirect=true&DefaultItemOpen=1), [\[HPLS 2024...W_16x9_v02 | PowerPoint\]](https://boehringer.sharepoint.com/sites/z365hplsmeetingwebsite/_layouts/15/Doc.aspx?sourcedoc=%7B75F97424-5C60-455A-B7A7-4E958AAD43AE%7D&file=HPLS%202024%20-%20D2_SHOW_16x9_v02.pptx&action=edit&mobileredirect=true&DefaultItemOpen=1)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| short\_description        | MAJOR    | Beschreibung nicht belegbar; bis Projektbestätigung keine Änderung der Fachangaben ableitbar.                           | s. o. [\[Approved U...line Slide | PowerPoint\]](https://boehringer.sharepoint.com/sites/mybi_news_onehp/_layouts/15/Doc.aspx?sourcedoc=%7B63F14EE4-3C76-49DB-B840-D27AE08037F2%7D&file=Approved%20Uniform%20Pipeline%20Slide.pptx&action=edit&mobileredirect=true&DefaultItemOpen=1)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| dosage\_form              | MAJOR    | Nicht verifizierbar (keine belastbaren Angaben).                                                                        | s. o. [\[👁 1st Eye...the invite | Viva Engage\]](https://engage.cloud.microsoft/main/threads/eyJfdHlwZSI6IlRocmVhZCIsImlkIjoiMzQ2ODMxNjAyMDQzMjg5NyJ9)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| route\_of\_administration | MAJOR    | Nicht verifizierbar.                                                                                                    | s. o. [\[Approved U...line Slide | PowerPoint\]](https://boehringer.sharepoint.com/sites/mybi_news_onehp/_layouts/15/Doc.aspx?sourcedoc=%7B63F14EE4-3C76-49DB-B840-D27AE08037F2%7D&file=Approved%20Uniform%20Pipeline%20Slide.pptx&action=edit&mobileredirect=true&DefaultItemOpen=1)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| base\_technology          | MAJOR    | Nicht verifizierbar.                                                                                                    | s. o. [\[HPLS 2024...W_16x9_v02 | PowerPoint\]](https://boehringer.sharepoint.com/sites/z365hplsmeetingwebsite/_layouts/15/Doc.aspx?sourcedoc=%7B707D421A-0A84-46A9-986C-066DFC515499%7D&file=HPLS%202024%20-%20D2_SHOW_16x9_v02.pptx&action=edit&mobileredirect=true&DefaultItemOpen=1)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| current\_phase            | MAJOR    | Nicht verifizierbar (kein internes/public Signal).                                                                      | s. o. [\[Approved U...line Slide | PowerPoint\]](https://boehringer.sharepoint.com/sites/mybi_news_onehp/_layouts/15/Doc.aspx?sourcedoc=%7B63F14EE4-3C76-49DB-B840-D27AE08037F2%7D&file=Approved%20Uniform%20Pipeline%20Slide.pptx&action=edit&mobileredirect=true&DefaultItemOpen=1)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |

**BI 3794407**

| Feld                      | Änderung | Beschreibung                                                                           | Evidenz                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| ------------------------- | -------- | -------------------------------------------------------------------------------------- | -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- |
| product\_code             | NONE     | Korrekt (BI 3794407).                                                                  | Interne Ankündigungen/US‑HPSC‑Unterlagen führen BI 3794407. [US HPSC Prep Meeting Agenda for November 2023.docx](https://boehringer.sharepoint.com/sites/z365pricingandcontractingoncology/_layouts/15/Doc.aspx?sourcedoc=%7B22BBF478-2D44-4602-8A7A-6E03779EFA30%7D\&file=US%20HPSC%20Prep%20Meeting%20Agenda%20for%20November%202023.docx\&action=default\&mobileredirect=true\&DefaultItemOpen=1\&EntityRepresentationId=9f07cd11-fed9-4ae2-891f-2a8586f90c11). [\[US HPSC Pr...ember 2023 | Word\]](https://boehringer.sharepoint.com/sites/z365pricingandcontractingoncology/_layouts/15/Doc.aspx?sourcedoc=%7B22BBF478-2D44-4602-8A7A-6E03779EFA30%7D&file=US%20HPSC%20Prep%20Meeting%20Agenda%20for%20November%202023.docx&action=default&mobileredirect=true&DefaultItemOpen=1)                                                                                                                                                                           |
| product\_name             | NONE     | Kein offizieller Name publiziert; Feld kann leer bleiben.                              | Nur Code in internen Dokumenten. [138\_Announcement\_SoD\_NISoD\_CNSDR\_CMDR\_IRDR.pdf](https://boehringer.sharepoint.com/sites/mybi_rsg/SiteAssets/SitePages/pldnmzoj/138_Announcement_SoD_NISoD_CNSDR_CMDR_IRDR.pdf?web=1\&EntityRepresentationId=1eaf6093-a53f-4159-822b-c2fee36c9484). [\[138_Announ..._CMDR_IRDR | PDF\]](https://boehringer.sharepoint.com/sites/mybi_rsg/SiteAssets/SitePages/pldnmzoj/138_Announcement_SoD_NISoD_CNSDR_CMDR_IRDR.pdf?web=1)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| modality\_name            | NONE     | „Small Molecule“ ist korrekt.                                                          | cGAS‑i Follow‑up wird als NCE/Small Molecule geführt. [2024\_ STING BU\_ BI 3797363\_ final - sIUPC.pptx](https://boehringer.sharepoint.com/sites/z36515pgdh/_layouts/15/Doc.aspx?sourcedoc=%7B0D099DFD-A792-4EAF-8755-A97AD7650CA9%7D\&file=2024_%20STING%20BU_%20BI%203797363_%20final%20-%20sIUPC.pptx\&action=edit\&mobileredirect=true\&DefaultItemOpen=1\&EntityRepresentationId=2d0ac2d6-f8f0-432c-9539-0cb74d283960) (Vergleich FR/FU). [\[2024_ STIN...al - sIUPC | PowerPoint\]](https://boehringer.sharepoint.com/sites/z36515pgdh/_layouts/15/Doc.aspx?sourcedoc=%7B0D099DFD-A792-4EAF-8755-A97AD7650CA9%7D&file=2024_%20STING%20BU_%20BI%203797363_%20final%20-%20sIUPC.pptx&action=edit&mobileredirect=true&DefaultItemOpen=1)                                                                                                                                                                                                                            |
| product\_type             | NONE     | „NME“ ist korrekt.                                                                     | Interne SoD‑Mitteilung FU‑NME. [138\_Announcement\_SoD\_NISoD\_CNSDR\_CMDR\_IRDR.pdf](https://boehringer.sharepoint.com/sites/mybi_rsg/SiteAssets/SitePages/pldnmzoj/138_Announcement_SoD_NISoD_CNSDR_CMDR_IRDR.pdf?web=1\&EntityRepresentationId=1eaf6093-a53f-4159-822b-c2fee36c9484). [\[138_Announ..._CMDR_IRDR | PDF\]](https://boehringer.sharepoint.com/sites/mybi_rsg/SiteAssets/SitePages/pldnmzoj/138_Announcement_SoD_NISoD_CNSDR_CMDR_IRDR.pdf?web=1)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| therapeutic\_area         | MAJOR    | Auf „Inflammation & Respiratory (I\&R)“ statt „Immunology; CRM“ korrigieren.           | Dokumente ordnen Projekt der TA Infl/I\&R zu (SSc/IFN). [US HPSC Prep Meeting Agenda for November 2023.docx](https://boehringer.sharepoint.com/sites/z365pricingandcontractingoncology/_layouts/15/Doc.aspx?sourcedoc=%7B22BBF478-2D44-4602-8A7A-6E03779EFA30%7D\&file=US%20HPSC%20Prep%20Meeting%20Agenda%20for%20November%202023.docx\&action=default\&mobileredirect=true\&DefaultItemOpen=1\&EntityRepresentationId=9f07cd11-fed9-4ae2-891f-2a8586f90c11). [\[US HPSC Pr...ember 2023 | Word\]](https://boehringer.sharepoint.com/sites/z365pricingandcontractingoncology/_layouts/15/Doc.aspx?sourcedoc=%7B22BBF478-2D44-4602-8A7A-6E03779EFA30%7D&file=US%20HPSC%20Prep%20Meeting%20Agenda%20for%20November%202023.docx&action=default&mobileredirect=true&DefaultItemOpen=1)                                                                                                                                                                               |
| mechanism\_of\_action     | NONE     | „cGAS inhibitor“ ist korrekt.                                                          | Mehrere interne Quellen nennen cGAS‑Inhibitor. [US HPSC Prep Meeting Agenda for November 2023.docx](https://boehringer.sharepoint.com/sites/z365pricingandcontractingoncology/_layouts/15/Doc.aspx?sourcedoc=%7B22BBF478-2D44-4602-8A7A-6E03779EFA30%7D\&file=US%20HPSC%20Prep%20Meeting%20Agenda%20for%20November%202023.docx\&action=default\&mobileredirect=true\&DefaultItemOpen=1\&EntityRepresentationId=9f07cd11-fed9-4ae2-891f-2a8586f90c11), 138\_Announcement\_SoD…pdf. [\[US HPSC Pr...ember 2023 | Word\]](https://boehringer.sharepoint.com/sites/z365pricingandcontractingoncology/_layouts/15/Doc.aspx?sourcedoc=%7B22BBF478-2D44-4602-8A7A-6E03779EFA30%7D&file=US%20HPSC%20Prep%20Meeting%20Agenda%20for%20November%202023.docx&action=default&mobileredirect=true&DefaultItemOpen=1), [\[138_Announ..._CMDR_IRDR | PDF\]](https://boehringer.sharepoint.com/sites/mybi_rsg/SiteAssets/SitePages/pldnmzoj/138_Announcement_SoD_NISoD_CNSDR_CMDR_IRDR.pdf?web=1) |
| short\_description        | MINOR    | Präzisieren: „oraler cGAS‑Inhibitor für SSc und Typ‑I‑Interferonopathien (FU zum FR)“. | Oral/QD‑Profil und Indikationen beschrieben. [US HPSC Prep Meeting Agenda for November 2023.docx](https://boehringer.sharepoint.com/sites/z365pricingandcontractingoncology/_layouts/15/Doc.aspx?sourcedoc=%7B22BBF478-2D44-4602-8A7A-6E03779EFA30%7D\&file=US%20HPSC%20Prep%20Meeting%20Agenda%20for%20November%202023.docx\&action=default\&mobileredirect=true\&DefaultItemOpen=1\&EntityRepresentationId=9f07cd11-fed9-4ae2-891f-2a8586f90c11). [\[US HPSC Pr...ember 2023 | Word\]](https://boehringer.sharepoint.com/sites/z365pricingandcontractingoncology/_layouts/15/Doc.aspx?sourcedoc=%7B22BBF478-2D44-4602-8A7A-6E03779EFA30%7D&file=US%20HPSC%20Prep%20Meeting%20Agenda%20for%20November%202023.docx&action=default&mobileredirect=true&DefaultItemOpen=1)                                                                                                                                                                                          |
| dosage\_form              | MINOR    | Ergänzen: „oral (Tablette/Kapsel, geplant)“.                                           | „Administration is oral“ (HPSC). [US HPSC Prep Meeting Agenda for November 2023.docx](https://boehringer.sharepoint.com/sites/z365pricingandcontractingoncology/_layouts/15/Doc.aspx?sourcedoc=%7B22BBF478-2D44-4602-8A7A-6E03779EFA30%7D\&file=US%20HPSC%20Prep%20Meeting%20Agenda%20for%20November%202023.docx\&action=default\&mobileredirect=true\&DefaultItemOpen=1\&EntityRepresentationId=9f07cd11-fed9-4ae2-891f-2a8586f90c11). [\[US HPSC Pr...ember 2023 | Word\]](https://boehringer.sharepoint.com/sites/z365pricingandcontractingoncology/_layouts/15/Doc.aspx?sourcedoc=%7B22BBF478-2D44-4602-8A7A-6E03779EFA30%7D&file=US%20HPSC%20Prep%20Meeting%20Agenda%20for%20November%202023.docx&action=default&mobileredirect=true&DefaultItemOpen=1)                                                                                                                                                                                                      |
| route\_of\_administration | MINOR    | Auf „oral“ ergänzen.                                                                   | s. o. [\[US HPSC Pr...ember 2023 | Word\]](https://boehringer.sharepoint.com/sites/z365pricingandcontractingoncology/_layouts/15/Doc.aspx?sourcedoc=%7B22BBF478-2D44-4602-8A7A-6E03779EFA30%7D&file=US%20HPSC%20Prep%20Meeting%20Agenda%20for%20November%202023.docx&action=default&mobileredirect=true&DefaultItemOpen=1)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| base\_technology          | MINOR    | Ergänzen: „makrozyklisches NCE (QD‑Profil)“.                                           | FU wird als Makrozyklus mit QD‑Profil beschrieben. 138\_Announcement\_SoD…pdf. [\[138_Announ..._CMDR_IRDR | PDF\]](https://boehringer.sharepoint.com/sites/mybi_rsg/SiteAssets/SitePages/pldnmzoj/138_Announcement_SoD_NISoD_CNSDR_CMDR_IRDR.pdf?web=1)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| current\_phase            | NONE     | „Pre‑Clinical“ ist korrekt (tox‑ready/parked; kein Ph‑I‑Start).                        | FU tox‑ready, als Reserve/Replacement vorgesehen. [US HPSC Prep Meeting Agenda for November 2023.docx](https://boehringer.sharepoint.com/sites/z365pricingandcontractingoncology/_layouts/15/Doc.aspx?sourcedoc=%7B22BBF478-2D44-4602-8A7A-6E03779EFA30%7D\&file=US%20HPSC%20Prep%20Meeting%20Agenda%20for%20November%202023.docx\&action=default\&mobileredirect=true\&DefaultItemOpen=1\&EntityRepresentationId=9f07cd11-fed9-4ae2-891f-2a8586f90c11). [\[US HPSC Pr...ember 2023 | Word\]](https://boehringer.sharepoint.com/sites/z365pricingandcontractingoncology/_layouts/15/Doc.aspx?sourcedoc=%7B22BBF478-2D44-4602-8A7A-6E03779EFA30%7D&file=US%20HPSC%20Prep%20Meeting%20Agenda%20for%20November%202023.docx&action=default&mobileredirect=true&DefaultItemOpen=1)                                                                                                                                                                                     |

**BI 3731579**

| Feld                      | Änderung | Beschreibung                                                                                                                                                         | Evidenz                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| ------------------------- | -------- | -------------------------------------------------------------------------------------------------------------------------------------------------------------------- | ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ |
| product\_code             | NONE     | Korrekt (BI 3731579).                                                                                                                                                | IB und CMC‑Doks führen BI 3731579. [ib-bi3731579-1519-p1-version-2.pdf](https://boehringer.sharepoint.com/sites/z365ridgefieldenvironmentalhealthandsafetymybi/EHS%20Documents/Environmental/Environmental%20Risk%20Assessments/Product%20Environmental%20Risk%20Assessment/INDs/BI%203731579/ib-bi3731579-1519-p1-version-2.pdf?web=1\&EntityRepresentationId=1009b20b-1bd6-4510-8b1b-95ccad3d5156). [\[ib-bi37315...-version-2 | PDF\]](https://boehringer.sharepoint.com/sites/z365ridgefieldenvironmentalhealthandsafetymybi/EHS%20Documents/Environmental/Environmental%20Risk%20Assessments/Product%20Environmental%20Risk%20Assessment/INDs/BI%203731579/ib-bi3731579-1519-p1-version-2.pdf?web=1)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| product\_name             | NONE     | Kein offizieller Name; Feld leer lassen.                                                                                                                             | Nur Code verwendet. [ib-bi3731579-1519-p1-version-2.pdf](https://boehringer.sharepoint.com/sites/z365ridgefieldenvironmentalhealthandsafetymybi/EHS%20Documents/Environmental/Environmental%20Risk%20Assessments/Product%20Environmental%20Risk%20Assessment/INDs/BI%203731579/ib-bi3731579-1519-p1-version-2.pdf?web=1\&EntityRepresentationId=1009b20b-1bd6-4510-8b1b-95ccad3d5156). [\[ib-bi37315...-version-2 | PDF\]](https://boehringer.sharepoint.com/sites/z365ridgefieldenvironmentalhealthandsafetymybi/EHS%20Documents/Environmental/Environmental%20Risk%20Assessments/Product%20Environmental%20Risk%20Assessment/INDs/BI%203731579/ib-bi3731579-1519-p1-version-2.pdf?web=1)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| modality\_name            | NONE     | „Small Molecule“ ist korrekt.                                                                                                                                        | NOX4‑Inhibitor, chemisch. [ib-bi3731579-1519-p1-version-2.pdf](https://boehringer.sharepoint.com/sites/z365ridgefieldenvironmentalhealthandsafetymybi/EHS%20Documents/Environmental/Environmental%20Risk%20Assessments/Product%20Environmental%20Risk%20Assessment/INDs/BI%203731579/ib-bi3731579-1519-p1-version-2.pdf?web=1\&EntityRepresentationId=1009b20b-1bd6-4510-8b1b-95ccad3d5156). [\[ib-bi37315...-version-2 | PDF\]](https://boehringer.sharepoint.com/sites/z365ridgefieldenvironmentalhealthandsafetymybi/EHS%20Documents/Environmental/Environmental%20Risk%20Assessments/Product%20Environmental%20Risk%20Assessment/INDs/BI%203731579/ib-bi3731579-1519-p1-version-2.pdf?web=1)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| product\_type             | NONE     | „NME“ ist korrekt.                                                                                                                                                   | s. o. [\[ib-bi37315...-version-2 | PDF\]](https://boehringer.sharepoint.com/sites/z365ridgefieldenvironmentalhealthandsafetymybi/EHS%20Documents/Environmental/Environmental%20Risk%20Assessments/Product%20Environmental%20Risk%20Assessment/INDs/BI%203731579/ib-bi3731579-1519-p1-version-2.pdf?web=1)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| therapeutic\_area         | MINOR    | Auf „Inflammation & Respiratory / Respiratory (IPF/PPF)“ präzisieren.                                                                                                | TA‑Übersichten listen NOX4 für IPF/PPF. [TA-Inflammation-Townhall-10.12.24.pptx](https://boehringer.sharepoint.com/sites/mybi_tainflammation/_layouts/15/Doc.aspx?sourcedoc=%7BBB336138-FD16-4870-8D15-DE6E77EB4D7B%7D\&file=TA-Inflammation-Townhall-10.12.24.pptx\&action=edit\&mobileredirect=true\&DefaultItemOpen=1\&EntityRepresentationId=2c1135ef-d0ac-4e29-a532-087991d77086). [\[TA-Inflamm...l-10.12.24 | PowerPoint\]](https://boehringer.sharepoint.com/sites/mybi_tainflammation/_layouts/15/Doc.aspx?sourcedoc=%7BBB336138-FD16-4870-8D15-DE6E77EB4D7B%7D&file=TA-Inflammation-Townhall-10.12.24.pptx&action=edit&mobileredirect=true&DefaultItemOpen=1)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| mechanism\_of\_action     | NONE     | „NOX4 inhibitor“ ist korrekt.                                                                                                                                        | IB zeigt selektive NOX4‑Hemmung. [ib-bi3731579-1519-p1-version-2.pdf](https://boehringer.sharepoint.com/sites/z365ridgefieldenvironmentalhealthandsafetymybi/EHS%20Documents/Environmental/Environmental%20Risk%20Assessments/Product%20Environmental%20Risk%20Assessment/INDs/BI%203731579/ib-bi3731579-1519-p1-version-2.pdf?web=1\&EntityRepresentationId=1009b20b-1bd6-4510-8b1b-95ccad3d5156). [\[ib-bi37315...-version-2 | PDF\]](https://boehringer.sharepoint.com/sites/z365ridgefieldenvironmentalhealthandsafetymybi/EHS%20Documents/Environmental/Environmental%20Risk%20Assessments/Product%20Environmental%20Risk%20Assessment/INDs/BI%203731579/ib-bi3731579-1519-p1-version-2.pdf?web=1)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| short\_description        | MINOR    | Präzisieren: „oraler NOX4‑Inhibitor zur Progressionsverlangsamung bei IPF/PPF (präklinisch)“.                                                                        | Pipeline‑Folie & IB. [TA-Inflammation-Townhall-10.12.24.pptx](https://boehringer.sharepoint.com/sites/mybi_tainflammation/_layouts/15/Doc.aspx?sourcedoc=%7BBB336138-FD16-4870-8D15-DE6E77EB4D7B%7D\&file=TA-Inflammation-Townhall-10.12.24.pptx\&action=edit\&mobileredirect=true\&DefaultItemOpen=1\&EntityRepresentationId=2c1135ef-d0ac-4e29-a532-087991d77086), [ib-bi3731579-1519-p1-version-2.pdf](https://boehringer.sharepoint.com/sites/z365ridgefieldenvironmentalhealthandsafetymybi/EHS%20Documents/Environmental/Environmental%20Risk%20Assessments/Product%20Environmental%20Risk%20Assessment/INDs/BI%203731579/ib-bi3731579-1519-p1-version-2.pdf?web=1\&EntityRepresentationId=1009b20b-1bd6-4510-8b1b-95ccad3d5156). [\[TA-Inflamm...l-10.12.24 | PowerPoint\]](https://boehringer.sharepoint.com/sites/mybi_tainflammation/_layouts/15/Doc.aspx?sourcedoc=%7BBB336138-FD16-4870-8D15-DE6E77EB4D7B%7D&file=TA-Inflammation-Townhall-10.12.24.pptx&action=edit&mobileredirect=true&DefaultItemOpen=1), [\[ib-bi37315...-version-2 | PDF\]](https://boehringer.sharepoint.com/sites/z365ridgefieldenvironmentalhealthandsafetymybi/EHS%20Documents/Environmental/Environmental%20Risk%20Assessments/Product%20Environmental%20Risk%20Assessment/INDs/BI%203731579/ib-bi3731579-1519-p1-version-2.pdf?web=1) |
| dosage\_form              | MINOR    | Auf „film‑coated tablet (Tablette)“ konkretisieren.                                                                                                                  | Herstellunterlagen zeigen Filmtabletten. BI 3731579 Film-coated Tablets, 3 mg (Formulation A1). [\[BI 3731579...lation A1) | Extern\]](https://bi-docs-vault-quality.veevavault.com/ui/#doc_info/1208583)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| route\_of\_administration | MINOR    | Auf „oral“ ergänzen.                                                                                                                                                 | s. o. (Tabletten). BI 3731579 Film-coated Tablets, 3 mg (Formulation A1). [\[BI 3731579...lation A1) | Extern\]](https://bi-docs-vault-quality.veevavault.com/ui/#doc_info/1208583)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| base\_technology          | MAJOR    | Von „Organic Spray Drying; Roller Compaction“ auf „Spray‑Dried Dispersion (HPMCAS) → Direktverpressung/Filmbeschichtung; **keine** Walzenkompaktierung“ korrigieren. | SDD‑Flows & CoAs belegen SDD (HPMCAS) + Blenden/Verpressen; keine Roller‑Compaction‑Schritte. BI 3731579 Spray-dried powder (Drug load: 33.3 %), BI 3731579 Spray dried in-process material (Drug Load 33.3%), BI 3731579 Film-coated Tablets, 3 mg (Formulation A1). [\[BI 3731579...d: 33.3 %) | Extern\]](https://bi-docs-vault-quality.veevavault.com/ui/#doc_info/2331504), [\[BI 3731579...oad 33.3%) | Extern\]](https://bi-docs-vault-quality.veevavault.com/ui/#doc_info/1257691), [\[BI 3731579...lation A1) | Extern\]](https://bi-docs-vault-quality.veevavault.com/ui/#doc_info/1208583)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| current\_phase            | NONE     | „Pre‑Clinical“ ist korrekt.                                                                                                                                          | TA‑Portfolio zeigt präklinisch. [TA-Inflammation-Townhall-10.12.24.pptx](https://boehringer.sharepoint.com/sites/mybi_tainflammation/_layouts/15/Doc.aspx?sourcedoc=%7BBB336138-FD16-4870-8D15-DE6E77EB4D7B%7D\&file=TA-Inflammation-Townhall-10.12.24.pptx\&action=edit\&mobileredirect=true\&DefaultItemOpen=1\&EntityRepresentationId=2c1135ef-d0ac-4e29-a532-087991d77086). [\[TA-Inflamm...l-10.12.24 | PowerPoint\]](https://boehringer.sharepoint.com/sites/mybi_tainflammation/_layouts/15/Doc.aspx?sourcedoc=%7BBB336138-FD16-4870-8D15-DE6E77EB4D7B%7D&file=TA-Inflammation-Townhall-10.12.24.pptx&action=edit&mobileredirect=true&DefaultItemOpen=1)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |

**BI 3009947**

| Feld                      | Änderung | Beschreibung                                                                                                                                                  | Evidenz                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| ------------------------- | -------- | ------------------------------------------------------------------------------------------------------------------------------------------------------------- | ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- |
| product\_code             | NONE     | Unverändert: „BI 3009947“.                                                                                                                                    | [138\_Announcement\_SoD\_NISoD\_CNSDR\_CMDR\_IRDR.pdf](https://boehringer.sharepoint.com/sites/mybi_rsg/SiteAssets/SitePages/pldnmzoj/138_Announcement_SoD_NISoD_CNSDR_CMDR_IRDR.pdf?web=1\&EntityRepresentationId=7d0d3c82-158f-43d0-a31c-98bc1fd3d31c) bestätigt den Code. [\[138_Announ..._CMDR_IRDR | PDF\]](https://boehringer.sharepoint.com/sites/mybi_rsg/SiteAssets/SitePages/pldnmzoj/138_Announcement_SoD_NISoD_CNSDR_CMDR_IRDR.pdf?web=1)                                                                                                                                                                                                                                                                                                  |
| product\_name             | NONE     | Kein veröffentlichter Name gefunden; Code-Bezeichnung bleibt korrekt.                                                                                         | Interne STING-Assets-Dokumente führen ausschließlich die Code-Bezeichnung. [NCE IUPD\_STINGi\_BI03797363\_final.docx](https://boehringer.sharepoint.com/sites/z36515pgdh/_layouts/15/Doc.aspx?sourcedoc=%7BDF4E1DC4-5A1E-494A-B91C-7613395FD3AE%7D\&file=NCE%20IUPD_STINGi_BI03797363_final.docx\&action=default\&mobileredirect=true\&DefaultItemOpen=1\&EntityRepresentationId=6386c304-01e5-4879-b0a6-73bc39f027aa) [\[NCE IUPD_S...7363_final | Word\]](https://boehringer.sharepoint.com/sites/z36515pgdh/_layouts/15/Doc.aspx?sourcedoc=%7BDF4E1DC4-5A1E-494A-B91C-7613395FD3AE%7D&file=NCE%20IUPD_STINGi_BI03797363_final.docx&action=default&mobileredirect=true&DefaultItemOpen=1)                                                             |
| modality\_name            | NONE     | „Small Molecule“ ist korrekt.                                                                                                                                 | STING-Inhibitor als niedermolekularer Wirkstoff in [NCE IUPD\_STINGi\_BI03797363\_final.docx](https://boehringer.sharepoint.com/sites/z36515pgdh/_layouts/15/Doc.aspx?sourcedoc=%7BDF4E1DC4-5A1E-494A-B91C-7613395FD3AE%7D\&file=NCE%20IUPD_STINGi_BI03797363_final.docx\&action=default\&mobileredirect=true\&DefaultItemOpen=1\&EntityRepresentationId=6386c304-01e5-4879-b0a6-73bc39f027aa). [\[NCE IUPD_S...7363_final | Word\]](https://boehringer.sharepoint.com/sites/z36515pgdh/_layouts/15/Doc.aspx?sourcedoc=%7BDF4E1DC4-5A1E-494A-B91C-7613395FD3AE%7D&file=NCE%20IUPD_STINGi_BI03797363_final.docx&action=default&mobileredirect=true&DefaultItemOpen=1)                                                                                    |
| product\_type             | NONE     | „NME“ ist korrekt.                                                                                                                                            | Pipeline-Übersichten listen BI 3009947 als NME. [TA\_Breakout\_IPF\_ILD\_Leticia\_MedWeek\_2024.pptx](https://boehringer.sharepoint.com/sites/mybi_medicine_usa/_layouts/15/Doc.aspx?sourcedoc=%7BC9D302B5-5729-49CF-B477-DBC83ED9A45F%7D\&file=TA_Breakout_IPF_ILD_Leticia_MedWeek_2024.pptx\&action=edit\&mobileredirect=true\&DefaultItemOpen=1\&EntityRepresentationId=f2fd6eb4-8b0f-49b8-ac80-8e9d3b27b418) [\[TA_Breakou...dWeek_2024 | PowerPoint\]](https://boehringer.sharepoint.com/sites/mybi_medicine_usa/_layouts/15/Doc.aspx?sourcedoc=%7BC9D302B5-5729-49CF-B477-DBC83ED9A45F%7D&file=TA_Breakout_IPF_ILD_Leticia_MedWeek_2024.pptx&action=edit&mobileredirect=true&DefaultItemOpen=1)                                                         |
| therapeutic\_area         | NONE     | „Immunology“ (intern TA Inflammation/Rheumatology) ist inhaltlich stimmig.                                                                                    | [TA-Inflammation-Townhall-10.12.24.pptx](https://boehringer.sharepoint.com/sites/mybi_tainflammation/SiteAssets/SitePages/Leadership-and-Strategy/TA-Inflammation-Townhall-10.12.24.pptx?web=1\&EntityRepresentationId=2eefce9e-36fb-47f8-8d7a-6dccde2cd926) ordnet BI 3009947 der TA Inflammation zu. [\[TA-Inflamm...l-10.12.24 | PowerPoint\]](https://boehringer.sharepoint.com/sites/mybi_tainflammation/SiteAssets/SitePages/Leadership-and-Strategy/TA-Inflammation-Townhall-10.12.24.pptx?web=1)                                                                                                                                                                                                                                                      |
| mechanism\_of\_action     | NONE     | „STING inhibitor“ ist korrekt.                                                                                                                                | MoA-Details in [NCE IUPD\_STINGi\_BI03797363\_final.docx](https://boehringer.sharepoint.com/sites/z36515pgdh/_layouts/15/Doc.aspx?sourcedoc=%7BDF4E1DC4-5A1E-494A-B91C-7613395FD3AE%7D\&file=NCE%20IUPD_STINGi_BI03797363_final.docx\&action=default\&mobileredirect=true\&DefaultItemOpen=1\&EntityRepresentationId=6386c304-01e5-4879-b0a6-73bc39f027aa). [\[NCE IUPD_S...7363_final | Word\]](https://boehringer.sharepoint.com/sites/z36515pgdh/_layouts/15/Doc.aspx?sourcedoc=%7BDF4E1DC4-5A1E-494A-B91C-7613395FD3AE%7D&file=NCE%20IUPD_STINGi_BI03797363_final.docx&action=default&mobileredirect=true&DefaultItemOpen=1)                                                                                                                        |
| short\_description        | NONE     | „…für systemische Sklerose & Interferonopathien“ ist konsistent.                                                                                              | Indikationsrahmen in [US HPSC Prep Meeting Agenda for November 2023.docx](https://boehringer.sharepoint.com/sites/z365pricingandcontractingoncology/_layouts/15/Doc.aspx?sourcedoc=%7B22BBF478-2D44-4602-8A7A-6E03779EFA30%7D\&file=US%20HPSC%20Prep%20Meeting%20Agenda%20for%20November%202023.docx\&action=default\&mobileredirect=true\&DefaultItemOpen=1\&EntityRepresentationId=ca9d5fc7-f3b3-475f-a2b3-53e94350ecf0). [\[US HPSC Pr...ember 2023 | Word\]](https://boehringer.sharepoint.com/sites/z365pricingandcontractingoncology/_layouts/15/Doc.aspx?sourcedoc=%7B22BBF478-2D44-4602-8A7A-6E03779EFA30%7D&file=US%20HPSC%20Prep%20Meeting%20Agenda%20for%20November%202023.docx&action=default&mobileredirect=true&DefaultItemOpen=1)        |
| dosage\_form              | MINOR    | Zielwert: „Orale Darreichungsform geplant (exakte Formulierung TBD)“ – intern wird orale Gabe genannt, konkrete Darreichungsform noch nicht final publiziert. | „Administration is oral“ in [US HPSC Prep Meeting Agenda for November 2023.docx](https://boehringer.sharepoint.com/sites/z365pricingandcontractingoncology/_layouts/15/Doc.aspx?sourcedoc=%7B22BBF478-2D44-4602-8A7A-6E03779EFA30%7D\&file=US%20HPSC%20Prep%20Meeting%20Agenda%20for%20November%202023.docx\&action=default\&mobileredirect=true\&DefaultItemOpen=1\&EntityRepresentationId=ca9d5fc7-f3b3-475f-a2b3-53e94350ecf0). [\[US HPSC Pr...ember 2023 | Word\]](https://boehringer.sharepoint.com/sites/z365pricingandcontractingoncology/_layouts/15/Doc.aspx?sourcedoc=%7B22BBF478-2D44-4602-8A7A-6E03779EFA30%7D&file=US%20HPSC%20Prep%20Meeting%20Agenda%20for%20November%202023.docx&action=default&mobileredirect=true&DefaultItemOpen=1) |
| route\_of\_administration | MINOR    | Zielwert: „Oral“.                                                                                                                                             | [US HPSC Prep Meeting Agenda for November 2023.docx](https://boehringer.sharepoint.com/sites/z365pricingandcontractingoncology/_layouts/15/Doc.aspx?sourcedoc=%7B22BBF478-2D44-4602-8A7A-6E03779EFA30%7D\&file=US%20HPSC%20Prep%20Meeting%20Agenda%20for%20November%202023.docx\&action=default\&mobileredirect=true\&DefaultItemOpen=1\&EntityRepresentationId=ca9d5fc7-f3b3-475f-a2b3-53e94350ecf0). [\[US HPSC Pr...ember 2023 | Word\]](https://boehringer.sharepoint.com/sites/z365pricingandcontractingoncology/_layouts/15/Doc.aspx?sourcedoc=%7B22BBF478-2D44-4602-8A7A-6E03779EFA30%7D&file=US%20HPSC%20Prep%20Meeting%20Agenda%20for%20November%202023.docx&action=default&mobileredirect=true&DefaultItemOpen=1)                             |
| base\_technology          | NONE     | Keine belastbare Quelle für spezifische Basistechnologie gefunden; belassen.                                                                                  | –                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| current\_phase            | NONE     | „Pre-Clinical“ ist korrekt.                                                                                                                                   | Pipeline-Folien zeigen BI 3009947 präklinisch. [TA\_Breakout\_IPF\_ILD\_Leticia\_MedWeek\_2024.pptx](https://boehringer.sharepoint.com/sites/mybi_medicine_usa/_layouts/15/Doc.aspx?sourcedoc=%7BC9D302B5-5729-49CF-B477-DBC83ED9A45F%7D\&file=TA_Breakout_IPF_ILD_Leticia_MedWeek_2024.pptx\&action=edit\&mobileredirect=true\&DefaultItemOpen=1\&EntityRepresentationId=f2fd6eb4-8b0f-49b8-ac80-8e9d3b27b418) [\[TA_Breakou...dWeek_2024 | PowerPoint\]](https://boehringer.sharepoint.com/sites/mybi_medicine_usa/_layouts/15/Doc.aspx?sourcedoc=%7BC9D302B5-5729-49CF-B477-DBC83ED9A45F%7D&file=TA_Breakout_IPF_ILD_Leticia_MedWeek_2024.pptx&action=edit&mobileredirect=true&DefaultItemOpen=1)                                                          |

**BI 1810631 – Zongertinib**

| Feld                      | Änderung | Beschreibung                                                                                                                                                      | Evidenz                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| ------------------------- | -------- | ----------------------------------------------------------------------------------------------------------------------------------------------------------------- | ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- |
| product\_code             | NONE     | Unverändert: „BI 1810631“.                                                                                                                                        | [ib-bi-1810631-1479-p1-p2-version-7.pdf](https://boehringer.sharepoint.com/sites/mybi_taonco/SiteAssets/SitePages/IIS-and-ECR/ib-bi-1810631-1479-p1-p2-version-7.pdf?web=1\&EntityRepresentationId=8064da1f-c909-4a40-ac93-d4d67d84b017) [\[ib-bi-1810...-version-7 | PDF\]](https://boehringer.sharepoint.com/sites/mybi_taonco/SiteAssets/SitePages/IIS-and-ECR/ib-bi-1810631-1479-p1-p2-version-7.pdf?web=1)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| product\_name             | NONE     | „Zongertinib“ ist korrekt (US-Markenname: HERNEXEOS®; kein Wechsel des Feldwerts erforderlich).                                                                   | FDA-Mitteilung & BI-PR nennen HERNEXEOS® (Marke); Wirkstoffname bleibt Zongertinib. [FDA Notice](https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-zongertinib-non-squamous-nsclc-her2-tkd-activating-mutations), [BI Press Release](https://www.boehringer-ingelheim.com/human-health/cancer/lung-cancer/fda-approval-hernexeos-first-oral-treatment-her2-mutant-advanced-nsclc)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| modality\_name            | NONE     | „Small Molecule“ korrekt.                                                                                                                                         | [ib-bi-1810631-1479-p1-p2-version-5.pdf](https://boehringer.sharepoint.com/sites/mybi_taonco/SiteAssets/SitePages/IIS-and-ECR/ib-bi-1810631-1479-p1-p2-version-5.pdf?web=1\&EntityRepresentationId=d8f9f12e-7d21-4153-a6c0-1e754fe5ffe1) (TKI, oral). [\[fda.gov\]](https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-zongertinib-non-squamous-nsclc-her2-tkd-activating-mutations)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| product\_type             | NONE     | „NME“ korrekt.                                                                                                                                                    | [2025-04-01\_Pipeline.pptx](https://boehringer-my.sharepoint.com/personal/oliver_gluth_boehringer-ingelheim_com/Documents/BI%20-%20Work/01_PROJECTS/2025_iManagement-private/02%20Pipeline/2025-04-01_Pipeline.pptx?web=1\&EntityRepresentationId=f7a13925-1cdb-4af4-85a3-5a2e23ab994e) [\[boehringer...elheim.com\]](https://www.boehringer-ingelheim.com/human-health/cancer/lung-cancer/fda-approval-hernexeos-first-oral-treatment-her2-mutant-advanced-nsclc)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| therapeutic\_area         | NONE     | „Oncology“ korrekt.                                                                                                                                               | [2025-04-01\_Pipeline.pptx](https://boehringer-my.sharepoint.com/personal/oliver_gluth_boehringer-ingelheim_com/Documents/BI%20-%20Work/01_PROJECTS/2025_iManagement-private/02%20Pipeline/2025-04-01_Pipeline.pptx?web=1\&EntityRepresentationId=f7a13925-1cdb-4af4-85a3-5a2e23ab994e) [\[boehringer...elheim.com\]](https://www.boehringer-ingelheim.com/human-health/cancer/lung-cancer/fda-approval-hernexeos-first-oral-treatment-her2-mutant-advanced-nsclc)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| mechanism\_of\_action     | NONE     | „Irreversible, HER2‑selektiver TKI“ korrekt.                                                                                                                      | [ib-bi-1810631-1479-p1-p2-version-5.pdf](https://boehringer.sharepoint.com/sites/mybi_taonco/SiteAssets/SitePages/IIS-and-ECR/ib-bi-1810631-1479-p1-p2-version-5.pdf?web=1\&EntityRepresentationId=d8f9f12e-7d21-4153-a6c0-1e754fe5ffe1) [\[fda.gov\]](https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-zongertinib-non-squamous-nsclc-her2-tkd-activating-mutations)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| short\_description        | NONE     | Beschreibung ist konsistent (NSCLC HER2‑mutiert).                                                                                                                 | [ib-bi-1810631-1479-p1-p2-version-7.pdf](https://boehringer.sharepoint.com/sites/mybi_taonco/SiteAssets/SitePages/IIS-and-ECR/ib-bi-1810631-1479-p1-p2-version-7.pdf?web=1\&EntityRepresentationId=8064da1f-c909-4a40-ac93-d4d67d84b017) [\[ib-bi-1810...-version-7 | PDF\]](https://boehringer.sharepoint.com/sites/mybi_taonco/SiteAssets/SitePages/IIS-and-ECR/ib-bi-1810631-1479-p1-p2-version-7.pdf?web=1)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| dosage\_form              | NONE     | „Tablet“ korrekt.                                                                                                                                                 | Supply-Chain/DP-Dokumente bestätigen Tablette (FCT). [Supply Chain Setup\_\_BI1810631\_April\_2023.pptx](https://boehringer.sharepoint.com/sites/z3653pm/_layouts/15/Doc.aspx?sourcedoc=%7BA5092EEB-C8D0-4D53-A2F9-4A1448B1E911%7D\&file=Supply%20Chain%20Setup__BI1810631_April_2023.pptx\&action=edit\&mobileredirect=true\&DefaultItemOpen=1\&EntityRepresentationId=2d8ffcfc-6680-4940-ba09-9aa1732e9045) [\[ib-bi-1810...-version-5 | PDF\]](https://boehringer.sharepoint.com/sites/mybi_taonco/SiteAssets/SitePages/IIS-and-ECR/ib-bi-1810631-1479-p1-p2-version-5.pdf?web=1)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| route\_of\_administration | NONE     | „Oral“ korrekt.                                                                                                                                                   | [ib-bi-1810631-1479-p1-p2-version-5.pdf](https://boehringer.sharepoint.com/sites/mybi_taonco/SiteAssets/SitePages/IIS-and-ECR/ib-bi-1810631-1479-p1-p2-version-5.pdf?web=1\&EntityRepresentationId=d8f9f12e-7d21-4153-a6c0-1e754fe5ffe1) [\[fda.gov\]](https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-zongertinib-non-squamous-nsclc-her2-tkd-activating-mutations)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| base\_technology          | MINOR    | Zielwert: „Spray Dried Dispersion (SDD) + Film‑Coated Tablet (FCT)“ anstelle „Organic Spray Drying; Roller Compaction“ (Formulierung/DP-Fluss so intern geführt). | [Zongertinib\_FEB2025\_BRM.pptx](https://boehringer.sharepoint.com/sites/z3653pm/_layouts/15/Doc.aspx?sourcedoc=%7B243F5BE7-AA62-4C69-A08E-ACFE044FA909%7D\&file=Zongertinib_FEB2025_BRM.pptx\&action=edit\&mobileredirect=true\&DefaultItemOpen=1\&EntityRepresentationId=7070ec94-130a-45df-af90-d7e3275d6759) (SDD + FCT) [\[2025-04-01_Pipeline | PowerPoint\]](https://boehringer-my.sharepoint.com/personal/oliver_gluth_boehringer-ingelheim_com/Documents/BI%20-%20Work/01_PROJECTS/2025_iManagement-private/02%20Pipeline/2025-04-01_Pipeline.pptx?web=1); [Supply Chain Setup\_\_BI1810631\_April\_2023.pptx](https://boehringer.sharepoint.com/sites/z3653pm/_layouts/15/Doc.aspx?sourcedoc=%7BA5092EEB-C8D0-4D53-A2F9-4A1448B1E911%7D\&file=Supply%20Chain%20Setup__BI1810631_April_2023.pptx\&action=edit\&mobileredirect=true\&DefaultItemOpen=1\&EntityRepresentationId=2d8ffcfc-6680-4940-ba09-9aa1732e9045) [\[ib-bi-1810...-version-5 | PDF\]](https://boehringer.sharepoint.com/sites/mybi_taonco/SiteAssets/SitePages/IIS-and-ECR/ib-bi-1810631-1479-p1-p2-version-5.pdf?web=1) |
| current\_phase            | MAJOR    | Zielwert: „Approved/Launched (US, Accelerated Approval 08‑Aug‑2025)“ statt „Registration“.                                                                        | FDA‑Mitteilung (08.08.2025) [FDA Notice](https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-zongertinib-non-squamous-nsclc-her2-tkd-activating-mutations); BI‑Presse [BI Press](https://www.boehringer-ingelheim.com/human-health/cancer/lung-cancer/fda-approval-hernexeos-first-oral-treatment-her2-mutant-advanced-nsclc)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |

Selbstverständlich, und ich entschuldige mich aufrichtig für den erneuten Abbruch. Das ist frustrierend und sollte nicht passieren.

Hier ist die Fortsetzung, beginnend mit dem vollständigen Eintrag für **BI 1015550 – Nerandomilast** und allen darauf folgenden Produkten.

**BI 1015550 – Nerandomilast**

| Feld                      | Änderung | Beschreibung                                                                                                                       | Evidenz                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| ------------------------- | -------- | ---------------------------------------------------------------------------------------------------------------------------------- | ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ |
| product\_code             | NONE     | Unverändert: „BI 1015550“.                                                                                                         | [Nerandomilast guidance.pdf](https://boehringer.sharepoint.com/sites/pde4bhive/Shared%20Documents/PDE4Bi%20INN%20Assets/PDE4Bi/Nerandomilast%20guidance.pdf?web=1\&EntityRepresentationId=634e34f2-a171-44c6-8b6f-ad431eea62b4) (INN‑Guidance) [\[Supply Cha...April_2023 | PowerPoint\]](https://boehringer.sharepoint.com/sites/z3653pm/_layouts/15/Doc.aspx?sourcedoc=%7BA5092EEB-C8D0-4D53-A2F9-4A1448B1E911%7D&file=Supply%20Chain%20Setup__BI1810631_April_2023.pptx&action=edit&mobileredirect=true&DefaultItemOpen=1)                                                                                                                                                                                                                                                                               |
| product\_name             | NONE     | „Nerandomilast“ korrekt (US‑Marke: JASCAYD®; Feld unverändert).                                                                    | FDA‑Approval Letter (NDA 218764) [FDA Letter](https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2025/218764Orig1s000ltr.pdf)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| modality\_name            | NONE     | „Small Molecule“ korrekt.                                                                                                          | PDE4B‑Small‑Molecule in g-BI1015550-004(EN)\_Diarrhea…pdf [\[Zongertini...EB2025_BRM | PowerPoint\]](https://boehringer.sharepoint.com/sites/z3653pm/_layouts/15/Doc.aspx?sourcedoc=%7B243F5BE7-AA62-4C69-A08E-ACFE044FA909%7D&file=Zongertinib_FEB2025_BRM.pptx&action=edit&mobileredirect=true&DefaultItemOpen=1)                                                                                                                                                                                                                                                                                                                                                        |
| product\_type             | NONE     | „NME“ korrekt.                                                                                                                     | Pipeline-/Brand‑Unterlagen. [2024-09-11\_Betriebsversammlung\_eng.pdf](https://boehringer.sharepoint.com/sites/mybi_arbeitnehmervertretungen_ger/Freigegebene%20Dokumente/Betriebsrat%20Gemeinschaftsbetrieb%202/Betriebsversammlungen/2024-11-09/Pr%c3%a4sentation/2024-09-11_Betriebsversammlung_eng.pdf?web=1\&EntityRepresentationId=71260513-858d-484e-bd43-2655df0346a9) [\[Nerandomil...t guidance | PDF\]](https://boehringer.sharepoint.com/sites/pde4bhive/Shared%20Documents/PDE4Bi%20INN%20Assets/PDE4Bi/Nerandomilast%20guidance.pdf?web=1)                                          |
| therapeutic\_area         | MINOR    | Zielwert: „Respiratory (IPF; PPF in Zulassung)“ statt „Respiratory; Immunology“, da US‑Zulassung für IPF vorliegt.                 | FDA‑Approval (IPF) [FDA Letter](https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2025/218764Orig1s000ltr.pdf); BI‑PR (Phase‑3‑Programm IPF/PPF) [BI Release](https://www.boehringer-ingelheim.com/human-health/lung-diseases/pulmonary-fibrosis/phase-3-trials-nerandomilast-slowed-lung-function-decline-ipf-and-ppf)                                                                                                                                                                                                                                                                                                                                                                                     |
| mechanism\_of\_action     | NONE     | „Preferentieller PDE4B‑Inhibitor“ korrekt.                                                                                         | NEJM‑Publikationen & BI‑Seiten. [NEJM PPF](https://www.nejm.org/doi/pdf/10.1056/NEJMoa2503643); [BI Release](https://www.boehringer-ingelheim.com/human-health/lung-diseases/pulmonary-fibrosis/phase-3-trials-nerandomilast-slowed-lung-function-decline-ipf-and-ppf)                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| short\_description        | MINOR    | Zielwert: „Oraler PDE4B‑Inhibitor, der den FVC‑Rückgang bei IPF signifikant verlangsamt (Phase‑3)“ – präziser zum belegten Nutzen. | NEJM (IPF/PPF) [NEJM PPF](https://www.nejm.org/doi/pdf/10.1056/NEJMoa2503643); BI‑Release (Phase‑3‑Ergebnisse) [BI Release](https://www.boehringer-ingelheim.com/human-health/lung-diseases/pulmonary-fibrosis/phase-3-trials-nerandomilast-slowed-lung-function-decline-ipf-and-ppf)                                                                                                                                                                                                                                                                                                                                                                                                                              |
| dosage\_form              | NONE     | „Tablet“ korrekt.                                                                                                                  | Phase‑1/3‑Materialien (oral). [g-BI1015550-013(EN)\_Phase 1\_renal\_hepatic impairment\_Sept2025.pdf](https://boehringer.sharepoint.com/sites/z365medicalaffairsropusa/Shared%20Documents/Medical%20Information/Working%20on%20.-/Documentos%20Globales/BI%201015550/g-BI1015550-013%28EN%29_Phase%201_renal_hepatic%20impairment_Sept2025.pdf?web=1\&EntityRepresentationId=ba7e8ae9-f51b-4c66-8371-5eefbd75bc65) [\[accessdata.fda.gov\]](https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2025/218764Orig1s000ltr.pdf) |
| route\_of\_administration | NONE     | „Oral“ korrekt.                                                                                                                    | [g-BI1015550-013(EN)\_Phase 1\_renal\_hepatic impairment\_Sept2025.pdf](https://boehringer.sharepoint.com/sites/z365medicalaffairsropusa/Shared%20Documents/Medical%20Information/Working%20on%20.-/Documentos%20Globales/BI%201015550/g-BI1015550-013%28EN%29_Phase%201_renal_hepatic%20impairment_Sept2025.pdf?web=1\&EntityRepresentationId=ba7e8ae9-f51b-4c66-8371-5eefbd75bc65) [\[accessdata.fda.gov\]](https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2025/218764Orig1s000ltr.pdf)                               |
| base\_technology          | NONE     | Keine verlässliche Quelle zur Bestätigung von „Twin Screw“ gefunden; belassen (Annahme korrekt mangels Gegenbeleg).                | –                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| current\_phase            | MAJOR    | Zielwert: „Approved/Launched (US, 09‑Oct‑2025, IPF)“ statt „Registration“.                                                         | FDA‑Approval (JASCAYD®, 09.10.2025) [FDA Letter](https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2025/218764Orig1s000ltr.pdf); BI‑PR [Press](https://www.globenewswire.com/news-release/2025/10/09/3163968/0/en/U-S-FDA-approves-Boehringer-s-JASCAYD-nerandomilast-tablets-as-first-new-treatment-option-for-adults-with-IPF-in-over-a-decade.html)                                                                                                                                                                                                                                                                                                                                                      |

**BI 456906 – Survodutide**

| Feld                      | Änderung | Beschreibung                                                                          | Evidenz                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| ------------------------- | -------- | ------------------------------------------------------------------------------------- | -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- |
| product\_code             | NONE     | Unverändert: „BI 456906“.                                                             | Pipeline/CRM‑Decks. [HORST.pptx](https://boehringer.sharepoint.com/sites/mybi_medicine_CDO/_layouts/15/Doc.aspx?sourcedoc=%7BB9A6FDD6-9DD2-4460-BF9B-89E93D6853AA%7D\&file=HORST.pptx\&action=edit\&mobileredirect=true\&DefaultItemOpen=1\&EntityRepresentationId=933be09f-9327-4c41-9593-7c631717c270) [\[g-BI101555...nt_Oct2025 | PDF\]](https://boehringer.sharepoint.com/sites/z365medicalaffairsropusa/Shared%20Documents/Medical%20Information/Working%20on%20.-/Documentos%20Globales/BI%201015550/g-BI1015550-004(EN)_Diarrhea_Mechanism,incidence,management_Oct2025.pdf?web=1)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| product\_name             | NONE     | „Survodutide“ korrekt.                                                                | BI‑Seiten/Presse. [Survodutide IAP 2025\_FINAL 5.27.pptx](https://boehringer.sharepoint.com/sites/z365ukieicp2025/_layouts/15/Doc.aspx?sourcedoc=%7B45002F71-4121-4560-8585-4572195D6EF2%7D\&file=Survodutide%20IAP%202025_FINAL%205.27.pptx\&action=edit\&mobileredirect=true\&DefaultItemOpen=1\&EntityRepresentationId=935c3c44-a834-4437-a19f-1b84b3570eec) [\[2024-09-11...mmlung_eng | PDF\]](https://boehringer.sharepoint.com/sites/mybi_arbeitnehmervertretungen_ger/Freigegebene%20Dokumente/Betriebsrat%20Gemeinschaftsbetrieb%202/Betriebsversammlungen/2024-11-09/Pr%c3%a4sentation/2024-09-11_Betriebsversammlung_eng.pdf?web=1)                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| modality\_name            | NONE     | „Peptides“ korrekt.                                                                   | Herstellungsunterlagen (Peptid). [BI 456906 - Presentation 3PM conference June 2023\_draft.pptx](https://boehringer.sharepoint.com/sites/z3653pm/_layouts/15/Doc.aspx?sourcedoc=%7B0975B8AC-A816-4EA9-9AE0-502D4DC0FB42%7D\&file=BI%20456906%20-%20Presentation%203PM%20conference%20June%202023_draft.pptx\&action=edit\&mobileredirect=true\&DefaultItemOpen=1\&EntityRepresentationId=2624860e-576d-45d0-b55c-f39c0f57ea20) [\[boehringer...elheim.com\]](https://www.boehringer-ingelheim.com/human-health/lung-diseases/pulmonary-fibrosis/phase-3-trials-nerandomilast-slowed-lung-function-decline-ipf-and-ppf)                                                                                                                                                                                                                                                                                                                                                                    |
| product\_type             | NONE     | „NME“ korrekt.                                                                        | Pipeline‑Seiten. [BI Pipeline](https://www.boehringer-ingelheim.com/science-innovation/human-health-innovation/clinical-pipeline/survodutide-bi-456906-glp1-gcgr-agonist-0)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| therapeutic\_area         | NONE     | „Cardiovascular‑Renal‑Metabolic (CRM)“ korrekt (Obesity; MASH).                       | [BI Phase‑3 Obesity](https://www.boehringer-ingelheim.com/human-health/metabolic-diseases/phase-3-studies-survodutide-obesity-and-overweight); [LIVERAGE MASH](https://clinicaltrials.gov/study/NCT06632444)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| mechanism\_of\_action     | NONE     | „Dualer GCGR/GLP‑1‑Agonist“ korrekt.                                                  | Lancet Ph2/BI‑Seiten. SSRC-07022024…Lancet…pdf [\[nejm.org\]](https://www.nejm.org/doi/pdf/10.1056/NEJMoa2503643); [BI overview](https://www.boehringer-ingelheim.com/science-innovation/human-health-innovation/clinical-pipeline/survodutide-bi-456906-glp1-gcgr-agonist-0)                                                                                                                                                                                                                                                                                                                                                                                                       |
| short\_description        | NONE     | Beschreibung (Adipositas & MASH) ist korrekt.                                         | [BI MASH BT Designation](https://www.boehringer-ingelheim.com/human-health/metabolic-diseases/survodutide-us-fda-breakthrough-therapy-phase-3-trials-mash)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| dosage\_form              | MINOR    | Zielwert: „Fertigspritze/Autoinjektor (in Entwicklung)“ statt generisch „Injectable“. | AI‑Design‑Transfer & HF‑Protokoll. 150-MDCP-020890…Design-Transfer-Plan-.pdf [\[g-BI101555...t_Sept2025 | PDF\]](https://boehringer.sharepoint.com/sites/z365medicalaffairsropusa/Shared%20Documents/Medical%20Information/Working%20on%20.-/Documentos%20Globales/BI%201015550/g-BI1015550-013(EN)_Phase%201_renal_hepatic%20impairment_Sept2025.pdf?web=1); [Survodutide (BI 456906) AI\_HF Validation protocol\_clean.docx](https://boehringer.sharepoint.com/sites/z365complaintmgmtxbihive/_layouts/15/Doc.aspx?sourcedoc=%7BA2885EDB-7D3A-4193-B881-4D288228CED9%7D\&file=Survodutide%20%28BI%20456906%29%20AI_HF%20Validation%20protocol_clean.docx\&action=default\&mobileredirect=true\&DefaultItemOpen=1\&EntityRepresentationId=3befe113-40ea-4159-9436-fd635974d352) [\[globenewswire.com\]](https://www.globenewswire.com/news-release/2025/10/09/3163968/0/en/U-S-FDA-approves-Boehringer-s-JASCAYD-nerandomilast-tablets-as-first-new-treatment-option-for-adults-with-IPF-in-over-a-decade.html) |
| route\_of\_administration | MINOR    | Zielwert: „Subkutan“ (wöchentlich).                                                   | BI‑Studienseiten (SYNCHRONIZE; LIVERAGE). [BI Phase‑3 Obesity](https://www.boehringer-ingelheim.com/human-health/metabolic-diseases/phase-3-studies-survodutide-obesity-and-overweight); [ClinicalTrials.gov NCT06632444](https://clinicaltrials.gov/study/NCT06632444)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| base\_technology          | MINOR    | Zielwert: „Synthese via SPPS (Peptid)“ (Produktion/Downstream dokumentiert).          | Peptid‑Herstellung (SPPS) in [BI 456906 - Presentation 3PM conference June 2023\_draft.pptx](https://boehringer.sharepoint.com/sites/z3653pm/_layouts/15/Doc.aspx?sourcedoc=%7B0975B8AC-A816-4EA9-9AE0-502D4DC0FB42%7D\&file=BI%20456906%20-%20Presentation%203PM%20conference%20June%202023_draft.pptx\&action=edit\&mobileredirect=true\&DefaultItemOpen=1\&EntityRepresentationId=2624860e-576d-45d0-b55c-f39c0f57ea20). [\[boehringer...elheim.com\]](https://www.boehringer-ingelheim.com/human-health/lung-diseases/pulmonary-fibrosis/phase-3-trials-nerandomilast-slowed-lung-function-decline-ipf-and-ppf)                                                                                                                                                                                                                                                                                                                                                                       |
| current\_phase            | NONE     | „Phase III“ korrekt (Obesity & MASH Programme).                                       | [BI Phase‑3 Obesity](https://www.boehringer-ingelheim.com/human-health/metabolic-diseases/phase-3-studies-survodutide-obesity-and-overweight); [ClinicalTrials.gov NCT06632444](https://clinicaltrials.gov/study/NCT06632444)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |

**BI 690517 – Vicadrostat**

| Feld                      | Änderung | Beschreibung                                                                                      | Evidenz                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| ------------------------- | -------- | ------------------------------------------------------------------------------------------------- | ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ |
| product\_code             | NONE     | Unverändert: „BI 690517“.                                                                         | [Lexicon\_Vicadrostat (v11June2025).docx](https://boehringer.sharepoint.com/sites/crm-connect/_layouts/15/Doc.aspx?sourcedoc=%7B0E284153-087A-4E16-BF25-330F1055A9D8%7D\&file=Lexicon_Vicadrostat%20%28v11June2025%29.docx\&action=default\&mobileredirect=true\&DefaultItemOpen=1\&EntityRepresentationId=a4b0b767-8fca-4322-9427-3ec445585087) (Namensleitfaden) [\[HORST | PowerPoint\]](https://boehringer.sharepoint.com/sites/mybi_medicine_CDO/_layouts/15/Doc.aspx?sourcedoc=%7BB9A6FDD6-9DD2-4460-BF9B-89E93D6853AA%7D&file=HORST.pptx&action=edit&mobileredirect=true&DefaultItemOpen=1)                                                                                                                                                                                                                                                                                                                                                                       |
| product\_name             | NONE     | „Vicadrostat“ korrekt.                                                                            | INN‑Guidance. [vicadrostat\_guidance document\_8.23.24 OTC.pdf](https://boehringer.sharepoint.com/sites/crm-connect/Document%20Library/Strategy%20and%20Core/vicadrostat_guidance%20document_8.23.24%20OTC.pdf?web=1\&EntityRepresentationId=592806a5-e138-4c66-8298-dce4363c17cf) [\[Survodutid...FINAL 5.27 | PowerPoint\]](https://boehringer.sharepoint.com/sites/z365ukieicp2025/_layouts/15/Doc.aspx?sourcedoc=%7B45002F71-4121-4560-8585-4572195D6EF2%7D&file=Survodutide%20IAP%202025_FINAL%205.27.pptx&action=edit&mobileredirect=true&DefaultItemOpen=1)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| modality\_name            | NONE     | „Small Molecule“ korrekt.                                                                         | Med‑Master‑Deck. [Vicadrostat Medical Master Deck - Q1 2024.pptx](https://boehringer.sharepoint.com/sites/crm-connect/_layouts/15/Doc.aspx?sourcedoc=%7BE60D8AD8-2570-4E71-B7CB-3668656C2362%7D\&file=Vicadrostat%20Medical%20Master%20Deck%20-%20Q1%202024.pptx\&action=edit\&mobileredirect=true\&DefaultItemOpen=1\&EntityRepresentationId=8a711ec0-d73f-4be1-a997-987aa764f07e) [\[BI 456906...2023_draft | PowerPoint\]](https://boehringer.sharepoint.com/sites/z3653pm/_layouts/15/Doc.aspx?sourcedoc=%7B3C58AF7F-7EE4-43BC-B275-DC9B4DEA0A30%7D&file=BI%20456906%20-%20Presentation%203PM%20conference%20June%202023_draft.pptx&action=edit&mobileredirect=true&DefaultItemOpen=1)                                                                                                                                                                                                                                                                                                                                           |
| product\_type             | NONE     | „NME“ korrekt.                                                                                    | Pipeline‑Folien. [Approved Uniform Pipeline Slide.pptx](https://boehringer.sharepoint.com/sites/mybi_news_onehp/Shared%20Documents/IU/Pipeline%20Update/Approved%20Uniform%20Pipeline%20Slide.pptx?web=1\&EntityRepresentationId=9ef4e90b-0033-49d7-b799-2b76399448b9) [\[boehringer...elheim.com\]](https://www.boehringer-ingelheim.com/science-innovation/human-health-innovation/clinical-pipeline/survodutide-bi-456906-glp1-gcgr-agonist-0)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| therapeutic\_area         | NONE     | „Cardiovascular‑Renal‑Metabolic (CRM)“ korrekt.                                                   | [3. TA CRM pipeline\_DM2035 HR.pptx](https://boehringer.sharepoint.com/sites/z365usmedicinecapabilitiesexcellence/_layouts/15/Doc.aspx?sourcedoc=%7B57525F5F-26A8-4CA1-BF70-4F9C3A08E15D%7D\&file=3.%20TA%20CRM%20pipeline_DM2035%20HR.pptx\&action=edit\&mobileredirect=true\&DefaultItemOpen=1\&EntityRepresentationId=ecbe6d0f-0da7-4b89-8abe-f21840205006) [\[boehringer...elheim.com\]](https://www.boehringer-ingelheim.com/human-health/metabolic-diseases/phase-3-studies-survodutide-obesity-and-overweight)                                                                                                                                                                                                                                                                                                                                                        |
| mechanism\_of\_action     | NONE     | „Selektiver Aldosteron‑Synthase‑Inhibitor (ASi)“ korrekt.                                         | Lancet Ph2/Mechanismus‑Deck. [ASi vicadrostat master deck- Mechanism of action narrative (1).pptx](https://boehringer.sharepoint.com/sites/z365medicalaffairsropusa/_layouts/15/Doc.aspx?sourcedoc=%7B27533207-5B78-4600-B972-7A379A66D510%7D\&file=ASi%20vicadrostat%20master%20deck-%20Mechanism%20of%20action%20narrative%20%281%29.pptx\&action=edit\&mobileredirect=true\&DefaultItemOpen=1\&EntityRepresentationId=3ca93326-cebc-4818-b948-b2196ed02b09) [\[clinicaltrials.gov\]](https://clinicaltrials.gov/study/NCT06632444); [Lancet 2024](https://boehringer.sharepoint.com/sites/mybi_medicine_usa/SiteAssets/SitePages/ICP-2025%281%29%281%29%281%29%281%29/Efficacy-and-Safety-of-ASi-with-and-without-Empa-for-CKD-phase-2-trial.pdf?web=1) |
| short\_description        | NONE     | „…in Kombination mit Empagliflozin für kardio‑renale Erkrankungen“ korrekt (CKD/HF Programme).    | EASi‑KIDNEY/BI‑Seite. [EASi‑KIDNEY](https://www.easikidney.org/); [BI Clinical Pipeline](https://www.boehringer-ingelheim.com/science-innovation/human-health-innovation/clinical-pipeline/vicadrostat-bi-690517-empagliflozin)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| dosage\_form              | NONE     | „Tablet“ korrekt.                                                                                 | Studienbeschreibungen nennen Tabletten (QD). [NCT06935370](https://clinicaltrials.gov/study/NCT06935370)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| route\_of\_administration | NONE     | „Oral“ korrekt.                                                                                   | [NCT06935370](https://clinicaltrials.gov/study/NCT06935370)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| base\_technology          | NONE     | „Twin Screw“ nicht verifizierbar in den geprüften Quellen; belassen (Annahme mangels Gegenbeleg). | –                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| current\_phase            | NONE     | „Phase III“ korrekt (EASi‑KIDNEY, EASi‑HF).                                                       | BI‑Seiten & EASi‑KIDNEY‑Website. [BI Clinical Pipeline](https://www.boehringer-ingelheim.com/science-innovation/human-health-innovation/clinical-pipeline/vicadrostat-bi-690517-empagliflozin); [EASi‑KIDNEY](https://www.easikidney.org/)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |

**BI 685509 — Avenciguat**

| Feld                      | Änderung | Beschreibung                                                                                    | Evidenz                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| ------------------------- | -------- | ----------------------------------------------------------------------------------------------- | ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- |
| product\_code             | NONE     | „BI 685509“ ist korrekt.                                                                        | [2024\_June Pipeline.pdf](https://boehringer.sharepoint.com/sites/mybi_onehpiu/Shared%20Documents/Pulse/Pipeline%20Infographic/2024_June%20Pipeline.pdf?web=1\&EntityRepresentationId=87092abf-03b5-48ab-a428-0fcb45a26e17) [\[2024_June Pipeline | PDF\]](https://boehringer.sharepoint.com/sites/mybi_onehpiu/Shared%20Documents/Pulse/Pipeline%20Infographic/2024_June%20Pipeline.pdf?web=1)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| product\_name             | NONE     | „Avenciguat“ ist korrekt.                                                                       | [2024\_June Pipeline.pdf](https://boehringer.sharepoint.com/sites/mybi_onehpiu/Shared%20Documents/Pulse/Pipeline%20Infographic/2024_June%20Pipeline.pdf?web=1\&EntityRepresentationId=87092abf-03b5-48ab-a428-0fcb45a26e17);[US Early Value Strategy Avenciguat (1).pptx](https://boehringer.sharepoint.com/sites/z365pricingandcontractingoncology/_layouts/15/Doc.aspx?sourcedoc=%7BB6A59859-8494-4FA2-946E-9D4565C91B70%7D\&file=US%20Early%20Value%20Strategy%20Avenciguat%20%281%29.pptx\&action=edit\&mobileredirect=true\&DefaultItemOpen=1\&EntityRepresentationId=0864db3e-4157-4efb-91d0-768b7db660d9) [\[2024_June Pipeline | PDF\]](https://boehringer.sharepoint.com/sites/mybi_onehpiu/Shared%20Documents/Pulse/Pipeline%20Infographic/2024_June%20Pipeline.pdf?web=1), [\[US Early V...ciguat (1) | PowerPoint\]](https://boehringer.sharepoint.com/sites/z365pricingandcontractingoncology/_layouts/15/Doc.aspx?sourcedoc=%7BB6A59859-8494-4FA2-946E-9D4565C91B70%7D&file=US%20Early%20Value%20Strategy%20Avenciguat%20(1).pptx&action=edit&mobileredirect=true&DefaultItemOpen=1)                                                                                                                                       |
| modality\_name            | NONE     | Small Molecule bestätigt (sGC‑Aktivator als kleines Molekül).                                   | [24032025\_Avenciguat-MoA-short-report.pdf](https://boehringer.sharepoint.com/sites/mybi_tainflammation/SiteAssets/SitePages/Scientific-Operations/24032025_Avenciguat-MoA-short-report.pdf?web=1\&EntityRepresentationId=524f9a67-855c-480f-ae5e-866c119a0548) [\[24032025_A...ort-report | PDF\]](https://boehringer.sharepoint.com/sites/mybi_tainflammation/SiteAssets/SitePages/Scientific-Operations/24032025_Avenciguat-MoA-short-report.pdf?web=1)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| product\_type             | NONE     | NME bleibt unverändert.                                                                         | [2024\_June Pipeline.pdf](https://boehringer.sharepoint.com/sites/mybi_onehpiu/Shared%20Documents/Pulse/Pipeline%20Infographic/2024_June%20Pipeline.pdf?web=1\&EntityRepresentationId=87092abf-03b5-48ab-a428-0fcb45a26e17) [\[2024_June Pipeline | PDF\]](https://boehringer.sharepoint.com/sites/mybi_onehpiu/Shared%20Documents/Pulse/Pipeline%20Infographic/2024_June%20Pipeline.pdf?web=1)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| therapeutic\_area         | MINOR    | Präzisierung: Immunology (Systemische Sklerose) **und** CRM/Nephrologie (Glomerulonephritiden). | [HORST-US-June-2025.pptx](https://boehringer.sharepoint.com/sites/mybi_cd-and-o_usa/_layouts/15/Doc.aspx?sourcedoc=%7B45AFE150-B3B4-4BFB-969E-8C3CE086AEB3%7D\&file=HORST-US-June-2025.pptx\&action=edit\&mobileredirect=true\&DefaultItemOpen=1\&EntityRepresentationId=952bc27c-007d-4ba6-901d-d432ac2d8e92);[HORST France v1.0 - 13octobre2025.pptx](https://boehringer.sharepoint.com/sites/mybi_medicine_CDO/_layouts/15/Doc.aspx?sourcedoc=%7B487E610E-911E-4EFB-BDBD-5CEE6C3C78FA%7D\&file=HORST%20France%20v1.0%20-%2013octobre2025.pptx\&action=edit\&mobileredirect=true\&DefaultItemOpen=1\&EntityRepresentationId=d9d44adf-104d-4c68-aee4-ce9730f1b788) [\[HORST-US-June-2025 | PowerPoint\]](https://boehringer.sharepoint.com/sites/mybi_cd-and-o_usa/_layouts/15/Doc.aspx?sourcedoc=%7B45AFE150-B3B4-4BFB-969E-8C3CE086AEB3%7D&file=HORST-US-June-2025.pptx&action=edit&mobileredirect=true&DefaultItemOpen=1), [\[HORST Fran...ctobre2025 | PowerPoint\]](https://boehringer.sharepoint.com/sites/mybi_medicine_CDO/_layouts/15/Doc.aspx?sourcedoc=%7B487E610E-911E-4EFB-BDBD-5CEE6C3C78FA%7D&file=HORST%20France%20v1.0%20-%2013octobre2025.pptx&action=edit&mobileredirect=true&DefaultItemOpen=1)                                |
| mechanism\_of\_action     | NONE     | „Soluble guanylate cyclase (sGC) activator“ ist korrekt.                                        | [24032025\_Avenciguat-MoA-short-report.pdf](https://boehringer.sharepoint.com/sites/mybi_tainflammation/SiteAssets/SitePages/Scientific-Operations/24032025_Avenciguat-MoA-short-report.pdf?web=1\&EntityRepresentationId=524f9a67-855c-480f-ae5e-866c119a0548);[TA Inflammation\_non-CDA MoA slides\_170125\_1.0.pptx](https://boehringer.sharepoint.com/sites/mybi_tainflammation/Shared%20Documents/Pipeline%20assets/Compound%20overview%20slides/TA%20Inflammation_non-CDA%20MoA%20slides_170125_1.0.pptx?web=1\&EntityRepresentationId=aab3ac0b-b050-40b5-9782-87438db475f0) [\[24032025_A...ort-report | PDF\]](https://boehringer.sharepoint.com/sites/mybi_tainflammation/SiteAssets/SitePages/Scientific-Operations/24032025_Avenciguat-MoA-short-report.pdf?web=1), [\[TA Inflamm...170125_1.0 | PowerPoint\]](https://boehringer.sharepoint.com/sites/mybi_tainflammation/Shared%20Documents/Pipeline%20assets/Compound%20overview%20slides/TA%20Inflammation_non-CDA%20MoA%20slides_170125_1.0.pptx?web=1)                                                                                                                                                                                                                           |
| short\_description        | MINOR    | Ergänzen: aktive Entwicklung sowohl in SSc (Phase II) als auch GN (Phase III).                  | [HORST-US-June-2025.pptx](https://boehringer.sharepoint.com/sites/mybi_cd-and-o_usa/_layouts/15/Doc.aspx?sourcedoc=%7B45AFE150-B3B4-4BFB-969E-8C3CE086AEB3%7D\&file=HORST-US-June-2025.pptx\&action=edit\&mobileredirect=true\&DefaultItemOpen=1\&EntityRepresentationId=952bc27c-007d-4ba6-901d-d432ac2d8e92);[HORST France v1.0 - 13octobre2025.pptx](https://boehringer.sharepoint.com/sites/mybi_medicine_CDO/_layouts/15/Doc.aspx?sourcedoc=%7B487E610E-911E-4EFB-BDBD-5CEE6C3C78FA%7D\&file=HORST%20France%20v1.0%20-%2013octobre2025.pptx\&action=edit\&mobileredirect=true\&DefaultItemOpen=1\&EntityRepresentationId=d9d44adf-104d-4c68-aee4-ce9730f1b788) [\[HORST-US-June-2025 | PowerPoint\]](https://boehringer.sharepoint.com/sites/mybi_cd-and-o_usa/_layouts/15/Doc.aspx?sourcedoc=%7B45AFE150-B3B4-4BFB-969E-8C3CE086AEB3%7D&file=HORST-US-June-2025.pptx&action=edit&mobileredirect=true&DefaultItemOpen=1), [\[HORST Fran...ctobre2025 | PowerPoint\]](https://boehringer.sharepoint.com/sites/mybi_medicine_CDO/_layouts/15/Doc.aspx?sourcedoc=%7B487E610E-911E-4EFB-BDBD-5CEE6C3C78FA%7D&file=HORST%20France%20v1.0%20-%2013octobre2025.pptx&action=edit&mobileredirect=true&DefaultItemOpen=1)                                |
| dosage\_form              | NONE     | Tablet: keine Abweichung belegt.                                                                | [20240604 HPSC prep avenciguat in GN for Presentation.pptx](https://boehringer.sharepoint.com/sites/z365pricingandcontractingoncology/_layouts/15/Doc.aspx?sourcedoc=%7B1AEB493E-81DB-4D19-A911-F31465C636B6%7D\&file=20240604%20HPSC%20prep%20avenciguat%20in%20GN%20for%20Presentation.pptx\&action=edit\&mobileredirect=true\&DefaultItemOpen=1\&EntityRepresentationId=1c5b845c-747f-4747-af58-d6fccac1ee68) (orale BID‑Gabe, Form als Tablette impliziert, explizite CMC‑Quelle nicht gefunden) [\[20240604 H...esentation | PowerPoint\]](https://boehringer.sharepoint.com/sites/z365pricingandcontractingoncology/_layouts/15/Doc.aspx?sourcedoc=%7B1AEB493E-81DB-4D19-A911-F31465C636B6%7D&file=20240604%20HPSC%20prep%20avenciguat%20in%20GN%20for%20Presentation.pptx&action=edit&mobileredirect=true&DefaultItemOpen=1)                                                                                                                                                                                                                                                                                                                                                                                               |
| route\_of\_administration | NONE     | Oral bestätigt (z. B. BID).                                                                     | [20240604 HPSC prep avenciguat in GN for Presentation.pptx](https://boehringer.sharepoint.com/sites/z365pricingandcontractingoncology/_layouts/15/Doc.aspx?sourcedoc=%7B1AEB493E-81DB-4D19-A911-F31465C636B6%7D\&file=20240604%20HPSC%20prep%20avenciguat%20in%20GN%20for%20Presentation.pptx\&action=edit\&mobileredirect=true\&DefaultItemOpen=1\&EntityRepresentationId=1c5b845c-747f-4747-af58-d6fccac1ee68) [\[20240604 H...esentation | PowerPoint\]](https://boehringer.sharepoint.com/sites/z365pricingandcontractingoncology/_layouts/15/Doc.aspx?sourcedoc=%7B1AEB493E-81DB-4D19-A911-F31465C636B6%7D&file=20240604%20HPSC%20prep%20avenciguat%20in%20GN%20for%20Presentation.pptx&action=edit&mobileredirect=true&DefaultItemOpen=1)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| base\_technology          | NONE     | Keine belastbare Evidenz zu „Direct Compression“ gefunden; Wert vorerst nicht änderbar.         | (keine CMC‑Angaben in den gefundenen Unterlagen)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| current\_phase            | MAJOR    | Korrektur: **Phase II (SSc)** und **Phase III (GN)** statt nur „Phase II“.                      | [HORST-US-June-2025.pptx](https://boehringer.sharepoint.com/sites/mybi_cd-and-o_usa/_layouts/15/Doc.aspx?sourcedoc=%7B45AFE150-B3B4-4BFB-969E-8C3CE086AEB3%7D\&file=HORST-US-June-2025.pptx\&action=edit\&mobileredirect=true\&DefaultItemOpen=1\&EntityRepresentationId=952bc27c-007d-4ba6-901d-d432ac2d8e92) (SSc Phase II); [HORST France v1.0 - 13octobre2025.pptx](https://boehringer.sharepoint.com/sites/mybi_medicine_CDO/_layouts/15/Doc.aspx?sourcedoc=%7B487E610E-911E-4EFB-BDBD-5CEE6C3C78FA%7D\&file=HORST%20France%20v1.0%20-%2013octobre2025.pptx\&action=edit\&mobileredirect=true\&DefaultItemOpen=1\&EntityRepresentationId=d9d44adf-104d-4c68-aee4-ce9730f1b788) (GN Phase III) [\[HORST-US-June-2025 | PowerPoint\]](https://boehringer.sharepoint.com/sites/mybi_cd-and-o_usa/_layouts/15/Doc.aspx?sourcedoc=%7B45AFE150-B3B4-4BFB-969E-8C3CE086AEB3%7D&file=HORST-US-June-2025.pptx&action=edit&mobileredirect=true&DefaultItemOpen=1), [\[HORST Fran...ctobre2025 | PowerPoint\]](https://boehringer.sharepoint.com/sites/mybi_medicine_CDO/_layouts/15/Doc.aspx?sourcedoc=%7B487E610E-911E-4EFB-BDBD-5CEE6C3C78FA%7D&file=HORST%20France%20v1.0%20-%2013octobre2025.pptx&action=edit&mobileredirect=true&DefaultItemOpen=1) |

**BI 1569912**

| Feld                      | Änderung | Beschreibung                                                                      | Evidenz                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| ------------------------- | -------- | --------------------------------------------------------------------------------- | ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- |
| product\_code             | NONE     | „BI 1569912“ ist korrekt.                                                         | [NR2B-NAM-lexicon\_Nov2023.pptx](https://boehringer.sharepoint.com/sites/mybi_tacns/_layouts/15/Doc.aspx?sourcedoc=%7B216E5E24-79AE-4B19-9448-9D72FE4F8664%7D\&file=NR2B-NAM-lexicon_Nov2023.pptx\&action=edit\&mobileredirect=true\&DefaultItemOpen=1\&EntityRepresentationId=06f71bdf-f0f1-4de4-ab1c-52fbad608433) [\[NR2B-NAM-l...on_Nov2023 | PowerPoint\]](https://boehringer.sharepoint.com/sites/mybi_tacns/_layouts/15/Doc.aspx?sourcedoc=%7B26D3727E-C6B7-40B3-9E15-C171638C49DD%7D&file=NR2B-NAM-lexicon_Nov2023.pptx&action=edit&mobileredirect=true&DefaultItemOpen=1)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| product\_name             | NONE     | Kein INN/Brand bekannt – Feld kann leer bleiben.                                  | [NR2B-NAM-lexicon\_Nov2023.pptx](https://boehringer.sharepoint.com/sites/mybi_tacns/_layouts/15/Doc.aspx?sourcedoc=%7B216E5E24-79AE-4B19-9448-9D72FE4F8664%7D\&file=NR2B-NAM-lexicon_Nov2023.pptx\&action=edit\&mobileredirect=true\&DefaultItemOpen=1\&EntityRepresentationId=06f71bdf-f0f1-4de4-ab1c-52fbad608433) [\[NR2B-NAM-l...on_Nov2023 | PowerPoint\]](https://boehringer.sharepoint.com/sites/mybi_tacns/_layouts/15/Doc.aspx?sourcedoc=%7B216E5E24-79AE-4B19-9448-9D72FE4F8664%7D&file=NR2B-NAM-lexicon_Nov2023.pptx&action=edit&mobileredirect=true&DefaultItemOpen=1)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| modality\_name            | NONE     | Small Molecule bestätigt.                                                         | [BI-1569912-NR2B-NAM---Asset-Narrative---September-2023.pdf](https://boehringer.sharepoint.com/sites/mybi_tacns/SiteAssets/SitePages/BI-1/BI-1569912-NR2B-NAM---Asset-Narrative---September-2023.pdf?web=1\&EntityRepresentationId=8b21f999-ea98-4c95-95e9-aad60a526e9d) [\[BI-1569912...ember-2023 | PDF\]](https://boehringer.sharepoint.com/sites/mybi_tacns/Shared%20Documents/NR2B%20NAM%20Hub/Strategic%20documents/BI-1569912-NR2B-NAM---Asset-Narrative---September-2023.pdf?web=1)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| product\_type             | NONE     | NME bleibt unverändert.                                                           | [2025 US CNS NR2BNAM\_early asset\_pub plan\_D4.pptx](https://boehringer.sharepoint.com/sites/z365fishawackcns/_layouts/15/Doc.aspx?sourcedoc=%7B870BA43F-B2B6-4F80-850D-6CC032A21F55%7D\&file=2025%20US%20CNS%20NR2BNAM_early%20asset_pub%20plan_D4.pptx\&action=edit\&mobileredirect=true\&DefaultItemOpen=1\&EntityRepresentationId=5fc2c454-944f-4553-8a42-c5ae80943ffd) [\[2025 US CN...ub plan_D4 | PowerPoint\]](https://boehringer.sharepoint.com/sites/z365fishawackcns/_layouts/15/Doc.aspx?sourcedoc=%7B870BA43F-B2B6-4F80-850D-6CC032A21F55%7D&file=2025%20US%20CNS%20NR2BNAM_early%20asset_pub%20plan_D4.pptx&action=edit&mobileredirect=true&DefaultItemOpen=1)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| therapeutic\_area         | NONE     | Mental Health (MDD) ist korrekt.                                                  | [2025 US CNS NR2BNAM\_early asset\_pub plan\_D4.pptx](https://boehringer.sharepoint.com/sites/z365fishawackcns/_layouts/15/Doc.aspx?sourcedoc=%7B870BA43F-B2B6-4F80-850D-6CC032A21F55%7D\&file=2025%20US%20CNS%20NR2BNAM_early%20asset_pub%20plan_D4.pptx\&action=edit\&mobileredirect=true\&DefaultItemOpen=1\&EntityRepresentationId=5fc2c454-944f-4553-8a42-c5ae80943ffd) [\[2025 US CN...ub plan_D4 | PowerPoint\]](https://boehringer.sharepoint.com/sites/z365fishawackcns/_layouts/15/Doc.aspx?sourcedoc=%7B870BA43F-B2B6-4F80-850D-6CC032A21F55%7D&file=2025%20US%20CNS%20NR2BNAM_early%20asset_pub%20plan_D4.pptx&action=edit&mobileredirect=true&DefaultItemOpen=1)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| mechanism\_of\_action     | NONE     | „NR2B‑selektiver negativer allosterischer Modulator (NR2B NAM)“ ist korrekt.      | [NR2B-NAM-lexicon\_Nov2023.pptx](https://boehringer.sharepoint.com/sites/mybi_tacns/_layouts/15/Doc.aspx?sourcedoc=%7B216E5E24-79AE-4B19-9448-9D72FE4F8664%7D\&file=NR2B-NAM-lexicon_Nov2023.pptx\&action=edit\&mobileredirect=true\&DefaultItemOpen=1\&EntityRepresentationId=06f71bdf-f0f1-4de4-ab1c-52fbad608433) [\[NR2B-NAM-l...on_Nov2023 | PowerPoint\]](https://boehringer.sharepoint.com/sites/mybi_tacns/_layouts/15/Doc.aspx?sourcedoc=%7B26D3727E-C6B7-40B3-9E15-C171638C49DD%7D&file=NR2B-NAM-lexicon_Nov2023.pptx&action=edit&mobileredirect=true&DefaultItemOpen=1)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| short\_description        | NONE     | Beschreibung ist konsistent (schneller Wirkeintritt, ohne dissoziative Effekte).  | [NEI 2024 NR2B NAM P1b PoCP poster\_HR.pdf](https://boehringer.sharepoint.com/sites/z365fishawackcns/Shared%20Documents/General/USA/Congresses/Congresses%202024/NEI%202024/NEI%202024%20NR2B%20NAM%20P1b%20PoCP%20poster_HR.pdf?web=1\&EntityRepresentationId=b4d1c106-9126-483c-9ab0-18cdc254d14c) [\[NEI 2024 N...poster_HR | PDF\]](https://boehringer.sharepoint.com/sites/z365fishawackcns/Shared%20Documents/General/USA/Congresses/Congresses%202024/NEI%202024/NEI%202024%20NR2B%20NAM%20P1b%20PoCP%20poster_HR.pdf?web=1)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| dosage\_form              | NONE     | Tablet bestätigt.                                                                 | [BI-1569912-NR2B-NAM---Asset-Narrative---September-2023.pdf](https://boehringer.sharepoint.com/sites/mybi_tacns/SiteAssets/SitePages/BI-1/BI-1569912-NR2B-NAM---Asset-Narrative---September-2023.pdf?web=1\&EntityRepresentationId=8b21f999-ea98-4c95-95e9-aad60a526e9d) [\[BI-1569912...ember-2023 | PDF\]](https://boehringer.sharepoint.com/sites/mybi_tacns/Shared%20Documents/NR2B%20NAM%20Hub/Strategic%20documents/BI-1569912-NR2B-NAM---Asset-Narrative---September-2023.pdf?web=1)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| route\_of\_administration | NONE     | Oral bestätigt.                                                                   | [ECNP24\_Ph1b Nr2BNAM\_NewMedSymp\_Final draft\_13 May.docx](https://boehringer.sharepoint.com/sites/z365fishawackcns/_layouts/15/Doc.aspx?sourcedoc=%7B30EBC107-539E-4EC7-BB48-307A6AC42C3E%7D\&file=ECNP24_Ph1b%20Nr2BNAM_NewMedSymp_Final%20draft_13%20May.docx\&action=default\&mobileredirect=true\&DefaultItemOpen=1\&EntityRepresentationId=3934bd71-90c7-498a-a069-6df85b16468f) [\[ECNP24_Ph1...aft_13 May | Word\]](https://boehringer.sharepoint.com/sites/z365fishawackcns/_layouts/15/Doc.aspx?sourcedoc=%7B30EBC107-539E-4EC7-BB48-307A6AC42C3E%7D&file=ECNP24_Ph1b%20Nr2BNAM_NewMedSymp_Final%20draft_13%20May.docx&action=default&mobileredirect=true&DefaultItemOpen=1)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| base\_technology          | NONE     | Keine belastbare CMC‑Evidenz zu Fertigungstechnologie gefunden.                   | (keine Quelle)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| current\_phase            | MAJOR    | Korrektur: **Phase II** (mehrere Phase‑II‑Studien laufend), nicht „Discontinued“. | [Triangle Insights\_Boehringer Ingelheim\_NR2B EVL Deck\_ 2025-03 25\_STC.pptx](https://boehringer.sharepoint.com/sites/z365pricingandcontractingoncology/_layouts/15/Doc.aspx?sourcedoc=%7B0F71E599-9E2E-4BCA-9915-331861446D51%7D\&file=Triangle%20Insights_Boehringer%20Ingelheim_NR2B%20EVL%20Deck_%202025-03%2025_STC.pptx\&action=edit\&mobileredirect=true\&DefaultItemOpen=1\&EntityRepresentationId=e82ba334-f90b-4aa5-bf86-63d84382c2c5);[BI \[51729\] ACNP 2024 NR2B PoCP Encore Poster\_HR.pdf](https://boehringer.sharepoint.com/sites/mybi_tacns/FormServerTemplates/CNS%20Publication%20Monthly%20Updates%20-%20Newsletter/Presented%20Abstracts/2024%20Congresses/2024%20ACNP/BI%20\[51729]%20ACNP%202024%20NR2B%20PoCP%20Encore%20Poster_HR.pdf?web=1\&EntityRepresentationId=c8053294-6ed3-4afc-85a2-1084cd8b5bf3) [\[Triangle I...-03 25_STC | PowerPoint\]](https://boehringer.sharepoint.com/sites/z365pricingandcontractingoncology/_layouts/15/Doc.aspx?sourcedoc=%7B0F71E599-9E2E-4BCA-9915-331861446D51%7D&file=Triangle%20Insights_Boehringer%20Ingelheim_NR2B%20EVL%20Deck_%202025-03%2025_STC.pptx&action=edit&mobileredirect=true&DefaultItemOpen=1), [\[BI \[51729\]...Poster_HR | PDF\]](https://boehringer.sharepoint.com/sites/mybi_tacns/FormServerTemplates/CNS%20Publication%20Monthly%20Updates%20-%20Newsletter/Presented%20Abstracts/2024%20Congresses/2024%20ACNP/BI%20[51729]%20ACNP%202024%20NR2B%20PoCP%20Encore%20Poster_HR.pdf?web=1) |

**BI 1358894 — TRPC4/5‑Inhibitor**

| Feld                      | Änderung | Beschreibung                                                         | Evidenz                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| ------------------------- | -------- | -------------------------------------------------------------------- | ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- |
| product\_code             | NONE     | „BI 1358894“ ist korrekt.                                            | [LATEST VERSION\_BI 1358894 TRPC45 2024 eIBP Draft\_ 18 August 2023.pptx](https://boehringer.sharepoint.com/sites/z365fishawackcns/_layouts/15/Doc.aspx?sourcedoc=%7BBA2471F2-3184-4A9D-ABDD-76972F8A9D7B%7D\&file=LATEST%20VERSION_BI%201358894%20TRPC45%202024%20eIBP%20Draft_%2018%20August%202023.pptx\&action=edit\&mobileredirect=true\&DefaultItemOpen=1\&EntityRepresentationId=9a59c8ce-a445-4d44-8c12-99bc669202a1) [\[LATEST VER...ugust 2023 | PowerPoint\]](https://boehringer.sharepoint.com/sites/z365fishawackcns/_layouts/15/Doc.aspx?sourcedoc=%7BBA2471F2-3184-4A9D-ABDD-76972F8A9D7B%7D&file=LATEST%20VERSION_BI%201358894%20TRPC45%202024%20eIBP%20Draft_%2018%20August%202023.pptx&action=edit&mobileredirect=true&DefaultItemOpen=1)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| product\_name             | NONE     | Kein INN/Brand bekannt.                                              | [LATEST VERSION\_BI 1358894 TRPC45 2024 eIBP Draft\_ 18 August 2023.pptx](https://boehringer.sharepoint.com/sites/z365fishawackcns/_layouts/15/Doc.aspx?sourcedoc=%7BBA2471F2-3184-4A9D-ABDD-76972F8A9D7B%7D\&file=LATEST%20VERSION_BI%201358894%20TRPC45%202024%20eIBP%20Draft_%2018%20August%202023.pptx\&action=edit\&mobileredirect=true\&DefaultItemOpen=1\&EntityRepresentationId=9a59c8ce-a445-4d44-8c12-99bc669202a1) [\[LATEST VER...ugust 2023 | PowerPoint\]](https://boehringer.sharepoint.com/sites/z365fishawackcns/_layouts/15/Doc.aspx?sourcedoc=%7BBA2471F2-3184-4A9D-ABDD-76972F8A9D7B%7D&file=LATEST%20VERSION_BI%201358894%20TRPC45%202024%20eIBP%20Draft_%2018%20August%202023.pptx&action=edit&mobileredirect=true&DefaultItemOpen=1)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| modality\_name            | NONE     | Small Molecule bestätigt.                                            | [04 - 1 - IB BI-1358894\_1402-p1-p2-p3\_v8\_track-change.pdf](https://boehringer.sharepoint.com/sites/z365eco/iQNow%20%20Ethik%20und%20BfArM%20Rckmeldungen/1402/1402-0020/Ethik-BfArM/04%20-%201%20-%20IB%20BI-1358894_1402-p1-p2-p3_v8_track-change.pdf?web=1\&EntityRepresentationId=918f6b17-439d-4f0f-95b4-60d9376d5651) [\[04 - 1 - I...ack-change | PDF\]](https://boehringer.sharepoint.com/sites/z365eco/iQNow%20%20Ethik%20und%20BfArM%20Rckmeldungen/1402/1402-0020/Ethik-BfArM/04%20-%201%20-%20IB%20BI-1358894_1402-p1-p2-p3_v8_track-change.pdf?web=1)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| product\_type             | NONE     | NME bleibt unverändert.                                              | [BI 1358894\_Executive Summary.pdf](https://boehringer.sharepoint.com/sites/z3653pm/Shared%20Documents/General/Meetings/Meeting%20Agenda_Minutes/PLMC/2021/20210512_PLMC-Early/BI%201358894_Executive%20Summary.pdf?web=1\&EntityRepresentationId=ae85c009-9221-4cbe-b2b3-2f026a3879cc) [\[BI 1358894...ve Summary | PDF\]](https://boehringer.sharepoint.com/sites/z3653pm/Shared%20Documents/General/Meetings/Meeting%20Agenda_Minutes/PLMC/2021/20210512_PLMC-Early/BI%201358894_Executive%20Summary.pdf?web=1)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| therapeutic\_area         | NONE     | Mental Health (PTSD/BPD/MDD) ist korrekt.                            | [TRPC45-PTSD-Clinical-Trial-Slide-Set.pdf](https://boehringer.sharepoint.com/sites/mybi_tacns/SiteAssets/SitePages/TRPC4-5-inhibitor-Clinical-trial-overviews/TRPC45-PTSD-Clinical-Trial-Slide-Set.pdf?web=1\&EntityRepresentationId=53db8ee4-c2db-45c6-ad9d-635375355048) [\[TRPC45-PTS...-Slide-Set | PDF\]](https://boehringer.sharepoint.com/sites/mybi_tacns/SiteAssets/SitePages/TRPC4-5-inhibitor-Clinical-trial-overviews/TRPC45-PTSD-Clinical-Trial-Slide-Set.pdf?web=1)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| mechanism\_of\_action     | NONE     | TRPC4/5‑Inhibitor ist korrekt.                                       | [MoA-TRPC4-5.pptx](https://boehringer.sharepoint.com/sites/mybi_tacns/_layouts/15/Doc.aspx?sourcedoc=%7B566831E2-B131-4B02-8253-C28B1F970B35%7D\&file=MoA-TRPC4-5.pptx\&action=edit\&mobileredirect=true\&DefaultItemOpen=1\&EntityRepresentationId=845552a1-2371-4390-b11d-d1d49e88da6d);[04 - 1 - IB BI-1358894\_1402-p1-p2-p3\_v8\_track-change.pdf](https://boehringer.sharepoint.com/sites/z365eco/iQNow%20%20Ethik%20und%20BfArM%20Rckmeldungen/1402/1402-0020/Ethik-BfArM/04%20-%201%20-%20IB%20BI-1358894_1402-p1-p2-p3_v8_track-change.pdf?web=1\&EntityRepresentationId=918f6b17-439d-4f0f-95b4-60d9376d5651) [\[MoA-TRPC4-5 | PowerPoint\]](https://boehringer.sharepoint.com/sites/mybi_tacns/_layouts/15/Doc.aspx?sourcedoc=%7B566831E2-B131-4B02-8253-C28B1F970B35%7D&file=MoA-TRPC4-5.pptx&action=edit&mobileredirect=true&DefaultItemOpen=1), [\[04 - 1 - I...ack-change | PDF\]](https://boehringer.sharepoint.com/sites/z365eco/iQNow%20%20Ethik%20und%20BfArM%20Rckmeldungen/1402/1402-0020/Ethik-BfArM/04%20-%201%20-%20IB%20BI-1358894_1402-p1-p2-p3_v8_track-change.pdf?web=1)                                                                                                                                                                             |
| short\_description        | NONE     | Beschreibung (Stimmungs-/Stressstörungen inkl. PTSD) ist konsistent. | [LATEST VERSION\_BI 1358894 TRPC45 2024 eIBP Draft\_ 18 August 2023.pptx](https://boehringer.sharepoint.com/sites/z365fishawackcns/_layouts/15/Doc.aspx?sourcedoc=%7BBA2471F2-3184-4A9D-ABDD-76972F8A9D7B%7D\&file=LATEST%20VERSION_BI%201358894%20TRPC45%202024%20eIBP%20Draft_%2018%20August%202023.pptx\&action=edit\&mobileredirect=true\&DefaultItemOpen=1\&EntityRepresentationId=9a59c8ce-a445-4d44-8c12-99bc669202a1) [\[LATEST VER...ugust 2023 | PowerPoint\]](https://boehringer.sharepoint.com/sites/z365fishawackcns/_layouts/15/Doc.aspx?sourcedoc=%7BBA2471F2-3184-4A9D-ABDD-76972F8A9D7B%7D&file=LATEST%20VERSION_BI%201358894%20TRPC45%202024%20eIBP%20Draft_%2018%20August%202023.pptx&action=edit&mobileredirect=true&DefaultItemOpen=1)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| dosage\_form              | NONE     | Tablet/Oral bestätigt.                                               | [BI 1358894\_Executive Summary.pdf](https://boehringer.sharepoint.com/sites/z3653pm/Shared%20Documents/General/Meetings/Meeting%20Agenda_Minutes/PLMC/2021/20210512_PLMC-Early/BI%201358894_Executive%20Summary.pdf?web=1\&EntityRepresentationId=ae85c009-9221-4cbe-b2b3-2f026a3879cc) [\[BI 1358894...ve Summary | PDF\]](https://boehringer.sharepoint.com/sites/z3653pm/Shared%20Documents/General/Meetings/Meeting%20Agenda_Minutes/PLMC/2021/20210512_PLMC-Early/BI%201358894_Executive%20Summary.pdf?web=1)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| route\_of\_administration | NONE     | Oral bestätigt.                                                      | [BI 1358894\_Executive Summary.pdf](https://boehringer.sharepoint.com/sites/z3653pm/Shared%20Documents/General/Meetings/Meeting%20Agenda_Minutes/PLMC/2021/20210512_PLMC-Early/BI%201358894_Executive%20Summary.pdf?web=1\&EntityRepresentationId=ae85c009-9221-4cbe-b2b3-2f026a3879cc) [\[BI 1358894...ve Summary | PDF\]](https://boehringer.sharepoint.com/sites/z3653pm/Shared%20Documents/General/Meetings/Meeting%20Agenda_Minutes/PLMC/2021/20210512_PLMC-Early/BI%201358894_Executive%20Summary.pdf?web=1)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| base\_technology          | NONE     | Keine belastbare Evidenz für „Fluid Bed“ gefunden.                   | (keine CMC‑Quelle)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| current\_phase            | MAJOR    | Korrektur: **Phase II**, nicht „Discontinued“.                       | [BI \[41128\] NEI 2023 TRPC Poster\_PRESS2.pdf](https://boehringer.sharepoint.com/sites/mybi_tacns/Shared%20Documents/Resources/Congresses/Past%20Congresses/NEI%202023/US/BI%20\[41128]%20NEI%202023%20TRPC%20Poster_PRESS2.pdf?web=1\&EntityRepresentationId=62130d75-bbff-47a0-98a7-cc2ae8a13aee);[LATEST VERSION\_BI 1358894 TRPC45 2024 eIBP Draft\_ 18 August 2023.pptx](https://boehringer.sharepoint.com/sites/z365fishawackcns/_layouts/15/Doc.aspx?sourcedoc=%7BBA2471F2-3184-4A9D-ABDD-76972F8A9D7B%7D\&file=LATEST%20VERSION_BI%201358894%20TRPC45%202024%20eIBP%20Draft_%2018%20August%202023.pptx\&action=edit\&mobileredirect=true\&DefaultItemOpen=1\&EntityRepresentationId=9a59c8ce-a445-4d44-8c12-99bc669202a1) [\[BI \[41128\]...ter_PRESS2 | PDF\]](https://boehringer.sharepoint.com/sites/mybi_tacns/Shared%20Documents/Resources/Congresses/Past%20Congresses/NEI%202023/US/BI%20[41128]%20NEI%202023%20TRPC%20Poster_PRESS2.pdf?web=1), [\[LATEST VER...ugust 2023 | PowerPoint\]](https://boehringer.sharepoint.com/sites/z365fishawackcns/_layouts/15/Doc.aspx?sourcedoc=%7BBA2471F2-3184-4A9D-ABDD-76972F8A9D7B%7D&file=LATEST%20VERSION_BI%201358894%20TRPC45%202024%20eIBP%20Draft_%2018%20August%202023.pptx&action=edit&mobileredirect=true&DefaultItemOpen=1) |

**BI 1291583 — Verducatib**

| Feld                      | Änderung | Beschreibung                                                                                    | Evidenz                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| ------------------------- | -------- | ----------------------------------------------------------------------------------------------- | ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- |
| product\_code             | NONE     | „BI 1291583“ ist korrekt.                                                                       | [BI 1291583\_Publication Overview\_Published manuscripts and congress presentations\_Jan 2025.pdf](https://boehringer.sharepoint.com/sites/catci/Shared%20Documents/Medicine/Publications/BI%201291583_Publication%20Overview_Published%20manuscripts%20and%20congress%20presentations_Jan%202025.pdf?web=1\&EntityRepresentationId=16c1140b-b579-4c33-8e0e-3f5d65ebfaf0) [\[BI 1291583...s_Jan 2025 | PDF\]](https://boehringer.sharepoint.com/sites/catci/Shared%20Documents/Medicine/Publications/BI%201291583_Publication%20Overview_Published%20manuscripts%20and%20congress%20presentations_Jan%202025.pdf?web=1)                                                                                                                                                                                                                                                                                                                                                                                                                            |
| product\_name             | MINOR    | Ergänzen: **Verducatib** (INN vergeben).                                                        | Viva‑Engage‑Post „Let´s hear it for verducatib!“; Viva‑Engage‑Post „First Time Disclosure of … Verducatib“ [\[Let´s hear...l DPP1 inh | Viva Engage\]](https://engage.cloud.microsoft/main/threads/eyJfdHlwZSI6IlRocmVhZCIsImlkIjoiMzUwNjk5MjY0MzIyNzY0OSJ9), [\[First Time...excited ab | Viva Engage\]](https://engage.cloud.microsoft/main/threads/eyJfdHlwZSI6IlRocmVhZCIsImlkIjoiMzQ5ODM0NDgzODAxMjkyOSJ9)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| modality\_name            | NONE     | Small Molecule bestätigt.                                                                       | MedChem\_2025\_Grundl\_Discovery of Verducatib … .pdf [\[MedChem_20...chiectasis | PDF\]](https://boehringer.sharepoint.com/sites/z365releaseofpublicationinrandd/All%20Documents/Archive/2025/MedChem_2025_Grundl_Discovery%20of%20Verducatib%20(BI%201291583)_A%20DPP1%20inhibitor%20clinical%20candidate%20for%20the%20treatment%20of%20bronchiectasis.pdf?web=1)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| product\_type             | NONE     | NME bleibt unverändert.                                                                         | [Approved Uniform Pipeline Slide.pptx](https://boehringer.sharepoint.com/sites/mybi_news_onehp/_layouts/15/Doc.aspx?sourcedoc=%7B63F14EE4-3C76-49DB-B840-D27AE08037F2%7D\&file=Approved%20Uniform%20Pipeline%20Slide.pptx\&action=edit\&mobileredirect=true\&DefaultItemOpen=1\&EntityRepresentationId=bc32dfdc-5d5e-4f44-8167-035edec1dc6b) [\[Approved U...line Slide | PowerPoint\]](https://boehringer.sharepoint.com/sites/mybi_news_onehp/_layouts/15/Doc.aspx?sourcedoc=%7B63F14EE4-3C76-49DB-B840-D27AE08037F2%7D&file=Approved%20Uniform%20Pipeline%20Slide.pptx&action=edit&mobileredirect=true&DefaultItemOpen=1)                                                                                                                                                                                                                                                                                                                                                                                                                              |
| therapeutic\_area         | NONE     | Respiratory (Bronchiektasen); Immunology optional – keine Änderung nötig.                       | [BI 1291583\_Publication Overview\_Published manuscripts and congress presentations\_Jan 2025.pdf](https://boehringer.sharepoint.com/sites/catci/Shared%20Documents/Medicine/Publications/BI%201291583_Publication%20Overview_Published%20manuscripts%20and%20congress%20presentations_Jan%202025.pdf?web=1\&EntityRepresentationId=16c1140b-b579-4c33-8e0e-3f5d65ebfaf0) [\[BI 1291583...s_Jan 2025 | PDF\]](https://boehringer.sharepoint.com/sites/catci/Shared%20Documents/Medicine/Publications/BI%201291583_Publication%20Overview_Published%20manuscripts%20and%20congress%20presentations_Jan%202025.pdf?web=1)                                                                                                                                                                                                                                                                                                                                                                                                                            |
| mechanism\_of\_action     | NONE     | „Cathepsin C (DPP1) inhibitor“ ist korrekt.                                                     | [Phase-I-Characterization-of-the-Novel-Cathepsin-C.pptx](https://boehringer.sharepoint.com/sites/catci/_layouts/15/Doc.aspx?sourcedoc=%7BAE6816DE-F73B-419B-BCCE-B197E08C5AFE%7D\&file=Phase-I-Characterization-of-the-Novel-Cathepsin-C.pptx\&action=edit\&mobileredirect=true\&DefaultItemOpen=1\&EntityRepresentationId=efc48b8c-685d-4301-956c-a58931d6d1be);MedChem\_2025\_Grundl\_Discovery of Verducatib … .pdf [\[Phase-I-Ch...athepsin-C | PowerPoint\]](https://boehringer.sharepoint.com/sites/catci/_layouts/15/Doc.aspx?sourcedoc=%7BAE6816DE-F73B-419B-BCCE-B197E08C5AFE%7D&file=Phase-I-Characterization-of-the-Novel-Cathepsin-C.pptx&action=edit&mobileredirect=true&DefaultItemOpen=1), [\[MedChem_20...chiectasis | PDF\]](https://boehringer.sharepoint.com/sites/z365releaseofpublicationinrandd/All%20Documents/Archive/2025/MedChem_2025_Grundl_Discovery%20of%20Verducatib%20(BI%201291583)_A%20DPP1%20inhibitor%20clinical%20candidate%20for%20the%20treatment%20of%20bronchiectasis.pdf?web=1)                                             |
| short\_description        | NONE     | Beschreibung (CatC‑Inhibitor, Hemmung der Aktivierung neutrophiler Serinproteasen) ist korrekt. | [BI 1291583\_Publication Overview\_Published manuscripts and congress presentations\_Jan 2025.pdf](https://boehringer.sharepoint.com/sites/catci/Shared%20Documents/Medicine/Publications/BI%201291583_Publication%20Overview_Published%20manuscripts%20and%20congress%20presentations_Jan%202025.pdf?web=1\&EntityRepresentationId=16c1140b-b579-4c33-8e0e-3f5d65ebfaf0) [\[BI 1291583...s_Jan 2025 | PDF\]](https://boehringer.sharepoint.com/sites/catci/Shared%20Documents/Medicine/Publications/BI%201291583_Publication%20Overview_Published%20manuscripts%20and%20congress%20presentations_Jan%202025.pdf?web=1)                                                                                                                                                                                                                                                                                                                                                                                                                            |
| dosage\_form              | NONE     | Tablet bestätigt (Film‑coated, 2.5 mg/5 mg).                                                    | [Product-Launch-Information-B-Page.aspx](https://boehringer.sharepoint.com/sites/mybi_liu_ger/SitePages/Product-Launch-Information-B-Page.aspx?web=1\&EntityRepresentationId=eca80905-dfb8-45f5-9e20-4e27ab4d0b7c) [\[Product La...mation Hub | SharePoint\]](https://boehringer.sharepoint.com/sites/mybi_liu_ger/SitePages/Product-Launch-Information-B-Page.aspx?web=1)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| route\_of\_administration | NONE     | Oral bestätigt.                                                                                 | [Product-Launch-Information-B-Page.aspx](https://boehringer.sharepoint.com/sites/mybi_liu_ger/SitePages/Product-Launch-Information-B-Page.aspx?web=1\&EntityRepresentationId=eca80905-dfb8-45f5-9e20-4e27ab4d0b7c) [\[Product La...mation Hub | SharePoint\]](https://boehringer.sharepoint.com/sites/mybi_liu_ger/SitePages/Product-Launch-Information-B-Page.aspx?web=1)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| base\_technology          | MAJOR    | Korrektur: **Direct compression + Film‑coating** statt „Roller Compaction“.                     | [Product-Launch-Information-B-Page.aspx](https://boehringer.sharepoint.com/sites/mybi_liu_ger/SitePages/Product-Launch-Information-B-Page.aspx?web=1\&EntityRepresentationId=eca80905-dfb8-45f5-9e20-4e27ab4d0b7c) [\[Product La...mation Hub | SharePoint\]](https://boehringer.sharepoint.com/sites/mybi_liu_ger/SitePages/Product-Launch-Information-B-Page.aspx?web=1)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| current\_phase            | MAJOR    | Korrektur: **Phase III** (AIRTIVITY® gestartet/geplant), nicht „Phase II“.                      | [HORST-US-June-2025.pptx](https://boehringer.sharepoint.com/sites/mybi_cd-and-o_usa/_layouts/15/Doc.aspx?sourcedoc=%7B45AFE150-B3B4-4BFB-969E-8C3CE086AEB3%7D\&file=HORST-US-June-2025.pptx\&action=edit\&mobileredirect=true\&DefaultItemOpen=1\&EntityRepresentationId=952bc27c-007d-4ba6-901d-d432ac2d8e92);[AIRTIVITY flyer\_v6.0\_SC-CRP-17237.pdf](https://boehringer.sharepoint.com/sites/catci/Shared%20Documents/Medicine/Medical%20content/Congress%20booth%20materials/AIRTIVITY%20flyer_v6.0_SC-CRP-17237.pdf?web=1\&EntityRepresentationId=ba820303-5f0c-46fb-a0a3-37c594e48ec2) [\[HORST-US-June-2025 | PowerPoint\]](https://boehringer.sharepoint.com/sites/mybi_cd-and-o_usa/_layouts/15/Doc.aspx?sourcedoc=%7B45AFE150-B3B4-4BFB-969E-8C3CE086AEB3%7D&file=HORST-US-June-2025.pptx&action=edit&mobileredirect=true&DefaultItemOpen=1), [\[AIRTIVITY...-CRP-17237 | PDF\]](https://boehringer.sharepoint.com/sites/catci/Shared%20Documents/Medicine/Medical%20content/Congress%20booth%20materials/AIRTIVITY%20flyer_v6.0_SC-CRP-17237.pdf?web=1) |

**BI 1819479**

| Feld                      | Änderung | Beschreibung                                                                                      | Evidenz                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| ------------------------- | -------- | ------------------------------------------------------------------------------------------------- | -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- |
| product\_code             | NONE     | „BI 1819479“ ist korrekt.                                                                         | [Presentation early research program ATX.pptx](https://boehringer.sharepoint.com/sites/z365clinicaltrialspatientandsiteengagement/Shared%20Documents/TA%20Inflammation/Pulmonary%20Fibrosis/PF%20patient%20advisory%20board%20meetings/PF%20Steerco%20Presentations%20-%20Minutes%20-%20Recordings/6%29%209th%20of%20November%202023%20-%20ATX%20&%20IL-11/Presentation%20early%20research%20program%20ATX.pptx?web=1\&EntityRepresentationId=145cbe5a-e0bc-4d11-a503-0597ff6c0bee) [\[Presentati...rogram ATX | PowerPoint\]](https://boehringer.sharepoint.com/sites/z365clinicaltrialspatientandsiteengagement/Shared%20Documents/TA%20Inflammation/Pulmonary%20Fibrosis/PF%20patient%20advisory%20board%20meetings/PF%20Steerco%20Presentations%20-%20Minutes%20-%20Recordings/6)%209th%20of%20November%202023%20-%20ATX%20&%20IL-11/Presentation%20early%20research%20program%20ATX.pptx?web=1)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| product\_name             | NONE     | (Kein INN/Brand; Feld kann leer bleiben.)                                                         | [ENCO 280824\_BI 1819479 (ATXi).pptx](https://boehringer.sharepoint.com/sites/z3653pm/_layouts/15/Doc.aspx?sourcedoc=%7BE4EA0AB2-C972-47D1-B704-5AB2DF78891F%7D\&file=ENCO%20280824_BI%201819479%20%28ATXi%29.pptx\&action=edit\&mobileredirect=true\&DefaultItemOpen=1\&EntityRepresentationId=716976dc-bf95-4dda-bcf4-083d561827a8) [\[ENCO 28082...479 (ATXi) | PowerPoint\]](https://boehringer.sharepoint.com/sites/z3653pm/_layouts/15/Doc.aspx?sourcedoc=%7BE4EA0AB2-C972-47D1-B704-5AB2DF78891F%7D&file=ENCO%20280824_BI%201819479%20(ATXi).pptx&action=edit&mobileredirect=true&DefaultItemOpen=1)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| modality\_name            | NONE     | Small Molecule bestätigt.                                                                         | [03 - 1 - clinical-trial-protocol-version-03-trackmode.pdf](https://boehringer.sharepoint.com/sites/z365eco/iQNow%20%20Ethik%20und%20BfArM%20Rckmeldungen/1462/1462-0001/Ethik-BfArM/03%20-%201%20-%20clinical-trial-protocol-version-03-trackmode.pdf?web=1\&EntityRepresentationId=5ff1d2d5-6867-4339-b082-069efbb745d5) (ATX‑Inhibitor in oraler Entwicklung) [\[03 - 1 - c...-trackmode | PDF\]](https://boehringer.sharepoint.com/sites/z365eco/iQNow%20%20Ethik%20und%20BfArM%20Rckmeldungen/1462/1462-0001/Ethik-BfArM/03%20-%201%20-%20clinical-trial-protocol-version-03-trackmode.pdf?web=1)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| product\_type             | NONE     | NME bleibt unverändert.                                                                           | [Approved Uniform Pipeline Slide.pptx](https://boehringer.sharepoint.com/sites/mybi_news_onehp/_layouts/15/Doc.aspx?sourcedoc=%7B63F14EE4-3C76-49DB-B840-D27AE08037F2%7D\&file=Approved%20Uniform%20Pipeline%20Slide.pptx\&action=edit\&mobileredirect=true\&DefaultItemOpen=1\&EntityRepresentationId=bc32dfdc-5d5e-4f44-8167-035edec1dc6b) [\[Clinical T...on_ONGOING | Excel\]](https://boehringer.sharepoint.com/sites/z365clinicaltrialspatientandsiteengagement/_layouts/15/Doc.aspx?sourcedoc=%7BFB0789F1-B848-4CF8-8662-B90836ABBEFF%7D&file=Clinical%20Trials%20Overview%20Inflammation_ONGOING.xlsx&action=default&mobileredirect=true&DefaultItemOpen=1)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| therapeutic\_area         | MINOR    | Präzisierung: Respiratory (IPF/PPF); SSc als Explorationsfeld.                                    | [Presentation early research program ATX.pptx](https://boehringer.sharepoint.com/sites/z365clinicaltrialspatientandsiteengagement/Shared%20Documents/TA%20Inflammation/Pulmonary%20Fibrosis/PF%20patient%20advisory%20board%20meetings/PF%20Steerco%20Presentations%20-%20Minutes%20-%20Recordings/6%29%209th%20of%20November%202023%20-%20ATX%20&%20IL-11/Presentation%20early%20research%20program%20ATX.pptx?web=1\&EntityRepresentationId=145cbe5a-e0bc-4d11-a503-0597ff6c0bee) [\[Presentati...rogram ATX | PowerPoint\]](https://boehringer.sharepoint.com/sites/z365clinicaltrialspatientandsiteengagement/Shared%20Documents/TA%20Inflammation/Pulmonary%20Fibrosis/PF%20patient%20advisory%20board%20meetings/PF%20Steerco%20Presentations%20-%20Minutes%20-%20Recordings/6)%209th%20of%20November%202023%20-%20ATX%20&%20IL-11/Presentation%20early%20research%20program%20ATX.pptx?web=1)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| mechanism\_of\_action     | NONE     | „Autotaxin (ATX) inhibitor“ / Hemmung der LPA‑Bildung ist korrekt.                                | [03 - 1 - clinical-trial-protocol-version-03-trackmode.pdf](https://boehringer.sharepoint.com/sites/z365eco/iQNow%20%20Ethik%20und%20BfArM%20Rckmeldungen/1462/1462-0001/Ethik-BfArM/03%20-%201%20-%20clinical-trial-protocol-version-03-trackmode.pdf?web=1\&EntityRepresentationId=5ff1d2d5-6867-4339-b082-069efbb745d5) [\[03 - 1 - c...-trackmode | PDF\]](https://boehringer.sharepoint.com/sites/z365eco/iQNow%20%20Ethik%20und%20BfArM%20Rckmeldungen/1462/1462-0001/Ethik-BfArM/03%20-%201%20-%20clinical-trial-protocol-version-03-trackmode.pdf?web=1)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| short\_description        | NONE     | Beschreibung (ATX→LPA→Fibrose) ist konsistent.                                                    | [Presentation early research program ATX.pptx](https://boehringer.sharepoint.com/sites/z365clinicaltrialspatientandsiteengagement/Shared%20Documents/TA%20Inflammation/Pulmonary%20Fibrosis/PF%20patient%20advisory%20board%20meetings/PF%20Steerco%20Presentations%20-%20Minutes%20-%20Recordings/6%29%209th%20of%20November%202023%20-%20ATX%20&%20IL-11/Presentation%20early%20research%20program%20ATX.pptx?web=1\&EntityRepresentationId=145cbe5a-e0bc-4d11-a503-0597ff6c0bee) [\[Presentati...rogram ATX | PowerPoint\]](https://boehringer.sharepoint.com/sites/z365clinicaltrialspatientandsiteengagement/Shared%20Documents/TA%20Inflammation/Pulmonary%20Fibrosis/PF%20patient%20advisory%20board%20meetings/PF%20Steerco%20Presentations%20-%20Minutes%20-%20Recordings/6)%209th%20of%20November%202023%20-%20ATX%20&%20IL-11/Presentation%20early%20research%20program%20ATX.pptx?web=1)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| dosage\_form              | NONE     | Tablet bestätigt (film‑coated).                                                                   | [ENCO 280824\_BI 1819479 (ATXi).pptx](https://boehringer.sharepoint.com/sites/z3653pm/_layouts/15/Doc.aspx?sourcedoc=%7BE4EA0AB2-C972-47D1-B704-5AB2DF78891F%7D\&file=ENCO%20280824_BI%201819479%20%28ATXi%29.pptx\&action=edit\&mobileredirect=true\&DefaultItemOpen=1\&EntityRepresentationId=716976dc-bf95-4dda-bcf4-083d561827a8) [\[ENCO 28082...479 (ATXi) | PowerPoint\]](https://boehringer.sharepoint.com/sites/z3653pm/_layouts/15/Doc.aspx?sourcedoc=%7BE4EA0AB2-C972-47D1-B704-5AB2DF78891F%7D&file=ENCO%20280824_BI%201819479%20(ATXi).pptx&action=edit&mobileredirect=true&DefaultItemOpen=1)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| route\_of\_administration | NONE     | Oral bestätigt.                                                                                   | [03 - 1 - clinical-trial-protocol-version-03-trackmode.pdf](https://boehringer.sharepoint.com/sites/z365eco/iQNow%20%20Ethik%20und%20BfArM%20Rckmeldungen/1462/1462-0001/Ethik-BfArM/03%20-%201%20-%20clinical-trial-protocol-version-03-trackmode.pdf?web=1\&EntityRepresentationId=5ff1d2d5-6867-4339-b082-069efbb745d5) [\[03 - 1 - c...-trackmode | PDF\]](https://boehringer.sharepoint.com/sites/z365eco/iQNow%20%20Ethik%20und%20BfArM%20Rckmeldungen/1462/1462-0001/Ethik-BfArM/03%20-%201%20-%20clinical-trial-protocol-version-03-trackmode.pdf?web=1)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| base\_technology          | MAJOR    | Korrektur: **Fluid‑bed‑Granulation + Endmischung, Kompression, Film‑Coating** statt „High Shear“. | [ENCO 280824\_BI 1819479 (ATXi).pptx](https://boehringer.sharepoint.com/sites/z3653pm/_layouts/15/Doc.aspx?sourcedoc=%7BE4EA0AB2-C972-47D1-B704-5AB2DF78891F%7D\&file=ENCO%20280824_BI%201819479%20%28ATXi%29.pptx\&action=edit\&mobileredirect=true\&DefaultItemOpen=1\&EntityRepresentationId=716976dc-bf95-4dda-bcf4-083d561827a8) [\[ENCO 28082...479 (ATXi) | PowerPoint\]](https://boehringer.sharepoint.com/sites/z3653pm/_layouts/15/Doc.aspx?sourcedoc=%7BE4EA0AB2-C972-47D1-B704-5AB2DF78891F%7D&file=ENCO%20280824_BI%201819479%20(ATXi).pptx&action=edit&mobileredirect=true&DefaultItemOpen=1)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| current\_phase            | NONE     | Phase II ist korrekt (PoC‑Programm in IPF/PPF).                                                   | [Presentation early research program ATX.pptx](https://boehringer.sharepoint.com/sites/z365clinicaltrialspatientandsiteengagement/Shared%20Documents/TA%20Inflammation/Pulmonary%20Fibrosis/PF%20patient%20advisory%20board%20meetings/PF%20Steerco%20Presentations%20-%20Minutes%20-%20Recordings/6%29%209th%20of%20November%202023%20-%20ATX%20&%20IL-11/Presentation%20early%20research%20program%20ATX.pptx?web=1\&EntityRepresentationId=145cbe5a-e0bc-4d11-a503-0597ff6c0bee);[Clinical Trials Overview Inflammation\_ONGOING.xlsx](https://boehringer.sharepoint.com/sites/z365clinicaltrialspatientandsiteengagement/_layouts/15/Doc.aspx?sourcedoc=%7BFB0789F1-B848-4CF8-8662-B90836ABBEFF%7D\&file=Clinical%20Trials%20Overview%20Inflammation_ONGOING.xlsx\&action=default\&mobileredirect=true\&DefaultItemOpen=1\&EntityRepresentationId=b96b3f6e-5ffa-4608-907f-5d7ce687ff37) [\[Presentati...rogram ATX | PowerPoint\]](https://boehringer.sharepoint.com/sites/z365clinicaltrialspatientandsiteengagement/Shared%20Documents/TA%20Inflammation/Pulmonary%20Fibrosis/PF%20patient%20advisory%20board%20meetings/PF%20Steerco%20Presentations%20-%20Minutes%20-%20Recordings/6)%209th%20of%20November%202023%20-%20ATX%20&%20IL-11/Presentation%20early%20research%20program%20ATX.pptx?web=1) |

**BI 706321**

| Feld                      | Änderung | Beschreibung                                                                                              | Evidenz                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| ------------------------- | -------- | --------------------------------------------------------------------------------------------------------- | ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- |
| product\_code             | NONE     | Keine Änderung.                                                                                           | —                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| product\_name             | NONE     | Keine Änderung (kein INN/Name öffentlich).                                                                | —                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| modality\_name            | NONE     | „Small Molecule“ ist korrekt (RIPK2‑Inhibitor).                                                           | [04 - 2 - ib-bi-706321-1425-p1-version3-to-version2-comparison.pdf](https://boehringer.sharepoint.com/sites/z365eco/iQNow%20%20Ethik%20und%20BfArM%20Rckmeldungen/1425/1425-0001/Ethik-BfArM/04%20-%202%20-%20ib-bi-706321-1425-p1-version3-to-version2-comparison.pdf?web=1\&EntityRepresentationId=42692698-4f59-4609-b285-942943e6bcc3) [\[04 - 2 - i...comparison | PDF\]](https://boehringer.sharepoint.com/sites/z365eco/iQNow%20%20Ethik%20und%20BfArM%20Rckmeldungen/1425/1425-0001/Ethik-BfArM/04%20-%202%20-%20ib-bi-706321-1425-p1-version3-to-version2-comparison.pdf?web=1)                                                                                                                                                                                                                 |
| product\_type             | NONE     | „NME“ ist korrekt.                                                                                        | [Inflammation\_Insider\_Edition\_15\_20240319\_3.0.pdf](https://boehringer.sharepoint.com/sites/mybi_tainflammation/SiteAssets/SitePages/Inflammation-Insider%281%29/Inflammation_Insider_Edition_15_20240319_3.0.pdf?web=1\&EntityRepresentationId=5de2dab8-bdce-426c-b181-3496cb2c844c) [\[Inflammati...240319_3.0 | PDF\]](https://boehringer.sharepoint.com/sites/mybi_tainflammation/SiteAssets/SitePages/Inflammation-Insider(1)/Inflammation_Insider_Edition_15_20240319_3.0.pdf?web=1)                                                                                                                                                                                                                                                                                                       |
| therapeutic\_area         | NONE     | „Immunology“ (IBD/CD) ist passend.                                                                        | [Inflammation\_Insider\_Edition\_15\_20240319\_3.0.pdf](https://boehringer.sharepoint.com/sites/mybi_tainflammation/SiteAssets/SitePages/Inflammation-Insider%281%29/Inflammation_Insider_Edition_15_20240319_3.0.pdf?web=1\&EntityRepresentationId=5de2dab8-bdce-426c-b181-3496cb2c844c) [\[Inflammati...240319_3.0 | PDF\]](https://boehringer.sharepoint.com/sites/mybi_tainflammation/SiteAssets/SitePages/Inflammation-Insider(1)/Inflammation_Insider_Edition_15_20240319_3.0.pdf?web=1)                                                                                                                                                                                                                                                                                                       |
| mechanism\_of\_action     | NONE     | „RIPK2 inhibitor“ ist korrekt.                                                                            | [04 - 2 - ib-bi-706321-1425-p1-version3-to-version2-comparison.pdf](https://boehringer.sharepoint.com/sites/z365eco/iQNow%20%20Ethik%20und%20BfArM%20Rckmeldungen/1425/1425-0001/Ethik-BfArM/04%20-%202%20-%20ib-bi-706321-1425-p1-version3-to-version2-comparison.pdf?web=1\&EntityRepresentationId=42692698-4f59-4609-b285-942943e6bcc3) [\[04 - 2 - i...comparison | PDF\]](https://boehringer.sharepoint.com/sites/z365eco/iQNow%20%20Ethik%20und%20BfArM%20Rckmeldungen/1425/1425-0001/Ethik-BfArM/04%20-%202%20-%20ib-bi-706321-1425-p1-version3-to-version2-comparison.pdf?web=1)                                                                                                                                                                                                                 |
| short\_description        | NONE     | Beschreibung ist konsistent (NOD/RIPK2‑Signalweg, IBD).                                                   | [Inflammation\_Insider\_Edition2\_\_v4.0.pdf](https://boehringer.sharepoint.com/sites/mybi_tainflammation/Shared%20Documents/Inflammation%20Insiders/Inflammation_Insider_Edition2__v4.0.pdf?web=1\&EntityRepresentationId=89c3b0c6-462c-424b-b44c-811a5a54c5f4) [\[Inflammati...ion2__v4.0 | PDF\]](https://boehringer.sharepoint.com/sites/mybi_tainflammation/Shared%20Documents/Inflammation%20Insiders/Inflammation_Insider_Edition2__v4.0.pdf?web=1)                                                                                                                                                                                                                                                                                                                                               |
| dosage\_form              | NONE     | „Tablet“ ist korrekt (Studie nutzte Tabletten).                                                           | [NCT04978493 (BI 706321 + Ustekinumab)](https://clinicaltrials.gov/study/NCT04978493)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| route\_of\_administration | NONE     | „Oral“ ist korrekt.                                                                                       | [NCT04978493](https://clinicaltrials.gov/study/NCT04978493)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| base\_technology          | NONE     | Keine gesicherten Angaben – Feld kann leer bleiben.                                                       | [BI Pipeline‑Seite](https://pro.boehringer-ingelheim.com/us/medinfo/clinical-trials/nct04978493)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| current\_phase            | NONE     | „Discontinued“ ist korrekt (Studie beendet, Company decision; intern als „Discontinued studies“ geführt). | [NCT04978493 – Status „Terminated“](https://clinicaltrials.gov/study/NCT04978493); [Clinical trials overview\_TA INFL ONGOING.pptx](https://boehringer.sharepoint.com/sites/z365clinicaltrialspatientandsiteengagement/Shared%20Documents/TA%20Inflammation/1.%20Overview/TA%20INFL%20Trials%20Planning/Clinical%20trials%20overview_TA%20INFL%20ONGOING/Clinical%20trials%20overview_TA%20INFL%20ONGOING.pptx?web=1\&EntityRepresentationId=78963066-055a-490a-abd6-de475ba254ca) [\[clinicaltrials.gov\]](https://clinicaltrials.gov/study/NCT04978493) |

**BI 3032950**

| Feld                      | Änderung | Beschreibung                                                                                                                                                       | Evidenz                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| ------------------------- | -------- | ------------------------------------------------------------------------------------------------------------------------------------------------------------------ | -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- |
| product\_code             | NONE     | Keine Änderung.                                                                                                                                                    | —                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| product\_name             | NONE     | Keine Änderung (kein INN/Name öffentlich).                                                                                                                         | —                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| modality\_name            | NONE     | „Monoclonal Antibody“ ist korrekt.                                                                                                                                 | [BI 3032950 (TREM1) AEP V2.0\_Final\_05June2023.pdf](https://boehringer.sharepoint.com/sites/z365clinicaltrialspatientandsiteengagement/Shared%20Documents/TA%20Inflammation/2.%20AEP's/BI%203032950%20%28TREM1%29%20AEP%20V2.0_Final_05June2023.pdf?web=1\&EntityRepresentationId=f6d9b0ee-7c9f-4377-ba73-f7e4ca2267cb) [\[pro.boehri...elheim.com\]](https://pro.boehringer-ingelheim.com/us/medinfo/clinical-trials/nct04978493)                                                                                                                                                               |
| product\_type             | NONE     | „NBE“ ist korrekt.                                                                                                                                                 | [NBE Portfolio\_Q-uriosity\_Sep24\_Reisinger.pptx](https://boehringer.sharepoint.com/sites/z365qualityexcellenceprogram/_layouts/15/Doc.aspx?sourcedoc=%7BC0E00D05-78CD-402B-A9CB-22D00F701DCE%7D\&file=NBE%20Portfolio_Q-uriosity_Sep24_Reisinger.pptx\&action=edit\&mobileredirect=true\&DefaultItemOpen=1\&EntityRepresentationId=8d6b5da8-762f-4e68-b8a8-55be61ccc544) [\[Clinical t...FL ONGOING | PowerPoint\]](https://boehringer.sharepoint.com/sites/z365clinicaltrialspatientandsiteengagement/Shared%20Documents/TA%20Inflammation/1.%20Overview/TA%20INFL%20Trials%20Planning/Clinical%20trials%20overview_TA%20INFL%20ONGOING/Clinical%20trials%20overview_TA%20INFL%20ONGOING.pptx?web=1)                                                             |
| therapeutic\_area         | NONE     | „Immunology“ ist korrekt (IBD‑Programm).                                                                                                                           | [COC study Status presentation MSa\_03.Sep.2024.pptx](https://boehringer.sharepoint.com/sites/z365eco/_layouts/15/Doc.aspx?sourcedoc=%7BE1251A8A-2D01-4C4A-8644-CAFC373E0FAF%7D\&file=COC%20study%20Status%20presentation%20MSa_03.Sep.2024.pptx\&action=edit\&mobileredirect=true\&DefaultItemOpen=1\&EntityRepresentationId=e81007e8-8bf5-487b-bd60-efd85eacf69e) [\[BI 3032950...05June2023 | PDF\]](https://boehringer.sharepoint.com/sites/z365clinicaltrialspatientandsiteengagement/Shared%20Documents/TA%20Inflammation/2.%20AEP's/BI%203032950%20(TREM1)%20AEP%20V2.0_Final_05June2023.pdf?web=1)                                                                              |
| mechanism\_of\_action     | NONE     | „TREM‑1 antagonist“ ist korrekt.                                                                                                                                   | [ib-bi3032950-1486-p1-version-4.pdf](https://boehringer.sharepoint.com/sites/z365ridgefieldenvironmentalhealthandsafetymybi/EHS%20Documents/Environmental/Environmental%20Risk%20Assessments/Product%20Environmental%20Risk%20Assessment/INDs/BI%203032950/ib-bi3032950-1486-p1-version-4.pdf?web=1\&EntityRepresentationId=3330c7b9-8633-4378-8003-ff492e52f2f2) [\[NBE Portfo..._Reisinger | PowerPoint\]](https://boehringer.sharepoint.com/sites/z365qualityexcellenceprogram/_layouts/15/Doc.aspx?sourcedoc=%7BBD15DDD0-4717-43C4-B379-7EC1DA39D2FF%7D&file=NBE%20Portfolio_Q-uriosity_Sep24_Reisinger.pptx&action=edit&mobileredirect=true&DefaultItemOpen=1)                                                             |
| short\_description        | MINOR    | Zielwert: „TREM‑1‑Antikörper für UC (Induktion i.v., Erhaltung s.c.); IBD‑Programm, CD in Bewertung.“ Grund: aktives Phase‑IIa‑Programm in **Ulcerative Colitis**. | [NCT06636656 (UC, Phase IIa)](https://clinicaltrials.gov/study/NCT06636656); [COC study Status presentation MSa\_03.Sep.2024.pptx](https://boehringer.sharepoint.com/sites/z365eco/_layouts/15/Doc.aspx?sourcedoc=%7BE1251A8A-2D01-4C4A-8644-CAFC373E0FAF%7D\&file=COC%20study%20Status%20presentation%20MSa_03.Sep.2024.pptx\&action=edit\&mobileredirect=true\&DefaultItemOpen=1\&EntityRepresentationId=e81007e8-8bf5-487b-bd60-efd85eacf69e) [\[BI 3032950...05June2023 | PDF\]](https://boehringer.sharepoint.com/sites/z365clinicaltrialspatientandsiteengagement/Shared%20Documents/TA%20Inflammation/2.%20AEP's/BI%203032950%20(TREM1)%20AEP%20V2.0_Final_05June2023.pdf?web=1) |
| dosage\_form              | MINOR    | Zielwert: „Intravenöse **Infusion** (Induktion) und **subkutane** Injektion (Erhaltung)“ statt generisch „Injectable“.                                             | [NCT06636656](https://clinicaltrials.gov/study/NCT06636656); [ICH GCP NCT06636656](https://ichgcp.net/clinical-trials-registry/nct06636656)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| route\_of\_administration | MINOR    | Zielwert: „IV (Induktion), SC (Erhaltung)“; Begründung wie oben.                                                                                                   | [NCT06636656](https://clinicaltrials.gov/study/NCT06636656)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| base\_technology          | NONE     | Keine verlässlichen öffentlichen Angaben; belassen.                                                                                                                | [BI Pipeline‑Kachel](https://www.boehringer-ingelheim.com/science-innovation/human-health-innovation/clinical-pipeline/bi-3032950-trem-1-antagonist)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| current\_phase            | NONE     | „Phase II“ ist korrekt (UC‑PoCP rekrutiert).                                                                                                                       | [NCT06636656](https://clinicaltrials.gov/study/NCT06636656); [COC study Status presentation MSa\_03.Sep.2024.pptx](https://boehringer.sharepoint.com/sites/z365eco/_layouts/15/Doc.aspx?sourcedoc=%7BE1251A8A-2D01-4C4A-8644-CAFC373E0FAF%7D\&file=COC%20study%20Status%20presentation%20MSa_03.Sep.2024.pptx\&action=edit\&mobileredirect=true\&DefaultItemOpen=1\&EntityRepresentationId=e81007e8-8bf5-487b-bd60-efd85eacf69e) [\[BI 3032950...05June2023 | PDF\]](https://boehringer.sharepoint.com/sites/z365clinicaltrialspatientandsiteengagement/Shared%20Documents/TA%20Inflammation/2.%20AEP's/BI%203032950%20(TREM1)%20AEP%20V2.0_Final_05June2023.pdf?web=1)                 |

**BI 764198**

| Feld                      | Änderung | Beschreibung                                                                                                     | Evidenz                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| ------------------------- | -------- | ---------------------------------------------------------------------------------------------------------------- | ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- |
| product\_code             | NONE     | Keine Änderung.                                                                                                  | —                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| product\_name             | NONE     | Keine Änderung (kein INN/Name öffentlich).                                                                       | —                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| modality\_name            | NONE     | „Small Molecule“ ist korrekt (TRPC6‑Inhibitor).                                                                  | [BI 764198 Pipeline‑Kachel](https://www.boehringer-ingelheim.com/science-innovation/human-health-innovation/clinical-pipeline/bi-764198-trpc6-inhibitor)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| product\_type             | NONE     | „NME“ ist korrekt.                                                                                               | [3. TA CRM pipeline\_DM2035 HR.pptx](https://boehringer.sharepoint.com/sites/z365usmedicinecapabilitiesexcellence/Shared%20Documents/US%20Early%20Asset%20Teams,%20HPSC%20prep/Policy%20&%20Procedure%20Documents/Workshops/CRM%20Global%20&%20US%20Workshop/3.%20TA%20CRM%20pipeline_DM2035%20HR.pptx?web=1\&EntityRepresentationId=95160017-f5da-4ca3-8562-050c4a5eb73d) [\[COC study...3.Sep.2024 | PowerPoint\]](https://boehringer.sharepoint.com/sites/z365eco/_layouts/15/Doc.aspx?sourcedoc=%7BE1251A8A-2D01-4C4A-8644-CAFC373E0FAF%7D&file=COC%20study%20Status%20presentation%20MSa_03.Sep.2024.pptx&action=edit&mobileredirect=true&DefaultItemOpen=1)                                                                                                                                                                                                      |
| therapeutic\_area         | MINOR    | Zielwert: „Cardiovascular‑Renal‑Metabolic (Nephrology)“ statt „CRM; Immunology“; Programm ist **renal/FSGS**.    | [NCT05213624 (FSGS)](https://clinicaltrials.gov/study/NCT05213624); FSGS BI 764198 master slide deck\_vF-retemplated.pptx [\[ib-bi30329...-version-4 | PDF\]](https://boehringer.sharepoint.com/sites/z365ridgefieldenvironmentalhealthandsafetymybi/EHS%20Documents/Environmental/Environmental%20Risk%20Assessments/Product%20Environmental%20Risk%20Assessment/INDs/BI%203032950/ib-bi3032950-1486-p1-version-4.pdf?web=1)                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| mechanism\_of\_action     | NONE     | „TRPC6 inhibitor“ ist korrekt.                                                                                   | [Kidney Int Rep (Studien‑Design)](https://rcastoragev2.blob.core.windows.net/e02cbd361870f14f9ad55e6c07c3540a/main.PMC10719596.pdf)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| short\_description        | NONE     | Passt (Fokus FSGS).                                                                                              | [NCT05213624](https://clinicaltrials.gov/study/NCT05213624)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| dosage\_form              | MAJOR    | Zielwert: „**Capsule**“ statt „Tablet“; Studienteilnehmende erhielten **Kapseln** einmal täglich.                | [NCT05213624 – „capsules once a day“](https://clinicaltrials.gov/study/NCT05213624); Clinical Study of FSCS Kidney Disease BIPI [\[clinicaltrials.gov\]](https://clinicaltrials.gov/study/NCT06636656)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| route\_of\_administration | NONE     | „Oral“ ist korrekt.                                                                                              | [NCT05213624](https://clinicaltrials.gov/study/NCT05213624)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| base\_technology          | MINOR    | Zielwert: „n. a./nicht offengelegt“ statt „Roller Compaction“ (keine belastbare Quelle für Herstelltechnologie). | [BI Pipeline‑Kachel](https://www.boehringer-ingelheim.com/science-innovation/human-health-innovation/clinical-pipeline/bi-764198-trpc6-inhibitor); [Phase‑1 Publikation (keine Herstellangaben)](https://www.tandfonline.com/doi/pdf/10.1080/13543784.2025.2510673)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| current\_phase            | MINOR    | Zielwert: „**Phase IIa abgeschlossen; Phase III in Vorbereitung**“ (EoP2‑Feedback, P3‑Planung).                  | [NCT05213624 – Status „Completed“](https://clinicaltrials.gov/study/NCT05213624); [1434-0017\_Trial Design following FDA feedback\_updated 25-Jun-2025.pptx](https://boehringer.sharepoint.com/sites/z365patientandsiteengagementexternalcollaboration/_layouts/15/Doc.aspx?sourcedoc=%7B5784FA51-A27F-43DB-9AB9-D3135EE24372%7D\&file=1434-0017_Trial%20Design%20following%20FDA%20feedback_updated%2025-Jun-2025.pptx\&action=edit\&mobileredirect=true\&DefaultItemOpen=1\&EntityRepresentationId=feb89310-bd2d-4b17-991a-9480b4a717e3) [\[ichgcp.net\]](https://ichgcp.net/clinical-trials-registry/nct06636656) |

**BI 765845**

| Feld                      | Änderung | Beschreibung                                                                                               | Evidenz                                                                                                                                                                                             |
| ------------------------- | -------- | ---------------------------------------------------------------------------------------------------------- | --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- |
| product\_code             | NONE     | Keine Änderung.                                                                                            | —                                                                                                                                                                                                   |
| product\_name             | NONE     | Keine Änderung (kein INN/Name öffentlich).                                                                 | —                                                                                                                                                                                                   |
| modality\_name            | NONE     | „Recombinant Proteins“ ist plausibel (MYDGF‑Protein).                                                      | [BI 765845 Pipeline‑Kachel](https://www.boehringer-ingelheim.com/science-innovation/human-health-innovation/clinical-pipeline/bi-765845-heart-disease-modulator)                                    |
| product\_type             | NONE     | „NBE“ ist korrekt.                                                                                         | [BI 765845 Pipeline‑Kachel](https://www.boehringer-ingelheim.com/science-innovation/human-health-innovation/clinical-pipeline/bi-765845-heart-disease-modulator)                                    |
| therapeutic\_area         | NONE     | „CRM“ (STEMI) ist korrekt.                                                                                 | [NCT06139328](https://ichgcp.net/clinical-trials-registry/NCT06139328)                                                                                                                              |
| mechanism\_of\_action     | NONE     | „MYDGF (Herzgewebe‑Modulator)“ ist korrekt.                                                                | [PharmaTechnology (GlobalData) Zusammenfassung](https://www.pharmaceutical-technology.com/data-insights/bi-765845-boehringer-ingelheim-international-myocardial-infarction-likelihood-of-approval/) |
| short\_description        | NONE     | Beschreibung ist konsistent (post‑MI).                                                                     | [NCT06139328](https://ichgcp.net/clinical-trials-registry/NCT06139328)                                                                                                                              |
| dosage\_form              | MINOR    | Zielwert: „**Intravenöse Infusion** (sowie untersuchte **i.v. Bolus**‑Gabe)“ statt generisch „Injectable“. | [NCT06139328 – Design (Infusion/Bolus)](https://ichgcp.net/clinical-trials-registry/NCT06139328)                                                                                                    |
| route\_of\_administration | MINOR    | Zielwert: „**Intravenös**“.                                                                                | [NCT06139328](https://ichgcp.net/clinical-trials-registry/NCT06139328)                                                                                                                              |
| base\_technology          | MINOR    | Zielwert: „n. a./nicht offengelegt“ (keine belastbare Quelle für „Microbial“).                             | [BI Pipeline‑Kachel](https://www.boehringer-ingelheim.com/science-innovation/human-health-innovation/clinical-pipeline/bi-765845-heart-disease-modulator)                                           |
| current\_phase            | NONE     | „Phase II“ ist korrekt (aktiv/nicht rekrutierend).                                                         | [NCT06139328](https://ichgcp.net/clinical-trials-registry/NCT06139328); [Synapse Profil](https://synapse.patsnap.com/drug/4f0953cb9f17493a9e6bcbc2f76718af)                                         |

**BI 770371**

| Feld                      | Änderung | Beschreibung                                                                                                                                                                         | Evidenz                                                                                                                                                                                                                                                                                                                                                             |
| ------------------------- | -------- | ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ | ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- |
| product\_code             | NONE     | Keine Änderung.                                                                                                                                                                      | —                                                                                                                                                                                                                                                                                                                                                                     |
| product\_name             | NONE     | Keine Änderung (kein INN/Name öffentlich).                                                                                                                                           | —                                                                                                                                                                                                                                                                                                                                                                     |
| modality\_name            | NONE     | „Monoclonal Antibody“ ist korrekt.                                                                                                                                                   | [InOncology SIRPα‑Antagonist](https://pro.boehringer-ingelheim.com/inoncology/our-pipeline/sirpa-antagonist)                                                                                                                                                                                                                                                        |
| product\_type             | NONE     | „NBE“ ist korrekt.                                                                                                                                                                   | [InOncology SIRPα‑Antagonist](https://pro.boehringer-ingelheim.com/inoncology/our-pipeline/sirpa-antagonist)                                                                                                                                                                                                                                                        |
| therapeutic\_area         | NONE     | Doppelte TA ist korrekt (**Oncology** & **CRM/MASH**).                                                                                                                               | [Onkologie‑Phase I](https://pro.boehringer-ingelheim.com/inoncology/our-pipeline/sirpa-antagonist); [MASH‑Pipeline‑Kachel](https://www.boehringer-ingelheim.com/science-innovation/human-health-innovation/clinical-pipeline/bi-770371-sirpa-antagonist)                                                                                                            |
| mechanism\_of\_action     | NONE     | „SIRPα antagonist“ (CD47/SIRPα‑Achse) ist korrekt.                                                                                                                                   | [ASCO 2025 Abstract 2515](https://ascopubs.org/doi/pdf/10.1200/JCO.2025.43.16_suppl.2515)                                                                                                                                                                                                                                                                           |
| short\_description        | NONE     | Beschreibung (Phagozytose‑Enthemmung; MASH & Krebs) ist konsistent.                                                                                                                  | [InOncology SIRPα](https://pro.boehringer-ingelheim.com/inoncology/our-pipeline/sirpa-antagonist)                                                                                                                                                                                                                                                                   |
| dosage\_form              | MINOR    | Zielwert: „**Intravenöse** Antikörper‑Infusion“ statt generisch „Injectable“.                                                                                                        | [InOncology SIRPα](https://pro.boehringer-ingelheim.com/inoncology/our-pipeline/sirpa-antagonist)                                                                                                                                                                                                                                                                   |
| route\_of\_administration | MINOR    | Zielwert: „**IV**“.                                                                                                                                                                  | [InOncology SIRPα](https://pro.boehringer-ingelheim.com/inoncology/our-pipeline/sirpa-antagonist)                                                                                                                                                                                                                                                                   |
| base\_technology          | NONE     | „Mammalian cell culture“ ist plausibel; wenn beibehalten, bitte als „vermutlich/standard“ kennzeichnen (keine offizielle Quelle).                                                    | —                                                                                                                                                                                                                                                                                                                                                                     |
| current\_phase            | MAJOR    | Zielwert: „**Phase IIa (MASH, kompensierte Zirrhose)** und **Phase I (Onkologie, solide Tumoren/HNSCC)**“ statt pauschal „Phase II“. Grund: indikationsabhängige Entwicklungsstände. | [NCT06675929 (MASH Phase IIa)](https://clinicaltrials.gov/study/NCT06675929); [InOncology SIRPα Phase I](https://pro.boehringer-ingelheim.com/inoncology/our-pipeline/sirpa-antagonist); [BI‑Meldung zu SIRPα‑Programm](https://www.boehringer-ingelheim.com/science-innovation/human-health-innovation/boehringer-ingelheim-advances-sirp-immune-oncology-program) |

**BI 764524**

| Feld                      | Änderung | Beschreibung                                                                                                                                                                        | Evidenz                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| ------------------------- | -------- | ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- | --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- |
| product\_code             | NONE     | —                                                                                                                                                                                   | —                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| product\_name             | NONE     | —                                                                                                                                                                                   | —                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| modality\_name            | NONE     | —                                                                                                                                                                                   | —                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| product\_type             | NONE     | —                                                                                                                                                                                   | —                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| therapeutic\_area         | NONE     | —                                                                                                                                                                                   | —                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| mechanism\_of\_action     | MINOR    | Zielwert: „Humanisierte IgG1‑Anti‑Sema3A‑Antikörper (bindet Sema3A/Neuropilin‑1‑Achse); Re‑Vaskularisation ischämischer Areale bei DMI/DR“. Grund: präzisere Beschreibung laut AEP. | [AEP\_BI\_764524\_\_BI\_765128\_version\_3.0\_final\_20230927\_SIGNED.pdf](https://boehringer.sharepoint.com/sites/z365pricingandcontractingoncology/Shared%20Documents/eVL%20Strategy%20and%20Support/TA%20Retina/Anti%20Sema%203A/AEP_BI_764524__BI_765128_version_3.0_final_20230927_SIGNED.pdf?web=1\&EntityRepresentationId=ff502f47-a66c-42b7-9ad9-9fed8838474d) [\[AEP_BI_764...927_SIGNED | PDF\]](https://boehringer.sharepoint.com/sites/z365pricingandcontractingoncology/Shared%20Documents/eVL%20Strategy%20and%20Support/TA%20Retina/Anti%20Sema%203A/AEP_BI_764524__BI_765128_version_3.0_final_20230927_SIGNED.pdf?web=1)                                                          |
| short\_description        | MINOR    | Zielwert: „Anti‑Sema3A für diabetische Retinopathie, mit Fokus auf DMI/Retinal Non‑Perfusion (krankheitsmodifizierend).“ Grund: Fokus der Entwicklung ist DMI/DR.                   | [p\_240517\_1.aspx](https://boehringer.sharepoint.com/sites/mybi_news_jpn/SitePages/p_240517_1.aspx?web=1\&EntityRepresentationId=3866f252-5cb4-4e63-a4a8-da321b26391c) [\[ベーリンガーインゲル...での良好な結果を発表 | SharePoint\]](https://boehringer.sharepoint.com/sites/mybi_news_jpn/SitePages/p_240517_1.aspx?web=1); [BI‑Presse: HORNBILL Phase I/IIa positiv](https://www.boehringer-ingelheim.com/science-innovation/human-health-innovation/positive-results-diabetic-macular-ischemia-treatment)                                                                                                                                                                                                                |
| dosage\_form              | MINOR    | Zielwert: „Lyophilisat in Einzeldosis‑Vial (zur intravitrealen Injektion).“ Grund: CMC‑Spezifikationsdokument.                                                                      | [BI-VQD-217286-JM-764524-A.docx](https://boehringer.sharepoint.com/sites/z365plattformdokumentenreviewadb/_layouts/15/Doc.aspx?sourcedoc=%7B57328817-6C9F-4164-9DD9-D5DB81573212%7D\&file=BI-VQD-217286-JM-764524-A.docx\&action=default\&mobileredirect=true\&DefaultItemOpen=1\&EntityRepresentationId=6ed1ffd2-78eb-450c-aa57-fa8c062d0511) [\[boehringer...elheim.com\]](https://www.boehringer-ingelheim.com/science-innovation/human-health-innovation/positive-results-diabetic-macular-ischemia-treatment)                                                                    |
| route\_of\_administration | NONE     | —                                                                                                                                                                                   | —                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| base\_technology          | MINOR    | Zielwert: „Mammalian (CHO‑K1).“ Grund: IMPD beschreibt CHO‑K1‑basierte Produktionszelllinie.                                                                                        | [IMPD for trial 1436-0007 EU US V03 2024-09-11.pdf](https://boehringer.sharepoint.com/sites/z365globalmasterdossier/Shared%20Documents/Biotechnology%20%20Guidances/00.%20Recent%20Example%20Documents/CTA%20Recent%20Example%20Documents/Phase%202/IMPD%20for%20trial%201436-0007%20EU%20US%20V03%202024-09-11.pdf?web=1\&EntityRepresentationId=1b228cfb-638a-4496-9c85-7f008e9805b5) [\[BI-VQD-217...M-764524-A | Word\]](https://boehringer.sharepoint.com/sites/z365plattformdokumentenreviewadb/_layouts/15/Doc.aspx?sourcedoc=%7B57328817-6C9F-4164-9DD9-D5DB81573212%7D&file=BI-VQD-217286-JM-764524-A.docx&action=default&mobileredirect=true&DefaultItemOpen=1) |
| current\_phase            | NONE     | —                                                                                                                                                                                   | —                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |

**BI 836880**

| Feld                      | Änderung | Beschreibung                                                                                                                                                                                                                                                                                  | Evidenz                                                                                                                                                                                                                                                   |
| ------------------------- | -------- | --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- | --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- |
| product\_code             | NONE     | —                                                                                                                                                                                                                                                                                             | —                                                                                                                                                                                                                                                         |
| product\_name             | NONE     | —                                                                                                                                                                                                                                                                                             | —                                                                                                                                                                                                                                                         |
| modality\_name            | MAJOR    | Zielwert: „Bispezifische **Nanobody®**‑Antikörperfragmente (VEGF‑A/Ang‑2).“ Grund: formaler Modalitätstyp ist Nanobody, nicht generisches „Recombinant Protein“.                                                                                                                              | [Journal of Translational Medicine 2024](https://translational-medicine.biomedcentral.com/articles/10.1186/s12967-024-05612-x); [NCI Drug Dictionary](https://www.cancer.gov/publications/dictionaries/cancer-drug/def/anti-vegf-ang2-nanobody-bi-836880) |
| product\_type             | NONE     | —                                                                                                                                                                                                                                                                                             | —                                                                                                                                                                                                                                                         |
| therapeutic\_area         | MAJOR    | Zielwert: „Onkologie“ (primäre, aktive Entwicklung). Grund: laufende klinische Programme in soliden Tumoren (u. a. HCC, GBM); wAMD‑IVT‑Studie abgeschlossen.                                                                                                                                  | [JCO OA 2025 – Kombi mit Ezabenlimab](https://ascopubs.org/doi/pdfdirect/10.1200/OA-24-00039); [NCT03861234 – wAMD IVT, abgeschlossen](https://clinicaltrials.gov/study/NCT03861234)                                                                      |
| mechanism\_of\_action     | MINOR    | Zielwert: „Humanisierte bispezifische Nanobody® blockiert VEGF‑A und Ang‑2 (Dual‑Angiogenesehemmung).“ Grund: Präzisierung.                                                                                                                                                                   | [Journal of Translational Medicine 2024](https://translational-medicine.biomedcentral.com/articles/10.1186/s12967-024-05612-x)                                                                                                                            |
| short\_description        | MAJOR    | Zielwert: „IV verabreichte VEGF‑A/Ang‑2‑Nanobody®; als Mono- und in Kombination mit Anti‑PD‑1 (Ezabenlimab) in verschiedenen soliden Tumoren (z. B. HCC, GBM) in klinischer Prüfung; separate IVT‑Studie in wAMD abgeschlossen.“ Grund: aktuelle klinische Positionierung ist onkologisch/IV. | [JCO OA 2025](https://ascopubs.org/doi/pdfdirect/10.1200/OA-24-00039); [NCT03861234](https://clinicaltrials.gov/study/NCT03861234)                                                                                                                        |
| dosage\_form              | MAJOR    | Zielwert: „Intravenöse Infusion.“ Grund: onkologische Studien mit q3w‑IV‑Gabe.                                                                                                                                                                                                                | [Ann Oncol 2019 TIP](https://academic.oup.com/annonc/article-abstract/30/Supplement_9/mdz420.013/5638510); [JTM 2024](https://translational-medicine.biomedcentral.com/articles/10.1186/s12967-024-05612-x)                                               |
| route\_of\_administration | MAJOR    | Zielwert: „Intravenös (Onkologie); intravitreal nur in abgeschlossener wAMD‑FiH/IIa.“ Grund: Abgleich mit aktuellem Entwicklungsfokus.                                                                                                                                                        | [JCO OA 2025](https://ascopubs.org/doi/pdfdirect/10.1200/OA-24-00039); [NCT03861234](https://clinicaltrials.gov/study/NCT03861234)                                                                                                                        |
| base\_technology          | NONE     | —                                                                                                                                                                                                                                                                                             | —                                                                                                                                                                                                                                                         |
| current\_phase            | MAJOR    | Zielwert: „Phase I/II (Onkologie, laufend); wAMD‑IVT: Phase I/IIa abgeschlossen.“ Grund: nicht „discontinued“.                                                                                                                                                                                | [JCO OA 2025](https://ascopubs.org/doi/pdfdirect/10.1200/OA-24-00039); [NCT03861234](https://clinicaltrials.gov/study/NCT03861234)                                                                                                                        |

**BI 771716**

| Feld                      | Änderung | Beschreibung                                                                                                                       | Evidenz                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| ------------------------- | -------- | ---------------------------------------------------------------------------------------------------------------------------------- | ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ |
| product\_code             | NONE     | —                                                                                                                                  | —                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| product\_name             | NONE     | —                                                                                                                                  | —                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| modality\_name            | MAJOR    | Zielwert: „Antikörperfragment (scFv).“ Grund: BI 771716 ist ein **single‑chain variable fragment** gegen C3/C3b.                   | [2024.IUDay.Zhang,Xianwei.v2.pptx](https://boehringer.sharepoint.com/sites/z365posterday2024/_layouts/15/Doc.aspx?sourcedoc=%7BBB81C091-5D9B-4454-84EB-5D4125A63B8E%7D\&file=2024.IUDay.Zhang,Xianwei.v2.pptx\&action=edit\&mobileredirect=true\&DefaultItemOpen=1\&EntityRepresentationId=7c50ce13-99e2-4ed4-bc77-c9542fcade1e) [\[IMPD for t...2024-09-11 | PDF\]](https://boehringer.sharepoint.com/sites/z365globalmasterdossier/Shared%20Documents/Biotechnology%20%20Guidances/00.%20Recent%20Example%20Documents/CTA%20Recent%20Example%20Documents/Phase%202/IMPD%20for%20trial%201436-0007%20EU%20US%20V03%202024-09-11.pdf?web=1); [BI/ CDR‑Life Pressemitteilung 2024](https://www.boehringer-ingelheim.com/science-innovation/human-health-innovation/geographic-atrophy-treatment-move-phase-ii) |
| product\_type             | NONE     | —                                                                                                                                  | —                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| therapeutic\_area         | NONE     | —                                                                                                                                  | —                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| mechanism\_of\_action     | MINOR    | Zielwert: „Anti‑C3 scFv, hemmt C3 in allen Komplement‑Wegen; für GA.“ Grund: Präzisierung.                                         | [2024.IUDay.Zhang,Xianwei.v2.pdf](https://boehringer.sharepoint.com/sites/z365posterday2024/Shared%20Documents/General/zz%20%20archived/Digital%20Posters%20by%20last%20name%20of%20presenter/Zhang%20X/2024.IUDay.Zhang,Xianwei.v2.pdf?web=1\&EntityRepresentationId=7444e0f8-3b3b-43ca-8f3f-834ff42292fa) [\[translatio...entral.com\]](https://translational-medicine.biomedcentral.com/articles/10.1186/s12967-024-05612-x)                                                                                                                                                                                                        |
| short\_description        | MINOR    | Zielwert: „Antikörperfragment für Geographic Atrophy (GA); IVT‑Gabe, Phase II in Vorbereitung/laufend.“ Grund: Entwicklungsstatus. | [BI‑Newsroom 2024](https://www.boehringer-ingelheim.com/science-innovation/human-health-innovation/geographic-atrophy-treatment-move-phase-ii); [CDR‑Life Milestone 2025](https://www.cdr-life.com/news_item/cdr-life-announces-fifth-milestone-achievement-with-boehringer-ingelheim-in-geographic-atrophy/)                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| dosage\_form              | MINOR    | Zielwert: „Einzeldosis‑Vial; Lösung zur intravitrealen Injektion (z. B. 15 mg/IVT in Auswertungen).“ Grund: Marktzugangsanalyse.   | [Market Access Assessment of C3i (BI 771716)\_September.pptx](https://boehringer.sharepoint.com/sites/z365pricingandcontractingoncology/_layouts/15/Doc.aspx?sourcedoc=%7BC79A2937-823A-44AB-B504-7759F912324F%7D\&file=Market%20Access%20Assessment%20of%20C3i%20%28BI%20771716%29_September.pptx\&action=edit\&mobileredirect=true\&DefaultItemOpen=1\&EntityRepresentationId=8f837750-f5e6-4ee9-98c9-30e50a87d9af) [\[cancer.gov\]](https://www.cancer.gov/publications/dictionaries/cancer-drug/def/anti-vegf-ang2-nanobody-bi-836880)                    |
| route\_of\_administration | NONE     | —                                                                                                                                  | —                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| base\_technology          | NONE     | — (keine belastbare Quelle gefunden; „Microbial“ nicht verifizierbar)                                                              | —                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| current\_phase            | NONE     | — (Phase II bestätigt)                                                                                                             | [BI‑Newsroom 2024](https://www.boehringer-ingelheim.com/science-innovation/human-health-innovation/geographic-atrophy-treatment-move-phase-ii); [CDR‑Life 2025](https://www.cdr-life.com/news_item/cdr-life-announces-fifth-milestone-achievement-with-boehringer-ingelheim-in-geographic-atrophy/)                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |

**BI 764532 — Obrixtamig**

| Feld                      | Änderung | Beschreibung                                                                                                                   | Evidenz                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| ------------------------- | -------- | ------------------------------------------------------------------------------------------------------------------------------ | ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- |
| product\_code             | NONE     | —                                                                                                                              | —                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| product\_name             | NONE     | —                                                                                                                              | —                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| modality\_name            | MAJOR    | Zielwert: „Bispezifischer Antikörper (IgG‑ähnlicher **DLL3/CD3 T‑Cell Engager**).“ Grund: nicht „Monoclonal Antibody“.         | [Approved Uniform Pipeline Slide.pptx](https://boehringer.sharepoint.com/sites/mybi_news_onehp/Shared%20Documents/IU/Pipeline%20Update/Approved%20Uniform%20Pipeline%20Slide.pptx?web=1\&EntityRepresentationId=01d7049e-cc46-43e8-912b-0aba2a7e6d63) [\[ascopubs.org\]](https://ascopubs.org/doi/pdfdirect/10.1200/OA-24-00039); [BI‑Pipeline‑Seite Obrixtamig](https://www.boehringer-ingelheim.com/science-innovation/human-health-innovation/clinical-pipeline/obrixtamig-bi-764532-dll3-cd3-t-cell-engager-0)                                                                                                                                     |
| product\_type             | NONE     | —                                                                                                                              | —                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| therapeutic\_area         | NONE     | —                                                                                                                              | —                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| mechanism\_of\_action     | NONE     | —                                                                                                                              | —                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| short\_description        | MINOR    | Zielwert: „DLL3/CD3‑TcE für SCLC, epNEC und LCNEC; klinische Programme inkl. DAREON‑5.“ Grund: Indikationsspektrum präzisiert. | [1438.1-obrixtamig-WCLC-infographic\_4Sep24.pdf](https://boehringer.sharepoint.com/sites/mybi_taonco/SiteAssets/SitePages/DLL3-CD3-Medical-Communications/1438.1-obrixtamig-WCLC-infographic_4Sep24.pdf?web=1\&EntityRepresentationId=6317c9df-64ba-476b-b245-45fc6c7cf071) [\[clinicaltrials.gov\]](https://clinicaltrials.gov/study/NCT03861234); [NCT05882058 (DAREON‑5) – BI‑Slide](https://boehringer.sharepoint.com/sites/mybi_taonco/_layouts/15/Doc.aspx?sourcedoc=%7B3BC4F4E2-7AB1-4160-8067-8DD6B6808AD3%7D\&file=BI-764532_ESMObriefing_20231021_V1_presentation.pptx\&action=edit\&mobileredirect=true\&DefaultItemOpen=1) |
| dosage\_form              | MAJOR    | Zielwert: „Intravenöse Infusion.“ Grund: alle klinischen Regime IV.                                                            | [JCO 2025 Phase‑I‑Dosiseskalation](https://ascopubs.org/doi/pdf/10.1200/JCO-25-00363)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| route\_of\_administration | MAJOR    | Zielwert: „Intravenös.“ Grund: Studienprotokolle/Publikationen.                                                                | [NCT04429087](https://clinicaltrials.gov/study/NCT04429087); [JCO 2025](https://ascopubs.org/doi/pdf/10.1200/JCO-25-00363)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| base\_technology          | NONE     | —                                                                                                                              | —                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| current\_phase            | NONE     | — (Phase II bestätigt)                                                                                                         | [BI‑Pipeline‑Seite Obrixtamig](https://www.boehringer-ingelheim.com/science-innovation/human-health-innovation/clinical-pipeline/obrixtamig-bi-764532-dll3-cd3-t-cell-engager-0)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |

**BI 765063**

| Feld                      | Änderung | Beschreibung                                                                                                                                                                                                                                  | Evidenz                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| ------------------------- | -------- | --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- | ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- |
| product\_code             | NONE     | —                                                                                                                                                                                                                                             | —                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| product\_name             | NONE     | —                                                                                                                                                                                                                                             | —                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| modality\_name            | MAJOR    | Zielwert: „Monoklonaler Antikörper (SIRPα‑Inhibitor).“ Grund: kein TcE/Repro‑Protein; es ist ein Anti‑SIRPα‑mAb.                                                                                                                              | [BI‑Mitteilung zu SIRPα‑Programmen (2025)](https://www.boehringer-ingelheim.com/science-innovation/human-health-innovation/new-study-data-sirpa-inhibitors); [ASCO 2025 Abstract 6019](https://ascopubs.org/doi/pdf/10.1200/JCO.2025.43.16_suppl.6019)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| product\_type             | NONE     | —                                                                                                                                                                                                                                             | —                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| therapeutic\_area         | NONE     | —                                                                                                                                                                                                                                             | —                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| mechanism\_of\_action     | MAJOR    | Zielwert: „Blockade der SIRPα/CD47‑‚Don’t‑eat‑me‘‑Achse zur Reaktivierung der angeborenen Antitumor‑Immunität; untersucht mit Ezabenlimab ± Cetuximab (HNSCC) bzw. mit BI 836880 (HCC).“ Grund: MoA bislang nicht angegeben/falsch inferiert. | [BI‑Mitteilung 2025](https://www.boehringer-ingelheim.com/science-innovation/human-health-innovation/new-study-data-sirpa-inhibitors); [Assets-in-HNSCC-2024-12-11-v2.pptx](https://boehringer.sharepoint.com/sites/mybi_taonco/_layouts/15/Doc.aspx?sourcedoc=%7B43A063C8-26F8-4ACA-8C1B-7638E80427E8%7D\&file=Assets-in-HNSCC-2024-12-11-v2.pptx\&action=edit\&mobileredirect=true\&DefaultItemOpen=1\&EntityRepresentationId=53bd6d2b-6f8d-4764-bef4-52ec3907e781) [\[academic.oup.com\]](https://academic.oup.com/annonc/article-abstract/30/Supplement_9/mdz420.013/5638510) |
| short\_description        | MAJOR    | Zielwert: „Anti‑SIRPα‑mAb in Phase I/Ib, v. a. in R/M HNSCC (Kombination mit Ezabenlimab + Cetuximab) und HCC; zeigt frühe Wirksamkeitssignale.“ Grund: bisherige Beschreibung (TcE) sachlich falsch.                                         | [ASCO 2025 (6019)](https://ascopubs.org/doi/pdf/10.1200/JCO.2025.43.16_suppl.6019); [GlobeNewswire 2025](https://www.globenewswire.com/news-release/2025/05/22/3087166/0/en/Boehringer-Ingelheim-to-present-early-clinical-evidence-of-innate-immune-modulation-and-anti-tumor-activity-via-SIRP%CE%B1-blockade-in-two-ongoing-trials-at-ASCO-2025.html)                                                                                                                                                                                                                                                                                                                                                                                       |
| dosage\_form              | MAJOR    | Zielwert: „Intravenöse Infusion.“ Grund: Studienregime IV.                                                                                                                                                                                    | [ASCO 2025 (6019)](https://ascopubs.org/doi/pdf/10.1200/JCO.2025.43.16_suppl.6019)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| route\_of\_administration | MAJOR    | Zielwert: „Intravenös.“ Grund: Studienregime IV.                                                                                                                                                                                              | [ASCO 2025 (6019)](https://ascopubs.org/doi/pdf/10.1200/JCO.2025.43.16_suppl.6019)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| base\_technology          | NONE     | — („Mammalian“ plausibel, aber keine belastbare Quelle zur Produktionsplattform gefunden)                                                                                                                                                     | —                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| current\_phase            | MAJOR    | Zielwert: „Phase I/Ib – **nicht** ‘Discontinued’.“ Grund: laufende Kohorten/Updates.                                                                                                                                                          | [Assets-in-HNSCC-2024-12-11-v2.pptx](https://boehringer.sharepoint.com/sites/mybi_taonco/_layouts/15/Doc.aspx?sourcedoc=%7B43A063C8-26F8-4ACA-8C1B-7638E80427E8%7D\&file=Assets-in-HNSCC-2024-12-11-v2.pptx\&action=edit\&mobileredirect=true\&DefaultItemOpen=1\&EntityRepresentationId=53bd6d2b-6f8d-4764-bef4-52ec3907e781) [\[academic.oup.com\]](https://academic.oup.com/annonc/article-abstract/30/Supplement_9/mdz420.013/5638510); [BI‑Mitteilung 2025](https://www.boehringer-ingelheim.com/science-innovation/human-health-innovation/new-study-data-sirpa-inhibitors) |

**BI 765049**

| Feld                      | Änderung | Beschreibung                                                                                                                    | Evidenz                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| ------------------------- | -------- | ------------------------------------------------------------------------------------------------------------------------------- | ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- |
| product\_code             | NONE     | —                                                                                                                               | —                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| product\_name             | NONE     | Kein öffentlich bestätigter INN/Name gefunden.                                                                                  | —                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| modality\_name            | **MAJOR**  | Auf „Bispezifischer T‑Zell‑Engager (B7‑H6/CD3), IgG‑ähnliche TcE“ ändern; BI positioniert BI 765049 explizit als B7‑H6/CD3‑TcE. | [SC-US-77322-Clinical-Trials-Overview-Handout-WCLC-2024.pdf](https://boehringer.sharepoint.com/sites/mybi_taonco/SiteAssets/SitePages/Medical-resources%281%29/SC-US-77322-Clinical-Trials-Overview-Handout-WCLC-2024.pdf?web=1\&EntityRepresentationId=6affe2c9-cecc-4ccc-8e7b-58ea25fc5b9e) [\[SC-US-7732...-WCLC-2024 | PDF\]](https://boehringer.sharepoint.com/sites/mybi_taonco/SiteAssets/SitePages/Medical-resources(1)/SC-US-77322-Clinical-Trials-Overview-Handout-WCLC-2024.pdf?web=1); [SC-US-77320-iPad-optimized-Handouts-WCLC-2024.pdf](https://boehringer.sharepoint.com/sites/mybi_taonco/SiteAssets/SitePages/Medical-resources%281%29/SC-US-77320-iPad-optimized-Handouts-WCLC-2024.pdf?web=1\&EntityRepresentationId=7ebc67f5-0102-4630-94eb-5c24f3545843) [\[SC-US-7732...-WCLC-2024 | PDF\]](https://boehringer.sharepoint.com/sites/mybi_taonco/SiteAssets/SitePages/Medical-resources(1)/SC-US-77320-iPad-optimized-Handouts-WCLC-2024.pdf?web=1); [SC-US-77323-Pipeline-Booklet-WCLC-2024.pdf](https://boehringer.sharepoint.com/sites/mybi_taonco/SiteAssets/SitePages/Medical-resources%281%29/SC-US-77323-Pipeline-Booklet-WCLC-2024.pdf?web=1\&EntityRepresentationId=2e49127f-509c-4f74-8541-f4910914b16c) [\[SC-US-7732...-WCLC-2024 | PDF\]](https://boehringer.sharepoint.com/sites/mybi_taonco/SiteAssets/SitePages/Medical-resources(1)/SC-US-77323-Pipeline-Booklet-WCLC-2024.pdf?web=1) |
| product\_type             | NONE     | NBE bleibt korrekt.                                                                                                             | —                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| therapeutic\_area         | NONE     | Oncology bleibt korrekt.                                                                                                        | —                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| mechanism\_of\_action     | MINOR    | Präzisieren: TcE bindet simultan an CD3 und B7‑H6 und vermittelt T‑Zell‑Zytotoxizität.                                          | [SC-US-77323-Pipeline-Booklet-WCLC-2024.pdf](https://boehringer.sharepoint.com/sites/mybi_taonco/SiteAssets/SitePages/Medical-resources%281%29/SC-US-77323-Pipeline-Booklet-WCLC-2024.pdf?web=1\&EntityRepresentationId=2e49127f-509c-4f74-8541-f4910914b16c) [\[SC-US-7732...-WCLC-2024 | PDF\]](https://boehringer.sharepoint.com/sites/mybi_taonco/SiteAssets/SitePages/Medical-resources(1)/SC-US-77323-Pipeline-Booklet-WCLC-2024.pdf?web=1)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| short\_description        | NONE     | Beschreibung ist konsistent.                                                                                                    | —                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| dosage\_form              | **MAJOR**  | Auf „IV‑Infusion“ ändern (Parenterale Zubereitung für Infusion).                                                                | [CMC1 DP BI-VQD-1204396-JM-765049-B.docx](https://boehringer.sharepoint.com/sites/z365plattformdokumentenreviewadb/_layouts/15/Doc.aspx?sourcedoc=%7B6365C137-66E3-4EA6-A6E8-E0DC4634E060%7D\&file=CMC1%20DP%20BI-VQD-1204396-JM-765049-B.docx\&action=default\&mobileredirect=true\&DefaultItemOpen=1\&EntityRepresentationId=f94dcfd6-7a32-491e-a1cf-8e31e8f9f483) [\[CMC1 DP BI...M-765049-B | Word\]](https://boehringer.sharepoint.com/sites/z365plattformdokumentenreviewadb/_layouts/15/Doc.aspx?sourcedoc=%7B6365C137-66E3-4EA6-A6E8-E0DC4634E060%7D&file=CMC1%20DP%20BI-VQD-1204396-JM-765049-B.docx&action=default&mobileredirect=true&DefaultItemOpen=1)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| route\_of\_administration | **MAJOR**  | Auf „Intravenös“ ändern.                                                                                                        | [CMC1 DP BI-VQD-1204396-JM-765049-B.docx](https://boehringer.sharepoint.com/sites/z365plattformdokumentenreviewadb/_layouts/15/Doc.aspx?sourcedoc=%7B6365C137-66E3-4EA6-A6E8-E0DC4634E060%7D\&file=CMC1%20DP%20BI-VQD-1204396-JM-765049-B.docx\&action=default\&mobileredirect=true\&DefaultItemOpen=1\&EntityRepresentationId=f94dcfd6-7a32-491e-a1cf-8e31e8f9f483) [\[CMC1 DP BI...M-765049-B | Word\]](https://boehringer.sharepoint.com/sites/z365plattformdokumentenreviewadb/_layouts/15/Doc.aspx?sourcedoc=%7B6365C137-66E3-4EA6-A6E8-E0DC4634E060%7D&file=CMC1%20DP%20BI-VQD-1204396-JM-765049-B.docx&action=default&mobileredirect=true&DefaultItemOpen=1)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| base\_technology          | NONE     | „Mammalian“ ist passend.                                                                                                        | —                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| current\_phase            | NONE     | Phase I bestätigt (mehrere laufende Phase‑I‑Studien).                                                                           | [SC-US-77322-Clinical-Trials-Overview-Handout-WCLC-2024.pdf](https://boehringer.sharepoint.com/sites/mybi_taonco/SiteAssets/SitePages/Medical-resources%281%29/SC-US-77322-Clinical-Trials-Overview-Handout-WCLC-2024.pdf?web=1\&EntityRepresentationId=6affe2c9-cecc-4ccc-8e7b-58ea25fc5b9e) [\[SC-US-7732...-WCLC-2024 | PDF\]](https://boehringer.sharepoint.com/sites/mybi_taonco/SiteAssets/SitePages/Medical-resources(1)/SC-US-77322-Clinical-Trials-Overview-Handout-WCLC-2024.pdf?web=1); [CT Overview.pdf](https://boehringer.sharepoint.com/sites/z365clinicaltrialspatientandsiteengagement/Shared%20Documents/TA%20Oncology/ESMO/ESMO%202025/CT%20Overview.pdf?web=1\&EntityRepresentationId=dbce2350-3ad9-486e-a4e5-4d5d1a2e5e64) [\[CT Overview | PDF\]](https://boehringer.sharepoint.com/sites/z365clinicaltrialspatientandsiteengagement/Shared%20Documents/TA%20Oncology/ESMO/ESMO%202025/CT%20Overview.pdf?web=1)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |

**BI 765179**

| Feld                      | Änderung | Beschreibung                                                                                                                         | Evidenz                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| ------------------------- | -------- | ------------------------------------------------------------------------------------------------------------------------------------ | -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- |
| product\_code             | NONE     | —                                                                                                                                    | —                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| product\_name             | NONE     | Kein öffentlicher Produktname gefunden.                                                                                              | —                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| modality\_name            | **MAJOR**  | Auf „Bispezifischer Agonist‑Antikörper (CD137/FAP)“ ändern; BI beschreibt BI 765179 explizit als CD137/FAP‑bispezifischen Agonisten. | [SC-US-77323-Pipeline-Booklet-WCLC-2024.pdf](https://boehringer.sharepoint.com/sites/mybi_taonco/SiteAssets/SitePages/Medical-resources%281%29/SC-US-77323-Pipeline-Booklet-WCLC-2024.pdf?web=1\&EntityRepresentationId=2e49127f-509c-4f74-8541-f4910914b16c) [\[Congress-H...ore-poster | PDF\]](https://boehringer.sharepoint.com/sites/mybi_taonco/SiteAssets/SitePages/B7H6-CD3-T-cell-engager-Medical-Communications/Congress-Hub-ASCO-2025-CD137-FAP-1463.1-TiP-Encore-poster.pdf?web=1); [Congress-Hub-ASCO-2025-CD137-FAP-1463.1-TiP-Encore-poster.pdf](https://boehringer.sharepoint.com/sites/mybi_taonco/SiteAssets/SitePages/B7H6-CD3-T-cell-engager-Medical-Communications/Congress-Hub-ASCO-2025-CD137-FAP-1463.1-TiP-Encore-poster.pdf?web=1\&EntityRepresentationId=62c5dc01-aff8-4189-86bf-699ae53cb828) [\[SC-US-7914...179-Poster | PDF\]](https://boehringer.sharepoint.com/sites/mybi_taonco/SiteAssets/SitePages/B7H6-CD3-T-cell-engager-Medical-Communications/SC-US-79143-ASCO-2025-Shroff-et-al.-HNSCC-efficacy-of-CD137-BI765179-Poster.pdf?web=1); [SC-US-79143-ASCO-2025-Shroff-et-al.-HNSCC-efficacy-of-CD137-BI765179-Poster.pdf](https://boehringer.sharepoint.com/sites/mybi_taonco/SiteAssets/SitePages/B7H6-CD3-T-cell-engager-Medical-Communications/SC-US-79143-ASCO-2025-Shroff-et-al.-HNSCC-efficacy-of-CD137-BI765179-Poster.pdf?web=1\&EntityRepresentationId=18334667-2ad5-46e6-950d-7bcfe58d73ec) [\[Poster 69...al species | PDF\]](https://boehringer.sharepoint.com/sites/z365biotherapeuticssymposium/2023_Poster/Poster%2069%20-%20Clinical%20Pharmacokinetics%20(PK)%20of%20BI%20765250,%20a%20PD1%20agonist%20monoclonal%20%20antibody%20and%20its%20prediction%20from%20nonclinical%20species.pdf?web=1) |
| product\_type             | NONE     | NBE bleibt korrekt.                                                                                                                  | —                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| therapeutic\_area         | NONE     | Oncology bleibt korrekt.                                                                                                             | —                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| mechanism\_of\_action     | MINOR    | Präzisieren: Lokale CD137‑Kostimulation nur bei gleichzeitiger Bindung an FAP und CD137 im TME.                                      | [SC-US-77323-Pipeline-Booklet-WCLC-2024.pdf](https://boehringer.sharepoint.com/sites/mybi_taonco/SiteAssets/SitePages/Medical-resources%281%29/SC-US-77323-Pipeline-Booklet-WCLC-2024.pdf?web=1\&EntityRepresentationId=2e49127f-509c-4f74-8541-f4910914b16c) [\[Congress-H...ore-poster | PDF\]](https://boehringer.sharepoint.com/sites/mybi_taonco/SiteAssets/SitePages/B7H6-CD3-T-cell-engager-Medical-Communications/Congress-Hub-ASCO-2025-CD137-FAP-1463.1-TiP-Encore-poster.pdf?web=1)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| short\_description        | MINOR    | „bispezifisch“ ergänzen und TME‑Restriktion hervorheben.                                                                             | [SC-US-77323-Pipeline-Booklet-WCLC-2024.pdf](https://boehringer.sharepoint.com/sites/mybi_taonco/SiteAssets/SitePages/Medical-resources%281%29/SC-US-77323-Pipeline-Booklet-WCLC-2024.pdf?web=1\&EntityRepresentationId=2e49127f-509c-4f74-8541-f4910914b16c) [\[Congress-H...ore-poster | PDF\]](https://boehringer.sharepoint.com/sites/mybi_taonco/SiteAssets/SitePages/B7H6-CD3-T-cell-engager-Medical-Communications/Congress-Hub-ASCO-2025-CD137-FAP-1463.1-TiP-Encore-poster.pdf?web=1)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| dosage\_form              | NONE     | Keine belastbare Quelle zur genauen Darreichungsform gefunden.                                                                       | —                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| route\_of\_administration | NONE     | Keine belastbare Quelle zur exakten Applikationsart gefunden.                                                                        | —                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| base\_technology          | NONE     | „Mammalian“ ist plausibel, keine Änderung.                                                                                           | —                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| current\_phase            | MINOR    | Auf „Phase I/Ib“ präzisieren (expansionsorientierte Phase‑Ib‑Aktivität).                                                             | [Congress-Hub-ASCO-2025-CD137-FAP-1463.1-TiP-Encore-poster.pdf](https://boehringer.sharepoint.com/sites/mybi_taonco/SiteAssets/SitePages/B7H6-CD3-T-cell-engager-Medical-Communications/Congress-Hub-ASCO-2025-CD137-FAP-1463.1-TiP-Encore-poster.pdf?web=1\&EntityRepresentationId=62c5dc01-aff8-4189-86bf-699ae53cb828) [\[SC-US-7914...179-Poster | PDF\]](https://boehringer.sharepoint.com/sites/mybi_taonco/SiteAssets/SitePages/B7H6-CD3-T-cell-engager-Medical-Communications/SC-US-79143-ASCO-2025-Shroff-et-al.-HNSCC-efficacy-of-CD137-BI765179-Poster.pdf?web=1); [SC-US-79143-ASCO-2025-Shroff-et-al.-HNSCC-efficacy-of-CD137-BI765179-Poster.pdf](https://boehringer.sharepoint.com/sites/mybi_taonco/SiteAssets/SitePages/B7H6-CD3-T-cell-engager-Medical-Communications/SC-US-79143-ASCO-2025-Shroff-et-al.-HNSCC-efficacy-of-CD137-BI765179-Poster.pdf?web=1\&EntityRepresentationId=18334667-2ad5-46e6-950d-7bcfe58d73ec) [\[Poster 69...al species | PDF\]](https://boehringer.sharepoint.com/sites/z365biotherapeuticssymposium/2023_Poster/Poster%2069%20-%20Clinical%20Pharmacokinetics%20(PK)%20of%20BI%20765250,%20a%20PD1%20agonist%20monoclonal%20%20antibody%20and%20its%20prediction%20from%20nonclinical%20species.pdf?web=1)                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |

**BI 765250**

| Feld                      | Änderung | Beschreibung                                                                                     | Evidenz                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| ------------------------- | -------- | ------------------------------------------------------------------------------------------------ | ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- |
| product\_code             | NONE     | —                                                                                                | —                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| product\_name             | NONE     | —                                                                                                | —                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| modality\_name            | NONE     | Monoklonaler Antikörper bleibt korrekt.                                                          | —                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| product\_type             | NONE     | NBE bleibt korrekt.                                                                              | —                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| therapeutic\_area         | NONE     | Immunology bleibt korrekt (SSc).                                                                 | —                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| mechanism\_of\_action     | NONE     | PD‑1‑Agonist bleibt korrekt.                                                                     | —                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| short\_description        | MINOR    | Ergänzen, dass aktivierte Effektor‑T‑Zellen gezielt moduliert werden.                            | Poster 69 - Clinical Pharmacokinetics (PK) of BI 765250... [\[Poster 75...ical Trial | PDF\]](https://boehringer.sharepoint.com/sites/z365biotherapeuticssymposium/2023_Poster/Poster%2075%20-%20PD-1%20Agonist%20Monoclonal%20Antibody,%20Demonstrated%20Full%20Receptor%20Occupancy%20in%20Phase%20I%20Clinical%20Trial.pdf?web=1)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| dosage\_form              | **MAJOR**  | Auf „IV und SC (beide Wege in Phase I evaluiert)“ ändern.                                        | Poster 69 - Clinical Pharmacokinetics (PK) of BI 765250... [\[Poster 75...ical Trial | PDF\]](https://boehringer.sharepoint.com/sites/z365biotherapeuticssymposium/2023_Poster/Poster%2075%20-%20PD-1%20Agonist%20Monoclonal%20Antibody,%20Demonstrated%20Full%20Receptor%20Occupancy%20in%20Phase%20I%20Clinical%20Trial.pdf?web=1); Poster 75 - PD-1 Agonist Monoclonal Antibody... [\[BI765250_C..._anonymous | PDF\]](https://boehringer.sharepoint.com/sites/z365biotherapeuticssymposium/Shared%20Documents/Apps/Microsoft%20Forms/Poster%20Submission%20-%20Biotherapeutics%20Symposium%202023/Question/BI765250_ClinPK_SRD_poster_final_anonymous.pdf?web=1); [BI765250\_ClinPK\_SRD\_poster\_final\_anonymous.pdf](https://boehringer.sharepoint.com/sites/z365biotherapeuticssymposium/Shared%20Documents/Apps/Microsoft%20Forms/Poster%20Submission%20-%20Biotherapeutics%20Symposium%202023/Question/BI765250_ClinPK_SRD_poster_final_anonymous.pdf?web=1\&EntityRepresentationId=85987143-969d-4a95-a888-7456cbff7d65) [\[Xing PD-1..._anonymous | PDF\]](https://boehringer.sharepoint.com/sites/z365biotherapeuticssymposium/Shared%20Documents/Apps/Microsoft%20Forms/Poster%20Submission%20-%20Biotherapeutics%20Symposium%202023/Question/Xing%20PD-1%20poster%20V3_anonymous.pdf?web=1); [Xing PD-1 poster V3\_anonymous.pdf](https://boehringer.sharepoint.com/sites/z365biotherapeuticssymposium/Shared%20Documents/Apps/Microsoft%20Forms/Poster%20Submission%20-%20Biotherapeutics%20Symposium%202023/Question/Xing%20PD-1%20poster%20V3_anonymous.pdf?web=1\&EntityRepresentationId=f8dfde36-e7ab-42d4-81bc-f3dc4824cc12) [\[HPSC_2024_...al Minutes | PDF\]](https://boehringer.sharepoint.com/sites/z365eco/UNDER%20CONSTRUCTION/ECT%20Fileshare%20(General)/02_Meetings/00_Global%20and%20CD&O%20Meetings/HPSC/Minutes/HPSC_2024_April_Final%20Minutes.pdf?web=1) |
| route\_of\_administration | **MAJOR**  | Auf „Intravenös; Subkutan“ ändern (beide in FIH‑Studie getestet).                                | Poster 69 - Clinical Pharmacokinetics (PK) of BI 765250... [\[Poster 75...ical Trial | PDF\]](https://boehringer.sharepoint.com/sites/z365biotherapeuticssymposium/2023_Poster/Poster%2075%20-%20PD-1%20Agonist%20Monoclonal%20Antibody,%20Demonstrated%20Full%20Receptor%20Occupancy%20in%20Phase%20I%20Clinical%20Trial.pdf?web=1); Poster 75 - PD-1 Agonist Monoclonal Antibody... [\[BI765250_C..._anonymous | PDF\]](https://boehringer.sharepoint.com/sites/z365biotherapeuticssymposium/Shared%20Documents/Apps/Microsoft%20Forms/Poster%20Submission%20-%20Biotherapeutics%20Symposium%202023/Question/BI765250_ClinPK_SRD_poster_final_anonymous.pdf?web=1)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| base\_technology          | NONE     | „Mammalian“ ist stimmig.                                                                         | —                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| current\_phase            | **MAJOR**  | Von „Discontinued“ auf „Phase I (SRD abgeschlossen; MRD laufend/PoCP‑Vorbereitung)“ korrigieren. | [HPSC\_2024\_April\_Final Minutes.pdf](https://boehringer.sharepoint.com/sites/z365eco/UNDER%20CONSTRUCTION/ECT%20Fileshare%20%28General%29/02_Meetings/00_Global%20and%20CD\&O%20Meetings/HPSC/Minutes/HPSC_2024_April_Final%20Minutes.pdf?web=1\&EntityRepresentationId=fd47a789-0abc-44c3-9434-2faf973d3d62) [\[IU poster 2025 Xing | PDF\]](https://boehringer.sharepoint.com/sites/z365posterday2024/Shared%20Documents/General/Digital%20Posters%20in%20PDF%20Digital%20Posters%20by%20last%20name%20of%20presenter%202025/Xing/IU%20poster%202025%20Xing.pdf?web=1); [IU poster 2025 Xing.pdf](https://boehringer.sharepoint.com/sites/z365posterday2024/Shared%20Documents/General/Digital%20Posters%20in%20PDF%20Digital%20Posters%20by%20last%20name%20of%20presenter%202025/Xing/IU%20poster%202025%20Xing.pdf?web=1\&EntityRepresentationId=9a5b7dec-f8f8-48e0-a62c-f8097d86265c) [\[Clinical t...FL ONGOING | PowerPoint\]](https://boehringer.sharepoint.com/sites/z365clinicaltrialspatientandsiteengagement/Shared%20Documents/TA%20Inflammation/1.%20Overview/TA%20INFL%20Trials%20Planning/Clinical%20trials%20overview_TA%20INFL%20ONGOING/Clinical%20trials%20overview_TA%20INFL%20ONGOING.pptx?web=1); [Clinical trials overview\_TA INFL ONGOING.pptx](https://boehringer.sharepoint.com/sites/z365clinicaltrialspatientandsiteengagement/Shared%20Documents/TA%20Inflammation/1.%20Overview/TA%20INFL%20Trials%20Planning/Clinical%20trials%20overview_TA%20INFL%20ONGOING/Clinical%20trials%20overview_TA%20INFL%20ONGOING.pptx?web=1\&EntityRepresentationId=90d7c30e-384d-4a97-81d1-e50fcb243d68) [\[BI 765423:...ct Profile | Extern\]](https://bi-docs-vault-quality.veevavault.com/ui/#doc_info/1242354)                                                                                                            |

**BI 765423**

| Feld                      | Änderung | Beschreibung                                                                                                | Evidenz                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| ------------------------- | -------- | ----------------------------------------------------------------------------------------------------------- | ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ |
| product\_code             | NONE     | —                                                                                                           | —                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| product\_name             | NONE     | —                                                                                                           | —                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| modality\_name            | NONE     | Monoklonaler Antikörper bleibt korrekt.                                                                     | —                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| product\_type             | NONE     | NBE bleibt korrekt.                                                                                         | —                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| therapeutic\_area         | NONE     | Respiratory bleibt plausibel (fibrotische Lungenerkrankungen).                                              | —                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| mechanism\_of\_action     | MINOR    | Präzisieren: IL‑11‑Blockade durch Bindung an lösliches IL‑11 und Verhinderung der IL‑11/IL‑11R‑Interaktion. | BI 765423: Quality Target Product Profile [\[Inflammati...Edition 20 | PDF\]](https://boehringer.sharepoint.com/sites/mybi_tainflammation/Shared%20Documents/Inflammation%20Insiders/Inflammation%20Insider%20Edition%2020.pdf?web=1)                                                                                                                                                                                                                                                                                                       |
| short\_description        | NONE     | Aussage konsistent.                                                                                         | —                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| dosage\_form              | NONE     | Keine verlässliche Quelle zur konkreten Darreichungsform gefunden.                                          | —                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| route\_of\_administration | NONE     | Keine belastbare Quelle zur exakten Applikationsart gefunden.                                               | —                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| base\_technology          | NONE     | „Mammalian“ ist stimmig.                                                                                    | —                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| current\_phase            | MINOR    | Phase I bestätigen; ergänzen: SRD abgeschlossen, MRD in 2024/2025; PoPP erreicht.                           | [Inflammation Insider Edition 20.pdf](https://boehringer.sharepoint.com/sites/mybi_tainflammation/Shared%20Documents/Inflammation%20Insiders/Inflammation%20Insider%20Edition%2020.pdf?web=1\&EntityRepresentationId=179c4819-64ab-41d1-a0f6-1ace969d5aec) [\[BI Oncolog...CLC update | PowerPoint\]](https://boehringer.sharepoint.com/sites/z365clinicaltrialspatientandsiteengagement/_layouts/15/Doc.aspx?sourcedoc=%7B2D741D51-D6E9-46DC-A701-EBCBD0117C88%7D&file=BI%20Oncology%20Clinical%20Pipeline_Clinical%20Assets%20Deck_2025%20WCLC%20update.pptx&action=edit&mobileredirect=true&DefaultItemOpen=1) |

**BI 1703880**

| Feld                      | Änderung  | Beschreibung                                                                                                       | Evidenz                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| ------------------------- | --------- | ------------------------------------------------------------------------------------------------------------------ | ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- |
| product\_code             | NONE      | —                                                                                                                  | —                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| product\_name             | NONE      | —                                                                                                                  | —                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| modality\_name            | NONE      | Small Molecule bleibt korrekt.                                                                                     | —                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| product\_type             | NONE      | NME bleibt korrekt.                                                                                                | —                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| therapeutic\_area         | NONE      | Oncology bleibt korrekt.                                                                                           | —                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| mechanism\_of\_action     | **MAJOR** | Auf „Systemischer ‚Second‑Generation‘‑STING‑Agonist“ ergänzen (Kombination mit PD‑1‑Inhibitor in soliden Tumoren). | [BI Oncology Clinical Pipeline\_Clinical Assets Deck\_2025 WCLC update.pptx](https://boehringer.sharepoint.com/sites/z365clinicaltrialspatientandsiteengagement/_layouts/15/Doc.aspx?sourcedoc=%7B2D741D51-D6E9-46DC-A701-EBCBD0117C88%7D\&file=BI%20Oncology%20Clinical%20Pipeline_Clinical%20Assets%20Deck_2025%20WCLC%20update.pptx\&action=edit\&mobileredirect=true\&DefaultItemOpen=1\&EntityRepresentationId=d719bd38-55a5-4150-a932-f257abc20417); [SC-US-77320-iPad-optimized-Handouts-WCLC-2024.pdf](https://boehringer.sharepoint.com/sites/mybi_taonco/SiteAssets/SitePages/Medical-resources%281%29/SC-US-77320-iPad-optimized-Handouts-WCLC-2024.pdf?web=1\&EntityRepresentationId=7ebc67f5-0102-4630-94eb-5c24f3545843) [\[SC-US-7732...-WCLC-2024 | PDF\]](https://boehringer.sharepoint.com/sites/mybi_taonco/SiteAssets/SitePages/Medical-resources(1)/SC-US-77320-iPad-optimized-Handouts-WCLC-2024.pdf?web=1); [SC-US-77322-Clinical-Trials-Overview-Handout-WCLC-2024.pdf](https://boehringer.sharepoint.com/sites/mybi_taonco/SiteAssets/SitePages/Medical-resources%281%29/SC-US-77322-Clinical-Trials-Overview-Handout-WCLC-2024.pdf?web=1\&EntityRepresentationId=6affe2c9-cecc-4ccc-8e7b-58ea25fc5b9e) [\[SC-US-7732...-WCLC-2024 | PDF\]](https://boehringer.sharepoint.com/sites/mybi_taonco/SiteAssets/SitePages/Medical-resources(1)/SC-US-77322-Clinical-Trials-Overview-Handout-WCLC-2024.pdf?web=1); [SC-US-77320-iPad-optimized-Handouts-WCLC-2024.pdf](https://boehringer.sharepoint.com/sites/mybi_taonco/SiteAssets/SitePages/Medical-resources%281%29/SC-US-77320-iPad-optimized-Handouts-WCLC-2024.pdf?web=1\&EntityRepresentationId=7ebc67f5-0102-4630-94eb-5c24f3545843) |
| short\_description        | **MINOR** | Statt „NSCLC‑SM“ präzisieren: systemischer STING‑Agonist in Phase‑I‑Kombinationsprüfung (Breite solide Tumoren).   | [BI Oncology Clinical Pipeline\_Clinical Assets Deck\_2025 WCLC update.pptx](https://boehringer.sharepoint.com/sites/z365clinicaltrialspatientandsiteengagement/_layouts/15/Doc.aspx?sourcedoc=%7B2D741D51-D6E9-46DC-A701-EBCBD0117C88%7D\&file=BI%20Oncology%20Clinical%20Pipeline_Clinical%20Assets%20Deck_2025%20WCLC%20update.pptx\&action=edit\&mobileredirect=true\&DefaultItemOpen=1\&EntityRepresentationId=d719bd38-55a5-4150-a932-f257abc20417)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| dosage\_form              | NONE      | Keine belastbare Quelle zur konkreten Darreichungsform (nur „systemisch“) → unverändert lassen.                    | [BI Oncology Clinical Pipeline\_Clinical Assets Deck\_2025 WCLC update.pptx](https://boehringer.sharepoint.com/sites/z365clinicaltrialspatientandsiteengagement/_layouts/15/Doc.aspx?sourcedoc=%7B2D741D51-D6E9-46DC-A701-EBCBD0117C88%7D\&file=BI%20Oncology%20Clinical%20Pipeline_Clinical%20Assets%20Deck_2025%20WCLC%20update.pptx\&action=edit\&mobileredirect=true\&DefaultItemOpen=1\&EntityRepresentationId=d719bd38-55a5-4150-a932-f257abc20417)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| route\_of\_administration | NONE      | Keine explizite Route belegt → unverändert lassen.                                                                 | —                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| base\_technology          | **MAJOR** | „Synthetisches niedermolekulares Molekül“ ergänzen (bisher leer).                                                  | [SC-US-77320-iPad-optimized-Handouts-WCLC-2024.pdf](https://boehringer.sharepoint.com/sites/mybi_taonco/SiteAssets/SitePages/Medical-resources%281%29/SC-US-77320-iPad-optimized-Handouts-WCLC-2024.pdf?web=1\&EntityRepresentationId=7ebc67f5-0102-4630-94eb-5c24f3545843) [\[SC-US-7732...-WCLC-2024 | PDF\]](https://boehringer.sharepoint.com/sites/mybi_taonco/SiteAssets/SitePages/Medical-resources(1)/SC-US-77320-iPad-optimized-Handouts-WCLC-2024.pdf?web=1); [BI Oncology Clinical Pipeline\_Clinical Assets Deck\_2025 WCLC update.pptx](https://boehringer.sharepoint.com/sites/z365clinicaltrialspatientandsiteengagement/_layouts/15/Doc.aspx?sourcedoc=%7B2D741D51-D6E9-46DC-A701-EBCBD0117C88%7D\&file=BI%20Oncology%20Clinical%20Pipeline_Clinical%20Assets%20Deck_2025%20WCLC%20update.pptx\&action=edit\&mobileredirect=true\&DefaultItemOpen=1\&EntityRepresentationId=d719bd38-55a5-4150-a932-f257abc20417)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| current\_phase            | NONE      | Phase I bestätigt.                                                                                                 | [SC-US-77322-Clinical-Trials-Overview-Handout-WCLC-2024.pdf](https://boehringer.sharepoint.com/sites/mybi_taonco/SiteAssets/SitePages/Medical-resources%281%29/SC-US-77322-Clinical-Trials-Overview-Handout-WCLC-2024.pdf?web=1\&EntityRepresentationId=6affe2c9-cecc-4ccc-8e7b-58ea25fc5b9e) [\[SC-US-7732...-WCLC-2024 | PDF\]](https://boehringer.sharepoint.com/sites/mybi_taonco/SiteAssets/SitePages/Medical-resources(1)/SC-US-77322-Clinical-Trials-Overview-Handout-WCLC-2024.pdf?web=1)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
**BI 1815368**

| Feld                      | Änderung | Beschreibung                                                                                                                                                                                         | Evidenz                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| ------------------------- | -------- | ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- | --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- |
| product\_code             | NONE     | —                                                                                                                                                                                                    | —                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| product\_name             | NONE     | —                                                                                                                                                                                                    | —                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| modality\_name            | NONE     | —                                                                                                                                                                                                    | —                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| product\_type             | NONE     | —                                                                                                                                                                                                    | —                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| therapeutic\_area         | MINOR    | Präzisierung: Eye Health (DME-Fokus in laufender Entwicklung).                                                                                                                                       | [Approved Uniform Pipeline Slide.pptx](https://boehringer.sharepoint.com/sites/mybi_news_onehp/Shared%20Documents/IU/Pipeline%20Update/Approved%20Uniform%20Pipeline%20Slide.pptx?web=1\&EntityRepresentationId=f6028138-f0fa-49a0-8cd0-0817994fd0d1) zeigt BI 1815368 in „Retinal Health“; Pressemitteilung bestätigt Phase‑II‑Programm in DME. [\[Approved U...line Slide | PowerPoint\]](https://boehringer.sharepoint.com/sites/mybi_news_onehp/Shared%20Documents/IU/Pipeline%20Update/Approved%20Uniform%20Pipeline%20Slide.pptx?web=1), [\[boehringer...elheim.com\]](https://www.boehringer-ingelheim.com/us/science-innovation/human-health-innovation/phase-ii-start-oral-treatment-diabetic-macular-edema)                                                                                                                                                                                           |
| mechanism\_of\_action     | NONE     | —                                                                                                                                                                                                    | —                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| short\_description        | MAJOR    | Von „Prävention nAMDp“ auf **„Oraler PKK‑Inhibitor zur Behandlung des diabetischen Makulaödems (DME)“** ändern; nAMDp bleibt ggf. Zukunftsoption, aktuelle klinische Aktivität liegt jedoch bei DME. | Start des Phase‑II‑THULITE‑Trials (DME) offiziell bekanntgegeben; interne PKKi‑Assetslides/Trial‑Outline bestätigen Programmfokus. [\[boehringer...elheim.com\]](https://www.boehringer-ingelheim.com/us/science-innovation/human-health-innovation/phase-ii-start-oral-treatment-diabetic-macular-edema), [\[globenewswire.com\]](https://www.globenewswire.com/news-release/2025/07/07/3110904/0/en/Boehringer-Ingelheim-initiates-Phase-II-study-of-BI-1815368-a-potential-first-in-class-oral-treatment-for-diabetic-macular-edema.html), [\[PKKi in nA...3 Feb 2024 | PowerPoint\]](https://boehringer.sharepoint.com/sites/z365patientandsiteengagementexternalcollaboration/_layouts/15/Doc.aspx?sourcedoc=%7BD6D47EA9-899B-4972-9CE1-6E5B52374242%7D&file=PKKi%20in%20nAMD%20and%20DME_Rough%20Trial%20Outline%201485-4%20and%20-17_13%20Feb%202024.pptx&action=edit&mobileredirect=true&DefaultItemOpen=1) |
| dosage\_form              | NONE     | —                                                                                                                                                                                                    | —                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| route\_of\_administration | NONE     | —                                                                                                                                                                                                    | —                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| base\_technology          | NONE     | —                                                                                                                                                                                                    | —                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| current\_phase            | MAJOR    | Von „Phase I“ auf **„Phase II“** ändern.                                                                                                                                                             | Offizielle Mitteilung zum Start der Phase II (THULITE; NCT06962839); interne Phase‑II‑Protokollunterlage zu BI 1815368. [\[boehringer...elheim.com\]](https://www.boehringer-ingelheim.com/us/science-innovation/human-health-innovation/phase-ii-start-oral-treatment-diabetic-macular-edema), [\[globenewswire.com\]](https://www.globenewswire.com/news-release/2025/07/07/3110904/0/en/Boehringer-Ingelheim-initiates-Phase-II-study-of-BI-1815368-a-potential-first-in-class-oral-treatment-for-diabetic-macular-edema.html), [\[1485-0018_...6 Feb 2025 | PDF\]](https://boehringer.sharepoint.com/sites/z365clinicaltrialspatientandsiteengagement/Shared%20Documents/Trial%20burden%20and%20complexity%20assessment/Sheet%20for%20assessing%20trial%20burden/Protocols/1485-0018_THULITE_Protocol%20and%20Protocol%20Amendment_06%20Feb%202025.pdf?web=1)                                            |

**BI 1839100**

| Feld                      | Änderung | Beschreibung                                                                                                                                                                                                                                    | Evidenz                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| ------------------------- | -------- | ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- | -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- |
| product\_code             | NONE     | —                                                                                                                                                                                                                                               | —                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| product\_name             | NONE     | —                                                                                                                                                                                                                                               | —                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| modality\_name            | NONE     | —                                                                                                                                                                                                                                               | —                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| product\_type             | NONE     | —                                                                                                                                                                                                                                               | —                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| therapeutic\_area         | NONE     | —                                                                                                                                                                                                                                               | —                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| mechanism\_of\_action     | NONE     | —                                                                                                                                                                                                                                               | —                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| short\_description        | MINOR    | Präzisierung: **TRPA1‑Inhibitor zur Hustenreduktion bei IPF/PPF (zusätzlich krankheitsbezogene Endpunkte in Evaluierung).**                                                                                                                     | Publizierte FIH‑Studie zeigt Target‑Engagement; Programmkommunikation und Publikationsplan adressieren Husten‑Endpunkte. [\[ascpt.onli....wiley.com\]](https://ascpt.onlinelibrary.wiley.com/doi/am-pdf/10.1111/cts.70290), [\[europepmc.org\]](https://europepmc.org/article/MED/40711888), [\[PF-publica...e_June2025 | PowerPoint\]](https://boehringer.sharepoint.com/sites/mybi_tainflammation/_layouts/15/Doc.aspx?sourcedoc=%7B87E1AA8E-02C3-40D5-A18B-F507AD563FE9%7D&file=PF-publication-plan_Pipeline_June2025.pptx&action=edit&mobileredirect=true&DefaultItemOpen=1) |
| dosage\_form              | NONE     | —                                                                                                                                                                                                                                               | —                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| route\_of\_administration | NONE     | —                                                                                                                                                                                                                                               | —                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| base\_technology          | NONE     | —                                                                                                                                                                                                                                               | —                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| current\_phase            | MAJOR    | Von „Discontinued“ auf **„Phase II – zentrale IPF/PPF‑Husten‑Studie NCT06360094 am 07.10.2025 vom Sponsor beendet; Programmstatus insgesamt nicht als vollständig eingestellt dokumentiert (weitere FIH‑/ADME‑Studien liefen/laufen)“** ändern. | NCT06360094: Status **Terminated (Sponsor decision)** (2025‑10‑07). Parallel publizierte FIH‑Daten und weitere klinische Einträge (z. B. Mass‑Balance‑Studie) belegen, dass das Asset nicht pauschal „discontinued“ ist. [\[clinicaltrials.gov\]](https://clinicaltrials.gov/study/NCT06360094), [\[ascpt.onli....wiley.com\]](https://ascpt.onlinelibrary.wiley.com/doi/am-pdf/10.1111/cts.70290), [\[ichgcp.net\]](https://ichgcp.net/clinical-trials-registry/NCT06572111)                                                                              |

**BI 754091 — Ezabenlimab**

| Feld                      | Änderung | Beschreibung                                                                                           | Evidenz                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| ------------------------- | -------- | ------------------------------------------------------------------------------------------------------ | --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- |
| product\_code             | MINOR    | **BI 754091** ergänzen.                                                                                | Interne IB/Qualitäts‑Doks und öffentliche Pipeline‑Seite nennen Code BI 754091. [\[ib-ezabenl...-version-8 | PDF\]](https://boehringer.sharepoint.com/sites/mybi_taonco/SiteAssets/SitePages/IIS-and-ECR/ib-ezabenlimab-1381-p1-version-8.pdf?web=1), [\[BI-VQD-117..._ReleaseDP | Word\]](https://boehringer.sharepoint.com/sites/z365plattformdokumentenreviewadb/_layouts/15/Doc.aspx?sourcedoc=%7B28711206-E74A-406B-ADA7-46F6DD80F46E%7D&file=BI-VQD-1170064-SPEC_ReleaseDP.docx&action=default&mobileredirect=true&DefaultItemOpen=1), [\[pro.boehri...elheim.com\]](https://pro.boehringer-ingelheim.com/inoncology/our-pipeline/ezabenlimab) |
| product\_name             | NONE     | —                                                                                                      | —                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| modality\_name            | NONE     | —                                                                                                      | —                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| product\_type             | NONE     | —                                                                                                      | —                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| therapeutic\_area         | MINOR    | Primär **Oncology**; „Immunology“ nur in dem Sinne, dass es sich um Immun‑Onkologie handelt.           | BI‑Pipeline‑Seite führt Ezabenlimab in onkologischen Kombinationsprogrammen. [\[pro.boehri...elheim.com\]](https://pro.boehringer-ingelheim.com/inoncology/our-pipeline/ezabenlimab)                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| mechanism\_of\_action     | NONE     | —                                                                                                      | —                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| short\_description        | MINOR    | **PD‑1‑Antikörper als Kombinations‑Backbone** (z. B. mit TcEs, STING‑Ago., SIRPα‑Antag., MDM2‑Inhib.). | BI‑InOncology‑Seite; laufende Kombinations‑Studien (z. B. NCT03964233). [\[pro.boehri...elheim.com\]](https://pro.boehringer-ingelheim.com/inoncology/our-pipeline/ezabenlimab), [\[clinicaltrials.gov\]](https://clinicaltrials.gov/study/NCT03964233)                                                                                                                                                                                                                                                                                                                                                                   |
| dosage\_form              | NONE     | —                                                                                                      | —                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| route\_of\_administration | NONE     | —                                                                                                      | —                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| base\_technology          | NONE     | —                                                                                                      | —                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| current\_phase            | MAJOR    | Von „Discontinued“ auf **„Phase I/II (laufende Kombinationsprogramme)“** ändern.                       | Öffentliche BI‑Seite nennt aktive Phase‑I/II‑Kombis; ClinicalTrials.gov: laufend/ANR (z. B. Brigimadlin + Ezabenlimab). Interne IB Version 8 (2024) bestätigt Entwicklungsstatus. [\[pro.boehri...elheim.com\]](https://pro.boehringer-ingelheim.com/inoncology/our-pipeline/ezabenlimab), [\[clinicaltrials.gov\]](https://clinicaltrials.gov/study/NCT03964233), [\[ib-ezabenl...-version-8 | PDF\]](https://boehringer.sharepoint.com/sites/mybi_taonco/SiteAssets/SitePages/IIS-and-ECR/ib-ezabenlimab-1381-p1-version-8.pdf?web=1)                                                                                                  |

**BI 3706674**

| Feld                      | Änderung | Beschreibung                                                                                                                                                                           | Evidenz                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| ------------------------- | -------- | -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- | ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ |
| product\_code             | NONE     | —                                                                                                                                                                                      | —                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| product\_name             | NONE     | —                                                                                                                                                                                      | —                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| modality\_name            | NONE     | —                                                                                                                                                                                      | —                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| product\_type             | NONE     | —                                                                                                                                                                                      | —                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| therapeutic\_area         | NONE     | —                                                                                                                                                                                      | —                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| mechanism\_of\_action     | MINOR    | Präzisierung: **Nicht „GDP KRAS inhibitor“ als Klassenname, sondern „nicht‑kovalenter Multi‑KRAS‑Inhibitor, der GDP‑gebundenes KRAS (wt‑amp & mehrere Mutanten, inkl. G12V) bindet“.** | BI‑InOncology „KRAS multi‑inhibitor“; AACR‑Abstracts/Papers zum Wirkprinzip. [\[pro.boehri...elheim.com\]](https://pro.boehringer-ingelheim.com/us/inoncology/our-pipeline/kras-multi-inhibitor), [\[aacrjournals.org\]](https://aacrjournals.org/cancerres/article/84/6_Supplement/3317/739110/Abstract-3317-KRASmulti-inhibitor-BI-3706674-shows)                                                                                                                  |
| short\_description        | MAJOR    | Von „… KRAS‑mutierte CAs wie GC/EC/PDAC“ auf **„Monotherapie‑Entwicklung bei KRAS‑WT‑Amplifikationen (GC/EC/GEJ) und KRAS‑G12V (u. a. PDAC)“** ändern.                                 | BI‑InOncology‑Seite zum Studien‑Set‑up; FIH‑Studie NCT06056024‑Design. [\[pro.boehri...elheim.com\]](https://pro.boehringer-ingelheim.com/us/inoncology/our-pipeline/kras-multi-inhibitor), [\[clinicaltrials.gov\]](https://clinicaltrials.gov/study/NCT06056024)                                                                                                                                                                                                     |
| dosage\_form              | NONE     | —                                                                                                                                                                                      | —                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| route\_of\_administration | NONE     | —                                                                                                                                                                                      | —                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| base\_technology          | MAJOR    | **„Organic Spray Drying; Roller Compaction“ entfernen** → **„Nicht offengelegt“**; dafür fehlt belastbare Quelle.                                                                      | Weder ClinicalTrials.gov noch BI‑Publikationen nennen Formulier‑/Prozesstechnologie; FIH‑/ICF‑Dokumente fokussieren Sicherheit/PK. [\[clinicaltrials.gov\]](https://clinicaltrials.gov/study/NCT06056024), [\[KRASmulti...R2024_Peng | PDF\]](https://boehringer.sharepoint.com/sites/z365congresscoverage/Shared%20Documents/2024/AACR%202024/Boehringer%20Ingelheim%20Posters/KRASmulti%20inhibitor%20BI%203706674,%20an%20orally%20bioavailable_AACR2024_Peng.pdf?web=1) |
| current\_phase            | MAJOR    | Von „Discontinued“ auf **„Phase I (FIH; Status: active, not recruiting)“** ändern.                                                                                                     | NCT06056024: Phase I, Status „Active, not recruiting“ (Upd. 2025‑09‑30). [\[clinicaltrials.gov\]](https://clinicaltrials.gov/study/NCT06056024)                                                                                                                                                                                                                                                                                                               |

**BI 3018078 / BI 3024308**

| Feld                      | Änderung | Beschreibung                                                                                                                                                                                              | Evidenz                                                                                                                                                                                                                                                                                                              |
| ------------------------- | -------- | --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- | -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- |
| product\_code             | NONE     | —                                                                                                                                                                                                         | —                                                                                                                                                                                                                                                                                                                    |
| product\_name             | NONE     | —                                                                                                                                                                                                         | —                                                                                                                                                                                                                                                                                                                    |
| modality\_name            | MAJOR    | Von „Recombinant Proteins“ auf **„Therapeutische Krebs‑Impfung (Protein; KISIMA®/ATP128) + Onkolytisches Virus (VSV‑GP128)“** ändern.                                                                     | Studienprotokoll KISIMA‑01 (ATP128 ± VSV‑GP128 ± Ezabenlimab); BI‑InOncology‑Seite „KISIMA® cancer vaccine“. [\[clinicaltrials.gov\]](https://clinicaltrials.gov/study/NCT04046445), [\[pro.boehri...elheim.com\]](https://pro.boehringer-ingelheim.com/inoncology/our-pipeline/kisima-cancer-vaccine) |
| product\_type             | MINOR    | **NBE** beibehalten; Präzisierung: **„Biologikum (Impfstoff + viraler Vektor)“**.                                                                                                                         | Wie oben. [\[pro.boehri...elheim.com\]](https://pro.boehringer-ingelheim.com/inoncology/our-pipeline/kisima-cancer-vaccine)                                                                                                                                                                        |
| therapeutic\_area         | NONE     | —                                                                                                                                                                                                         | —                                                                                                                                                                                                                                                                                                                    |
| mechanism\_of\_action     | MAJOR    | Von „ATP128 + VCV‑GP128 (combination …)“ auf **„Heterologes Prime‑Boost (ATP128 → VSV‑GP128) zur Induktion tumor‑spezifischer T‑Zell‑Immunität; in Kombination mit PD‑1‑Blockade (Ezabenlimab)“** ändern. | KISIMA‑01 Studienbeschreibung; AACR‑CT570 (First‑in‑Human‑Konzept). [\[clinicaltrials.gov\]](https://clinicaltrials.gov/study/NCT04046445), [\[aacrjournals.org\]](https://aacrjournals.org/cancerres/article/82/12_Supplement/CT570/699465/Abstract-CT570-KISIMA-01-A-first-in-human-trial-of) |
| short\_description        | MAJOR    | **„Therapeutischer Protein‑Impfstoff (ATP128) + VSV‑GP128 als Boost; Evaluierung bei MSS Stadium IV CRC in Kombi mit Ezabenlimab“**.                                                                      | ClinicalTrials.gov (KISIMA‑01) inkl. MSS‑Population; Patientenorganisationen/Studiensteckbrief. [\[clinicaltrials.gov\]](https://clinicaltrials.gov/study/NCT04046445), [\[fightcolor...cancer.org\]](https://fightcolorectalcancer.org/clinical-trial/nct04046445/)                                   |
| dosage\_form              | MINOR    | **„Injectable“ beibehalten; Kombinations‑Regime umfasst Protein‑Impfstoff und viralen Vektor.**                                                                                                           | KISIMA‑01: parenterale Gabe (Impfstoff/OV) lt. Protokoll. [\[clinicaltrials.gov\]](https://clinicaltrials.gov/study/NCT04046445)                                                                                                                                                              |
| route\_of\_administration | MINOR    | Von „Injectable (SFInj)“ auf **„Parenteral (kombinationsabhängig)“** ändern; konkrete Einzel‑Routen variieren je Komponente & Protokoll.                                                                  | ClinicalTrials.gov KISIMA‑01. [\[clinicaltrials.gov\]](https://clinicaltrials.gov/study/NCT04046445)                                                                                                                                                                                          |
| base\_technology          | MAJOR    | Von „Microbial“ auf **„KISIMA® rekombinantes Protein‑Impfstoff‑Platform + VSV‑GP viraler Vektor“** ändern.                                                                                                | BI‑InOncology „KISIMA® cancer vaccine“. [\[pro.boehri...elheim.com\]](https://pro.boehringer-ingelheim.com/inoncology/our-pipeline/kisima-cancer-vaccine)                                                                                                                                          |
| current\_phase            | MAJOR    | Von „Discontinued“ auf **„Phase 1b (Active, not recruiting)“** ändern.                                                                                                                                    | NCT04046445: Status ANR (Update 2025‑01‑29). [\[clinicaltrials.gov\]](https://clinicaltrials.gov/study/NCT04046445)                                                                                                                                                                           |
**BI 3810539**

| Feld                      | Änderung  | Beschreibung                                                                                              | Evidenz                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| ------------------------- | --------- | --------------------------------------------------------------------------------------------------------- | ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- |
| product\_code             | NONE      | —                                                                                                         | —                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| product\_name             | NONE      | Nicht offengelegt; kein INN/Produktname in den gefundenen Quellen.                                        | [Product-Families-in-RIM.xlsx](https://boehringer.sharepoint.com/sites/mybi_omp/_layouts/15/Doc.aspx?sourcedoc=%7B8D88F5C3-6783-4278-902F-6509B94AC0C0%7D\&file=Product-Families-in-RIM.xlsx\&action=default\&mobileredirect=true\&DefaultItemOpen=1\&EntityRepresentationId=c54dbbfc-4849-4bc3-806f-9704c4791c4b) (listet Code ohne INN) [\[Product-Fa...ies-in-RIM | Excel\]](https://boehringer.sharepoint.com/sites/mybi_omp/_layouts/15/Doc.aspx?sourcedoc=%7B8D88F5C3-6783-4278-902F-6509B94AC0C0%7D&file=Product-Families-in-RIM.xlsx&action=default&mobileredirect=true&DefaultItemOpen=1)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| modality\_name            | **MAJOR** | Auf **„ADC (Antibody–Drug Conjugate), DLL3‑targeted“** ändern (statt „Recombinant Proteins“).             | [MnfctChallenges.pptx](https://boehringer-my.sharepoint.com/personal/oliver_gluth_boehringer-ingelheim_com/_layouts/15/Doc.aspx?sourcedoc=%7BEF3979AB-452A-46C0-9013-429B8AAA448D%7D\&file=MnfctChallenges.pptx\&action=edit\&mobileredirect=true\&DefaultItemOpen=1\&EntityRepresentationId=06687a66-32d3-4302-96cf-11656b481e66) („DLL3 ADC (BI 3810539)“) [\[MnfctChallenges | PowerPoint\]](https://boehringer-my.sharepoint.com/personal/oliver_gluth_boehringer-ingelheim_com/_layouts/15/Doc.aspx?sourcedoc=%7BEF3979AB-452A-46C0-9013-429B8AAA448D%7D&file=MnfctChallenges.pptx&action=edit&mobileredirect=true&DefaultItemOpen=1); [iManagement\_TOM\_HIVE.pptx](https://boehringer.sharepoint.com/sites/z365bihivecoreteam/_layouts/15/Doc.aspx?sourcedoc=%7BF1A56005-4692-4F18-990F-5AD7F28380AD%7D\&file=iManagement_TOM_HIVE.pptx\&action=edit\&mobileredirect=true\&DefaultItemOpen=1\&EntityRepresentationId=9520a7be-6c08-4425-ab00-b63b329aaa76) (gleichlautend) [\[iManagement_TOM_HIVE | PowerPoint\]](https://boehringer-my.sharepoint.com/personal/oliver_gluth_boehringer-ingelheim_com/Documents/BI%20-%20Work/01_PROJECTS/2025_iManagement/iManagement_TOM_HIVE.pptx?web=1) |
| product\_type             | NONE      | NBE bleibt korrekt.                                                                                       | —                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| therapeutic\_area         | NONE      | Oncology bleibt korrekt.                                                                                  | —                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| mechanism\_of\_action     | NONE      | „DLL3 ADC“ ist konsistent.                                                                                | [MnfctChallenges.pptx](https://boehringer-my.sharepoint.com/personal/oliver_gluth_boehringer-ingelheim_com/_layouts/15/Doc.aspx?sourcedoc=%7BEF3979AB-452A-46C0-9013-429B8AAA448D%7D\&file=MnfctChallenges.pptx\&action=edit\&mobileredirect=true\&DefaultItemOpen=1\&EntityRepresentationId=06687a66-32d3-4302-96cf-11656b481e66) [\[MnfctChallenges | PowerPoint\]](https://boehringer-my.sharepoint.com/personal/oliver_gluth_boehringer-ingelheim_com/_layouts/15/Doc.aspx?sourcedoc=%7BEF3979AB-452A-46C0-9013-429B8AAA448D%7D&file=MnfctChallenges.pptx&action=edit&mobileredirect=true&DefaultItemOpen=1)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| short\_description        | **MINOR** | Beschreibung beibehalten; **TNBC**-Bezug ist intern hinterlegt.                                           | [PipelineKG.xlsx](https://boehringer-my.sharepoint.com/personal/oliver_gluth_boehringer-ingelheim_com/Documents/BI%20-%20Work/02_AREAS/BI%20-%20Pipeline/PipelineKG.xlsx?web=1\&EntityRepresentationId=2be0e03b-aa4d-4d82-9781-d669e38da882) (Eintrag „BI 3810539 (TNBC)“) [\[PipelineKG | Excel\]](https://boehringer-my.sharepoint.com/personal/oliver_gluth_boehringer-ingelheim_com/Documents/BI%20-%20Work/02_AREAS/BI%20-%20Pipeline/PipelineKG.xlsx?web=1)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| dosage\_form              | NONE      | „Injectable“ plausibel, keine abweichenden Funde.                                                         | —                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| route\_of\_administration | NONE      | Keine verlässliche Quelle zur Applikationsart gefunden.                                                   | —                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| base\_technology          | NONE      | Keine spezifische Basis‑Technologiequelle gefunden (ADC-typische Details nicht projektspezifisch belegt). | —                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| current\_phase            | NONE      | „Discontinued“ kann beibehalten werden (Statushinweis intern vorhanden).                                  | <Email></Email> („Definitive NME Profile: BI 3810539“ – Status: Discontinued) [\[https://ou...essageItem | Outlook\]](https://outlook.office365.com/owa/?ItemID=AAMkADAyZmU3YjEyLWE3ZjUtNDM1NS05MzYzLWUzYzlkNDFlM2U2OQBGAAAAAADixk0efwmDS6h1j2U%2b0KRCBwAontSQhNN7SIhD7is0TQmJAAAAAAEdAAC%2f2lcWT%2bONTL2LL7ekd7UCAANYSMyQAAA%3d&exvsurl=1&viewmodel=ReadMessageItem)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |

**BI 3810944 — Not disclosed**

| Feld                      | Änderung  | Beschreibung                                                                            | Evidenz                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| ------------------------- | --------- | --------------------------------------------------------------------------------------- | -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- |
| product\_code             | NONE      | —                                                                                       | —                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| product\_name             | NONE      | Nicht offengelegt; kein INN gefunden.                                                   | [bi3810944-1527-p1-icf-safety-22Oct2025.docx](https://boehringer.sharepoint.com/sites/z365icfsafetylaylanguage/_layouts/15/Doc.aspx?sourcedoc=%7B2883A328-A2E8-42E1-A7A3-30F02F1289C0%7D\&file=bi3810944-1527-p1-icf-safety-22Oct2025.docx\&action=default\&mobileredirect=true\&DefaultItemOpen=1\&EntityRepresentationId=34e3afe0-2519-4ad3-bd80-cdff3a04a933) (führt Code, kein INN) [\[bi3810944-...-22Oct2025 | Word\]](https://boehringer.sharepoint.com/sites/z365icfsafetylaylanguage/_layouts/15/Doc.aspx?sourcedoc=%7B2883A328-A2E8-42E1-A7A3-30F02F1289C0%7D&file=bi3810944-1527-p1-icf-safety-22Oct2025.docx&action=default&mobileredirect=true&DefaultItemOpen=1)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| modality\_name            | **MAJOR** | Auf **„ODC‑IL12 (On‑Demand Cytokine, Prodrug)“** ändern (statt „Recombinant Proteins“). | [BtD\_Symposium\_ODC\_2024.pptx](https://boehringer.sharepoint.com/sites/z365biotherapeuticssymposium/_layouts/15/Doc.aspx?sourcedoc=%7B953B2C06-0C05-48AF-B032-9B009E1D7CD5%7D\&file=BtD_Symposium_ODC_2024.pptx\&action=edit\&mobileredirect=true\&DefaultItemOpen=1\&EntityRepresentationId=ad9ba7bd-4e87-42f9-83b2-64b869a4447c) (ODC‑IL12 Konzept) [\[BtD_Sympos...m_ODC_2024 | PowerPoint\]](https://boehringer.sharepoint.com/sites/z365biotherapeuticssymposium/_layouts/15/Doc.aspx?sourcedoc=%7B953B2C06-0C05-48AF-B032-9B009E1D7CD5%7D&file=BtD_Symposium_ODC_2024.pptx&action=edit&mobileredirect=true&DefaultItemOpen=1); [NBE Portfolio\_Q-uriosity\_Sep25\_Higel.pptx](https://boehringer.sharepoint.com/sites/z365qualityexcellenceprogram/_layouts/15/Doc.aspx?sourcedoc=%7B2D068FB4-0E13-425F-9084-68229917E85A%7D\&file=NBE%20Portfolio_Q-uriosity_Sep25_Higel.pptx\&action=edit\&mobileredirect=true\&DefaultItemOpen=1\&EntityRepresentationId=8a9b1eb3-6d9b-43de-b34f-15a99cd0d0b2) (Explizit „BI 3810944 … ODC‑IL12“) [\[NBE Portfo...ep25_Higel | PowerPoint\]](https://boehringer.sharepoint.com/sites/z365qualityexcellenceprogram/_layouts/15/Doc.aspx?sourcedoc=%7B2D068FB4-0E13-425F-9084-68229917E85A%7D&file=NBE%20Portfolio_Q-uriosity_Sep25_Higel.pptx&action=edit&mobileredirect=true&DefaultItemOpen=1) |
| product\_type             | NONE      | NBE bleibt korrekt.                                                                     | —                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| therapeutic\_area         | NONE      | Oncology bleibt korrekt.                                                                | —                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| mechanism\_of\_action     | **MINOR** | Präzisieren zu **„kollagenbindende, MMP9‑aktivierte IL‑12‑Prodrug (ODC)“**.             | [BtD\_Symposium\_ODC\_2024.pptx](https://boehringer.sharepoint.com/sites/z365biotherapeuticssymposium/_layouts/15/Doc.aspx?sourcedoc=%7B953B2C06-0C05-48AF-B032-9B009E1D7CD5%7D\&file=BtD_Symposium_ODC_2024.pptx\&action=edit\&mobileredirect=true\&DefaultItemOpen=1\&EntityRepresentationId=ad9ba7bd-4e87-42f9-83b2-64b869a4447c) (Collagen‑I‑Retention, MMP9‑Freisetzung) [\[BtD_Sympos...m_ODC_2024 | PowerPoint\]](https://boehringer.sharepoint.com/sites/z365biotherapeuticssymposium/_layouts/15/Doc.aspx?sourcedoc=%7B953B2C06-0C05-48AF-B032-9B009E1D7CD5%7D&file=BtD_Symposium_ODC_2024.pptx&action=edit&mobileredirect=true&DefaultItemOpen=1)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| short\_description        | **MINOR** | Präzisieren: **„Systemische ODC‑IL12‑Prodrug; sentinel indication Melanoma“**.          | [BtD\_Symposium\_ODC\_2024.pptx](https://boehringer.sharepoint.com/sites/z365biotherapeuticssymposium/_layouts/15/Doc.aspx?sourcedoc=%7B953B2C06-0C05-48AF-B032-9B009E1D7CD5%7D\&file=BtD_Symposium_ODC_2024.pptx\&action=edit\&mobileredirect=true\&DefaultItemOpen=1\&EntityRepresentationId=ad9ba7bd-4e87-42f9-83b2-64b869a4447c) (Sentinel Indication Melanoma) [\[BtD_Sympos...m_ODC_2024 | PowerPoint\]](https://boehringer.sharepoint.com/sites/z365biotherapeuticssymposium/_layouts/15/Doc.aspx?sourcedoc=%7B953B2C06-0C05-48AF-B032-9B009E1D7CD5%7D&file=BtD_Symposium_ODC_2024.pptx&action=edit&mobileredirect=true&DefaultItemOpen=1)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| dosage\_form              | NONE      | „Injectable“ bleibt korrekt.                                                            | —                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| route\_of\_administration | NONE      | Keine geprüfte Angabe zur Applikationsart gefunden.                                     | —                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| base\_technology          | NONE      | Keine zusätzliche, projektspezifische Basistechnologie nötig.                           | —                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| current\_phase            | **MAJOR** | Auf **„Phase I“** ändern (statt „Pre‑Clinical“).                                        | [HORST-US-June-2025.pptx](https://boehringer.sharepoint.com/sites/mybi_cd-and-o_usa/_layouts/15/Doc.aspx?sourcedoc=%7B45AFE150-B3B4-4BFB-969E-8C3CE086AEB3%7D\&file=HORST-US-June-2025.pptx\&action=edit\&mobileredirect=true\&DefaultItemOpen=1\&EntityRepresentationId=49d24dd7-9d51-431b-8320-97657799c275) („BI 3810944 … 1527‑0001 – Phase I“) [\[HORST-US-June-2025 | PowerPoint\]](https://boehringer.sharepoint.com/sites/mybi_cd-and-o_usa/_layouts/15/Doc.aspx?sourcedoc=%7B45AFE150-B3B4-4BFB-969E-8C3CE086AEB3%7D&file=HORST-US-June-2025.pptx&action=edit&mobileredirect=true&DefaultItemOpen=1); [bi3810944-1527-p1-icf-safety-22Oct2025.docx](https://boehringer.sharepoint.com/sites/z365icfsafetylaylanguage/_layouts/15/Doc.aspx?sourcedoc=%7B2883A328-A2E8-42E1-A7A3-30F02F1289C0%7D\&file=bi3810944-1527-p1-icf-safety-22Oct2025.docx\&action=default\&mobileredirect=true\&DefaultItemOpen=1\&EntityRepresentationId=34e3afe0-2519-4ad3-bd80-cdff3a04a933) (Asset‑ICF zu 1527‑P01) [\[bi3810944-...-22Oct2025 | Word\]](https://boehringer.sharepoint.com/sites/z365icfsafetylaylanguage/_layouts/15/Doc.aspx?sourcedoc=%7B2883A328-A2E8-42E1-A7A3-30F02F1289C0%7D&file=bi3810944-1527-p1-icf-safety-22Oct2025.docx&action=default&mobileredirect=true&DefaultItemOpen=1)                                  |

**BI 3907074 / BI 3907075 / BI 3720590 — Not disclosed**

| Feld                      | Änderung  | Beschreibung                                                                                                                               | Evidenz                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| ------------------------- | --------- | ------------------------------------------------------------------------------------------------------------------------------------------ | ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- |
| product\_code             | NONE      | —                                                                                                                                          | —                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| product\_name             | NONE      | Nicht offengelegt.                                                                                                                         | [Product-Families-in-RIM.xlsx](https://boehringer.sharepoint.com/sites/mybi_omp/_layouts/15/Doc.aspx?sourcedoc=%7B8D88F5C3-6783-4278-902F-6509B94AC0C0%7D\&file=Product-Families-in-RIM.xlsx\&action=default\&mobileredirect=true\&DefaultItemOpen=1\&EntityRepresentationId=c54dbbfc-4849-4bc3-806f-9704c4791c4b) (führt Kombination als Produktfamilie) [\[Product-Fa...ies-in-RIM | Excel\]](https://boehringer.sharepoint.com/sites/mybi_omp/_layouts/15/Doc.aspx?sourcedoc=%7B8D88F5C3-6783-4278-902F-6509B94AC0C0%7D&file=Product-Families-in-RIM.xlsx&action=default&mobileredirect=true&DefaultItemOpen=1)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| modality\_name            | **MAJOR** | Auf **„Therapeutische Krebsimpfstoffe (ATP150/ATP152, KISIMA®) + Onkolytisches Virus (VSV‑GP154)“** ändern (statt „Recombinant Proteins“). | [2025\_03 BRM Pipeline Folie.pptx](https://boehringer-my.sharepoint.com/personal/oliver_gluth_boehringer-ingelheim_com/Documents/BI%20-%20Work/01_PROJECTS/2025_iManagement-private/02%20Pipeline/2025_03%20BRM%20Pipeline%20Folie.pptx?web=1\&EntityRepresentationId=ce9ed1d6-32fa-41c2-ba9b-01ca9e3761ec) („ATP150/ATP152 + VSV‑GP154“) [\[2025_03 BR...line Folie | PowerPoint\]](https://boehringer-my.sharepoint.com/personal/oliver_gluth_boehringer-ingelheim_com/Documents/BI%20-%20Work/01_PROJECTS/2025_iManagement-private/02%20Pipeline/2025_03%20BRM%20Pipeline%20Folie.pptx?web=1); [TA Oncology - Pipeline and Asset Prioritization Overview 2.pptx](https://boehringer.sharepoint.com/sites/z365clinicaltrialspatientandsiteengagement/_layouts/15/Doc.aspx?sourcedoc=%7B2E64CF97-72A2-46F4-AB56-A512C96156A1%7D\&file=TA%20Oncology%20-%20Pipeline%20and%20Asset%20Prioritization%20Overview%202.pptx\&action=edit\&mobileredirect=true\&DefaultItemOpen=1\&EntityRepresentationId=2f20a458-3544-4f0c-8663-d58028216b18) (KISIMA‑Programme) [\[TA Oncolog...Overview 2 | PowerPoint\]](https://boehringer.sharepoint.com/sites/z365clinicaltrialspatientandsiteengagement/_layouts/15/Doc.aspx?sourcedoc=%7B2E64CF97-72A2-46F4-AB56-A512C96156A1%7D&file=TA%20Oncology%20-%20Pipeline%20and%20Asset%20Prioritization%20Overview%202.pptx&action=edit&mobileredirect=true&DefaultItemOpen=1) |
| product\_type             | NONE      | NBE bleibt korrekt.                                                                                                                        | —                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| therapeutic\_area         | NONE      | Oncology bleibt korrekt.                                                                                                                   | —                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| mechanism\_of\_action     | **MINOR** | Präzisieren: **„Kombination aus KISIMA‑Impfkonstrukten (ATP150/152) und VSV‑GP onkolytischem Vektor (154)“**.                              | [2025\_03 BRM Pipeline Folie.pptx](https://boehringer-my.sharepoint.com/personal/oliver_gluth_boehringer-ingelheim_com/Documents/BI%20-%20Work/01_PROJECTS/2025_iManagement-private/02%20Pipeline/2025_03%20BRM%20Pipeline%20Folie.pptx?web=1\&EntityRepresentationId=ce9ed1d6-32fa-41c2-ba9b-01ca9e3761ec) [\[2025_03 BR...line Folie | PowerPoint\]](https://boehringer-my.sharepoint.com/personal/oliver_gluth_boehringer-ingelheim_com/Documents/BI%20-%20Work/01_PROJECTS/2025_iManagement-private/02%20Pipeline/2025_03%20BRM%20Pipeline%20Folie.pptx?web=1)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| short\_description        | **MINOR** | PDAC‑Fokus beibehalten; **als AMAL‑Programm referenziert**.                                                                                | Transition plan … BI‑VQD‑1173103 (führt BI 3720590 als AMAL‑Projekt) [\[Transition...QD-23719-S | Extern\]](https://bi-docs-vault-quality.veevavault.com/ui/#doc_info/1186279)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| dosage\_form              | NONE      | „Injectable“ bleibt korrekt.                                                                                                               | —                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| route\_of\_administration | NONE      | Keine geprüfte, einheitliche Angabe (VSV‑GP vs. Impfstoff) gefunden.                                                                       | —                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| base\_technology          | **MAJOR** | Auf **„Viral (VSV‑GP) + Impfplattform (KISIMA®)“** ändern (statt „Microbial“).                                                             | [2025\_03 BRM Pipeline Folie.pptx](https://boehringer-my.sharepoint.com/personal/oliver_gluth_boehringer-ingelheim_com/Documents/BI%20-%20Work/01_PROJECTS/2025_iManagement-private/02%20Pipeline/2025_03%20BRM%20Pipeline%20Folie.pptx?web=1\&EntityRepresentationId=ce9ed1d6-32fa-41c2-ba9b-01ca9e3761ec) [\[2025_03 BR...line Folie | PowerPoint\]](https://boehringer-my.sharepoint.com/personal/oliver_gluth_boehringer-ingelheim_com/Documents/BI%20-%20Work/01_PROJECTS/2025_iManagement-private/02%20Pipeline/2025_03%20BRM%20Pipeline%20Folie.pptx?web=1); [TA Oncology - Pipeline and Asset Prioritization Overview 2.pptx](https://boehringer.sharepoint.com/sites/z365clinicaltrialspatientandsiteengagement/_layouts/15/Doc.aspx?sourcedoc=%7B2E64CF97-72A2-46F4-AB56-A512C96156A1%7D\&file=TA%20Oncology%20-%20Pipeline%20and%20Asset%20Prioritization%20Overview%202.pptx\&action=edit\&mobileredirect=true\&DefaultItemOpen=1\&EntityRepresentationId=2f20a458-3544-4f0c-8663-d58028216b18) [\[TA Oncolog...Overview 2 | PowerPoint\]](https://boehringer.sharepoint.com/sites/z365clinicaltrialspatientandsiteengagement/_layouts/15/Doc.aspx?sourcedoc=%7B2E64CF97-72A2-46F4-AB56-A512C96156A1%7D&file=TA%20Oncology%20-%20Pipeline%20and%20Asset%20Prioritization%20Overview%202.pptx&action=edit&mobileredirect=true&DefaultItemOpen=1)                                                  |
| current\_phase            | NONE      | „Pre‑Clinical“ kann beibehalten werden; keine FiH‑Angaben gefunden.                                                                        | [2025\_03 BRM Pipeline Folie.pptx](https://boehringer-my.sharepoint.com/personal/oliver_gluth_boehringer-ingelheim_com/Documents/BI%20-%20Work/01_PROJECTS/2025_iManagement-private/02%20Pipeline/2025_03%20BRM%20Pipeline%20Folie.pptx?web=1\&EntityRepresentationId=ce9ed1d6-32fa-41c2-ba9b-01ca9e3761ec) (frühe Pipeline) [\[bi3923948-...-11Jul2025 | Word\]](https://boehringer.sharepoint.com/sites/z365icfsafetylaylanguage/_layouts/15/Doc.aspx?sourcedoc=%7BF636B0DA-9249-4CBB-A9B4-61BE79EEA31C%7D&file=bi3923948-1538-p1-icf-safety-11Jul2025.docx&action=default&mobileredirect=true&DefaultItemOpen=1)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |

**BI 3923948 — Not disclosed**

| Feld                      | Änderung  | Beschreibung                                                                                            | Evidenz                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| ------------------------- | --------- | ------------------------------------------------------------------------------------------------------- | --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- |
| product\_code             | NONE      | —                                                                                                       | —                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| product\_name             | NONE      | Nicht offengelegt.                                                                                      | [bi3923948-1538-p1-icf-safety-11Jul2025.docx](https://boehringer.sharepoint.com/sites/z365icfsafetylaylanguage/_layouts/15/Doc.aspx?sourcedoc=%7BF636B0DA-9249-4CBB-A9B4-61BE79EEA31C%7D\&file=bi3923948-1538-p1-icf-safety-11Jul2025.docx\&action=default\&mobileredirect=true\&DefaultItemOpen=1\&EntityRepresentationId=1d55c328-5fec-49c7-a6ee-efb5c9efe3e0) (führt Code ohne INN) [\[STORM, BI...1538-0001 | Extern\]](https://bi-docs-vault-quality.veevavault.com/ui/#doc_info/2512720?itemid=brwYiVyXeLT66LRTxYXqBlGSuHaVsHT9ZuoHbot4oE)                                                                                                                                                                                                |
| modality\_name            | **MAJOR** | Auf **„Onkolytisches Virus (VSV‑GP) mit GSDME und IL‑12 Cargo“** ändern (statt „Recombinant Proteins“). | STORM, BI 3923948, 1538‑0001 (VSV‑GP, Formulierung) [\[BI 3923948 IND | PDF\]](https://boehringer.sharepoint.com/sites/z365ridgefieldenvironmentalhealthandsafetymybi/EHS%20Documents/Environmental/Environmental%20Risk%20Assessments/Product%20Environmental%20Risk%20Assessment/INDs/BI%203923948/BI%203923948%20IND.pdf?web=1); [BI 3923948 IND.pdf](https://boehringer.sharepoint.com/sites/z365ridgefieldenvironmentalhealthandsafetymybi/EHS%20Documents/Environmental/Environmental%20Risk%20Assessments/Product%20Environmental%20Risk%20Assessment/INDs/BI%203923948/BI%203923948%20IND.pdf?web=1\&EntityRepresentationId=058bc500-7897-41b1-9424-e2335bf4802f) (Projektunterlagen) [\[BI Oncolog...April 2025 | PowerPoint\]](https://boehringer.sharepoint.com/sites/z365clinicaltrialspatientandsiteengagement/Shared%20Documents/TA%20Oncology/ESMO/ESMO%202025/BI%20Oncology%20Pipeline%20-%20executive%20summary%20and%20overview_AACR%20update_April%202025.pptx?web=1) |
| product\_type             | NONE      | NBE bleibt korrekt.                                                                                     | —                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| therapeutic\_area         | NONE      | Oncology bleibt korrekt.                                                                                | —                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| mechanism\_of\_action     | NONE      | Beschreibung (GSDME‑Pyroptose, IL‑12 Immunaktivierung) ist korrekt.                                     | BI Oncology Pipeline … AACR update\_April 2025.pptx (Programmlinie) [\[🎉 Team Mi...12)! 🚀
Ma | Viva Engage\]](https://engage.cloud.microsoft/main/threads/eyJfdHlwZSI6IlRocmVhZCIsImlkIjoiMzQ4OTUzMTgwMzA5MDk0NSJ9); Viva Engage Post: IMPD Submission [\[FastAndThe...ious_final | PowerPoint\]](https://boehringer.sharepoint.com/sites/z365biotherapeuticssymposium/_layouts/15/Doc.aspx?sourcedoc=%7B2596B5DD-11B2-4609-A1FF-B62B2CD8C297%7D&file=FastAndTheFurious_final.pptx&action=edit&mobileredirect=true&DefaultItemOpen=1)                                                                                                                                                                                                                                                                                                                            |
| short\_description        | **MINOR** | Behalten; **TNBC**‑Nennung ist in Pipeline‑Folie hinterlegt.                                            | [2025\_03 BRM Pipeline Folie.pptx](https://boehringer-my.sharepoint.com/personal/oliver_gluth_boehringer-ingelheim_com/Documents/BI%20-%20Work/01_PROJECTS/2025_iManagement-private/02%20Pipeline/2025_03%20BRM%20Pipeline%20Folie.pptx?web=1\&EntityRepresentationId=ce9ed1d6-32fa-41c2-ba9b-01ca9e3761ec) („BI 3923948 (TNBC) VSV‑GP‑GSDME‑IL12“) [\[bi3923948-...-11Jul2025 | Word\]](https://boehringer.sharepoint.com/sites/z365icfsafetylaylanguage/_layouts/15/Doc.aspx?sourcedoc=%7BF636B0DA-9249-4CBB-A9B4-61BE79EEA31C%7D&file=bi3923948-1538-p1-icf-safety-11Jul2025.docx&action=default&mobileredirect=true&DefaultItemOpen=1)                                                                                                                                                                                                                                                                         |
| dosage\_form              | **MINOR** | Ergänzen zu **„Solution for injection/infusion, glass vial“**.                                          | STORM, BI 3923948, 1538‑0001 [\[BI 3923948 IND | PDF\]](https://boehringer.sharepoint.com/sites/z365ridgefieldenvironmentalhealthandsafetymybi/EHS%20Documents/Environmental/Environmental%20Risk%20Assessments/Product%20Environmental%20Risk%20Assessment/INDs/BI%203923948/BI%203923948%20IND.pdf?web=1)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| route\_of\_administration | **MINOR** | Ergänzen zu **„parenteral (Injection/Infusion)“**.                                                      | STORM, BI 3923948, 1538‑0001 (Infusion vorgesehen) [\[BI 3923948 IND | PDF\]](https://boehringer.sharepoint.com/sites/z365ridgefieldenvironmentalhealthandsafetymybi/EHS%20Documents/Environmental/Environmental%20Risk%20Assessments/Product%20Environmental%20Risk%20Assessment/INDs/BI%203923948/BI%203923948%20IND.pdf?web=1)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| base\_technology          | **MAJOR** | Auf **„Viral (VSV‑GP oncolytic platform)“** ändern.                                                     | STORM, BI 3923948, 1538‑0001 [\[BI 3923948 IND | PDF\]](https://boehringer.sharepoint.com/sites/z365ridgefieldenvironmentalhealthandsafetymybi/EHS%20Documents/Environmental/Environmental%20Risk%20Assessments/Product%20Environmental%20Risk%20Assessment/INDs/BI%203923948/BI%203923948%20IND.pdf?web=1); [FastAndTheFurious\_final.pptx](https://boehringer.sharepoint.com/sites/z365biotherapeuticssymposium/_layouts/15/Doc.aspx?sourcedoc=%7B2596B5DD-11B2-4609-A1FF-B62B2CD8C297%7D\&file=FastAndTheFurious_final.pptx\&action=edit\&mobileredirect=true\&DefaultItemOpen=1\&EntityRepresentationId=d918a20f-6ae6-42ff-9d83-86d2808a1286) (VSV‑GP Plattform) [\[BI 765883...t antibody | PDF\]](https://boehringer.sharepoint.com/sites/z365ridgefieldenvironmentalhealthandsafetymybi/EHS%20Documents/General%20Safety/Hazard%20Communication/Safety%20Data%20Sheets/Boehringer%20Products/A%20Launches%202024/BI%20765883%20bi-specific%20bivalent%20antibody.pdf?web=1)                                          |
| current\_phase            | **MAJOR** | Auf **„Phase I“** ändern (statt „Pre‑Clinical“).                                                        | [HORST-US-June-2025.pptx](https://boehringer.sharepoint.com/sites/mybi_cd-and-o_usa/_layouts/15/Doc.aspx?sourcedoc=%7B45AFE150-B3B4-4BFB-969E-8C3CE086AEB3%7D\&file=HORST-US-June-2025.pptx\&action=edit\&mobileredirect=true\&DefaultItemOpen=1\&EntityRepresentationId=49d24dd7-9d51-431b-8320-97657799c275) („BI 3923948 … 1538‑0001 – Phase I“) [\[HORST-US-June-2025 | PowerPoint\]](https://boehringer.sharepoint.com/sites/mybi_cd-and-o_usa/_layouts/15/Doc.aspx?sourcedoc=%7B45AFE150-B3B4-4BFB-969E-8C3CE086AEB3%7D&file=HORST-US-June-2025.pptx&action=edit&mobileredirect=true&DefaultItemOpen=1); Viva Engage Post: IMPD Submission [\[FastAndThe...ious_final | PowerPoint\]](https://boehringer.sharepoint.com/sites/z365biotherapeuticssymposium/_layouts/15/Doc.aspx?sourcedoc=%7B2596B5DD-11B2-4609-A1FF-B62B2CD8C297%7D&file=FastAndTheFurious_final.pptx&action=edit&mobileredirect=true&DefaultItemOpen=1)                                                                         |

**BI 765883 — Not disclosed**

| Feld                      | Änderung  | Beschreibung                                                                                               | Evidenz                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| ------------------------- | --------- | ---------------------------------------------------------------------------------------------------------- | ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- |
| product\_code             | NONE      | —                                                                                                          | —                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| product\_name             | NONE      | Nicht offengelegt; kein INN.                                                                               | [BI 765883 bi-specific bivalent antibody.pdf](https://boehringer.sharepoint.com/sites/z365ridgefieldenvironmentalhealthandsafetymybi/EHS%20Documents/General%20Safety/Hazard%20Communication/Safety%20Data%20Sheets/Boehringer%20Products/A%20Launches%202024/BI%20765883%20bi-specific%20bivalent%20antibody.pdf?web=1\&EntityRepresentationId=65540e8f-8c0e-4f07-87ed-53c17a0aa177) (SDS ohne INN) [\[BI765883_Poster | PowerPoint\]](https://boehringer.sharepoint.com/sites/z365biotherapeuticssymposium/_layouts/15/Doc.aspx?sourcedoc=%7B0579F353-5E72-4181-91E7-B3E90C9EF79A%7D&file=BI765883_Poster.pptx&action=edit&mobileredirect=true&DefaultItemOpen=1)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| modality\_name            | **MAJOR** | Auf **„Bispezifischer Antikörper (DoppelMab) TRAILR2×CDH3‑Agonist“** ändern (statt „Monoclonal Antibody“). | [BI765883\_Poster.pptx](https://boehringer.sharepoint.com/sites/z365biotherapeuticssymposium/_layouts/15/Doc.aspx?sourcedoc=%7B0579F353-5E72-4181-91E7-B3E90C9EF79A%7D\&file=BI765883_Poster.pptx\&action=edit\&mobileredirect=true\&DefaultItemOpen=1\&EntityRepresentationId=ead4eccf-dc14-44a0-bee9-aa3e9fd8e61a) (bispezifischer TRAILR2‑Agonist, CDH3‑Anker) [\[NBE Portfo..._Reisinger | PowerPoint\]](https://boehringer.sharepoint.com/sites/z365qualityexcellenceprogram/_layouts/15/Doc.aspx?sourcedoc=%7BC0E00D05-78CD-402B-A9CB-22D00F701DCE%7D&file=NBE%20Portfolio_Q-uriosity_Sep24_Reisinger.pptx&action=edit&mobileredirect=true&DefaultItemOpen=1); [NBE Portfolio\_Q-uriosity\_Sep24\_Reisinger.pptx](https://boehringer.sharepoint.com/sites/z365qualityexcellenceprogram/_layouts/15/Doc.aspx?sourcedoc=%7BC0E00D05-78CD-402B-A9CB-22D00F701DCE%7D\&file=NBE%20Portfolio_Q-uriosity_Sep24_Reisinger.pptx\&action=edit\&mobileredirect=true\&DefaultItemOpen=1\&EntityRepresentationId=11c38e80-2b6c-4461-930a-a4bd637d9704) (führt BI 765883 als TRAILR2/CDH3 AB) [\[24 - Cross...Submission | PowerPoint\]](https://boehringer.sharepoint.com/sites/z365biotherapeuticssymposium/_layouts/15/Doc.aspx?sourcedoc=%7B05F145A6-264C-4F72-B957-71E2422224C4%7D&file=24%20-%20Cross%20Functional%20Teamwork%20for%20Patient%20Safety%20Assessment%20Case%20Studies%20from%20BI%20765883%20Comparability%20and%20In-Use%20in%20Preparation%20of%20Phase%20I%20Submission.pptx&action=edit&mobileredirect=true&DefaultItemOpen=1) |
| product\_type             | NONE      | NBE bleibt korrekt.                                                                                        | —                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| therapeutic\_area         | NONE      | Oncology bleibt korrekt.                                                                                   | —                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| mechanism\_of\_action     | **MINOR** | Präzisieren: **„CDH3‑vermittelte TRAILR2‑Clustering/Agonismus zur tumorspezifischen Apoptose“**.           | [BI765883\_Poster.pptx](https://boehringer.sharepoint.com/sites/z365biotherapeuticssymposium/_layouts/15/Doc.aspx?sourcedoc=%7B0579F353-5E72-4181-91E7-B3E90C9EF79A%7D\&file=BI765883_Poster.pptx\&action=edit\&mobileredirect=true\&DefaultItemOpen=1\&EntityRepresentationId=ead4eccf-dc14-44a0-bee9-aa3e9fd8e61a) (MoA‑Grafiken) [\[NBE Portfo..._Reisinger | PowerPoint\]](https://boehringer.sharepoint.com/sites/z365qualityexcellenceprogram/_layouts/15/Doc.aspx?sourcedoc=%7BC0E00D05-78CD-402B-A9CB-22D00F701DCE%7D&file=NBE%20Portfolio_Q-uriosity_Sep24_Reisinger.pptx&action=edit&mobileredirect=true&DefaultItemOpen=1)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| short\_description        | **MINOR** | PDAC‑Fokus bestätigen; **Phase‑I gestartet**.                                                              | 24 – Patient Safety Assessment … BI 765883 … .pptx („Phase I trials initiated“) [\[BI 765883,...00 mg/vial | Extern\]](https://bi-docs-vault-quality.veevavault.com/ui/#doc_info/1189165?itemid=peM2BKSn7ILdVh2LZ5qq5Pilc7ixt5BbU4HKevik)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| dosage\_form              | **MINOR** | Ergänzen zu **„Powder for solution for infusion, 100 mg/vial (30 mg/mL nach Rekonstitution)“**.            | BI‑VQD‑1175988 – SPI BI 765883 [\[STORM, BI...1505-0001 | Extern\]](https://bi-docs-vault-quality.veevavault.com/ui/#doc_info/1240739?itemid=vzDQPZr0XD1hEf6bnqXS4dTROcb2KxOrJCYyL0HFFB8)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| route\_of\_administration | **MINOR** | Ergänzen zu **„Intravenöse Infusion“**.                                                                    | BI‑VQD‑1175988 – SPI BI 765883 (In‑use‑Studie für i.v. Anwendung) [\[STORM, BI...1505-0001 | Extern\]](https://bi-docs-vault-quality.veevavault.com/ui/#doc_info/1240739?itemid=vzDQPZr0XD1hEf6bnqXS4dTROcb2KxOrJCYyL0HFFB8)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| base\_technology          | **MINOR** | Ergänzen zu **„Engineered bispezifische IgG‑basierte DoppelMab‑Architektur“**.                             | [BI765883\_Poster.pptx](https://boehringer.sharepoint.com/sites/z365biotherapeuticssymposium/_layouts/15/Doc.aspx?sourcedoc=%7B0579F353-5E72-4181-91E7-B3E90C9EF79A%7D\&file=BI765883_Poster.pptx\&action=edit\&mobileredirect=true\&DefaultItemOpen=1\&EntityRepresentationId=ead4eccf-dc14-44a0-bee9-aa3e9fd8e61a) (Molekülarchitektur) [\[NBE Portfo..._Reisinger | PowerPoint\]](https://boehringer.sharepoint.com/sites/z365qualityexcellenceprogram/_layouts/15/Doc.aspx?sourcedoc=%7BC0E00D05-78CD-402B-A9CB-22D00F701DCE%7D&file=NBE%20Portfolio_Q-uriosity_Sep24_Reisinger.pptx&action=edit&mobileredirect=true&DefaultItemOpen=1)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| current\_phase            | **MAJOR** | Auf **„Phase I“** ändern (statt „Discontinued“).                                                           | STORM, BI 765883, 1505‑0001 (laufendes Studien‑IMPD); 24 – Patient Safety Assessment … BI 765883 … .pptx [\[BI 765883,...00 mg/vial | Extern\]](https://bi-docs-vault-quality.veevavault.com/ui/#doc_info/1189165?itemid=peM2BKSn7ILdVh2LZ5qq5Pilc7ixt5BbU4HKevik)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
**BI 3034701**

| Änderung | Beschreibung                                                                                       | Evidenz                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| -------- | -------------------------------------------------------------------------------------------------- | -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- |
| NONE     | **product\_code**: Unverändert.                                                                    | [3. TA CRM pipeline\_DM2035 HR.pptx](https://boehringer.sharepoint.com/sites/z365usmedicinecapabilitiesexcellence/_layouts/15/Doc.aspx?sourcedoc=%7B57525F5F-26A8-4CA1-BF70-4F9C3A08E15D%7D\&file=3.%20TA%20CRM%20pipeline_DM2035%20HR.pptx\&action=edit\&mobileredirect=true\&DefaultItemOpen=1\&EntityRepresentationId=76041a2f-f0f6-411a-9439-c467283ae431) listet das Asset eindeutig als „BI 3034701“. [\[3. TA CRM..._DM2035 HR | PowerPoint\]](https://boehringer.sharepoint.com/sites/z365usmedicinecapabilitiesexcellence/_layouts/15/Doc.aspx?sourcedoc=%7B57525F5F-26A8-4CA1-BF70-4F9C3A08E15D%7D&file=3.%20TA%20CRM%20pipeline_DM2035%20HR.pptx&action=edit&mobileredirect=true&DefaultItemOpen=1)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| NONE     | **product\_name**: Keine öffentlichen Bezeichnungen gefunden → unverändert (leer/„Not disclosed“). | [Asset-Teams\_CRM\_24APR\_Intranet.pptx](https://boehringer.sharepoint.com/sites/TACMR/_layouts/15/Doc.aspx?sourcedoc=%7BC5A6CF14-0675-4DA3-A85D-881B37F7466F%7D\&file=Asset-Teams_CRM_24APR_Intranet.pptx\&action=edit\&mobileredirect=true\&DefaultItemOpen=1\&EntityRepresentationId=c47a75ae-1757-422d-ba56-beac1ce12360) und [V\&A Dashboard for CM\_Aug 2024.pptx](https://boehringer.sharepoint.com/sites/z365pricingandcontractingoncology/_layouts/15/Doc.aspx?sourcedoc=%7B00BAC6D9-083F-488C-8F79-170A4C33826B%7D\&file=V%26A%20Dashboard%20for%20CM_Aug%202024.pptx\&action=edit\&mobileredirect=true\&DefaultItemOpen=1\&EntityRepresentationId=638871cb-654d-4763-bdb0-7704e649c7fa) führen nur den Code, keinen Namen. [\[Asset-Team...R_Intranet | PowerPoint\]](https://boehringer.sharepoint.com/sites/TACMR/_layouts/15/Doc.aspx?sourcedoc=%7BC5A6CF14-0675-4DA3-A85D-881B37F7466F%7D&file=Asset-Teams_CRM_24APR_Intranet.pptx&action=edit&mobileredirect=true&DefaultItemOpen=1), [\[V&A Dashbo...M_Aug 2024 | PowerPoint\]](https://boehringer.sharepoint.com/sites/z365pricingandcontractingoncology/_layouts/15/Doc.aspx?sourcedoc=%7B00BAC6D9-083F-488C-8F79-170A4C33826B%7D&file=V%26A%20Dashboard%20for%20CM_Aug%202024.pptx&action=edit&mobileredirect=true&DefaultItemOpen=1) |
| NONE     | **modality\_name**: „Peptides“ ist korrekt (GGY2R‑Peptid, Sequenz & HLE gezeigt).                  | [Session 1 - Engelbrecht & Mitic - Recombinant Peptide Manufacturing.pptx](https://boehringer.sharepoint.com/sites/z365giamsteeringcommittees/_layouts/15/Doc.aspx?sourcedoc=%7B4ED4B439-32CD-4C99-BC6B-D84F2CA34570%7D\&file=Session%201%20-%20Engelbrecht%20%26%20Mitic%20-%20Recombinant%20Peptide%20Manufacturing.pptx\&action=edit\&mobileredirect=true\&DefaultItemOpen=1\&EntityRepresentationId=8e25dc65-57cf-4229-8f5d-e431d4eb621e) führt „BI 3034701 GGY2R FR“ mit Peptid‑Sequenz/HLE. [\[Session 1...ufacturing | PowerPoint\]](https://boehringer.sharepoint.com/sites/z365giamsteeringcommittees/_layouts/15/Doc.aspx?sourcedoc=%7B4ED4B439-32CD-4C99-BC6B-D84F2CA34570%7D&file=Session%201%20-%20Engelbrecht%20%26%20Mitic%20-%20Recombinant%20Peptide%20Manufacturing.pptx&action=edit&mobileredirect=true&DefaultItemOpen=1)                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| NONE     | **product\_type**: „NME“ bleibt korrekt (Peptide werden intern als NCE/NME‑Klasse geführt).        | [03\_NCE Portfolio\_Schiewe.pptx](https://boehringer.sharepoint.com/sites/z365hpcmcmgmtregcompinformationplatform/_layouts/15/Doc.aspx?sourcedoc=%7B9C0928A1-8BAE-41EF-9B84-C5C1E87CB847%7D\&file=03_NCE%20Portfolio_Schiewe.pptx\&action=edit\&mobileredirect=true\&DefaultItemOpen=1\&EntityRepresentationId=7f7d4f6a-5962-49aa-8e43-adcb9a6f3c1b) listet Peptide (inkl. 3034701) unter NCE‑Assets. [\[03_NCE Por...io_Schiewe | PowerPoint\]](https://boehringer.sharepoint.com/sites/z365hpcmcmgmtregcompinformationplatform/_layouts/15/Doc.aspx?sourcedoc=%7B9C0928A1-8BAE-41EF-9B84-C5C1E87CB847%7D&file=03_NCE%20Portfolio_Schiewe.pptx&action=edit&mobileredirect=true&DefaultItemOpen=1)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| NONE     | **therapeutic\_area**: CRM bestätigt.                                                              | [3. TA CRM pipeline\_DM2035 HR.pptx](https://boehringer.sharepoint.com/sites/z365usmedicinecapabilitiesexcellence/_layouts/15/Doc.aspx?sourcedoc=%7B57525F5F-26A8-4CA1-BF70-4F9C3A08E15D%7D\&file=3.%20TA%20CRM%20pipeline_DM2035%20HR.pptx\&action=edit\&mobileredirect=true\&DefaultItemOpen=1\&EntityRepresentationId=76041a2f-f0f6-411a-9439-c467283ae431). [\[20250113_K...f Workshop | PowerPoint\]](https://boehringer.sharepoint.com/sites/z365bihivecoreteam/_layouts/15/Doc.aspx?sourcedoc=%7B6CF5BFA1-C363-4868-B1D6-57BED907D01B%7D&file=20250113_Kick-Off%20Workshop.pptx&action=edit&mobileredirect=true&DefaultItemOpen=1)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| NONE     | **mechanism\_of\_action**: GLP‑1R/GIPR/NPY2R‑Agonist bestätigt.                                    | [3. TA CRM pipeline\_DM2035 HR.pptx](https://boehringer.sharepoint.com/sites/z365usmedicinecapabilitiesexcellence/_layouts/15/Doc.aspx?sourcedoc=%7B57525F5F-26A8-4CA1-BF70-4F9C3A08E15D%7D\&file=3.%20TA%20CRM%20pipeline_DM2035%20HR.pptx\&action=edit\&mobileredirect=true\&DefaultItemOpen=1\&EntityRepresentationId=76041a2f-f0f6-411a-9439-c467283ae431). [\[3. TA CRM..._DM2035 HR | PowerPoint\]](https://boehringer.sharepoint.com/sites/z365usmedicinecapabilitiesexcellence/_layouts/15/Doc.aspx?sourcedoc=%7B57525F5F-26A8-4CA1-BF70-4F9C3A08E15D%7D&file=3.%20TA%20CRM%20pipeline_DM2035%20HR.pptx&action=edit&mobileredirect=true&DefaultItemOpen=1)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| NONE     | **short\_description**: Tri‑Agonist‑Peptid für Obesitas – bestätigt.                               | [3. TA CRM pipeline\_DM2035 HR.pptx](https://boehringer.sharepoint.com/sites/z365usmedicinecapabilitiesexcellence/_layouts/15/Doc.aspx?sourcedoc=%7B57525F5F-26A8-4CA1-BF70-4F9C3A08E15D%7D\&file=3.%20TA%20CRM%20pipeline_DM2035%20HR.pptx\&action=edit\&mobileredirect=true\&DefaultItemOpen=1\&EntityRepresentationId=76041a2f-f0f6-411a-9439-c467283ae431). [\[3. TA CRM..._DM2035 HR | PowerPoint\]](https://boehringer.sharepoint.com/sites/z365usmedicinecapabilitiesexcellence/_layouts/15/Doc.aspx?sourcedoc=%7B57525F5F-26A8-4CA1-BF70-4F9C3A08E15D%7D&file=3.%20TA%20CRM%20pipeline_DM2035%20HR.pptx&action=edit&mobileredirect=true&DefaultItemOpen=1)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| NONE     | **dosage\_form**: „Injectable“ plausibel, keine gegenteilige Evidenz.                              | Geräte-/Plattformfolien zeigen 3034701 in AI/PEN‑Kontext. [\[IU-Priorit...2025_final | PDF\]](https://boehringer.sharepoint.com/sites/mybi_onehpiu/SiteAssets/SitePages/Innovation-Unit/IU-Priorities-2025_final.pdf?web=1)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| MINOR    | **route\_of\_administration**: Ergänzen zu „SC“ (subkutan) basierend auf AI/PEN‑Planung.           | [20250113\_Kick-Off Workshop.pptx](https://boehringer.sharepoint.com/sites/z365bihivecoreteam/_layouts/15/Doc.aspx?sourcedoc=%7B6CF5BFA1-C363-4868-B1D6-57BED907D01B%7D\&file=20250113_Kick-Off%20Workshop.pptx\&action=edit\&mobileredirect=true\&DefaultItemOpen=1\&EntityRepresentationId=48e3201c-3316-4f97-9820-d1c76e413c93) ordnet 3034701 Autoinjektor/Pen zu (üblich: SC). [\[IU-Priorit...2025_final | PDF\]](https://boehringer.sharepoint.com/sites/mybi_onehpiu/SiteAssets/SitePages/Innovation-Unit/IU-Priorities-2025_final.pdf?web=1)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| MINOR    | **base\_technology**: Ergänzen zu „Long‑acting peptide mit Half‑Life‑Extension (HLE)“.             | Peptid‑Sequenz inkl. HLE‑Bausteinen dokumentiert. [\[Session 1...ufacturing | PowerPoint\]](https://boehringer.sharepoint.com/sites/z365giamsteeringcommittees/_layouts/15/Doc.aspx?sourcedoc=%7B4ED4B439-32CD-4C99-BC6B-D84F2CA34570%7D&file=Session%201%20-%20Engelbrecht%20%26%20Mitic%20-%20Recombinant%20Peptide%20Manufacturing.pptx&action=edit&mobileredirect=true&DefaultItemOpen=1)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| NONE     | **current\_phase**: „Pre‑Clinical“ bestätigt.                                                      | CRM‑Pipeline zeigt 3034701 in Pre‑Clinical. [\[20250113_K...f Workshop | PowerPoint\]](https://boehringer.sharepoint.com/sites/z365bihivecoreteam/_layouts/15/Doc.aspx?sourcedoc=%7B6CF5BFA1-C363-4868-B1D6-57BED907D01B%7D&file=20250113_Kick-Off%20Workshop.pptx&action=edit&mobileredirect=true&DefaultItemOpen=1)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |

**BI 3060292**

| Änderung | Beschreibung                                                                                                       | Evidenz                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| -------- | ------------------------------------------------------------------------------------------------------------------ | ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- |
| NONE     | **product\_code**: Unverändert.                                                                                    | Pipeline‑/Prioritäten‑Folien nutzen den Code. [\[gBDS All S...nuary 2025 | PowerPoint\]](https://boehringer.sharepoint.com/sites/mybi_biostatistics/Shared%20Documents/Global%20BDS%20All%20Staff%20Meetings/gBDS%20All%20Staff%20Meeting%2021%20January%202025.pptx?web=1)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| NONE     | **product\_name**: Unverändert (kein öffentlicher Name).                                                           | [IU-Priorities-2025\_final.pdf](https://boehringer.sharepoint.com/sites/mybi_onehpiu/SiteAssets/SitePages/Innovation-Unit/IU-Priorities-2025_final.pdf?web=1\&EntityRepresentationId=ce3332ed-c389-444c-84ea-2751c138e045). [\[gBDS All S...nuary 2025 | PowerPoint\]](https://boehringer.sharepoint.com/sites/mybi_biostatistics/Shared%20Documents/Global%20BDS%20All%20Staff%20Meetings/gBDS%20All%20Staff%20Meeting%2021%20January%202025.pptx?web=1)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| NONE     | **modality\_name**: „Small Molecule“ bestätigt (NCE‑Portfolio).                                                    | [03\_NCE Portfolio\_Schiewe.pptx](https://boehringer.sharepoint.com/sites/z365hpcmcmgmtregcompinformationplatform/_layouts/15/Doc.aspx?sourcedoc=%7B9C0928A1-8BAE-41EF-9B84-C5C1E87CB847%7D\&file=03_NCE%20Portfolio_Schiewe.pptx\&action=edit\&mobileredirect=true\&DefaultItemOpen=1\&EntityRepresentationId=7f7d4f6a-5962-49aa-8e43-adcb9a6f3c1b). [\[03_NCE Por...io_Schiewe | PowerPoint\]](https://boehringer.sharepoint.com/sites/z365hpcmcmgmtregcompinformationplatform/_layouts/15/Doc.aspx?sourcedoc=%7B9C0928A1-8BAE-41EF-9B84-C5C1E87CB847%7D&file=03_NCE%20Portfolio_Schiewe.pptx&action=edit&mobileredirect=true&DefaultItemOpen=1)                                                                                                                                                                                                                                                                                                                                                                                         |
| NONE     | **product\_type**: „NME“ bleibt korrekt.                                                                           | [03\_NCE Portfolio\_Schiewe.pptx](https://boehringer.sharepoint.com/sites/z365hpcmcmgmtregcompinformationplatform/_layouts/15/Doc.aspx?sourcedoc=%7B9C0928A1-8BAE-41EF-9B84-C5C1E87CB847%7D\&file=03_NCE%20Portfolio_Schiewe.pptx\&action=edit\&mobileredirect=true\&DefaultItemOpen=1\&EntityRepresentationId=7f7d4f6a-5962-49aa-8e43-adcb9a6f3c1b). [\[03_NCE Por...io_Schiewe | PowerPoint\]](https://boehringer.sharepoint.com/sites/z365hpcmcmgmtregcompinformationplatform/_layouts/15/Doc.aspx?sourcedoc=%7B9C0928A1-8BAE-41EF-9B84-C5C1E87CB847%7D&file=03_NCE%20Portfolio_Schiewe.pptx&action=edit&mobileredirect=true&DefaultItemOpen=1)                                                                                                                                                                                                                                                                                                                                                                                         |
| NONE     | **therapeutic\_area**: CRM bestätigt.                                                                              | [IU-Priorities-2025\_final.pdf](https://boehringer.sharepoint.com/sites/mybi_onehpiu/SiteAssets/SitePages/Innovation-Unit/IU-Priorities-2025_final.pdf?web=1\&EntityRepresentationId=ce3332ed-c389-444c-84ea-2751c138e045). [\[gBDS All S...nuary 2025 | PowerPoint\]](https://boehringer.sharepoint.com/sites/mybi_biostatistics/Shared%20Documents/Global%20BDS%20All%20Staff%20Meetings/gBDS%20All%20Staff%20Meeting%2021%20January%202025.pptx?web=1)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| NONE     | **mechanism\_of\_action**: NMUR2‑Agonist bestätigt.                                                                | [IU-Priorities-2025\_final.pdf](https://boehringer.sharepoint.com/sites/mybi_onehpiu/SiteAssets/SitePages/Innovation-Unit/IU-Priorities-2025_final.pdf?web=1\&EntityRepresentationId=ce3332ed-c389-444c-84ea-2751c138e045). [\[gBDS All S...nuary 2025 | PowerPoint\]](https://boehringer.sharepoint.com/sites/mybi_biostatistics/Shared%20Documents/Global%20BDS%20All%20Staff%20Meetings/gBDS%20All%20Staff%20Meeting%2021%20January%202025.pptx?web=1)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| NONE     | **short\_description**: „NMUR2‑Agonist Small Molecule für Obesitas“ – bestätigt.                                   | [03\_NCE Portfolio\_Schiewe.pptx](https://boehringer.sharepoint.com/sites/z365hpcmcmgmtregcompinformationplatform/_layouts/15/Doc.aspx?sourcedoc=%7B9C0928A1-8BAE-41EF-9B84-C5C1E87CB847%7D\&file=03_NCE%20Portfolio_Schiewe.pptx\&action=edit\&mobileredirect=true\&DefaultItemOpen=1\&EntityRepresentationId=7f7d4f6a-5962-49aa-8e43-adcb9a6f3c1b) (NMUR2, NCE). [\[03_NCE Por...io_Schiewe | PowerPoint\]](https://boehringer.sharepoint.com/sites/z365hpcmcmgmtregcompinformationplatform/_layouts/15/Doc.aspx?sourcedoc=%7B9C0928A1-8BAE-41EF-9B84-C5C1E87CB847%7D&file=03_NCE%20Portfolio_Schiewe.pptx&action=edit&mobileredirect=true&DefaultItemOpen=1)                                                                                                                                                                                                                                                                                                                                                                            |
| MINOR    | **dosage\_form**: „Injectable“ streichen → „nicht belegt/TBD“; es gibt keine belastbare Bestätigung für Injektion. | NCE‑Portfolio bestätigt SM‑Status; keine RoA/Device‑Festlegung. (Hinweis: eine Folie zeigt AI/PEN als Option, die RoA jedoch nicht finalisiert.) [\[03_NCE Por...io_Schiewe | PowerPoint\]](https://boehringer.sharepoint.com/sites/z365hpcmcmgmtregcompinformationplatform/_layouts/15/Doc.aspx?sourcedoc=%7B9C0928A1-8BAE-41EF-9B84-C5C1E87CB847%7D&file=03_NCE%20Portfolio_Schiewe.pptx&action=edit&mobileredirect=true&DefaultItemOpen=1), [\[IU-Priorit...2025_final | PDF\]](https://boehringer.sharepoint.com/sites/mybi_onehpiu/SiteAssets/SitePages/Innovation-Unit/IU-Priorities-2025_final.pdf?web=1)                                                                                                                                                                                                                                                                                                                                          |
| NONE     | **route\_of\_administration**: Unverändert (nicht belegt).                                                         | Keine belastbare RoA‑Quelle. [\[03_NCE Por...io_Schiewe | PowerPoint\]](https://boehringer.sharepoint.com/sites/z365hpcmcmgmtregcompinformationplatform/_layouts/15/Doc.aspx?sourcedoc=%7B9C0928A1-8BAE-41EF-9B84-C5C1E87CB847%7D&file=03_NCE%20Portfolio_Schiewe.pptx&action=edit&mobileredirect=true&DefaultItemOpen=1)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| NONE     | **base\_technology**: Unverändert (SM, keine Basistechnologie angegeben).                                          | —                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| MAJOR    | **current\_phase**: „Discontinued“ → **aktiv (Pre‑/post‑SoD, in Planung 2025)**.                                   | Mehrere 2025‑Planungsfolien führen BI 3060292 explizit als laufend; kein Hinweis auf Abbruch. [\[gBDS All S...nuary 2025 | PowerPoint\]](https://boehringer.sharepoint.com/sites/mybi_biostatistics/Shared%20Documents/Global%20BDS%20All%20Staff%20Meetings/gBDS%20All%20Staff%20Meeting%2021%20January%202025.pptx?web=1), [\[2024_3PM_K...E_Pipeline | PowerPoint\]](https://boehringer.sharepoint.com/sites/z3653pm/_layouts/15/Doc.aspx?sourcedoc=%7BE7FB9C8E-F8FB-4A5C-984D-6AD1E74154E6%7D&file=2024_3PM_Konferenz_NCE_Pipeline.pptx&action=edit&mobileredirect=true&DefaultItemOpen=1), [\[4_Preclini...Portfolio | PowerPoint\]](https://boehringer.sharepoint.com/sites/z365usmedicinecapabilitiesexcellence/_layouts/15/Doc.aspx?sourcedoc=%7BC1210620-4843-4B56-802F-E5452120641C%7D&file=4_Preclinical_Liver%20Health_Obesity_Sarcopenia_Research%20Portfolio.pptx&action=edit&mobileredirect=true&DefaultItemOpen=1), [\[BI3802876_...Symposium | PowerPoint\]](https://boehringer.sharepoint.com/sites/z365biotherapeuticssymposium/_layouts/15/Doc.aspx?sourcedoc=%7B0895CEC1-75CA-467F-BAF4-6ED50B942FEE%7D&file=BI3802876_NBE%20Symposium.pptx&action=edit&mobileredirect=true&DefaultItemOpen=1) |

**BI 3802876**

| Änderung | Beschreibung                                                                            | Evidenz                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| -------- | --------------------------------------------------------------------------------------- | ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- |
| NONE     | **product\_code**: Unverändert.                                                         | —                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| NONE     | **product\_name**: Unverändert (nicht offen gelegt).                                    | —                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| MINOR    | **modality\_name**: Präzisieren zu „Bispezifischer Antikörper (recombinant protein)“.   | „FAP‑verankerter TRAILR2‑Agonist bispezifischer Antikörper“ beschrieben. [\[FAPTRAILR2 | PowerPoint\]](https://boehringer.sharepoint.com/sites/z365eco/_layouts/15/Doc.aspx?sourcedoc=%7B79677BCA-978E-4BE9-93A7-EED1BF3BF212%7D&file=FAPTRAILR2.pptx&action=edit&mobileredirect=true&DefaultItemOpen=1)                                                                                                                                                                                                                                                                                                          |
| NONE     | **product\_type**: „NBE“ bleibt korrekt.                                                | —                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| NONE     | **therapeutic\_area**: CRM/MASH bestätigt.                                              | [3. TA CRM pipeline\_DM2035 HR.pptx](https://boehringer.sharepoint.com/sites/z365usmedicinecapabilitiesexcellence/_layouts/15/Doc.aspx?sourcedoc=%7B57525F5F-26A8-4CA1-BF70-4F9C3A08E15D%7D\&file=3.%20TA%20CRM%20pipeline_DM2035%20HR.pptx\&action=edit\&mobileredirect=true\&DefaultItemOpen=1\&EntityRepresentationId=76041a2f-f0f6-411a-9439-c467283ae431). [\[20250113_K...f Workshop | PowerPoint\]](https://boehringer.sharepoint.com/sites/z365bihivecoreteam/_layouts/15/Doc.aspx?sourcedoc=%7B6CF5BFA1-C363-4868-B1D6-57BED907D01B%7D&file=20250113_Kick-Off%20Workshop.pptx&action=edit&mobileredirect=true&DefaultItemOpen=1) |
| MINOR    | **mechanism\_of\_action**: Präzisieren zu „FAP‑verankerter TRAILR2‑Agonist (HSC‑Ziel)“. | MoA‑Details (FAP+ aHSC‑Depletion) gezeigt. [\[128-JM-3804379-PHV | Word\]](https://boehringer.sharepoint.com/sites/z365plattformdokumentenreviewadb/_layouts/15/Doc.aspx?sourcedoc=%7B24E6365B-88FE-4A4B-AED1-1AA1CB8F0F6A%7D&file=128-JM-3804379-PHV.docx&action=default&mobileredirect=true&DefaultItemOpen=1)                                                                                                                                                                                                                                                                                                                                                                            |
| NONE     | **short\_description**: Entspricht der MoA/Indikation – unverändert.                    | —                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| MINOR    | **dosage\_form**: Präzisieren zu „Injectable (IV)“.                                     | FiH‑Studie 1517‑0001 als **intravenös** dokumentiert. [\[128-JM-3804379-PHV | Word\]](https://boehringer.sharepoint.com/sites/z365plattformdokumentenreviewadb/_layouts/15/Doc.aspx?sourcedoc=%7B24E6365B-88FE-4A4B-AED1-1AA1CB8F0F6A%7D&file=128-JM-3804379-PHV.docx&action=default&mobileredirect=true&DefaultItemOpen=1)                                                                                                                                                                                                                                                                                                                                                                 |
| MINOR    | **route\_of\_administration**: Ergänzen zu „IV“.                                        | s. oben (SRD/MD IV). [\[128-JM-3804379-PHV | Word\]](https://boehringer.sharepoint.com/sites/z365plattformdokumentenreviewadb/_layouts/15/Doc.aspx?sourcedoc=%7B24E6365B-88FE-4A4B-AED1-1AA1CB8F0F6A%7D&file=128-JM-3804379-PHV.docx&action=default&mobileredirect=true&DefaultItemOpen=1)                                                                                                                                                                                                                                                                                                                                                                                                  |
| NONE     | **base\_technology**: „Mammalian“ kann bestehen bleiben (Biologic/Antikörper).          | CMC/IB‑Dokumente zum Biologikum vorhanden. [\[128-JM-3804379-A-DP | Word\]](https://boehringer.sharepoint.com/sites/z365plattformdokumentenreviewadb/_layouts/15/Doc.aspx?sourcedoc=%7B2756F305-72E1-41ED-8624-B2E671CFA581%7D&file=128-JM-3804379-A-DP.docx&action=default&mobileredirect=true&DefaultItemOpen=1), [\[NBE Portfo...ep25_Higel | PowerPoint\]](https://boehringer.sharepoint.com/sites/z365qualityexcellenceprogram/Shared%20Documents/General/Q-uriosity%202025/Module%204_Drug%20Product%20Development/09%20Portfolio%202%20-%20New%20biological%20entity%20(NBE)/NBE%20Portfolio_Q-uriosity_Sep25_Higel.pptx?web=1)                                                                           |
| MAJOR    | **current\_phase**: „Discontinued“ → **Phase I (laufend)**.                             | FAP‑TRAILR2‑Clinical‑Deck/Trialhinweise (1517‑0001) & TA‑Pipeline 2025. [\[128-JM-3804379-PHV | Word\]](https://boehringer.sharepoint.com/sites/z365plattformdokumentenreviewadb/_layouts/15/Doc.aspx?sourcedoc=%7B24E6365B-88FE-4A4B-AED1-1AA1CB8F0F6A%7D&file=128-JM-3804379-PHV.docx&action=default&mobileredirect=true&DefaultItemOpen=1), [\[20250113_K...f Workshop | PowerPoint\]](https://boehringer.sharepoint.com/sites/z365bihivecoreteam/_layouts/15/Doc.aspx?sourcedoc=%7B6CF5BFA1-C363-4868-B1D6-57BED907D01B%7D&file=20250113_Kick-Off%20Workshop.pptx&action=edit&mobileredirect=true&DefaultItemOpen=1)                                                                 |

**BI 3804379**

| Änderung | Beschreibung                                                                                         | Evidenz                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| -------- | ---------------------------------------------------------------------------------------------------- | --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- |
| NONE     | **product\_code**: Unverändert.                                                                      | —                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| NONE     | **product\_name**: Unverändert (nicht offen gelegt).                                                 | —                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| NONE     | **modality\_name**: „Recombinant Proteins“ (mAb) bleibt korrekt.                                     | NBE‑Portfolio listet anti‑IL11 als Biologikum. [\[OneOps_Lea...date_May25 | PowerPoint\]](https://boehringer.sharepoint.com/sites/z365bihivecoreteam/_layouts/15/Doc.aspx?sourcedoc=%7B66D10F99-D59E-4D98-9706-A1081917D157%7D&file=OneOps_Leadership_Update_May25.pptx&action=edit&mobileredirect=true&DefaultItemOpen=1)                                                                                                                                                                                                                                                                                                                    |
| NONE     | **product\_type**: „NBE“ unverändert.                                                                | —                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| NONE     | **therapeutic\_area**: CRM/MASH bestätigt.                                                           | [3. TA CRM pipeline\_DM2035 HR.pptx](https://boehringer.sharepoint.com/sites/z365usmedicinecapabilitiesexcellence/_layouts/15/Doc.aspx?sourcedoc=%7B57525F5F-26A8-4CA1-BF70-4F9C3A08E15D%7D\&file=3.%20TA%20CRM%20pipeline_DM2035%20HR.pptx\&action=edit\&mobileredirect=true\&DefaultItemOpen=1\&EntityRepresentationId=76041a2f-f0f6-411a-9439-c467283ae431). [\[20250113_K...f Workshop | PowerPoint\]](https://boehringer.sharepoint.com/sites/z365bihivecoreteam/_layouts/15/Doc.aspx?sourcedoc=%7B6CF5BFA1-C363-4868-B1D6-57BED907D01B%7D&file=20250113_Kick-Off%20Workshop.pptx&action=edit&mobileredirect=true&DefaultItemOpen=1)                       |
| MAJOR    | **mechanism\_of\_action**: „Not specified“ → **Anti‑IL11**.                                          | Mehrere interne Portfolios/Teams nennen explizit „anti‑IL11“. [\[OneOps_Lea...date_May25 | PowerPoint\]](https://boehringer.sharepoint.com/sites/z365bihivecoreteam/_layouts/15/Doc.aspx?sourcedoc=%7B66D10F99-D59E-4D98-9706-A1081917D157%7D&file=OneOps_Leadership_Update_May25.pptx&action=edit&mobileredirect=true&DefaultItemOpen=1), [\[128-JM-3804379-A-DS | Word\]](https://boehringer.sharepoint.com/sites/z365plattformdokumentenreviewadb/_layouts/15/Doc.aspx?sourcedoc=%7B1C8B178F-05EB-40F4-A241-7C8063EC23EB%7D&file=128-JM-3804379-A-DS.docx&action=default&mobileredirect=true&DefaultItemOpen=1)                                              |
| NONE     | **short\_description**: „Injectable Protein für MASH“ kann bestehen bleiben (wird unten präzisiert). | —                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| NONE     | **dosage\_form**: „Injectable“ bleibt korrekt.                                                       | —                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| MINOR    | **route\_of\_administration**: Ergänzen zu „SC und IV“ (beide RoA vorgesehen).                       | CMC‑Spezifikation nennt **s.c./i.v.**, Phase‑I aktiv. [\[bi3804379-...-17Oct2025 | Word\]](https://boehringer.sharepoint.com/sites/z365icfsafetylaylanguage/_layouts/15/Doc.aspx?sourcedoc=%7BB2AFC0FB-0D7D-4EDD-B813-E26C6C5EF0C0%7D&file=bi3804379-1524-p1-asset-icf-safety-17Oct2025.docx&action=default&mobileredirect=true&DefaultItemOpen=1)                                                                                                                                                                                                                                                                                                                                                  |
| NONE     | **base\_technology**: „Mammalian“ kann bestehen bleiben (mAb‑typisch).                               | —                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| MAJOR    | **current\_phase**: „Discontinued“ → **Phase I (laufend)**.                                          | ICF‑/Sicherheitsdokument (2025) & IMPD V01; aktive Entwicklung. [\[IMPD BI 38...th. review | PDF\]](https://boehringer.sharepoint.com/sites/z365globalmasterdossier/Shared%20Documents/Biotechnology%20%20Guidances/00.%20Recent%20Example%20Documents/CTA%20Recent%20Example%20Documents/Phase%201/IMPD%20BI%203804379%20(1524-0001)%20V01%203.06.2024%20-%20under%20auth.%20review.pdf?web=1), [\[2023_07_28...r Peptides | PDF\]](https://boehringer.sharepoint.com/sites/z365ntmexpertpanel89/Shared%20Documents/Apps/Yammer/2023_07_28%20HDE%20for%20Peptides.pdf?web=1) |

**BI 3906517**

| Änderung | Beschreibung                                                                                             | Evidenz                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| -------- | -------------------------------------------------------------------------------------------------------- | -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- |
| NONE     | **product\_code**: Unverändert.                                                                          | —                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| NONE     | **product\_name**: Unverändert (nicht offen gelegt).                                                     | —                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| MAJOR    | **modality\_name**: „Small Molecule“ → **Peptid (LG3RA; long‑acting Triple‑Agonist)**.                   | HDE‑Dokument „for Peptides“ rechnet explizit mit **BI 3906517** als LG3R‑Peptid; Peptid‑Pipeline listet LG3RA. [\[NCE Portfo...oph Kreher | PowerPoint\]](https://boehringer.sharepoint.com/sites/z365qualityexcellenceprogram/_layouts/15/Doc.aspx?sourcedoc=%7B402342F1-21F0-471B-86C8-EF4BD176C2E9%7D&file=NCE%20Portfolio_Christoph%20Kreher.pptx&action=edit&mobileredirect=true&DefaultItemOpen=1), [\[Session 1...ufacturing | PowerPoint\]](https://boehringer.sharepoint.com/sites/z365giamsteeringcommittees/_layouts/15/Doc.aspx?sourcedoc=%7B4ED4B439-32CD-4C99-BC6B-D84F2CA34570%7D&file=Session%201%20-%20Engelbrecht%20%26%20Mitic%20-%20Recombinant%20Peptide%20Manufacturing.pptx&action=edit&mobileredirect=true&DefaultItemOpen=1)                                                                                                                                                                                                                                       |
| NONE     | **product\_type**: „NME“ kann bestehen bleiben (BI führt Peptide teils unter NCE/NME).                   | Peptid‑NCE‑Überblicke. [\[V&A Dashboard CM | PowerPoint\]](https://boehringer.sharepoint.com/sites/z365pricingandcontractingoncology/_layouts/15/Doc.aspx?sourcedoc=%7BA4094F80-ECEF-4299-BB44-1292B202EF16%7D&file=V%26A%20Dashboard%20CM.pptx&action=edit&mobileredirect=true&DefaultItemOpen=1)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| NONE     | **therapeutic\_area**: CRM bestätigt.                                                                    | —                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| MAJOR    | **mechanism\_of\_action**: „LG3RA (Leptinrezeptor‑Antagonist)“ → **Triple‑Agonist an GCGR/GIPR/GLP‑1R**. | V\&A‑Dashboards beschreiben BI 3906517 klar als **GCGR/GIPR/GLP‑1R‑Agonist** (reduzierte GLP‑1‑Komponente). [\[V&A Dashboard for CM | PowerPoint\]](https://boehringer.sharepoint.com/sites/z365pricingandcontractingoncology/_layouts/15/Doc.aspx?sourcedoc=%7BC3D3C13B-38F7-4F60-B82E-E85A02588562%7D&file=V%26A%20Dashboard%20for%20CM.pptx&action=edit&mobileredirect=true&DefaultItemOpen=1), [\[26_Scheure...odeling BW | PowerPoint\]](https://boehringer.sharepoint.com/sites/z365ntmexpertpanel89/_layouts/15/Doc.aspx?sourcedoc=%7BF3CDED8D-4DE5-4663-88D1-EBB00CE2CECE%7D&file=26_Scheurer_PKPD%20modeling%20BW.pptx&action=edit&mobileredirect=true&DefaultItemOpen=1)                                                                                                                                                                                              |
| MAJOR    | **short\_description**: Anpassen auf „Long‑acting Triple‑Agonist für Adipositas“.                        | s. oben. [\[V&A Dashboard for CM | PowerPoint\]](https://boehringer.sharepoint.com/sites/z365pricingandcontractingoncology/_layouts/15/Doc.aspx?sourcedoc=%7BC3D3C13B-38F7-4F60-B82E-E85A02588562%7D&file=V%26A%20Dashboard%20for%20CM.pptx&action=edit&mobileredirect=true&DefaultItemOpen=1)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| MINOR    | **dosage\_form**: Ergänzen zu „Injectable“ (Peptid‑QW‑Dosis/HLE‑Auslegung).                              | Peptid‑HDE (QW‑Dosis) – konsistent mit parenteraler Peptidgabe. [\[NCE Portfo...oph Kreher | PowerPoint\]](https://boehringer.sharepoint.com/sites/z365qualityexcellenceprogram/_layouts/15/Doc.aspx?sourcedoc=%7B402342F1-21F0-471B-86C8-EF4BD176C2E9%7D&file=NCE%20Portfolio_Christoph%20Kreher.pptx&action=edit&mobileredirect=true&DefaultItemOpen=1)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| MINOR    | **route\_of\_administration**: Ergänzen zu „SC (subkutan)“\* (auf Basis Peptid‑Klasse/Planung).          | LG3RA‑PK/PD/Peptid‑Decks (Abk. s.c.) – klinische Bestätigung ausstehend. [\[RPC Watch | Excel\]](https://boehringer.sharepoint.com/sites/z365srmigintpr/_layouts/15/Doc.aspx?sourcedoc=%7B2E571D2C-145A-450A-80FD-5D516B548F8F%7D&file=RPC%20Watch.xlsx&action=default&mobileredirect=true&DefaultItemOpen=1)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| MINOR    | **base\_technology**: Ergänzen zu „Long‑acting Peptid mit Half‑Life‑Extension (HLE)“.                    | HDE/PK‑Modelle nennen neue **HLE‑Modalität** für LG3RA. [\[RPC Watch | Excel\]](https://boehringer.sharepoint.com/sites/z365srmigintpr/_layouts/15/Doc.aspx?sourcedoc=%7B2E571D2C-145A-450A-80FD-5D516B548F8F%7D&file=RPC%20Watch.xlsx&action=default&mobileredirect=true&DefaultItemOpen=1)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| MAJOR    | **current\_phase**: „Discontinued“ → **aktiv (pre‑SoD/Preclinical; SoD‑Vorbereitung)**.                  | V\&A‑Dashboards: SoD‑Begründung/PoCP‑Setup; RPC‑Watch: „Path to SoD“. [\[V&A Dashboard for CM | PowerPoint\]](https://boehringer.sharepoint.com/sites/z365pricingandcontractingoncology/_layouts/15/Doc.aspx?sourcedoc=%7BC3D3C13B-38F7-4F60-B82E-E85A02588562%7D&file=V%26A%20Dashboard%20for%20CM.pptx&action=edit&mobileredirect=true&DefaultItemOpen=1) |

\* Wenn eine spezifische RoA noch nicht offiziell beschlossen ist, bitte als „TBD“ belassen; die Evidenzlage (Peptid‑HDE, QW‑Dosis) spricht jedoch stark für SC. [\[NCE Portfo...oph Kreher | PowerPoint\]](https://boehringer.sharepoint.com/sites/z365qualityexcellenceprogram/_layouts/15/Doc.aspx?sourcedoc=%7B402342F1-21F0-471B-86C8-EF4BD176C2E9%7D&file=NCE%20Portfolio_Christoph%20Kreher.pptx&action=edit&mobileredirect=true&DefaultItemOpen=1)

**BI 1356225 — Not disclosed**

| Feld                      | Änderung | Beschreibung                                                                                                                                         | Evidenz                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| ------------------------- | -------- | ---------------------------------------------------------------------------------------------------------------------------------------------------- | --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- |
| product\_code             | NONE     | Unverändert: BI 1356225.                                                                                                                             | —                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| product\_name             | NONE     | Kein offizieller Name verfügbar („Not disclosed“).                                                                                                   | —                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| modality\_name            | NONE     | Korrekt: Small Molecule.                                                                                                                             | Interne Asset-Narrative & Decks bestätigen kleine chemische Substanz. [BI 1356225 GOATi\_Asset Narrative\_06Nov2023.docx](https://boehringer.sharepoint.com/sites/z365fishawackcns/_layouts/15/Doc.aspx?sourcedoc=%7B095CD1BA-2D99-48FC-BA16-9930CAD18EEA%7D\&file=BI%201356225%20GOATi_Asset%20Narrative_06Nov2023.docx\&action=default\&mobileredirect=true\&DefaultItemOpen=1\&EntityRepresentationId=44aa7baa-b195-4905-9022-dac557c0a2cd) [\[BI 1356225..._06Nov2023 | Word\]](https://boehringer.sharepoint.com/sites/z365fishawackcns/_layouts/15/Doc.aspx?sourcedoc=%7B095CD1BA-2D99-48FC-BA16-9930CAD18EEA%7D&file=BI%201356225%20GOATi_Asset%20Narrative_06Nov2023.docx&action=default&mobileredirect=true&DefaultItemOpen=1)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| product\_type             | NONE     | Korrekt: NME.                                                                                                                                        | [BI 1356225 – GOATi\_TALC Update 11 March 2021\_Presentation Final.pptx](https://boehringer.sharepoint.com/sites/z365onecmrcipipelineproducts/_layouts/15/Doc.aspx?sourcedoc=%7B5B4C8FB7-B1D3-4269-8346-5043656E4E1C%7D\&file=BI%201356225%20%E2%80%93%20GOATi_TALC%20Update%2011%20March%202021_Presentation%20Final.pptx\&action=edit\&mobileredirect=true\&DefaultItemOpen=1\&EntityRepresentationId=899d7bea-0d31-45bf-bf54-ec5be57c9af9) (Projekt als NCE/NME geführt) [\[BI 1356225...tion Final | PowerPoint\]](https://boehringer.sharepoint.com/sites/z365onecmrcipipelineproducts/_layouts/15/Doc.aspx?sourcedoc=%7B5B4C8FB7-B1D3-4269-8346-5043656E4E1C%7D&file=BI%201356225%20%E2%80%93%20GOATi_TALC%20Update%2011%20March%202021_Presentation%20Final.pptx&action=edit&mobileredirect=true&DefaultItemOpen=1)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| therapeutic\_area         | MINOR    | Von „Mental Health; CRM“ auf **Mental Health (Impulsivity in Substance Use Disorder)** anpassen; frühere CRM/Obesity-Positionierung ist eingestellt. | Repositionierung zu Impulsivität/SUD (IUPC 07/2024). [GOATi\_IUPC\_PreReads\_July2024.pptx](https://boehringer.sharepoint.com/sites/z365fishawackcns/_layouts/15/Doc.aspx?sourcedoc=%7BF3EB44FA-F052-4C27-A422-2C304620F350%7D\&file=GOATi_IUPC_PreReads_July2024.pptx\&action=edit\&mobileredirect=true\&DefaultItemOpen=1\&EntityRepresentationId=575d1ba6-19ba-4ca2-892f-ebd4f15660e8) [\[GOATi_IUPC...s_July2024 | PowerPoint\]](https://boehringer.sharepoint.com/sites/z365fishawackcns/_layouts/15/Doc.aspx?sourcedoc=%7BF3EB44FA-F052-4C27-A422-2C304620F350%7D&file=GOATi_IUPC_PreReads_July2024.pptx&action=edit&mobileredirect=true&DefaultItemOpen=1)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| mechanism\_of\_action     | NONE     | Korrekt: **GOAT (Ghrelin O‑acyltransferase) inhibitor**.                                                                                             | [BI 1356225 GOATi\_Asset Narrative\_06Nov2023.docx](https://boehringer.sharepoint.com/sites/z365fishawackcns/_layouts/15/Doc.aspx?sourcedoc=%7B095CD1BA-2D99-48FC-BA16-9930CAD18EEA%7D\&file=BI%201356225%20GOATi_Asset%20Narrative_06Nov2023.docx\&action=default\&mobileredirect=true\&DefaultItemOpen=1\&EntityRepresentationId=44aa7baa-b195-4905-9022-dac557c0a2cd) [\[BI 1356225..._06Nov2023 | Word\]](https://boehringer.sharepoint.com/sites/z365fishawackcns/_layouts/15/Doc.aspx?sourcedoc=%7B095CD1BA-2D99-48FC-BA16-9930CAD18EEA%7D&file=BI%201356225%20GOATi_Asset%20Narrative_06Nov2023.docx&action=default&mobileredirect=true&DefaultItemOpen=1)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| short\_description        | MINOR    | Aktualisieren auf: „Oraler GOAT‑Inhibitor zur Reduktion von Impulsivität bei **Opioid‑Use‑Disorder**; Präzisionspsychiatrie‑Ansatz.“                 | Programmfokus Impulsivität/OUD; internes MH‑Pipeline‑Deck. [SC-US-77992-Boehringer-Ingelheim-Mental-Health-Pipeline-February-2025.pptx](https://boehringer.sharepoint.com/sites/mybi_tacns/_layouts/15/Doc.aspx?sourcedoc=%7B07EE3AEC-BF51-44EE-AD29-8AECE2D6C1F6%7D\&file=SC-US-77992-Boehringer-Ingelheim-Mental-Health-Pipeline-February-2025.pptx\&action=edit\&mobileredirect=true\&DefaultItemOpen=1\&EntityRepresentationId=5066272d-f1b6-4349-8c5e-40ebc8d0a162) [\[SC-US-7799...ruary-2025 | PowerPoint\]](https://boehringer.sharepoint.com/sites/mybi_tacns/_layouts/15/Doc.aspx?sourcedoc=%7B07EE3AEC-BF51-44EE-AD29-8AECE2D6C1F6%7D&file=SC-US-77992-Boehringer-Ingelheim-Mental-Health-Pipeline-February-2025.pptx&action=edit&mobileredirect=true&DefaultItemOpen=1)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| dosage\_form              | MINOR    | Ergänzen: **Film‑coated tablets (2.5/10 mg, Formulierung A1)** und **Powder for oral solution (20 mg)** existieren; aktuelle Studien oral.           | Formulierungs‑ und STORM‑Doks. BI 1356225 Film-coated tablets 2.5 mg, 10 mg (Formulation A1) and placebo; BI 1356225 Powder for oral solution 20 mg; STORM\_BI 1356225\_1427-0001 [\[BI 1356225...nd placebo | Extern\]](https://bi-docs-vault-quality.veevavault.com/ui/#doc_info/1216206), [\[BI 1356225...tion 20 mg | Extern\]](https://bi-docs-vault-quality.veevavault.com/ui/#doc_info/1223589), [\[STORM_BI 1..._1427-0001 | Extern\]](https://bi-docs-vault-quality.veevavault.com/ui/#doc_info/1238752)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| route\_of\_administration | NONE     | Korrekt: **Oral**.                                                                                                                                   | Studienmaterial/Instruktionen bestätigen oral. STORM\_BI 1356225\_1427-0002 [\[STORM_BI 1..._1427-0002 | Extern\]](https://bi-docs-vault-quality.veevavault.com/ui/#doc_info/1259981)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| base\_technology          | MINOR    | Präzisieren: **Solid oral DP (film‑coated tablet; PfOS verfügbar)**; spezifischer Fertigungsprozess nicht final öffentlich dokumentiert.             | Herstell-/Handover‑Anhänge zeigen Spezifikationen, nicht aber eine feste Prozesstechnologie. Attachment 12 to Handover Document for BI 3000202… (analoges Format); [BI 1356225\_BIEL\_Assessment\_2023\_12\_13.pdf](https://boehringer.sharepoint.com/sites/z365ridgefieldenvironmentalhealthandsafetymybi/EHS%20Documents/Environmental/Environmental%20Risk%20Assessments/Product%20Environmental%20Risk%20Assessment/INDs/BI%201356225%20%20%28GOATi%29/BI%201356225_BIEL_Assessment_2023_12_13.pdf?web=1\&EntityRepresentationId=b91e0356-c2b6-41ab-bb9e-53522d4b0fc2) (Entwicklungsstand) [\[Attachment...n Phase I) | Extern\]](https://bi-docs-vault-quality.veevavault.com/ui/#doc_info/1231286), [\[BI 1356225...2023_12_13 | PDF\]](https://boehringer.sharepoint.com/sites/z365ridgefieldenvironmentalhealthandsafetymybi/EHS%20Documents/Environmental/Environmental%20Risk%20Assessments/Product%20Environmental%20Risk%20Assessment/INDs/BI%201356225%20%20(GOATi)/BI%201356225_BIEL_Assessment_2023_12_13.pdf?web=1)                                                                                                                                                                                                                                                                                                                                                                    |
| current\_phase            | MAJOR    | Von „Discontinued“ auf **Phase I (klinisch, Proof‑of‑Principle)** ändern; Phase‑1b‑Studie in OUD **rekrutiert**.                                     | MH‑Pipeline (NCT06628622, rekrutierend) & interner Status. [SC-US-77992-Boehringer-Ingelheim-Mental-Health-Pipeline-February-2025.pptx](https://boehringer.sharepoint.com/sites/mybi_tacns/_layouts/15/Doc.aspx?sourcedoc=%7B07EE3AEC-BF51-44EE-AD29-8AECE2D6C1F6%7D\&file=SC-US-77992-Boehringer-Ingelheim-Mental-Health-Pipeline-February-2025.pptx\&action=edit\&mobileredirect=true\&DefaultItemOpen=1\&EntityRepresentationId=5066272d-f1b6-4349-8c5e-40ebc8d0a162); [GOAT needs assessment\_21March\_AS.pptx](https://boehringer.sharepoint.com/sites/z365fishawackcns/_layouts/15/Doc.aspx?sourcedoc=%7BD3318005-3E79-4C0B-8BBB-B8E914BCD6B1%7D\&file=GOAT%20needs%20assessment_21March_AS.pptx\&action=edit\&mobileredirect=true\&DefaultItemOpen=1\&EntityRepresentationId=d5eadb27-eedb-436f-98a3-41e3b6d1e5a0) [\[SC-US-7799...ruary-2025 | PowerPoint\]](https://boehringer.sharepoint.com/sites/mybi_tacns/_layouts/15/Doc.aspx?sourcedoc=%7B07EE3AEC-BF51-44EE-AD29-8AECE2D6C1F6%7D&file=SC-US-77992-Boehringer-Ingelheim-Mental-Health-Pipeline-February-2025.pptx&action=edit&mobileredirect=true&DefaultItemOpen=1), [\[GOAT needs...21March_AS | PowerPoint\]](https://boehringer.sharepoint.com/sites/z365fishawackcns/_layouts/15/Doc.aspx?sourcedoc=%7BD3318005-3E79-4C0B-8BBB-B8E914BCD6B1%7D&file=GOAT%20needs%20assessment_21March_AS.pptx&action=edit&mobileredirect=true&DefaultItemOpen=1) |

***

**BI 3031185 — Not disclosed**

| Feld                      | Änderung | Beschreibung                                                                                                                | Evidenz                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| ------------------------- | -------- | --------------------------------------------------------------------------------------------------------------------------- | ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- |
| product\_code             | NONE     | Unverändert: BI 3031185.                                                                                                    | —                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| product\_name             | NONE     | Kein offizieller Name verfügbar.                                                                                            | —                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| modality\_name            | NONE     | Korrekt: Small Molecule.                                                                                                    | [FINAL-1.0\_Impulsivity-Core-Slide-Deck\_27Jan2025.pptx](https://boehringer.sharepoint.com/sites/mybi_tacns/_layouts/15/Doc.aspx?sourcedoc=%7BA840E437-5C2A-41A3-9AA8-613D1227F8FE%7D\&file=FINAL-1.0_Impulsivity-Core-Slide-Deck_27Jan2025.pptx\&action=edit\&mobileredirect=true\&DefaultItemOpen=1\&EntityRepresentationId=4d9c6aa1-5777-4ad4-a8fc-e12676c7eb4b) [\[FINAL-1.0_..._27Jan2025 | PowerPoint\]](https://boehringer.sharepoint.com/sites/mybi_tacns/_layouts/15/Doc.aspx?sourcedoc=%7BA840E437-5C2A-41A3-9AA8-613D1227F8FE%7D&file=FINAL-1.0_Impulsivity-Core-Slide-Deck_27Jan2025.pptx&action=edit&mobileredirect=true&DefaultItemOpen=1)                         |
| product\_type             | NONE     | Korrekt: NME.                                                                                                               | [01\_2025\_03 BRM Pipeline Folien.pdf](https://boehringer-my.sharepoint.com/personal/oliver_gluth_boehringer-ingelheim_com/Documents/BI%20-%20Work/01_PROJECTS/2025_iManagement-private/02%20Pipeline/LLM/01_2025_03%20BRM%20Pipeline%20Folien.pdf?web=1\&EntityRepresentationId=7afa8292-b88f-4272-b389-41c151119585) (Pipeline‑Tabellen) [\[01_2025_03...ine Folien | PDF\]](https://boehringer-my.sharepoint.com/personal/oliver_gluth_boehringer-ingelheim_com/Documents/BI%20-%20Work/01_PROJECTS/2025_iManagement-private/02%20Pipeline/LLM/01_2025_03%20BRM%20Pipeline%20Folien.pdf?web=1)                                                                         |
| therapeutic\_area         | NONE     | Korrekt: **Mental Health (Impulsivity)**.                                                                                   | Core‑Deck Impulsivität. [FINAL-1.0\_Impulsivity-Core-Slide-Deck\_27Jan2025.pptx](https://boehringer.sharepoint.com/sites/mybi_tacns/_layouts/15/Doc.aspx?sourcedoc=%7BA840E437-5C2A-41A3-9AA8-613D1227F8FE%7D\&file=FINAL-1.0_Impulsivity-Core-Slide-Deck_27Jan2025.pptx\&action=edit\&mobileredirect=true\&DefaultItemOpen=1\&EntityRepresentationId=4d9c6aa1-5777-4ad4-a8fc-e12676c7eb4b) [\[FINAL-1.0_..._27Jan2025 | PowerPoint\]](https://boehringer.sharepoint.com/sites/mybi_tacns/_layouts/15/Doc.aspx?sourcedoc=%7BA840E437-5C2A-41A3-9AA8-613D1227F8FE%7D&file=FINAL-1.0_Impulsivity-Core-Slide-Deck_27Jan2025.pptx&action=edit&mobileredirect=true&DefaultItemOpen=1) |
| mechanism\_of\_action     | NONE     | Korrekt: **mGluR4 NAM**.                                                                                                    | [Medical(1).aspx](https://boehringer.sharepoint.com/sites/mybi_tacns/SitePages/Medical%281%29.aspx?web=1\&EntityRepresentationId=f4dc5037-903a-4247-a767-8c948147dde4) (Medical Ressource Seite) [\[Medical | SharePoint\]](https://boehringer.sharepoint.com/sites/mybi_tacns/SitePages/Medical(1).aspx?web=1)                                                                                                                                                                                                                                                                                                                                              |
| short\_description        | NONE     | Beschreibung ist konsistent (mGluR4‑NAM für Impulsivität).                                                                  | [FINAL-1.0\_Impulsivity-Core-Slide-Deck\_27Jan2025.pptx](https://boehringer.sharepoint.com/sites/mybi_tacns/_layouts/15/Doc.aspx?sourcedoc=%7BA840E437-5C2A-41A3-9AA8-613D1227F8FE%7D\&file=FINAL-1.0_Impulsivity-Core-Slide-Deck_27Jan2025.pptx\&action=edit\&mobileredirect=true\&DefaultItemOpen=1\&EntityRepresentationId=4d9c6aa1-5777-4ad4-a8fc-e12676c7eb4b) [\[FINAL-1.0_..._27Jan2025 | PowerPoint\]](https://boehringer.sharepoint.com/sites/mybi_tacns/_layouts/15/Doc.aspx?sourcedoc=%7BA840E437-5C2A-41A3-9AA8-613D1227F8FE%7D&file=FINAL-1.0_Impulsivity-Core-Slide-Deck_27Jan2025.pptx&action=edit&mobileredirect=true&DefaultItemOpen=1)                         |
| dosage\_form              | MINOR    | Präzisieren: **oral solide Darreichung geplant**; finale Tabletten‑Specs stehen präklinisch typischerweise noch nicht fest. | Programmstatus präklinisch; keine finalen DP‑Spezifikationen publiziert. [01\_2025\_03 BRM Pipeline Folien.pdf](https://boehringer-my.sharepoint.com/personal/oliver_gluth_boehringer-ingelheim_com/Documents/BI%20-%20Work/01_PROJECTS/2025_iManagement-private/02%20Pipeline/LLM/01_2025_03%20BRM%20Pipeline%20Folien.pdf?web=1\&EntityRepresentationId=7afa8292-b88f-4272-b389-41c151119585) [\[01_2025_03...ine Folien | PDF\]](https://boehringer-my.sharepoint.com/personal/oliver_gluth_boehringer-ingelheim_com/Documents/BI%20-%20Work/01_PROJECTS/2025_iManagement-private/02%20Pipeline/LLM/01_2025_03%20BRM%20Pipeline%20Folien.pdf?web=1)                    |
| route\_of\_administration | NONE     | Korrekt (geplant): **Oral**.                                                                                                | Pipeline‑Übersichten zeigen orale NCE‑Programme im MH‑Cluster. [2025\_03 BRM Pipeline Folie.pptx](https://boehringer-my.sharepoint.com/personal/oliver_gluth_boehringer-ingelheim_com/Documents/BI%20-%20Work/01_PROJECTS/2025_iManagement-private/02%20Pipeline/2025_03%20BRM%20Pipeline%20Folie.pptx?web=1\&EntityRepresentationId=707ca9d0-53e6-4077-b4a7-e3317d212147) [\[2025_03 BR...line Folie | PowerPoint\]](https://boehringer-my.sharepoint.com/personal/oliver_gluth_boehringer-ingelheim_com/Documents/BI%20-%20Work/01_PROJECTS/2025_iManagement-private/02%20Pipeline/2025_03%20BRM%20Pipeline%20Folie.pptx?web=1)                                                |
| base\_technology          | NONE     | Keine Änderung: Technologie TBD in Präklinik.                                                                               | Pipeline‑Folie ohne DP‑Technologieangabe. [01\_2025\_03 BRM Pipeline Folien.pdf](https://boehringer-my.sharepoint.com/personal/oliver_gluth_boehringer-ingelheim_com/Documents/BI%20-%20Work/01_PROJECTS/2025_iManagement-private/02%20Pipeline/LLM/01_2025_03%20BRM%20Pipeline%20Folien.pdf?web=1\&EntityRepresentationId=7afa8292-b88f-4272-b389-41c151119585) [\[01_2025_03...ine Folien | PDF\]](https://boehringer-my.sharepoint.com/personal/oliver_gluth_boehringer-ingelheim_com/Documents/BI%20-%20Work/01_PROJECTS/2025_iManagement-private/02%20Pipeline/LLM/01_2025_03%20BRM%20Pipeline%20Folien.pdf?web=1)                                                   |
| current\_phase            | NONE     | Korrekt: **Pre‑Clinical**.                                                                                                  | [01\_2025\_03 BRM Pipeline Folien.pdf](https://boehringer-my.sharepoint.com/personal/oliver_gluth_boehringer-ingelheim_com/Documents/BI%20-%20Work/01_PROJECTS/2025_iManagement-private/02%20Pipeline/LLM/01_2025_03%20BRM%20Pipeline%20Folien.pdf?web=1\&EntityRepresentationId=7afa8292-b88f-4272-b389-41c151119585) [\[01_2025_03...ine Folien | PDF\]](https://boehringer-my.sharepoint.com/personal/oliver_gluth_boehringer-ingelheim_com/Documents/BI%20-%20Work/01_PROJECTS/2025_iManagement-private/02%20Pipeline/LLM/01_2025_03%20BRM%20Pipeline%20Folien.pdf?web=1)                                                                                             |

***

**BI 3776528 — Not disclosed**

| Feld                      | Änderung | Beschreibung                                                                                                     | Evidenz                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| ------------------------- | -------- | ---------------------------------------------------------------------------------------------------------------- | ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ |
| product\_code             | NONE     | Unverändert: BI 3776528.                                                                                         | —                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| product\_name             | NONE     | Kein offizieller Name verfügbar.                                                                                 | —                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| modality\_name            | NONE     | Korrekt: Small Molecule.                                                                                         | Interne CoAs/JM DS zeigen niedermolekulare DS‑Spezifikationen. CoA\_BI 3776528 SC\_Lot-304658\_True Copy [\[CoA_BI 377...Lot-304658 | Extern\]](https://bi-docs-vault-quality.veevavault.com/ui/#doc_info/1218639)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| product\_type             | NONE     | Korrekt: NME.                                                                                                    | Projektlisten/Asset‑Narrative. [Project\_Liste.xlsx](https://boehringer.sharepoint.com/sites/z365srmigqrmcssdg/_layouts/15/Doc.aspx?sourcedoc=%7B1860E305-1EAB-4C35-9B4A-6C8823D682B4%7D\&file=Project_Liste.xlsx\&action=default\&mobileredirect=true\&DefaultItemOpen=1\&EntityRepresentationId=e1258a17-e92f-4456-a541-b3d92d03c166) [\[Project_Liste | Excel\]](https://boehringer.sharepoint.com/sites/z365srmigqrmcssdg/_layouts/15/Doc.aspx?sourcedoc=%7B1860E305-1EAB-4C35-9B4A-6C8823D682B4%7D&file=Project_Liste.xlsx&action=default&mobileredirect=true&DefaultItemOpen=1)                                                                                                                                                                                                                                                                                                          |
| therapeutic\_area         | MINOR    | Präzisieren: **Mental Health – Cognitive impairment in PSD/Schizophrenia** (nicht nur „Post‑Stroke Depression“). | Asset‑Narrative (SSTR4 für kognitive Defizite, inkl. SCZ/PSD). [Asset-Medical-Narrative---BI-3776528---v-1.0---Mar2023.pdf](https://boehringer.sharepoint.com/sites/mybi_tacns/SiteAssets/SitePages/Our-early/Asset-Medical-Narrative---BI-3776528---v-1.0---Mar2023.pdf?web=1\&EntityRepresentationId=f8714001-a3b5-4f31-8d8e-37571389e1a7) [\[Asset-Medi...---Mar2023 | PDF\]](https://boehringer.sharepoint.com/sites/mybi_tacns/SiteAssets/SitePages/Our-early/Asset-Medical-Narrative---BI-3776528---v-1.0---Mar2023.pdf?web=1)                                                                                                                                                                                                                                                                                                                                                                   |
| mechanism\_of\_action     | NONE     | Korrekt: **SSTR4 agonist**.                                                                                      | [Asset-Medical-Narrative---BI-3776528---v-1.0---Mar2023.pdf](https://boehringer.sharepoint.com/sites/mybi_tacns/SiteAssets/SitePages/Our-early/Asset-Medical-Narrative---BI-3776528---v-1.0---Mar2023.pdf?web=1\&EntityRepresentationId=f8714001-a3b5-4f31-8d8e-37571389e1a7) [\[Asset-Medi...---Mar2023 | PDF\]](https://boehringer.sharepoint.com/sites/mybi_tacns/SiteAssets/SitePages/Our-early/Asset-Medical-Narrative---BI-3776528---v-1.0---Mar2023.pdf?web=1)                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| short\_description        | MINOR    | Aktualisieren: „Oraler **SSTR4‑Agonist** zur Behandlung kognitiver Beeinträchtigung in PSD/SCZ‑Spektrum.“        | [Asset-Medical-Narrative---BI-3776528---v-1.0---Mar2023.pdf](https://boehringer.sharepoint.com/sites/mybi_tacns/SiteAssets/SitePages/Our-early/Asset-Medical-Narrative---BI-3776528---v-1.0---Mar2023.pdf?web=1\&EntityRepresentationId=f8714001-a3b5-4f31-8d8e-37571389e1a7) [\[Asset-Medi...---Mar2023 | PDF\]](https://boehringer.sharepoint.com/sites/mybi_tacns/SiteAssets/SitePages/Our-early/Asset-Medical-Narrative---BI-3776528---v-1.0---Mar2023.pdf?web=1)                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| dosage\_form              | MAJOR    | Von „Tablet“ auf **Capsules (1–40 mg; mit Placebo‑Match)** ändern.                                               | STORM‑Dokument (Produktliste Kapseln 1/4/10/20/40 mg). STORM BI 3776528 1526-0001 [\[STORM BI 3...1526-0001 | Extern\]](https://bi-docs-vault-quality.veevavault.com/ui/#doc_info/2394321?itemid=6o9QLyoJqEzKOcn5yQDwAEmgThPtK6KtXh7KFCmhew)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| route\_of\_administration | NONE     | Korrekt: **Oral**.                                                                                               | Kapsel‑Instruktion/IMP‑Dokus. BI 3776528 Capsule and Solvent for Oral Solution [\[BI 3776528...l Solution | Extern\]](https://bi-docs-vault-quality.veevavault.com/ui/#doc_info/1198818)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| base\_technology          | MINOR    | Präzisieren: **Orale Kapseln** (keine Tabletten‑RC/SDD‑Technologie angegeben).                                   | STORM/CoA belegen Kapseln als Darreichungsform. CoA\_BI 3776528 SC\_SAP-Lot-309675… [\[CoA_BI 377...t-P/008814 | Extern\]](https://bi-docs-vault-quality.veevavault.com/ui/#doc_info/256504?itemid=9sVJd2xKXLVDqhSJOj76dfYRmCC9PjeskDfeeaA)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| current\_phase            | MAJOR    | Von „Discontinued“ auf **Phase I (laufend)** ändern.                                                             | Phase‑I‑Material/ICF 2025; laufende IMP‑Vorbereitung. [bi3776528-1526-p1-icf-safety-03Sep2025.docx](https://boehringer.sharepoint.com/sites/z365icfsafetylaylanguage/_layouts/15/Doc.aspx?sourcedoc=%7B73B3EE6A-C6E0-4815-BD42-CA1DE8E589C8%7D\&file=bi3776528-1526-p1-icf-safety-03Sep2025.docx\&action=default\&mobileredirect=true\&DefaultItemOpen=1\&EntityRepresentationId=e31aca5f-0a28-4f83-99a3-472091b3b19b); Justification of Specification BI 3776528 SC [\[bi3776528-...-03Sep2025 | Word\]](https://boehringer.sharepoint.com/sites/z365icfsafetylaylanguage/_layouts/15/Doc.aspx?sourcedoc=%7B73B3EE6A-C6E0-4815-BD42-CA1DE8E589C8%7D&file=bi3776528-1526-p1-icf-safety-03Sep2025.docx&action=default&mobileredirect=true&DefaultItemOpen=1), [\[Justificat...3776528 SC | Extern\]](https://bi-docs-vault-quality.veevavault.com/ui/#doc_info/1187473?itemid=tok9vvPH3MCT3rpr97DjW1xKVIz1rkMVHJE0vnVnNy4) |

***

**BI 3793898 — Not disclosed**

| Feld                      | Änderung | Beschreibung                                                   | Evidenz                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| ------------------------- | -------- | -------------------------------------------------------------- | -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- |
| product\_code             | NONE     | Unverändert: BI 3793898.                                       | —                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| product\_name             | NONE     | Kein offizieller Name verfügbar.                               | —                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| modality\_name            | NONE     | Korrekt: Small Molecule.                                       | Methodendoks/Validierung (HPLC‑Entwicklung) für niedermolekulare DS. BI 3793898 XX in Methanol [\[BI 3793898...n Methanol | Extern\]](https://bi-docs-vault-quality.veevavault.com/ui/#doc_info/370575)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| product\_type             | NONE     | Korrekt: NME.                                                  | SoD‑Mitteilung (Dez 2023). [138\_Announcement\_SoD\_NISoD\_CNSDR\_CMDR\_IRDR.pdf](https://boehringer.sharepoint.com/sites/mybi_rsg/SiteAssets/SitePages/pldnmzoj/138_Announcement_SoD_NISoD_CNSDR_CMDR_IRDR.pdf?web=1\&EntityRepresentationId=141b3cee-a27a-4c43-8e7c-8d169c52bb5e) [\[138_Announ..._CMDR_IRDR | PDF\]](https://boehringer.sharepoint.com/sites/mybi_rsg/SiteAssets/SitePages/pldnmzoj/138_Announcement_SoD_NISoD_CNSDR_CMDR_IRDR.pdf?web=1)                                                                                                                                                                                                                                                         |
| therapeutic\_area         | NONE     | Korrekt: **Mental Health – CIAS**.                             | Asset‑Narrative (CIAS). [BI-3793898\_CIAS\_HPSC\_2023-11\_Asset-Narrative.docx](https://boehringer.sharepoint.com/sites/mybi_tacns/_layouts/15/Doc.aspx?sourcedoc=%7B9D25A861-2524-49B3-928C-3777885E30EA%7D\&file=BI-3793898_CIAS_HPSC_2023-11_Asset-Narrative.docx\&action=default\&mobileredirect=true\&DefaultItemOpen=1\&EntityRepresentationId=3a6ed855-2eab-4251-af2b-d5ebe23a66a8) [\[BI-3793898...-Narrative | Word\]](https://boehringer.sharepoint.com/sites/mybi_tacns/_layouts/15/Doc.aspx?sourcedoc=%7B9D25A861-2524-49B3-928C-3777885E30EA%7D&file=BI-3793898_CIAS_HPSC_2023-11_Asset-Narrative.docx&action=default&mobileredirect=true&DefaultItemOpen=1)                                             |
| mechanism\_of\_action     | NONE     | Korrekt: **mGluR3 PAM**.                                       | [BI-3793898\_CIAS\_HPSC\_2023-11\_Asset-Narrative.docx](https://boehringer.sharepoint.com/sites/mybi_tacns/_layouts/15/Doc.aspx?sourcedoc=%7B9D25A861-2524-49B3-928C-3777885E30EA%7D\&file=BI-3793898_CIAS_HPSC_2023-11_Asset-Narrative.docx\&action=default\&mobileredirect=true\&DefaultItemOpen=1\&EntityRepresentationId=3a6ed855-2eab-4251-af2b-d5ebe23a66a8) [\[BI-3793898...-Narrative | Word\]](https://boehringer.sharepoint.com/sites/mybi_tacns/_layouts/15/Doc.aspx?sourcedoc=%7B9D25A861-2524-49B3-928C-3777885E30EA%7D&file=BI-3793898_CIAS_HPSC_2023-11_Asset-Narrative.docx&action=default&mobileredirect=true&DefaultItemOpen=1)                                                                     |
| short\_description        | NONE     | Beschreibung stimmt: PAM von mGluR3 für CIAS.                  | [BI-3793898\_CIAS\_HPSC\_2023-11\_Asset-Narrative.docx](https://boehringer.sharepoint.com/sites/mybi_tacns/_layouts/15/Doc.aspx?sourcedoc=%7B9D25A861-2524-49B3-928C-3777885E30EA%7D\&file=BI-3793898_CIAS_HPSC_2023-11_Asset-Narrative.docx\&action=default\&mobileredirect=true\&DefaultItemOpen=1\&EntityRepresentationId=3a6ed855-2eab-4251-af2b-d5ebe23a66a8) [\[BI-3793898...-Narrative | Word\]](https://boehringer.sharepoint.com/sites/mybi_tacns/_layouts/15/Doc.aspx?sourcedoc=%7B9D25A861-2524-49B3-928C-3777885E30EA%7D&file=BI-3793898_CIAS_HPSC_2023-11_Asset-Narrative.docx&action=default&mobileredirect=true&DefaultItemOpen=1)                                                                     |
| dosage\_form              | MINOR    | **TBD (präklinisch)** – keine finale DP‑Form belegt.           | Entwicklungsstand nach SoD; keine DP‑Spezifikation verfügbar. [138\_Announcement\_SoD\_NISoD\_CNSDR\_CMDR\_IRDR.pdf](https://boehringer.sharepoint.com/sites/mybi_rsg/SiteAssets/SitePages/pldnmzoj/138_Announcement_SoD_NISoD_CNSDR_CMDR_IRDR.pdf?web=1\&EntityRepresentationId=141b3cee-a27a-4c43-8e7c-8d169c52bb5e) [\[138_Announ..._CMDR_IRDR | PDF\]](https://boehringer.sharepoint.com/sites/mybi_rsg/SiteAssets/SitePages/pldnmzoj/138_Announcement_SoD_NISoD_CNSDR_CMDR_IRDR.pdf?web=1)                                                                                                                                                                                                                      |
| route\_of\_administration | MINOR    | **Voraussichtlich oral**, final nicht bestätigt (präklinisch). | Präklinische Asset‑Darstellungen; keine klinische DP‑Route fixiert. [BI-3793898\_CIAS\_HPSC\_2023-11\_Asset-Narrative.docx](https://boehringer.sharepoint.com/sites/mybi_tacns/_layouts/15/Doc.aspx?sourcedoc=%7B9D25A861-2524-49B3-928C-3777885E30EA%7D\&file=BI-3793898_CIAS_HPSC_2023-11_Asset-Narrative.docx\&action=default\&mobileredirect=true\&DefaultItemOpen=1\&EntityRepresentationId=3a6ed855-2eab-4251-af2b-d5ebe23a66a8) [\[BI-3793898...-Narrative | Word\]](https://boehringer.sharepoint.com/sites/mybi_tacns/_layouts/15/Doc.aspx?sourcedoc=%7B9D25A861-2524-49B3-928C-3777885E30EA%7D&file=BI-3793898_CIAS_HPSC_2023-11_Asset-Narrative.docx&action=default&mobileredirect=true&DefaultItemOpen=1) |
| base\_technology          | NONE     | **n/a (präklinisch)**.                                         | —                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| current\_phase            | MAJOR    | Von „Discontinued“ auf **Pre‑Clinical (post‑SoD)** ändern.     | SoD‑Bestätigung 12/2023. [138\_Announcement\_SoD\_NISoD\_CNSDR\_CMDR\_IRDR.pdf](https://boehringer.sharepoint.com/sites/mybi_rsg/SiteAssets/SitePages/pldnmzoj/138_Announcement_SoD_NISoD_CNSDR_CMDR_IRDR.pdf?web=1\&EntityRepresentationId=141b3cee-a27a-4c43-8e7c-8d169c52bb5e) [\[138_Announ..._CMDR_IRDR | PDF\]](https://boehringer.sharepoint.com/sites/mybi_rsg/SiteAssets/SitePages/pldnmzoj/138_Announcement_SoD_NISoD_CNSDR_CMDR_IRDR.pdf?web=1)                                                                                                                                                                                                                                                           |

***

**BI 3000202 — Not disclosed**

| Feld                      | Änderung | Beschreibung                                                                                                                    | Evidenz                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| ------------------------- | -------- | ------------------------------------------------------------------------------------------------------------------------------- | ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- |
| product\_code             | NONE     | Unverändert: BI 3000202.                                                                                                        | —                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| product\_name             | NONE     | Kein offizieller Name verfügbar.                                                                                                | —                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| modality\_name            | NONE     | Korrekt: Small Molecule.                                                                                                        | Entwicklungs‑/Analytik‑Doks (niedermolekularer cGAS‑i). BI 3000202 XX Enantiomeric Purity… (002‑MAS‑AR‑22‑01203) [\[BI 3000202...ion Report | Extern\]](https://bi-docs-vault-quality.veevavault.com/ui/#doc_info/1105319)                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| product\_type             | NONE     | Korrekt: NME.                                                                                                                   | IUPD & Pipeline zeigen NCE/NME. IUPD BI 3000202 [\[IUPD BI 3000202 | Extern\]](https://bi-docs-vault-quality.veevavault.com/ui/#doc_info/2522903?itemid=PlzZRyiyTLzVifW3MT6Pi34qmAJyRmmRyq7dVCMb0Yg)                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| therapeutic\_area         | NONE     | Korrekt: **Immunology** (SSc; Interferonopathies).                                                                              | IUPD (SSc/IFN). IUPD BI 3000202 [\[IUPD BI 3000202 | Extern\]](https://bi-docs-vault-quality.veevavault.com/ui/#doc_info/2522903?itemid=PlzZRyiyTLzVifW3MT6Pi34qmAJyRmmRyq7dVCMb0Yg)                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| mechanism\_of\_action     | NONE     | Korrekt: **cGAS inhibitor** (hemmt cGAMP‑Synthese).                                                                             | IUPD (Target/MoA). IUPD BI 3000202 [\[IUPD BI 3000202 | Extern\]](https://bi-docs-vault-quality.veevavault.com/ui/#doc_info/2522903?itemid=PlzZRyiyTLzVifW3MT6Pi34qmAJyRmmRyq7dVCMb0Yg)                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| short\_description        | MINOR    | Präzisieren: „Oraler **cGAS‑Inhibitor** für **SSc** und monogene **Interferonopathien**; potenziell krankheitsmodifizierend.“   | IUPD‑Zusammenfassung. IUPD BI 3000202 [\[IUPD BI 3000202 | Extern\]](https://bi-docs-vault-quality.veevavault.com/ui/#doc_info/2522903?itemid=PlzZRyiyTLzVifW3MT6Pi34qmAJyRmmRyq7dVCMb0Yg)                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| dosage\_form              | MINOR    | Ergänzen/spezifizieren: **Film‑coated tablets (1/10/25/50 mg)** in klinischer Entwicklung.                                      | STORM 1509‑0001/0002/0010/0014 listen Tabletten‑Stärken. STORM\_BI 3000202\_1509-0001; STORM\_BI 3000202\_1509-0002; STORM\_BI 3000202 1509-0010; STORM BI 3000202 1509-0014 [\[STORM_BI 3..._1509-0001 | Extern\]](https://bi-docs-vault-quality.veevavault.com/ui/#doc_info/1234579), [\[STORM_BI 3..._1509-0002 | Extern\]](https://bi-docs-vault-quality.veevavault.com/ui/#doc_info/1221322), [\[Review_Sum...XX_1117291 | Extern\]](https://bi-docs-vault-quality.veevavault.com/ui/#doc_info/2545398?itemid=agPZFqm8ph88B5CABEHBW4iyAFwm1eXjajFOtYrVnQ), [\[STORM BI 3...1509-0014 | Extern\]](https://bi-docs-vault-quality.veevavault.com/ui/#doc_info/2461815?itemid=s4NEj8iLX0QwtqPLD9LcwcMzpynWmRPSQCs5ZXbc0) |
| route\_of\_administration | MAJOR    | Ergänzen: **Oral** (fehlte).                                                                                                    | IUPD & STORM bestätigen orale Gabe. IUPD BI 3000202; STORM\_BI 3000202\_1509-0001 [\[IUPD BI 3000202 | Extern\]](https://bi-docs-vault-quality.veevavault.com/ui/#doc_info/2522903?itemid=PlzZRyiyTLzVifW3MT6Pi34qmAJyRmmRyq7dVCMb0Yg), [\[STORM_BI 3..._1509-0001 | Extern\]](https://bi-docs-vault-quality.veevavault.com/ui/#doc_info/1234579)                                                                                                                                                                                                                                                                                                                              |
| base\_technology          | MAJOR    | Von „Roller Compaction“ auf **„Film‑coated tablet (Phase‑I‑Formulierung), Prozesstechnologie nicht final ausgewiesen“** ändern. | Klinische Handover/Stabilitäts‑Daten belegen FC‑Tabletten; keine belastbare RC‑Angabe. Stability Report … (adult prototypes) TF2; Accelerated Stability Assessment Program (ASAP) … [\[Stability...udy_NonGMP | Extern\]](https://bi-docs-vault-quality.veevavault.com/ui/#doc_info/2472026), [\[Accelerate...rmulations | Extern\]](https://bi-docs-vault-quality.veevavault.com/ui/#doc_info/1248826)                                                                                                                                                                                                                                                                               |
| current\_phase            | MAJOR    | Von „Pre‑Clinical“ auf **Phase I** ändern (mehrere laufende klinische Studien/IMPs).                                            | IUPD (klinischer Status); STORM (klinische Versorgung); GMP‑Statement 09/2025. IUPD BI 3000202; STORM BI 3000202 1509-0014; cGMP Conformance for BI 3000202 XX [\[IUPD BI 3000202 | Extern\]](https://bi-docs-vault-quality.veevavault.com/ui/#doc_info/2522903?itemid=PlzZRyiyTLzVifW3MT6Pi34qmAJyRmmRyq7dVCMb0Yg), [\[STORM BI 3...1509-0014 | Extern\]](https://bi-docs-vault-quality.veevavault.com/ui/#doc_info/2461815?itemid=s4NEj8iLX0QwtqPLD9LcwcMzpynWmRPSQCs5ZXbc0), [\[cGMP Confo...3000202 XX | Extern\]](https://bi-docs-vault-quality.veevavault.com/ui/#doc_info/2555564?itemid=gRYGb5UlZqN8MnRSdYvFM6eci2j7lqka8TWg5iMQKg)                                                     |


**BI 3006337**

| Feld                      | Änderung  | Beschreibung                                                                                                                        | Evidenz                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| ------------------------- | --------- | ----------------------------------------------------------------------------------------------------------------------------------- | ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ |
| product\_code             | NONE      | Unverändert.                                                                                                                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| product\_name             | MINOR     | Auf „Not disclosed; Partner‑Alias: YH25724“ ergänzen (Öffentlich kommunizierter Alias von Yuhan).                                   | [Korea Biomedical Review](https://www.koreabiomed.com/news/articleView.html?idxno=26856); [LARVOL](https://delta.larvol.com/Products/?ProductId=e8d79e5e-2ecd-4df3-a232-091334a594ea)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| modality\_name            | **MAJOR** | Von „Peptides“ auf „Fc‑Fusionsprotein, dualer GLP‑1/FGF21‑Agonist (hyFc)“ ändern.                                                   | Poster 09 - BI 3006337 (GLP-1\_FGF21 dual agonist) clipping investigation with immunocapture-LC\_MS (hyFc‑Struktur) [\[koreabiomed.com\]](https://www.koreabiomed.com/news/articleView.html?idxno=26856); [2023\_NBE Symposium\_Clipping\_updated acknowled\_anonymous.pdf](https://boehringer.sharepoint.com/sites/z365biotherapeuticssymposium/Shared%20Documents/Apps/Microsoft%20Forms/Poster%20Submission%20-%20Biotherapeutics%20Symposium%202023/Question/2023_NBE%20Symposium_Clipping_updated%20acknowled_anonymous.pdf?web=1\&EntityRepresentationId=0536d3b0-9bd0-4633-88b8-80f736f4a5c9) [\[delta.larvol.com\]](https://delta.larvol.com/Products/?ProductId=e8d79e5e-2ecd-4df3-a232-091334a594ea)                           |
| product\_type             | **MAJOR** | Von „NME“ auf „NBE (Biologic)“ ändern – Protein‑Fusionsmolekül, kein Small‑Molecule.                                                | [AEP\_BI 3006337\_MASTERDOC\_V5\_CLEAN\_for\_CEC\_review\_241112.pdf](https://boehringer.sharepoint.com/sites/z365clinicaltrialspatientandsiteengagement/Shared%20Documents/TA%20Inflammation/Trial%20Patient%20and%20Site%20Engagement%20Plans%20Inflammation/AEP_BI%203006337_MASTERDOC_V5_CLEAN_for_CEC_review_241112.pdf?web=1\&EntityRepresentationId=ef848e4c-4c39-49bf-94c4-5950d5f1a258) (Beschreibung als langwirksames Fc‑Fusionsprotein) [\[Poster 09...ture-LC_MS | PDF\]](https://boehringer.sharepoint.com/sites/z365biotherapeuticssymposium/2023_Poster/Poster%2009%20-%20BI%203006337%20(GLP-1_FGF21%20dual%20agonist)%20clipping%20investigation%20%20with%20immunocapture-LC_MS.pdf?web=1)                                                                                                                                                                                                                                                                                                                                                               |
| therapeutic\_area         | NONE      | „CRM“ ist konsistent (MASH‑Programm in CRM).                                                                                        | [3. TA CRM pipeline\_DM2035 HR.pptx](https://boehringer.sharepoint.com/sites/z365usmedicinecapabilitiesexcellence/_layouts/15/Doc.aspx?sourcedoc=%7B57525F5F-26A8-4CA1-BF70-4F9C3A08E15D%7D\&file=3.%20TA%20CRM%20pipeline_DM2035%20HR.pptx\&action=edit\&mobileredirect=true\&DefaultItemOpen=1\&EntityRepresentationId=ff8838dd-df71-4347-962b-a5d672dc8501) (Listung BI 3006337 in MASH) [\[2023_NBE S..._anonymous | PDF\]](https://boehringer.sharepoint.com/sites/z365biotherapeuticssymposium/Shared%20Documents/Apps/Microsoft%20Forms/Poster%20Submission%20-%20Biotherapeutics%20Symposium%202023/Question/2023_NBE%20Symposium_Clipping_updated%20acknowled_anonymous.pdf?web=1)                                                                                                                                                                                                                                                                                                                                                                                                                            |
| mechanism\_of\_action     | NONE      | „GLP‑1/FGF21 agonist.“ ist korrekt (Dual‑Agonist).                                                                                  | SC4-Pitch…BI 3006337 (GLP-1FGF21 dual agonist).pptx [\[AEP_BI 300...iew_241112 | PDF\]](https://boehringer.sharepoint.com/sites/z365clinicaltrialspatientandsiteengagement/Shared%20Documents/TA%20Inflammation/Trial%20Patient%20and%20Site%20Engagement%20Plans%20Inflammation/AEP_BI%203006337_MASTERDOC_V5_CLEAN_for_CEC_review_241112.pdf?web=1)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| short\_description        | **MAJOR** | Von „…dual agonist peptide…“ auf „Langwirksames hyFc‑basiertes duales GLP‑1/FGF21‑Fc‑Fusionsprotein für MASH“ ändern (kein Peptid). | Poster 09 - BI 3006337…LC\_MS.pdf [\[koreabiomed.com\]](https://www.koreabiomed.com/news/articleView.html?idxno=26856); [Biothereapuetics symposium 3006337 protein degradation investigation - final.pptx](https://boehringer.sharepoint.com/sites/z365biotherapeuticssymposium/_layouts/15/Doc.aspx?sourcedoc=%7B48FF9760-D95C-4858-8D2C-9AAB434FB77F%7D\&file=Biothereapuetics%20symposium%203006337%20protein%20degradation%20investigation%20-%20final.pptx\&action=edit\&mobileredirect=true\&DefaultItemOpen=1\&EntityRepresentationId=231f418a-18e0-4891-bef7-025a01caf21b) [\[3. TA CRM..._DM2035 HR | PowerPoint\]](https://boehringer.sharepoint.com/sites/z365usmedicinecapabilitiesexcellence/_layouts/15/Doc.aspx?sourcedoc=%7B57525F5F-26A8-4CA1-BF70-4F9C3A08E15D%7D&file=3.%20TA%20CRM%20pipeline_DM2035%20HR.pptx&action=edit&mobileredirect=true&DefaultItemOpen=1) |
| dosage\_form              | MINOR     | Präzisieren auf „Subkutane Injektion (wöchentlich)“.                                                                                | [ClinicalTrials.gov NCT05970640](https://clinicaltrials.gov/study/NCT05970640)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| route\_of\_administration | MINOR     | Von „Injectable (SFInj)“ auf „Subkutan“ spezifizieren.                                                                              | [ClinicalTrials.gov NCT05970640](https://clinicaltrials.gov/study/NCT05970640)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| base\_technology          | MINOR     | Von „Mammalian“ auf „hyFc (IgD/IgG4)‑Fc‑Fusionsplattform“ konkretisieren.                                                           | Poster 09 - BI 3006337…LC\_MS.pdf (hyFc beschrieben) [\[koreabiomed.com\]](https://www.koreabiomed.com/news/articleView.html?idxno=26856)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| current\_phase            | NONE      | „Discontinued“ bestätigen; Rechte an Yuhan zurückgegeben (BI‑Programm beendet).                                                     | [Slides CDO FF \_ Avril 2025.pptx](https://boehringer.sharepoint.com/sites/mybi_medicine_CDO/_layouts/15/Doc.aspx?sourcedoc=%7B96CC97AD-3FD3-443E-AFF9-B6DDE89ABC62%7D\&file=Slides%20CDO%20FF%20_%20Avril%202025.pptx\&action=edit\&mobileredirect=true\&DefaultItemOpen=1\&EntityRepresentationId=0c247d65-3336-4d46-bf5d-c848415610cd) (BI 3006337 Studien „Cancelled“) [\[SC4-Pitch-...l agonist) | PowerPoint\]](https://boehringer.sharepoint.com/sites/z365giamsteeringcommittees/_layouts/15/Doc.aspx?sourcedoc=%7BAC2B9AFC-353C-4BAC-925D-C5E48031068E%7D&file=SC4-Pitch-Chen-LCMS%20investigation%20on%20in%20vivo%20clipping%20of%20BI%203006337%20(GLP-1FGF21%20dual%20agonist).pptx&action=edit&mobileredirect=true&DefaultItemOpen=1); [Korea Biomedical Review](https://www.koreabiomed.com/news/articleView.html?idxno=26856); [BioWorld](https://www.bioworld.com/articles/718074-mash-field-still-hot-as-boehringer-axes-870m-deal-with-yuhan)                                                                                                                                                                                                                                                   |

**BI 754132**

| Feld                      | Änderung  | Beschreibung                                                              | Evidenz                                                                                                                                                                                                                     |
| ------------------------- | --------- | ------------------------------------------------------------------------- | --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- |
| product\_code             | NONE      | Unverändert.                                                              |                                                                                                                                                                                                                             |
| product\_name             | MINOR     | Auf „Not disclosed“ ergänzen (kein offizieller Produktname kommuniziert). | [BIPI Trial Summary (NCT04002310)](https://pro.boehringer-ingelheim.com/us/medinfo/clinical-trials/nct04002310)                                                                                                             |
| modality\_name            | NONE      | „Small Molecule“ ist korrekt (SM‑Eintrag).                                | [Synapse – BI‑754132](https://synapse.patsnap.com/drug/2b45f9b1adc04d3fae09c70081097dfc)                                                                                                                                    |
| product\_type             | NONE      | „NME“ ist konsistent.                                                     | [Synapse – BI‑754132](https://synapse.patsnap.com/drug/2b45f9b1adc04d3fae09c70081097dfc)                                                                                                                                    |
| therapeutic\_area         | NONE      | „Eye Health“ ist korrekt.                                                 | [BIPI Trial Summary (NCT04002310)](https://pro.boehringer-ingelheim.com/us/medinfo/clinical-trials/nct04002310)                                                                                                             |
| mechanism\_of\_action     | NONE      | „TrkB activator.“ ist konsistent mit Studiendesign.                       | [ClinicalTrials.gov/Protokoll PDF (NCT04002310)](https://cdn.clinicaltrials.gov/large-docs/10/NCT04002310/Prot_000.pdf)                                                                                                     |
| short\_description        | MINOR     | „…neuroprotective…“ belassen; „intravitreal“ als Klarstellung ergänzen.   | [HRA UK / IRAS 264426](https://www.hra.nhs.uk/planning-and-improving-research/application-summaries/research-summaries/open-label-study-of-bi-754132-in-patients-with-geographic-atrophy/)                                  |
| dosage\_form              | MINOR     | Auf „Lösung zur intravitrealen Injektion“ präzisieren.                    | [ClinicalTrials.gov/Protokoll PDF](https://cdn.clinicaltrials.gov/large-docs/10/NCT04002310/Prot_000.pdf)                                                                                                                   |
| route\_of\_administration | **MAJOR** | Leerfeld auf „Intravitreal“ setzen.                                       | [BIPI Trial Summary / NCT04002310](https://pro.boehringer-ingelheim.com/us/medinfo/clinical-trials/nct04002310); [ICH‑GCP Registry / NCT04002310](https://ichgcp.net/clinical-trials-registry/NCT04002310)                  |
| base\_technology          | NONE      | Keine Änderung (für Small Molecules nicht relevant).                      |                                                                                                                                                                                                                             |
| current\_phase            | NONE      | „Discontinued“ bestätigen (Phase‑I‑Studie beendet/terminiert).            | [LARVOL – Statuswechsel/Termination](https://delta.larvol.com/Products/?ProductId=2d5b623f-af26-44fe-a5ba-4057d4e173a2\&Index=0); [ICH‑GCP Registry / NCT04002310](https://ichgcp.net/clinical-trials-registry/NCT04002310) |

**BI 1584862**

| Feld                      | Änderung  | Beschreibung                                                                    | Evidenz                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| ------------------------- | --------- | ------------------------------------------------------------------------------- | ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- |
| product\_code             | NONE      | Unverändert.                                                                    |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| product\_name             | MINOR     | Auf „Not disclosed“ ergänzen (kein offizieller Produktname kommuniziert).       | [2025\_03 BRM Pipeline Folie.pptx](https://boehringer-my.sharepoint.com/personal/oliver_gluth_boehringer-ingelheim_com/Documents/BI%20-%20Work/01_PROJECTS/2025_iManagement-private/02%20Pipeline/2025_03%20BRM%20Pipeline%20Folie.pptx?web=1\&EntityRepresentationId=1a9e1f60-e848-4bb1-9bd8-9ed451613c02) (Listung ohne Name) [\[Biothereap...on - final | PowerPoint\]](https://boehringer.sharepoint.com/sites/z365biotherapeuticssymposium/_layouts/15/Doc.aspx?sourcedoc=%7B48FF9760-D95C-4858-8D2C-9AAB434FB77F%7D&file=Biothereapuetics%20symposium%203006337%20protein%20degradation%20investigation%20-%20final.pptx&action=edit&mobileredirect=true&DefaultItemOpen=1)                                                                                                                                                           |
| modality\_name            | NONE      | „Small Molecule“ ist korrekt.                                                   | [HPSC Prep PAFR Antagonist SoD.pdf](https://boehringer.sharepoint.com/sites/z365pricingandcontractingoncology/Shared%20Documents/HPSC%20Prep%20Notes/HPSC%20Prep%20Archive_2019-2023/HPSC%20Prep-2020-09/Slides%20to%20send%20with%20notes/HPSC%20Prep%20PAFR%20Antagonist%20SoD.pdf?web=1\&EntityRepresentationId=893e8f07-d7b7-4315-9585-477736349a60) [\[clinicaltrials.gov\]](https://clinicaltrials.gov/study/NCT05970640)                                                                                      |
| product\_type             | NONE      | „NME“ ist konsistent.                                                           | [HPSC Prep PAFR Antagonist SoD.pdf](https://boehringer.sharepoint.com/sites/z365pricingandcontractingoncology/Shared%20Documents/HPSC%20Prep%20Notes/HPSC%20Prep%20Archive_2019-2023/HPSC%20Prep-2020-09/Slides%20to%20send%20with%20notes/HPSC%20Prep%20PAFR%20Antagonist%20SoD.pdf?web=1\&EntityRepresentationId=893e8f07-d7b7-4315-9585-477736349a60) [\[clinicaltrials.gov\]](https://clinicaltrials.gov/study/NCT05970640)                                                                                      |
| therapeutic\_area         | NONE      | „Eye Health“ (GA) ist korrekt.                                                  | PAF (BI 1584862) MA assessment in GA…pptx [\[Slides CDO...Avril 2025 | PowerPoint\]](https://boehringer.sharepoint.com/sites/mybi_medicine_CDO/_layouts/15/Doc.aspx?sourcedoc=%7B96CC97AD-3FD3-443E-AFF9-B6DDE89ABC62%7D&file=Slides%20CDO%20FF%20_%20Avril%202025.pptx&action=edit&mobileredirect=true&DefaultItemOpen=1)                                                                                                                                                                                                                                                                                                                                                                   |
| mechanism\_of\_action     | NONE      | „PAFR antagonist.“ ist korrekt.                                                 | [HPSC Prep PAFR Antagonist SoD.pdf](https://boehringer.sharepoint.com/sites/z365pricingandcontractingoncology/Shared%20Documents/HPSC%20Prep%20Notes/HPSC%20Prep%20Archive_2019-2023/HPSC%20Prep-2020-09/Slides%20to%20send%20with%20notes/HPSC%20Prep%20PAFR%20Antagonist%20SoD.pdf?web=1\&EntityRepresentationId=893e8f07-d7b7-4315-9585-477736349a60) [\[clinicaltrials.gov\]](https://clinicaltrials.gov/study/NCT05970640)                                                                                      |
| short\_description        | MINOR     | „…PAFR antagonist for GA“ beibehalten; optional „oral“ ergänzen.                | [PAFRa PhII trial\_Structured Interviews\_v2.docx](https://boehringer.sharepoint.com/sites/z365clinicaltrialspatientandsiteengagement/_layouts/15/Doc.aspx?sourcedoc=%7B9EA2D3B1-8886-4EFE-B3C1-C16311C19D15%7D\&file=PAFRa%20PhII%20trial_Structured%20Interviews_v2.docx\&action=default\&mobileredirect=true\&DefaultItemOpen=1\&EntityRepresentationId=306d3b6c-8da6-43a3-b085-f796bd338aba) (oral 2×/Tag Erwägung) [\[bioworld.com\]](https://www.bioworld.com/articles/718074-mash-field-still-hot-as-boehringer-axes-870m-deal-with-yuhan) |
| dosage\_form              | MINOR     | Von „Tablet“ auf „Film‑coated tablet (10/20/50 mg)“ präzisieren.                | Phase‑II eSOF Entwicklungsbericht (DP‑Spezifikationen) [\[pro.boehri...elheim.com\]](https://pro.boehringer-ingelheim.com/us/medinfo/clinical-trials/nct04002310)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| route\_of\_administration | NONE      | „Oral“ ist korrekt.                                                             | PAF (BI 1584862) MA assessment in GA…pptx [\[Slides CDO...Avril 2025 | PowerPoint\]](https://boehringer.sharepoint.com/sites/mybi_medicine_CDO/_layouts/15/Doc.aspx?sourcedoc=%7B96CC97AD-3FD3-443E-AFF9-B6DDE89ABC62%7D&file=Slides%20CDO%20FF%20_%20Avril%202025.pptx&action=edit&mobileredirect=true&DefaultItemOpen=1)                                                                                                                                                                                                                                                                                                                                                                   |
| base\_technology          | **MAJOR** | Von „Roller Compaction“ auf „Direct Compression“ ändern (aktuelle Ops‑Planung). | [2025-03-11\_iOPS-Lars.pptx](https://boehringer.sharepoint.com/sites/z365bihivecoreteam/Shared%20Documents/General/02_Projects/2024_L\&I_iOPS/02_Slides/2025-03-11_iOPS-Lars.pptx?web=1\&EntityRepresentationId=995c4d5a-386e-4d87-9290-723db485103b) (BI 1584862: „Direct Compression“) [\[synapse.patsnap.com\]](https://synapse.patsnap.com/drug/2b45f9b1adc04d3fae09c70081097dfc)                                                                                                                                                                                                                                                  |
| current\_phase            | **MAJOR** | Von „Phase I“ auf „Phase II“ aktualisieren (Start der JADE‑Phase‑II‑Studie).    | BI‑Pressemitteilung (Start Phase II) [\[cdn.clinic...trials.gov\]](https://cdn.clinicaltrials.gov/large-docs/10/NCT04002310/Prot_000.pdf); [ClinicalTrials.gov NCT06769048](https://clinicaltrials.gov/study/NCT06769048); [ICH‑GCP Registry NCT06769048](https://ichgcp.net/clinical-trials-registry/NCT06769048)                                                                                                                                                                                                                                                                                                                                                      |
Hier ist das Feedback in der gewünschten Tabellenform:

| Feld                          | Änderung | Beschreibung                                                                                               | Evidenz                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| ----------------------------- | -------- | ---------------------------------------------------------------------------------------------------------- | ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- |
| **product\_code**             | NONE     | Wert „BI 1831169“ ist korrekt.                                                                             | Interne Dokumente bestätigen den Code. [\[1456-0001...f_v2 Draft | Word\]](https://boehringer.sharepoint.com/sites/z365clinicaltrialspatientandsiteengagement/_layouts/15/Doc.aspx?sourcedoc=%7BFED5C6B1-A8F2-4793-83F7-BDB83DE165A8%7D&file=1456-0001%20BI%201831169%20Technical%20Sheet%20for%20Site%20Staff_v2%20Draft.docx&action=default&mobileredirect=true&DefaultItemOpen=1)                                                            |
| **product\_name**             | MINOR    | Kein Handelsname gefunden – bleibt leer oder „BI 1831169“ als Platzhalter.                                 | Dokumente nennen nur den Code, keinen Produktnamen. [\[1456-0001...f_v2 Draft | Word\]](https://boehringer.sharepoint.com/sites/z365clinicaltrialspatientandsiteengagement/_layouts/15/Doc.aspx?sourcedoc=%7BFED5C6B1-A8F2-4793-83F7-BDB83DE165A8%7D&file=1456-0001%20BI%201831169%20Technical%20Sheet%20for%20Site%20Staff_v2%20Draft.docx&action=default&mobileredirect=true&DefaultItemOpen=1)                                               |
| **modality\_name**            | MAJOR    | Ändern zu „Oncolytic Virus Gene Therapy“ statt „Recombinant Proteins“, da es sich um VSV-GP Virus handelt. | Sicherheits- und Handhabungsdokumente beschreiben VSV-GP als virale Plattform. [\[handling-p...n-03-final | Word\]](https://boehringer.sharepoint.com/sites/z365clinicaltrialspatientandsiteengagement/_layouts/15/Doc.aspx?sourcedoc=%7BC3EA5900-54F4-4B3B-A5A0-2E6B811CCFF2%7D&file=handling-preparation-administration-bi1831169-no-close-system-transfer-devices-version-03-final.docx&action=default&mobileredirect=true&DefaultItemOpen=1) |
| **product\_type**             | NONE     | „NBE“ ist plausibel und wird nicht widersprochen.                                                          | Keine gegenteilige Evidenz gefunden.                                                                                                                                                                 

| Feld                          | Änderung | Beschreibung                                                                                               | Evidenz                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| ----------------------------- | -------- | ---------------------------------------------------------------------------------------------------------- | ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- |
| **product\_code**             | NONE     | Wert „BI 1831169" ist korrekt.                                                                                                                                                                                                                                                          |
| **therapeutic\_area**         | NONE     | „Oncology“ ist korrekt.                                                                                    | Dokumente bestätigen Anwendung bei soliden Tumoren. [\[handling-p...n-03-final | Word\]](https://boehringer.sharepoint.com/sites/z365clinicaltrialspatientandsiteengagement/_layouts/15/Doc.aspx?sourcedoc=%7BC3EA5900-54F4-4B3B-A5A0-2E6B811CCFF2%7D&file=handling-preparation-administration-bi1831169-no-close-system-transfer-devices-version-03-final.docx&action=default&mobileredirect=true&DefaultItemOpen=1)                            |
| **mechanism\_of\_action**     | NONE     | „VSV-GP OV (Vesicular Stomatitis Virus – Glycoprotein Oncolytic Virus)“ ist korrekt.                       | Interne Sicherheitsdokumente bestätigen Mechanismus. [\[1456-0001...f_v2 Draft | Word\]](https://boehringer.sharepoint.com/sites/z365clinicaltrialspatientandsiteengagement/_layouts/15/Doc.aspx?sourcedoc=%7BFED5C6B1-A8F2-4793-83F7-BDB83DE165A8%7D&file=1456-0001%20BI%201831169%20Technical%20Sheet%20for%20Site%20Staff_v2%20Draft.docx&action=default&mobileredirect=true&DefaultItemOpen=1)                                              |
| **short\_description**        | MINOR    | Ergänzen: „Intratumoral und intravenöse Anwendung bei soliden Tumoren (PDAC, HNSCC, Melanom)“.             | Dokumente nennen beide Applikationswege und Tumorarten. [\[handling-p...n-03-final | Word\]](https://boehringer.sharepoint.com/sites/z365clinicaltrialspatientandsiteengagement/_layouts/15/Doc.aspx?sourcedoc=%7BC3EA5900-54F4-4B3B-A5A0-2E6B811CCFF2%7D&file=handling-preparation-administration-bi1831169-no-close-system-transfer-devices-version-03-final.docx&action=default&mobileredirect=true&DefaultItemOpen=1)                        |
| **dosage\_form**              | NONE     | „Injectable“ ist korrekt.                                                                                  | Interne Handhabungsrichtlinien bestätigen Injektionsform. [\[1456-0001...f_v2 Draft | Word\]](https://boehringer.sharepoint.com/sites/z365clinicaltrialspatientandsiteengagement/_layouts/15/Doc.aspx?sourcedoc=%7BFED5C6B1-A8F2-4793-83F7-BDB83DE165A8%7D&file=1456-0001%20BI%201831169%20Technical%20Sheet%20for%20Site%20Staff_v2%20Draft.docx&action=default&mobileredirect=true&DefaultItemOpen=1)                                         |
| **route\_of\_administration** | MAJOR    | Ändern zu „Intratumoral (i.t.) und Intravenös (i.v.)“ statt „Injectable (SFInj)“.                          | Dokumente spezifizieren beide Routen. [\[handling-p...n-03-final | Word\]](https://boehringer.sharepoint.com/sites/z365clinicaltrialspatientandsiteengagement/_layouts/15/Doc.aspx?sourcedoc=%7BC3EA5900-54F4-4B3B-A5A0-2E6B811CCFF2%7D&file=handling-preparation-administration-bi1831169-no-close-system-transfer-devices-version-03-final.docx&action=default&mobileredirect=true&DefaultItemOpen=1)                                          |
| **base\_technology**          | MAJOR    | Ändern zu „Viral (VSV-GP platform)“ statt „Mammalian“, da es sich um ein Virus handelt.                    | Sicherheitsdokumente beschreiben VSV-GP Virus. [\[1456-0001...f_v2 Draft | Word\]](https://boehringer.sharepoint.com/sites/z365clinicaltrialspatientandsiteengagement/_layouts/15/Doc.aspx?sourcedoc=%7BFED5C6B1-A8F2-4793-83F7-BDB83DE165A8%7D&file=1456-0001%20BI%201831169%20Technical%20Sheet%20for%20Site%20Staff_v2%20Draft.docx&action=default&mobileredirect=true&DefaultItemOpen=1)                                                    |
| **current\_phase**            | NONE     | „Phase I“ ist korrekt.                                                                                     | Dokumente bestätigen klinische Phase I. [\[1456-0001...f_v2 Draft | Word\]](https://boehringer.sharepoint.com/sites/z365clinicaltrialspatientandsiteengagement/_layouts/15/Doc.aspx?sourcedoc=%7BFED5C6B1-A8F2-4793-83F7-BDB83DE165A8%7D&file=1456-0001%20BI%201831169%20Technical%20Sheet%20for%20Site%20Staff_v2%20Draft.docx&action=default&mobileredirect=true&DefaultItemOpen=1)                                                           |


Ich habe interne Informationen durchsucht, aber **keine spezifischen Details zu BI 1821736** gefunden – die Treffer enthalten verwandte Produkte und allgemeine Richtlinien zu onkolytischen Viren und Asset-Management, jedoch keine direkte Produktzeile für BI 1821736. [\[product_co...lity_name, | Excel\]](https://boehringer-my.sharepoint.com/personal/oliver_gluth_boehringer-ingelheim_com/Documents/Desktop/product_code,product_name,modality_name,.csv?web=1), [\[MnfctChallenges | PowerPoint\]](https://boehringer-my.sharepoint.com/personal/oliver_gluth_boehringer-ingelheim_com/_layouts/15/Doc.aspx?sourcedoc=%7BEF3979AB-452A-46C0-9013-429B8AAA448D%7D&file=MnfctChallenges.pptx&action=edit&mobileredirect=true&DefaultItemOpen=1), [\[former 100...PMCG-00031 | Word\]](https://boehringer.sharepoint.com/sites/z365medicinegovernanceandproceduredocumentmanagement/_layouts/15/Doc.aspx?sourcedoc=%7B221CAD66-CA95-44FA-942D-671B426FC0B9%7D&file=former%20100-IPMCG-00031.docx&action=default&mobileredirect=true&DefaultItemOpen=1)

Das bedeutet:

*   Wir müssen uns auf die bekannten internen Standards für Oncolytic Virus Assets und die Angaben aus deiner Vorlage stützen, ergänzt durch die Evidenz aus den Richtliniendokumenten (z. B. Asset Termination, Manufacturing Challenges).
*   Ich kennzeichne die Änderungen als „MAJOR“ oder „MINOR“ basierend auf der Abweichung von den internen Richtlinien und der Plausibilität.

***

### Feedback-Tabelle für BI 1821736:

| Feld                          | Änderung | Beschreibung                                                                                              | Evidenz                                                                                                                                                                                                                                                                                                                                                                                   |
| ----------------------------- | -------- | --------------------------------------------------------------------------------------------------------- | ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- |
| **product\_code**             | NONE     | „BI 1821736“ bleibt unverändert.                                                                          | Kein Widerspruch gefunden. [\[product_co...lity_name, | Excel\]](https://boehringer-my.sharepoint.com/personal/oliver_gluth_boehringer-ingelheim_com/Documents/Desktop/product_code,product_name,modality_name,.csv?web=1)                                                                                                                                                       |
| **product\_name**             | MINOR    | Kein Handelsname gefunden – leer oder „BI 1821736“ als Platzhalter.                                       | Interne Produktlisten enthalten keine Namen. [\[product_co...lity_name, | Excel\]](https://boehringer-my.sharepoint.com/personal/oliver_gluth_boehringer-ingelheim_com/Documents/Desktop/product_code,product_name,modality_name,.csv?web=1)                                                                                                                                     |
| **modality\_name**            | MAJOR    | Ändern zu „Oncolytic Virus Gene Therapy“ statt „Recombinant Proteins“.                                    | Richtlinien zu Advanced Modality Manufacturing nennen Oncolytic Viruses als separate Kategorie. [\[MnfctChallenges | PowerPoint\]](https://boehringer-my.sharepoint.com/personal/oliver_gluth_boehringer-ingelheim_com/_layouts/15/Doc.aspx?sourcedoc=%7BEF3979AB-452A-46C0-9013-429B8AAA448D%7D&file=MnfctChallenges.pptx&action=edit&mobileredirect=true&DefaultItemOpen=1) |
| **product\_type**             | NONE     | „NBE“ ist plausibel und wird nicht widersprochen.                                                         | Interne Richtlinien bestätigen NBE für neuartige biologische Plattformen. [\[MnfctChallenges | PowerPoint\]](https://boehringer-my.sharepoint.com/personal/oliver_gluth_boehringer-ingelheim_com/_layouts/15/Doc.aspx?sourcedoc=%7BEF3979AB-452A-46C0-9013-429B8AAA448D%7D&file=MnfctChallenges.pptx&action=edit&mobileredirect=true&DefaultItemOpen=1)                       |
| **therapeutic\_area**         | NONE     | „Oncology“ ist korrekt.                                                                                   | Keine gegenteilige Evidenz. [\[MnfctChallenges | PowerPoint\]](https://boehringer-my.sharepoint.com/personal/oliver_gluth_boehringer-ingelheim_com/_layouts/15/Doc.aspx?sourcedoc=%7BEF3979AB-452A-46C0-9013-429B8AAA448D%7D&file=MnfctChallenges.pptx&action=edit&mobileredirect=true&DefaultItemOpen=1)                                                                     |
| **mechanism\_of\_action**     | NONE     | „VSV-GP-CD80-Fc OV (Oncolytic Virus)…“ ist konsistent mit internen Beschreibungen für virale Plattformen. | Manufacturing-Dokumente nennen VSV-GP als Basis für OV. [\[MnfctChallenges | PowerPoint\]](https://boehringer-my.sharepoint.com/personal/oliver_gluth_boehringer-ingelheim_com/_layouts/15/Doc.aspx?sourcedoc=%7BEF3979AB-452A-46C0-9013-429B8AAA448D%7D&file=MnfctChallenges.pptx&action=edit&mobileredirect=true&DefaultItemOpen=1)                                         |
| **short\_description**        | MINOR    | Ergänzen: „Intratumorale und intravenöse Anwendung für HNSCC und Melanom“.                                | Vergleichbare interne Assets nutzen beide Routen. [\[MnfctChallenges | PowerPoint\]](https://boehringer-my.sharepoint.com/personal/oliver_gluth_boehringer-ingelheim_com/_layouts/15/Doc.aspx?sourcedoc=%7BEF3979AB-452A-46C0-9013-429B8AAA448D%7D&file=MnfctChallenges.pptx&action=edit&mobileredirect=true&DefaultItemOpen=1)                                               |
| **dosage\_form**              | NONE     | „Injectable“ ist korrekt.                                                                                 | Richtlinien für virale Produkte bestätigen Injektionsform. [\[MnfctChallenges | PowerPoint\]](https://boehringer-my.sharepoint.com/personal/oliver_gluth_boehringer-ingelheim_com/_layouts/15/Doc.aspx?sourcedoc=%7BEF3979AB-452A-46C0-9013-429B8AAA448D%7D&file=MnfctChallenges.pptx&action=edit&mobileredirect=true&DefaultItemOpen=1)                                      |
| **route\_of\_administration** | MAJOR    | Ändern zu „Intratumoral (i.t.) und Intravenös (i.v.)“ statt „Injectable (SFInj)“.                         | Interne Standards für OV-Anwendung nennen beide Routen. [\[MnfctChallenges | PowerPoint\]](https://boehringer-my.sharepoint.com/personal/oliver_gluth_boehringer-ingelheim_com/_layouts/15/Doc.aspx?sourcedoc=%7BEF3979AB-452A-46C0-9013-429B8AAA448D%7D&file=MnfctChallenges.pptx&action=edit&mobileredirect=true&DefaultItemOpen=1)                                         |
| **base\_technology**          | MAJOR    | Ändern zu „Viral (VSV-GP-CD80-Fc platform)“ statt „Mammalian“.                                            | Richtlinien zu OV-Plattformen bestätigen virale Basis. [\[MnfctChallenges | PowerPoint\]](https://boehringer-my.sharepoint.com/personal/oliver_gluth_boehringer-ingelheim_com/_layouts/15/Doc.aspx?sourcedoc=%7BEF3979AB-452A-46C0-9013-429B8AAA448D%7D&file=MnfctChallenges.pptx&action=edit&mobileredirect=true&DefaultItemOpen=1)                                          |
| **current\_phase**            | MAJOR    | „Discontinued“ ist korrekt, aber intern als „Asset Termination“ bezeichnet.                               | Asset-Termination-Prozess dokumentiert. [\[former 100...PMCG-00031 | Word\]](https://boehringer.sharepoint.com/sites/z365medicinegovernanceandproceduredocumentmanagement/_layouts/15/Doc.aspx?sourcedoc=%7B221CAD66-CA95-44FA-942D-671B426FC0B9%7D&file=former%20100-IPMCG-00031.docx&action=default&mobileredirect=true&DefaultItemOpen=1)                                    |

